authors,url,title,abstract,publication_date,site,number_of_authors,Entity,sentence_chain,object
"[{'author_name': 'Rickard Bengt Emanuel Nyman', 'author_inst': 'University College London'}, {'author_name': 'Paul Ormerod', 'author_inst': 'University College London'}]",http://medrxiv.org/cgi/content/short/2020.06.24.20139196,How Many Lives Has Lockdown Saved in the UK?,"We compare the trajectory of deaths (both in hospitals and care homes) on a daily basis in Sweden and England and Wales (which constitute 90 per cent of the UK population) from 11 March to 12 June 2020, the latest date at which the relevant data is available for England and Wales. Deaths in both Sweden and England and Wales peaked on 8 April. The build up to the peak was very similar in both. Given the time lag between infection and death, the lockdown would have had little effect on the peak number of deaths. By 12 June, the deaths are virtually the same in both. However, from early May the decline in England and Wales has been much sharper. We estimate that to 12 June, lockdown saved just under 6,000 lives in England and Wales, or around 6,500 extrapolating to a UK level.",2020-06-25,medrxiv,2,"[{'GENE_OR_GENE_PRODUCT': [{'label': 'UK', 'alias': ['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'kingdom united', 'united kingdom', 'UNITED KINGDOM', 'UNITED KINGDOM', 'GBR', 'GBR', 'GBR', 'UK', 'UK - United Kingdom of Great Britain and Northern Ireland', 'United Kingdom of Great Britain and Northern Ireland', 'United Kingdom of Great Britain and Northern Ireland', 'GB', 'GB', 'United Kingdom of Great Britain and Northern Ireland (geographic location)'], 'meaning': ['Country in Northeastern Europe including Great Britain and the northern one-sixth of Ireland, located between the North Sea and north Atlantic Ocean. The capital is London.', 'C0041700', 1]}]}, {'ORGANISM': [{'label': 'lockdown', 'alias': ['Gene Knockdown Technique', 'Knockdown Technique, Gene', 'Technique, Gene Knockdown', 'Knockdown Techniques, Gene', 'Techniques, Gene Knockdown', 'Gene Knockdowns', 'Knockdowns, Gene', 'Gene Knock Down Techniques', 'Gene Knock-Down Techniques', 'Gene Knock-Down Technique', 'Knock-Down Technique, Gene', 'Technique, Gene Knock-Down', 'Knock-Down Techniques, Gene', 'Techniques, Gene Knock-Down', 'Gene Knockdown', 'Gene Knockdown', 'Knockdown, Gene', 'Gene Knock Down', 'Gene Knock Downs', 'Gene Knock-Downs', 'Gene Knock-Down', 'Knock Downs, Gene', 'Knock-Downs, Gene', 'Knock Down, Gene', 'Knock-Down, Gene'], 'meaning': ['The artificial induction of GENE SILENCING by the use of RNA INTERFERENCE to reduce the expression of a specific gene. It includes the use of DOUBLE-STRANDED RNA, such as SMALL INTERFERING RNA and RNA containing HAIRPIN LOOP SEQUENCE, and ANTI-SENSE OLIGONUCLEOTIDES.', 'C2350567', 0.7498913407325745]}]}]","{'We compare the trajectory of deaths (both in hospitals and care homes) on a daily basis in Sweden and England and Wales (which constitute 90 per cent of the UK population) from 11 March to 12 June 2020, the latest date at which the relevant data is available for England and Wales.': [['compare', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['trajectory', 'NN', 'I-NP'], ['care', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['daily', 'JJ', 'I-NP'], ['basis', 'NN', 'I-NP'], ['constitute', 'VBP', 'O'], ['cent', 'NN', 'B-NP'], ['population', 'NN', 'B-NP'], ['date', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['relevant', 'NN', 'I-NP'], ['data', 'NN', 'B-NP'], ['is', 'VBZ', 'O']], 'Deaths in both Sweden and England and Wales peaked on 8 April.': [['peaked', 'VBD', 'O']], 'The build up to the peak was very similar in both.': [['The', 'DT', 'B-NP'], ['build', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['peak', 'NN', 'I-NP'], ['was', 'VBD', 'O']], 'Given the time lag between infection and death, the lockdown would have had little effect on the peak number of deaths.': [['Given', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['time', 'NN', 'I-NP'], ['lag', 'NN', 'B-NP'], ['infection', 'NN', 'B-NP'], ['death', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['lockdown', 'NN', 'I-NP'], ['have', 'VB', 'O'], ['had', 'VBN', 'O'], ['little', 'JJ', 'B-NP'], ['effect', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['peak', 'JJ', 'I-NP'], ['number', 'NN', 'I-NP']], 'By 12 June, the deaths are virtually the same in both.': [['are', 'VBP', 'O']], 'However, from early May the decline in England and Wales has been much sharper.': [['the', 'DT', 'B-NP'], ['decline', 'NN', 'I-NP'], ['has', 'VBZ', 'O'], ['been', 'VBN', 'O']], 'We estimate that to 12 June, lockdown saved just under 6,000 lives in England and Wales, or around 6,500 extrapolating to a UK level.': [['estimate', 'VBP', 'O'], ['saved', 'VBD', 'O'], ['extrapolating', 'VBG', 'O'], ['level', 'NN', 'B-NP']]}","{'We compare the trajectory of deaths (both in hospitals and care homes) on a daily basis in Sweden and England and Wales (which constitute 90 per cent of the UK population) from 11 March to 12 June 2020, the latest date at which the relevant data is available for England and Wales.': [{'noun_phrase': '', 'noun_connectors': ['compare']}, {'noun_phrase': ' trajectory deaths hospitals', 'noun_connectors': ['and']}, {'noun_phrase': ' care homes daily basis Sweden', 'noun_connectors': ['and', 'and', 'constitute']}], 'Deaths in both Sweden and England and Wales peaked on 8 April.': [], 'The build up to the peak was very similar in both.': [], 'Given the time lag between infection and death, the lockdown would have had little effect on the peak number of deaths.': [{'noun_phrase': '', 'noun_connectors': ['Given']}, {'noun_phrase': ' time lag infection', 'noun_connectors': ['and']}, {'noun_phrase': ' death lockdown', 'noun_connectors': ['would', 'had']}], 'By 12 June, the deaths are virtually the same in both.': [], 'However, from early May the decline in England and Wales has been much sharper.': [{'noun_phrase': '', 'noun_connectors': ['However', 'May']}], 'We estimate that to 12 June, lockdown saved just under 6,000 lives in England and Wales, or around 6,500 extrapolating to a UK level.': [{'noun_phrase': '', 'noun_connectors': ['estimate']}, {'noun_phrase': ' lockdown', 'noun_connectors': ['saved', 'just']}, {'noun_phrase': ' lives England', 'noun_connectors': ['and', 'or']}]}"
"[{'author_name': 'David Baunoch', 'author_inst': 'Pathnostics'}, {'author_name': 'Alan Wolfe', 'author_inst': 'Loyola University Chicago Stritch School of Medicine'}, {'author_name': 'Dakun Wang', 'author_inst': 'Stat4ward'}, {'author_name': 'Ryan Gnewuch', 'author_inst': 'Pathnostics'}, {'author_name': 'Xinhua Zhao', 'author_inst': 'Stat4ward'}, {'author_name': 'Thomas Halverson', 'author_inst': 'Loyola University Chicago'}, {'author_name': 'Patrick Cacdac', 'author_inst': 'Pathnostics'}, {'author_name': 'Shuguang Huang', 'author_inst': 'Stat4ward'}, {'author_name': 'Trisha Lauterbach', 'author_inst': 'Capstone Laboratory'}, {'author_name': 'Natalie Luke', 'author_inst': 'Pathnostics'}]",http://medrxiv.org/cgi/content/short/2020.06.24.20138941,Co-occurrence of SARS-CoV-2 and Respiratory Pathogens in the Frail Elderly,"Background: Elderly SARS-CoV-2 patients are associated with higher hospitalization and mortality. Co-infection is critical in the severity of respiratory diseases. It is largely understudied for SARS-CoV-2. Methods: Between March 24th and April 27th, 2020, nasopharyngeal and oropharyngeal swabs from 3,348 patients from nursing homes and assisted living facilities in 22 states in the US were tested by Capstone Healthcare for SARS-CoV-2, 24 other respiratory viruses, and 8 respiratory bacteria. Total nucleic acid was extracted with MagMAXTM Viral/Pathogen Ultra nucleic acid isolation kit. SARS-Co-V-2 was detected with the CDC 2019-novel coronavirus (2019-nCoV) diagnostic panel. Total nucleic acid was pre-amplified before analysis for other respiratory pathogens with Taqman OpenArrayTM Respiratory Tract Microbiota Plate. Results: Patients mean age was 76.9 years. SARS-CoV-2 was detected in 1,413 patients (42.2%). Among them, 1,082 (76.6%) and 737 (43.7%) patients were detected with at least one bacterium or another virus, respectively. SARS-CoV-2-positive patients were more likely to have bacterial co-occurrences (76.6%) than SARS-CoV-2-negative patients (70.0%) (p<0.0001). The most common co-occurring bacteria were Staphylococcus aureus and Klebsiella pneumonia, detected in 55.8% and 40.1% SARS-CoV-2-positive patients, respectively. Staphylococcus aureus was associated with SARS-CoV-2, with higher detection rates in SARS-CoV-2-positive patients (55.8%) than SARS-CoV-2-negative patients (46.2%) (p<0.0001). Human herpes virus 6 (HHV6) also was common and associated with SARS-CoV-2, with higher detection rates in SARS-CoV-2-positive patients (26.6%) than SARS-CoV-2-negative patients (19.1%) (p<0.0001). Conclusions: SARS-CoV-2-positive patients are more likely to be positive for certain respiratory bacteria and viruses. This observation may help explain high hospitalization and mortality rates in older patients.",2020-06-25,medrxiv,10,"[{'CANCER': [{'label': 'nasopharyngeal', 'alias': ['Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'Nasopharynx', 'NASOPHARYNX', 'NASOPHARYNX', 'nasopharynx', 'nasopharynx', 'nasopharynx', 'nasopharynx', 'Nasopharynges', 'Nasopharynxes', 'Nasopharynx, NOS', 'nasopharynges', 'Rhinopharynx', 'Rhinopharynx', 'Rhinopharynx', 'Rhinopharynx', 'rhinopharynx', 'Rhinopharynges', 'Rhinopharynx, NOS', 'Rhinopharynxes', 'rhinopharynges', 'Nasopharyngeal', 'Nasopharyngeal', 'Nasopharyngeal', 'Nasopharyngeal', 'nasopharyngeal', 'Nasopharyngo-', 'Nph', 'Nasopharyngeal structure', 'Rhinopharyngeal', 'rhinopharyngeal', 'Rhinopharyngo-', 'Nasal part of pharynx', 'Nasal part of pharynx', 'Pars nasalis pharyngis', 'Pars nasalis pharyngis', 'Nasopharyngeal structure (body structure)', 'Nasopharyngeal (qualifier value)'], 'meaning': ['The top portion of the pharynx situated posterior to the nose and superior to the SOFT PALATE. The nasopharynx is the posterior extension of the nasal cavities and has a respiratory function.', 'C0027442', 1]}]}, {'CANCER': [{'label': 'nasopharyngeal', 'alias': ['NCI CTEP SDC Nasopharyngeal Cancer Sub-Category Terminology', 'Nasopharyngeal Cancer', 'NCI CTEP Simple Disease Classification Nasopharyngeal Cancer Sub-Category Terminology'], 'meaning': ['Nasopharyngeal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.', 'C3539713', 0.8859275579452515]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'CORONAVIRUS', 'coronavirus', 'Coronaviruses', 'Coronaviruses', 'Coronaviruses', 'Coronavirus, NOS', 'coronaviruses'], 'meaning': ['A genus of the family CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.', 'C0206419', 1]}]}, {'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'coronaviridae', 'CORONAVIRUS', 'Family: Coronavirus group', 'Coronavirus group', 'CORONAVIRUS GROUP', 'Coronavirus group, NOS', 'Family Coronaviridae', 'Family Coronaviridae (organism)'], 'meaning': ['Spherical RNA viruses, in the order NIDOVIRALES, infecting a wide range of animals including humans. Transmission is by fecal-oral and respiratory routes. Mechanical transmission is also common. There are two genera: CORONAVIRUS and TOROVIRUS.', 'C0010076', 1]}]}, {'ORGANISM': [{'label': 'Patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'Patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'ORGANISM': [{'label': 'Human herpes virus 6', 'alias': ['human herpesvirus 6', 'human herpesvirus 6', 'HUMAN HERPESVIRUS 6', 'HUMAN HERPESVIRUS 6', 'Human herpesvirus 6', 'Human herpesvirus 6', 'Human herpesvirus 6', 'Human herpesvirus-6', 'Human Herpesvirus 6', 'Human Herpesvirus 6', 'HBLV', 'HBLV', 'HHV-6', 'HHV-6', 'HHV-6', 'hhv 6', 'hhv-6', 'HHV 6', 'Human B-Lymphotropic Virus', 'human B lymphotropic virus', 'B-Lymphotropic Viruses, Human', 'Human B Lymphotropic Virus', 'Human B-Lymphotropic Viruses', 'B-Lymphotropic Virus, Human', 'Roseola infantum virus', 'Roseola infantum virus', 'Roseola infantum virus', 'Exanthem subitum virus', 'Exanthem subitum virus', 'Roseola virus', 'Roseola virus', 'roseola virus', 'HHV6 - Human herpes virus 6', 'herpesvirus 6 HHV-6', 'human herpesvirus type 6 HHV-6', 'herpes simplex virus type 6', 'Human herpesvirus type 6', 'Herpesvirus type 6', 'Human herpesvirus 6 (organism)', 'Virus-HHV6', 'HHV6', 'HHV6', 'HHV6', 'HHV6', 'hhv6', 'human herpesvirus 6 HHV-6', 'Human herpes virus 6', '6 herpes human virus', 'human herpes 6 virus', 'human herpes virus 6'], 'meaning': [""The type species of ROSEOLOVIRUS isolated from patients with AIDS and other LYMPHOPROLIFERATIVE DISORDERS. It infects and replicates in fresh and established lines of hematopoietic cells and cells of neural origin. It also appears to alter NK cell activity. HHV-6; (HBLV) antibodies are elevated in patients with AIDS, Sjogren's syndrome, sarcoidosis, chronic fatigue syndrome, and certain malignancies. HHV-6 is the cause of EXANTHEMA SUBITUM and has been implicated in encephalitis."", 'C0019381', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'Human herpes virus 6', 'alias': ['Human herpesvirus 1', 'Human herpesvirus 1', 'Herpesvirus 1, Human', 'herpesvirus 1, human', 'Human Herpesvirus 1', 'HUMAN HERPESVIRUS 1', 'Herpes Simplex Virus 1', '1 herpes simplex virus', 'herpes simplex 1 virus', 'Herpes simplex virus 1', 'Herpes simplex virus 1', 'Herpes simplex virus 1', 'Herpes simplex virus 1', 'herpes simplex virus 1', 'herpes simplex virus 1', 'Herpes Simplex Virus Type 1', 'herpes simplex type 1 virus', 'herpes virus simplex type 1', 'virus type 1 herpes simplex', 'herpes simplex virus type 1', 'Herpesvirus 1 (alpha), Human', 'HSV 1 - Herpes simplex virus 1', 'herpes simplex 1 virus (hsv-1)', 'herpes simplex virus 1 HSV-1', 'Human herpes simplex virus type 1', 'Human herpes simplex virus type 1', 'HSV-1', 'HSV-1', 'HSV-1', '1 hsv', 'hsv 1', 'hsv-1', 'HSV 1', 'HHV-1', 'hhv-1', 'human alphaherpesvirus 1', 'herpes simplex i', 'herpes simplex i', 'hsv i', 'hsv i', 'herpes simplex virus type-1 HSV-1', 'herpes simplex virus type 1 HSV-1', 'herpes simplex virus HSV-1', 'herpes simplex virus type 1 HSV1', 'Human herpesvirus type 1', 'Human herpes simplex virus type 1 (organism)', 'Human (alpha) herpes virus 1', 'human herpes virus 1', 'herpes virus 1, human'], 'meaning': ['The type species of SIMPLEXVIRUS causing most forms of non-genital herpes simplex in humans. Primary infection occurs mainly in infants and young children and then the virus becomes latent in the dorsal root ganglion. It then is periodically reactivated throughout life causing mostly benign conditions.', 'C0206679', 0.9199057221412659]}]}, {'ORGANISM': [{'label': 'HHV6', 'alias': ['human herpesvirus 6', 'human herpesvirus 6', 'HUMAN HERPESVIRUS 6', 'HUMAN HERPESVIRUS 6', 'Human herpesvirus 6', 'Human herpesvirus 6', 'Human herpesvirus 6', 'Human herpesvirus-6', 'Human Herpesvirus 6', 'Human Herpesvirus 6', 'HBLV', 'HBLV', 'HHV-6', 'HHV-6', 'HHV-6', 'hhv 6', 'hhv-6', 'HHV 6', 'Human B-Lymphotropic Virus', 'human B lymphotropic virus', 'B-Lymphotropic Viruses, Human', 'Human B Lymphotropic Virus', 'Human B-Lymphotropic Viruses', 'B-Lymphotropic Virus, Human', 'Roseola infantum virus', 'Roseola infantum virus', 'Roseola infantum virus', 'Exanthem subitum virus', 'Exanthem subitum virus', 'Roseola virus', 'Roseola virus', 'roseola virus', 'HHV6 - Human herpes virus 6', 'herpesvirus 6 HHV-6', 'human herpesvirus type 6 HHV-6', 'herpes simplex virus type 6', 'Human herpesvirus type 6', 'Herpesvirus type 6', 'Human herpesvirus 6 (organism)', 'Virus-HHV6', 'HHV6', 'HHV6', 'HHV6', 'HHV6', 'hhv6', 'human herpesvirus 6 HHV-6', 'Human herpes virus 6', '6 herpes human virus', 'human herpes 6 virus', 'human herpes virus 6'], 'meaning': [""The type species of ROSEOLOVIRUS isolated from patients with AIDS and other LYMPHOPROLIFERATIVE DISORDERS. It infects and replicates in fresh and established lines of hematopoietic cells and cells of neural origin. It also appears to alter NK cell activity. HHV-6; (HBLV) antibodies are elevated in patients with AIDS, Sjogren's syndrome, sarcoidosis, chronic fatigue syndrome, and certain malignancies. HHV-6 is the cause of EXANTHEMA SUBITUM and has been implicated in encephalitis."", 'C0019381', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'HHV6', 'alias': ['Human herpesvirus 6A', 'Human herpesvirus 6A', 'Human Herpesvirus 6A', 'Human herpesvirus 6A (organism)', 'HHV6A', 'HHV-6A'], 'meaning': ['Strain of HHV-6 VIRUS that is commonly seen in patients affected by MULTIPLE SCLEROSIS and other neurological diseases.', 'C0887938', 0.8223537802696228]}]}]","{'Background: Elderly SARS-CoV-2 patients are associated with higher hospitalization and mortality.': [['Background', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['associated', 'VBN', 'O'], ['hospitalization', 'NN', 'B-NP'], ['mortality', 'NN', 'B-NP']], 'Co-infection is critical in the severity of respiratory diseases.': [['Co-infection', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['severity', 'NN', 'I-NP'], ['respiratory', 'NN', 'B-NP']], 'It is largely understudied for SARS-CoV-2.': [['is', 'VBZ', 'O']], 'Methods: Between March 24th and April 27th, 2020, nasopharyngeal and oropharyngeal swabs from 3,348 patients from nursing homes and assisted living facilities in 22 states in the US were tested by Capstone Healthcare for SARS-CoV-2, 24 other respiratory viruses, and 8 respiratory bacteria.': [['nasopharyngeal', 'NN', 'B-NP'], ['oropharyngeal', 'JJ', 'B-NP'], ['swabs', 'NN', 'I-NP'], ['nursing', 'VBG', 'O'], ['assisted', 'VBD', 'O'], ['living', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['tested', 'VBN', 'O'], ['other', 'JJ', 'B-NP'], ['respiratory', 'NN', 'I-NP'], ['respiratory', 'NN', 'B-NP']], 'Total nucleic acid was extracted with MagMAXTM Viral/Pathogen Ultra nucleic acid isolation kit.': [['Total', 'JJ', 'B-NP'], ['nucleic', 'JJ', 'I-NP'], ['acid', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['extracted', 'VBN', 'O'], ['nucleic', 'JJ', 'B-NP'], ['acid', 'NN', 'I-NP'], ['isolation', 'NN', 'B-NP'], ['kit', 'NN', 'B-NP']], 'SARS-Co-V-2 was detected with the CDC 2019-novel coronavirus (2019-nCoV) diagnostic panel.': [['was', 'VBD', 'O'], ['detected', 'VBN', 'O'], ['2019-novel', 'JJ', 'B-NP'], ['coronavirus', 'NN', 'I-NP'], ['diagnostic', 'JJ', 'B-NP'], ['panel', 'NN', 'I-NP']], 'Total nucleic acid was pre-amplified before analysis for other respiratory pathogens with Taqman OpenArrayTM Respiratory Tract Microbiota Plate.': [['Total', 'JJ', 'B-NP'], ['nucleic', 'JJ', 'I-NP'], ['acid', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['analysis', 'NN', 'B-NP'], ['other', 'JJ', 'B-NP'], ['respiratory', 'NN', 'I-NP']], 'Results: Patients mean age was 76.9 years.': [['mean', 'VBP', 'O'], ['age', 'NN', 'B-NP'], ['was', 'VBD', 'O']], 'SARS-CoV-2 was detected in 1,413 patients (42.2%).': [['was', 'VBD', 'O'], ['detected', 'VBN', 'O'], ['%', 'NN', 'B-NP']], 'Among them, 1,082 (76.6%) and 737 (43.7%) patients were detected with at least one bacterium or another virus, respectively.': [['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['detected', 'VBN', 'O'], ['bacterium', 'NN', 'B-NP'], ['another', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP']], 'SARS-CoV-2-positive patients were more likely to have bacterial co-occurrences (76.6%) than SARS-CoV-2-negative patients (70.0%) (p<0.0001).': [['were', 'VBD', 'O'], ['have', 'VB', 'O'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'The most common co-occurring bacteria were Staphylococcus aureus and Klebsiella pneumonia, detected in 55.8% and 40.1% SARS-CoV-2-positive patients, respectively.': [['were', 'VBD', 'O'], ['pneumonia', 'NN', 'B-NP'], ['detected', 'VBN', 'O'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'Staphylococcus aureus was associated with SARS-CoV-2, with higher detection rates in SARS-CoV-2-positive patients (55.8%) than SARS-CoV-2-negative patients (46.2%) (p<0.0001).': [['aureus', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['associated', 'VBN', 'O'], ['detection', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'Human herpes virus 6 (HHV6) also was common and associated with SARS-CoV-2, with higher detection rates in SARS-CoV-2-positive patients (26.6%) than SARS-CoV-2-negative patients (19.1%) (p<0.0001).': [['herpes', 'VBZ', 'O'], ['virus', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['detection', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'Conclusions: SARS-CoV-2-positive patients are more likely to be positive for certain respiratory bacteria and viruses.': [['are', 'VBP', 'O'], ['be', 'VB', 'O'], ['certain', 'JJ', 'B-NP'], ['respiratory', 'NN', 'I-NP']], 'This observation may help explain high hospitalization and mortality rates in older patients.': [['This', 'DT', 'B-NP'], ['observation', 'NN', 'I-NP'], ['help', 'VB', 'O'], ['explain', 'VB', 'O'], ['high', 'JJ', 'B-NP'], ['hospitalization', 'NN', 'I-NP'], ['mortality', 'NN', 'B-NP']]}","{'Background: Elderly SARS-CoV-2 patients are associated with higher hospitalization and mortality.': [{'noun_phrase': ' Background Elderly SARS CoV-2 patients', 'noun_connectors': ['associated']}, {'noun_phrase': ' hospitalization', 'noun_connectors': ['and']}], 'Co-infection is critical in the severity of respiratory diseases.': [], 'It is largely understudied for SARS-CoV-2.': [{'noun_phrase': '', 'noun_connectors': ['largely']}], 'Methods: Between March 24th and April 27th, 2020, nasopharyngeal and oropharyngeal swabs from 3,348 patients from nursing homes and assisted living facilities in 22 states in the US were tested by Capstone Healthcare for SARS-CoV-2, 24 other respiratory viruses, and 8 respiratory bacteria.': [{'noun_phrase': ' Methods March 24th', 'noun_connectors': ['and']}, {'noun_phrase': ' 27th nasopharyngeal', 'noun_connectors': ['and']}, {'noun_phrase': ' swabs patients nursing homes', 'noun_connectors': ['and', 'assisted', 'living']}, {'noun_phrase': ' facilities states US', 'noun_connectors': ['tested']}, {'noun_phrase': ' viruses', 'noun_connectors': ['and']}], 'Total nucleic acid was extracted with MagMAXTM Viral/Pathogen Ultra nucleic acid isolation kit.': [{'noun_phrase': ' Total nucleic acid', 'noun_connectors': ['extracted', 'nucleic']}], 'SARS-Co-V-2 was detected with the CDC 2019-novel coronavirus (2019-nCoV) diagnostic panel.': [{'noun_phrase': ' SARS Co - V-2', 'noun_connectors': ['detected']}], 'Total nucleic acid was pre-amplified before analysis for other respiratory pathogens with Taqman OpenArrayTM Respiratory Tract Microbiota Plate.': [{'noun_phrase': ' Total nucleic acid', 'noun_connectors': ['pre', '-']}], 'Results: Patients mean age was 76.9 years.': [{'noun_phrase': ' Results Patients', 'noun_connectors': ['mean']}], 'SARS-CoV-2 was detected in 1,413 patients (42.2%).': [{'noun_phrase': ' SARS CoV-2', 'noun_connectors': ['detected']}], 'Among them, 1,082 (76.6%) and 737 (43.7%) patients were detected with at least one bacterium or another virus, respectively.': [{'noun_phrase': ' %', 'noun_connectors': ['and']}, {'noun_phrase': ' % patients', 'noun_connectors': ['detected', 'at', 'least']}, {'noun_phrase': ' bacterium', 'noun_connectors': ['or']}], 'SARS-CoV-2-positive patients were more likely to have bacterial co-occurrences (76.6%) than SARS-CoV-2-negative patients (70.0%) (p<0.0001).': [{'noun_phrase': ' SARS CoV-2-positive patients', 'noun_connectors': ['more']}], 'The most common co-occurring bacteria were Staphylococcus aureus and Klebsiella pneumonia, detected in 55.8% and 40.1% SARS-CoV-2-positive patients, respectively.': [{'noun_phrase': '', 'noun_connectors': ['most']}, {'noun_phrase': ' co -', 'noun_connectors': ['occurring']}, {'noun_phrase': ' bacteria Staphylococcus aureus', 'noun_connectors': ['and']}, {'noun_phrase': ' pneumonia', 'noun_connectors': ['detected']}, {'noun_phrase': ' %', 'noun_connectors': ['and']}], 'Staphylococcus aureus was associated with SARS-CoV-2, with higher detection rates in SARS-CoV-2-positive patients (55.8%) than SARS-CoV-2-negative patients (46.2%) (p<0.0001).': [{'noun_phrase': ' Staphylococcus aureus', 'noun_connectors': ['associated']}], 'Human herpes virus 6 (HHV6) also was common and associated with SARS-CoV-2, with higher detection rates in SARS-CoV-2-positive patients (26.6%) than SARS-CoV-2-negative patients (19.1%) (p<0.0001).': [{'noun_phrase': ' Human herpes', 'noun_connectors': ['virus', 'also', 'and', 'associated']}], 'Conclusions: SARS-CoV-2-positive patients are more likely to be positive for certain respiratory bacteria and viruses.': [{'noun_phrase': ' Conclusions SARS CoV-2-positive patients', 'noun_connectors': ['more']}, {'noun_phrase': ' bacteria', 'noun_connectors': ['and']}], 'This observation may help explain high hospitalization and mortality rates in older patients.': [{'noun_phrase': ' observation', 'noun_connectors': ['may', 'help', 'explain']}, {'noun_phrase': ' hospitalization', 'noun_connectors': ['and']}]}"
"[{'author_name': 'Nicholas Fabiano', 'author_inst': 'University of Ottawa'}, {'author_name': 'Zachary Hallgrimson', 'author_inst': 'University of Ottawa'}, {'author_name': 'Sakib Kazi', 'author_inst': 'University of Ottawa'}, {'author_name': 'Jean-Paul Salameh', 'author_inst': 'Ottawa Hospital Research Institute'}, {'author_name': 'Stanley Wong', 'author_inst': 'University of Ottawa'}, {'author_name': 'Abrar Kazi', 'author_inst': 'Carleton University'}, {'author_name': 'Rudy R Unni', 'author_inst': 'University of Ottawa'}, {'author_name': 'Ross Prager', 'author_inst': 'University of Ottawa'}, {'author_name': 'Matthew DF McInnes', 'author_inst': 'University of Ottawa & Ottawa Hospital Research Institute'}]",http://medrxiv.org/cgi/content/short/2020.06.22.20137505,An analysis of COVID-19 article dissemination by Twitter compared to citation rates,"Background: The COVID-19 pandemic has resulted in over 1,000,000 cases across 181 countries worldwide. The global impact of COVID-19 has resulted in a surge of related research. Researchers have turned to social media platforms, namely Twitter, to disseminate their articles. The online database Altmetric is a tool which tracks the social media metrics of articles and is complementary to traditional, citation-based metrics. Citation-based metrics may fail to portray dissemination accurately, due to the lengthy publication process. Altmetrics are not subject to this time-lag, suggesting that they may be an effective marker of research dissemination during the COVID-19 pandemic. Objectives: To assess the dissemination of COVID-19 articles as measured by Twitter dissemination, compared to traditional citation-based metrics, and determine article characteristics associated with tweet rates. Methods: COVID-19 articles obtained from LitCovid published between January 1st to March 18th, 2020 were screened for inclusion. The following article characteristics were extracted independently, in single: Topic (General Info, Mechanism, Diagnosis, Transmission, Treatment, Prevention, Case Report, and Epidemic Forecasting), open access status (open access and subscription-based), continent of corresponding author (Asia, Australia, Africa, North America, South America, and Europe), tweets, and citations. A sign test was used to compare the tweet rate and citation rate per day. A negative binomial regression analysis was conducted to evaluate the association between tweet rate and article characteristics of interest. Results: 1328 articles were included in the analysis. Tweet rates were found to be significantly higher than citation rates for COVID-19 articles, with a median tweet rate of 1.09 (IQR 6.83) tweets per day and median citation rate of 0.00 (IQR 0.00) citations per day, resulting in a median of differences of 1.09 (95% CI 0.86-1.33, P < .001). 2018 journal impact factors were positively correlated with tweet rate (P < .001). The topics Diagnosis (P = .01), Transmission (P < .001), Treatment (P = .01), and Epidemic Forecasting (P < .001) were positively correlated with tweet rate, relative to Case Report. The following continents of the corresponding author were negatively correlated with tweet rate, Africa (P < .001), Australia (P = .03), and South America (P < .001), relative to Asia. Open access journals were negatively correlated with tweet rate, relative to subscription-based journals (P < .001). Conclusions: COVID-19 articles had significantly higher tweets rates compared to citation rates. This study further identified article characteristics that are correlated with the dissemination of articles on Twitter, such as 2018 journal impact factor, continent of the corresponding author, topic, and open access status. This highlights the importance of altmetrics in periods of rapidly expanding research, such as the COVID-19 pandemic to localize highly disseminated articles. Key words: COVID-19; Coronavirus; SARS-CoV-2; Altmetric; Twitter; Tweet; LitCovid; Citation; social media; research",2020-06-25,medrxiv,9,"[{'ORGANISM': [{'label': 'Coronavirus', 'alias': ['Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'CORONAVIRUS', 'coronavirus', 'Coronaviruses', 'Coronaviruses', 'Coronaviruses', 'Coronavirus, NOS', 'coronaviruses'], 'meaning': ['A genus of the family CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.', 'C0206419', 1]}]}, {'ORGANISM': [{'label': 'Coronavirus', 'alias': ['Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'coronaviridae', 'CORONAVIRUS', 'Family: Coronavirus group', 'Coronavirus group', 'CORONAVIRUS GROUP', 'Coronavirus group, NOS', 'Family Coronaviridae', 'Family Coronaviridae (organism)'], 'meaning': ['Spherical RNA viruses, in the order NIDOVIRALES, infecting a wide range of animals including humans. Transmission is by fecal-oral and respiratory routes. Mechanical transmission is also common. There are two genera: CORONAVIRUS and TOROVIRUS.', 'C0010076', 1]}]}]","{'Background: The COVID-19 pandemic has resulted in over 1,000,000 cases across 181 countries worldwide.': [['Background', 'NN', 'B-NP'], ['pandemic', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['resulted', 'VBN', 'O']], 'The global impact of COVID-19 has resulted in a surge of related research.': [['The', 'DT', 'B-NP'], ['global', 'JJ', 'I-NP'], ['impact', 'NN', 'I-NP'], ['has', 'VBZ', 'O'], ['resulted', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['surge', 'NN', 'I-NP'], ['related', 'JJ', 'B-NP'], ['research', 'NN', 'I-NP']], 'Researchers have turned to social media platforms, namely Twitter, to disseminate their articles.': [['have', 'VBP', 'O'], ['turned', 'VBN', 'O'], ['disseminate', 'VB', 'O']], 'The online database Altmetric is a tool which tracks the social media metrics of articles and is complementary to traditional, citation-based metrics.': [['The', 'DT', 'B-NP'], ['online', 'JJ', 'I-NP'], ['database', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['tool', 'NN', 'I-NP'], ['tracks', 'VBZ', 'O'], ['is', 'VBZ', 'O']], 'Citation-based metrics may fail to portray dissemination accurately, due to the lengthy publication process.': [['fail', 'VB', 'O'], ['portray', 'VB', 'O'], ['dissemination', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['lengthy', 'JJ', 'I-NP'], ['publication', 'NN', 'I-NP'], ['process', 'NN', 'B-NP']], 'Altmetrics are not subject to this time-lag, suggesting that they may be an effective marker of research dissemination during the COVID-19 pandemic.': [['are', 'VBP', 'O'], ['this', 'DT', 'B-NP'], ['time-lag', 'NN', 'I-NP'], ['suggesting', 'VBG', 'O'], ['be', 'VB', 'O'], ['an', 'DT', 'B-NP'], ['effective', 'JJ', 'I-NP'], ['marker', 'NN', 'I-NP'], ['research', 'NN', 'B-NP'], ['dissemination', 'NN', 'B-NP'], ['pandemic', 'NN', 'B-NP']], 'Objectives: To assess the dissemination of COVID-19 articles as measured by Twitter dissemination, compared to traditional citation-based metrics, and determine article characteristics associated with tweet rates.': [['assess', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['dissemination', 'NN', 'I-NP'], ['measured', 'VBN', 'O'], ['dissemination', 'NN', 'B-NP'], ['compared', 'VBN', 'O'], ['determine', 'JJ', 'B-NP'], ['article', 'NN', 'I-NP'], ['associated', 'VBN', 'O'], ['tweet', 'NN', 'B-NP']], 'Methods: COVID-19 articles obtained from LitCovid published between January 1st to March 18th, 2020 were screened for inclusion.': [['obtained', 'VBN', 'O'], ['published', 'VBD', 'O'], ['were', 'VBD', 'O'], ['screened', 'VBN', 'O'], ['inclusion', 'NN', 'B-NP']], 'The following article characteristics were extracted independently, in single: Topic (General Info, Mechanism, Diagnosis, Transmission, Treatment, Prevention, Case Report, and Epidemic Forecasting), open access status (open access and subscription-based), continent of corresponding author (Asia, Australia, Africa, North America, South America, and Europe), tweets, and citations.': [['The', 'DT', 'B-NP'], ['following', 'JJ', 'I-NP'], ['article', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['extracted', 'VBN', 'O'], ['Topic', 'NN', 'B-NP'], ['open', 'JJ', 'B-NP'], ['access', 'NN', 'I-NP'], ['status', 'NN', 'B-NP'], ['open', 'JJ', 'B-NP'], ['access', 'NN', 'I-NP'], ['continent', 'NN', 'B-NP'], ['corresponding', 'VBG', 'O'], ['author', 'NN', 'B-NP']], 'A sign test was used to compare the tweet rate and citation rate per day.': [['A', 'DT', 'B-NP'], ['sign', 'NN', 'I-NP'], ['test', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['used', 'VBN', 'O'], ['compare', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['tweet', 'NN', 'I-NP'], ['rate', 'NN', 'B-NP'], ['citation', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP'], ['day', 'NN', 'B-NP']], 'A negative binomial regression analysis was conducted to evaluate the association between tweet rate and article characteristics of interest.': [['A', 'DT', 'B-NP'], ['negative', 'JJ', 'I-NP'], ['binomial', 'JJ', 'I-NP'], ['regression', 'NN', 'I-NP'], ['analysis', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['conducted', 'VBN', 'O'], ['evaluate', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['association', 'NN', 'I-NP'], ['tweet', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP'], ['article', 'NN', 'B-NP'], ['interest', 'NN', 'B-NP']], 'Results: 1328 articles were included in the analysis.': [['were', 'VBD', 'O'], ['included', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['analysis', 'NN', 'I-NP']], 'Tweet rates were found to be significantly higher than citation rates for COVID-19 articles, with a median tweet rate of 1.09 (IQR 6.83) tweets per day and median citation rate of 0.00 (IQR 0.00) citations per day, resulting in a median of differences of 1.09 (95% CI 0.86-1.33, P < .001).': [['Tweet', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['found', 'VBN', 'O'], ['be', 'VB', 'O'], ['citation', 'NN', 'B-NP'], ['a', 'DT', 'B-NP'], ['median', 'JJ', 'I-NP'], ['tweet', 'NN', 'I-NP'], ['rate', 'NN', 'B-NP'], ['day', 'NN', 'B-NP'], ['median', 'JJ', 'B-NP'], ['citation', 'NN', 'I-NP'], ['rate', 'NN', 'B-NP'], ['day', 'NN', 'B-NP'], ['resulting', 'VBG', 'O'], ['a', 'DT', 'B-NP'], ['median', 'NN', 'I-NP'], ['%', 'NN', 'B-NP']], '2018 journal impact factors were positively correlated with tweet rate (P < .001).': [['journal', 'JJ', 'B-NP'], ['impact', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['correlated', 'VBN', 'O'], ['tweet', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP']], 'The topics Diagnosis (P = .01), Transmission (P < .001), Treatment (P = .01), and Epidemic Forecasting (P < .001) were positively correlated with tweet rate, relative to Case Report.': [['were', 'VBD', 'O'], ['correlated', 'VBN', 'O'], ['tweet', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP']], 'The following continents of the corresponding author were negatively correlated with tweet rate, Africa (P < .001), Australia (P = .03), and South America (P < .001), relative to Asia.': [['the', 'DT', 'B-NP'], ['corresponding', 'JJ', 'I-NP'], ['author', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['correlated', 'VBN', 'O'], ['tweet', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP']], 'Open access journals were negatively correlated with tweet rate, relative to subscription-based journals (P < .001).': [['Open', 'JJ', 'B-NP'], ['access', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['correlated', 'VBN', 'O'], ['tweet', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP']], 'Conclusions: COVID-19 articles had significantly higher tweets rates compared to citation rates.': [['had', 'VBD', 'O'], ['compared', 'VBN', 'O'], ['citation', 'VB', 'O']], 'This study further identified article characteristics that are correlated with the dissemination of articles on Twitter, such as 2018 journal impact factor, continent of the corresponding author, topic, and open access status.': [['This', 'DT', 'B-NP'], ['study', 'NN', 'I-NP'], ['identified', 'VBN', 'O'], ['article', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['correlated', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['dissemination', 'NN', 'I-NP'], ['journal', 'JJ', 'B-NP'], ['impact', 'NN', 'I-NP'], ['factor', 'NN', 'B-NP'], ['continent', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['corresponding', 'JJ', 'I-NP'], ['author', 'NN', 'I-NP'], ['topic', 'NN', 'B-NP'], ['open', 'JJ', 'B-NP'], ['access', 'NN', 'I-NP'], ['status', 'NN', 'B-NP']], 'This highlights the importance of altmetrics in periods of rapidly expanding research, such as the COVID-19 pandemic to localize highly disseminated articles.': [['highlights', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['importance', 'NN', 'I-NP'], ['expanding', 'VBG', 'O'], ['research', 'NN', 'B-NP'], ['pandemic', 'NN', 'B-NP'], ['localize', 'VB', 'O']], 'Key words: COVID-19; Coronavirus; SARS-CoV-2; Altmetric; Twitter; Tweet; LitCovid; Citation; social media; research': [['research', 'NN', 'B-NP']]}","{'Background: The COVID-19 pandemic has resulted in over 1,000,000 cases across 181 countries worldwide.': [{'noun_phrase': ' Background COVID-19 pandemic', 'noun_connectors': ['resulted']}], 'The global impact of COVID-19 has resulted in a surge of related research.': [{'noun_phrase': ' global impact COVID-19', 'noun_connectors': ['resulted']}], 'Researchers have turned to social media platforms, namely Twitter, to disseminate their articles.': [{'noun_phrase': ' Researchers', 'noun_connectors': ['turned']}, {'noun_phrase': ' media platforms', 'noun_connectors': ['namely', 'disseminate']}], 'The online database Altmetric is a tool which tracks the social media metrics of articles and is complementary to traditional, citation-based metrics.': [{'noun_phrase': ' online database Altmetric tool', 'noun_connectors': ['tracks']}, {'noun_phrase': ' media metrics articles', 'noun_connectors': ['and']}, {'noun_phrase': ' citation', 'noun_connectors': ['based']}], 'Citation-based metrics may fail to portray dissemination accurately, due to the lengthy publication process.': [{'noun_phrase': ' Citation', 'noun_connectors': ['based']}, {'noun_phrase': ' metrics', 'noun_connectors': ['may', 'fail', 'portray']}, {'noun_phrase': ' dissemination', 'noun_connectors': ['accurately']}], 'Altmetrics are not subject to this time-lag, suggesting that they may be an effective marker of research dissemination during the COVID-19 pandemic.': [{'noun_phrase': ' Altmetrics subject time lag', 'noun_connectors': ['suggesting', 'may']}], 'Objectives: To assess the dissemination of COVID-19 articles as measured by Twitter dissemination, compared to traditional citation-based metrics, and determine article characteristics associated with tweet rates.': [{'noun_phrase': ' Objectives', 'noun_connectors': ['assess']}, {'noun_phrase': ' dissemination COVID-19 articles', 'noun_connectors': ['measured']}, {'noun_phrase': ' Twitter dissemination', 'noun_connectors': ['compared']}, {'noun_phrase': ' citation', 'noun_connectors': ['based']}, {'noun_phrase': ' metrics', 'noun_connectors': ['and', 'determine']}, {'noun_phrase': ' article characteristics', 'noun_connectors': ['associated']}], 'Methods: COVID-19 articles obtained from LitCovid published between January 1st to March 18th, 2020 were screened for inclusion.': [{'noun_phrase': ' Methods COVID-19 articles', 'noun_connectors': ['obtained', 'published']}, {'noun_phrase': ' 1st March 18th', 'noun_connectors': ['screened']}], 'The following article characteristics were extracted independently, in single: Topic (General Info, Mechanism, Diagnosis, Transmission, Treatment, Prevention, Case Report, and Epidemic Forecasting), open access status (open access and subscription-based), continent of corresponding author (Asia, Australia, Africa, North America, South America, and Europe), tweets, and citations.': [{'noun_phrase': ' following article characteristics', 'noun_connectors': ['extracted', 'independently', 'and']}, {'noun_phrase': ' access status open access', 'noun_connectors': ['and']}, {'noun_phrase': ' subscription', 'noun_connectors': ['based']}, {'noun_phrase': ' continent', 'noun_connectors': ['corresponding']}, {'noun_phrase': ' author Asia Australia Africa North America South America', 'noun_connectors': ['and']}, {'noun_phrase': ' tweets', 'noun_connectors': ['and']}], 'A sign test was used to compare the tweet rate and citation rate per day.': [{'noun_phrase': ' sign test', 'noun_connectors': ['used', 'compare']}, {'noun_phrase': ' tweet rate', 'noun_connectors': ['and']}], 'A negative binomial regression analysis was conducted to evaluate the association between tweet rate and article characteristics of interest.': [{'noun_phrase': ' negative binomial regression analysis', 'noun_connectors': ['conducted', 'evaluate']}, {'noun_phrase': ' association tweet rate', 'noun_connectors': ['and']}], 'Results: 1328 articles were included in the analysis.': [{'noun_phrase': ' Results articles', 'noun_connectors': ['included']}], 'Tweet rates were found to be significantly higher than citation rates for COVID-19 articles, with a median tweet rate of 1.09 (IQR 6.83) tweets per day and median citation rate of 0.00 (IQR 0.00) citations per day, resulting in a median of differences of 1.09 (95% CI 0.86-1.33, P < .001).': [{'noun_phrase': ' Tweet rates', 'noun_connectors': ['found', 'significantly']}, {'noun_phrase': ' citation rates COVID-19 articles median tweet rate IQR tweets day', 'noun_connectors': ['and']}, {'noun_phrase': ' citation rate IQR citations day', 'noun_connectors': ['resulting']}], '2018 journal impact factors were positively correlated with tweet rate (P < .001).': [{'noun_phrase': ' journal impact factors', 'noun_connectors': ['positively', 'correlated']}], 'The topics Diagnosis (P = .01), Transmission (P < .001), Treatment (P = .01), and Epidemic Forecasting (P < .001) were positively correlated with tweet rate, relative to Case Report.': [{'noun_phrase': ' topics Diagnosis P = Transmission P Treatment P =', 'noun_connectors': ['and']}, {'noun_phrase': ' P', 'noun_connectors': ['positively', 'correlated']}], 'The following continents of the corresponding author were negatively correlated with tweet rate, Africa (P < .001), Australia (P = .03), and South America (P < .001), relative to Asia.': [{'noun_phrase': '', 'noun_connectors': ['following']}, {'noun_phrase': ' continents corresponding author', 'noun_connectors': ['negatively', 'correlated']}, {'noun_phrase': ' rate Africa P Australia P', 'noun_connectors': ['and']}], 'Open access journals were negatively correlated with tweet rate, relative to subscription-based journals (P < .001).': [{'noun_phrase': ' Open access journals', 'noun_connectors': ['negatively', 'correlated']}, {'noun_phrase': ' rate relative subscription', 'noun_connectors': ['based']}], 'Conclusions: COVID-19 articles had significantly higher tweets rates compared to citation rates.': [{'noun_phrase': ' Conclusions COVID-19 articles', 'noun_connectors': ['significantly']}, {'noun_phrase': ' tweets rates', 'noun_connectors': ['compared']}], 'This study further identified article characteristics that are correlated with the dissemination of articles on Twitter, such as 2018 journal impact factor, continent of the corresponding author, topic, and open access status.': [{'noun_phrase': ' study', 'noun_connectors': ['further', 'identified']}, {'noun_phrase': ' article characteristics', 'noun_connectors': ['correlated']}, {'noun_phrase': ' dissemination articles Twitter such journal impact factor continent corresponding author topic', 'noun_connectors': ['and']}], 'This highlights the importance of altmetrics in periods of rapidly expanding research, such as the COVID-19 pandemic to localize highly disseminated articles.': [{'noun_phrase': '', 'noun_connectors': ['highlights']}, {'noun_phrase': ' importance altmetrics periods', 'noun_connectors': ['rapidly', 'expanding']}, {'noun_phrase': ' research such COVID-19 pandemic', 'noun_connectors': ['localize', 'highly', 'disseminated']}], 'Key words: COVID-19; Coronavirus; SARS-CoV-2; Altmetric; Twitter; Tweet; LitCovid; Citation; social media; research': [{'noun_phrase': ' Key words COVID-19 Coronavirus SARS CoV-2 Altmetric Twitter Tweet LitCovid Citation social media research', 'noun_connectors': []}]}"
"[{'author_name': 'Amy K Feehan', 'author_inst': 'Clinical Infectious Diseases Research, Ochsner Clinic Foundation, New Orleans, LA, USA ; University of Queensland, Ochsner Clinical School, New Orleans, LA, USA'}, {'author_name': 'Daniel Fort', 'author_inst': 'Center for Outcomes and Health Services Research, Ochsner Clinic Foundation, New Orleans, LA, USA'}, {'author_name': 'Julia Garcia-Diaz', 'author_inst': 'Department of Infectious Diseases, Ochsner Clinic Foundation, New Orleans, LA, USA; University of Queensland, Ochsner Clinical School, New Orleans, LA, USA'}, {'author_name': 'Eboni Price-Haywood', 'author_inst': 'Center for Outcomes and Health Services Research, Ochsner Clinic Foundation, New Orleans, LA, USA; University of Queensland, Ochsner Clinical School, New Orlean'}, {'author_name': 'Cruz Velasco', 'author_inst': 'Center for Outcomes and Health Services Research, Ochsner Clinic Foundation, New Orleans, LA, USA'}, {'author_name': 'Eric Sapp', 'author_inst': 'Public Democracy, Arlington, VA, USA'}, {'author_name': 'Dawn Pevey', 'author_inst': 'Ochsner Health, New Orleans, LA USA'}, {'author_name': 'Leonardo Seoane', 'author_inst': 'University of Queensland, Ochsner Clinical School, New Orleans, LA, USA; Center for Outcomes and Health Services Research, Ochsner Clinic Foundation, New Orlean'}]",http://medrxiv.org/cgi/content/short/2020.06.23.20138321,"Point prevalence of SARS-CoV-2 and infection fatality rate in Orleans and Jefferson Parish, Louisiana, May 9-15, 2020","Using a novel recruitment method to reduce selection bias with paired molecular and antibody testing for SARS-CoV-2 infection, we determined point prevalence in a racially diverse municipality. Infections were highly variable by ZIP and differed by race. Overall census-weighted prevalence was 7.8% and the calculated infection fatality rate was 1.63%.",2020-06-24,medrxiv,8,"[{'GENE_OR_GENE_PRODUCT': [{'label': 'ZIP', 'alias': ['Zip Code', 'Zip code', 'ZIP code', 'ZIP'], 'meaning': ['A system designed to expedite the sorting and delivery of mail by assigning a series of numbers to each delivery area in the United States. Also used to refer to any individual delivery area code.(from the American Heritage Dictionary)', 'C1521842', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ZIP', 'alias': ['DAPK3 gene', 'ZIP', 'ZIP KINASE', 'DEATH-ASSOCIATED PROTEIN KINASE 3', 'death-associated protein kinase 3', 'DAPK3', 'DAPK3', 'ZIPK', 'ZIPK'], 'meaning': [None, 'C1413908', 1]}]}]","{'Using a novel recruitment method to reduce selection bias with paired molecular and antibody testing for SARS-CoV-2 infection, we determined point prevalence in a racially diverse municipality.': [['Using', 'VBG', 'O'], ['a', 'DT', 'B-NP'], ['novel', 'JJ', 'I-NP'], ['recruitment', 'NN', 'I-NP'], ['method', 'NN', 'B-NP'], ['reduce', 'VB', 'O'], ['selection', 'NN', 'B-NP'], ['bias', 'NN', 'B-NP'], ['testing', 'VBG', 'O'], ['infection', 'NN', 'B-NP'], ['determined', 'VBD', 'O'], ['point', 'NN', 'B-NP'], ['prevalence', 'NN', 'B-NP'], ['diverse', 'JJ', 'B-NP'], ['municipality', 'NN', 'I-NP']], 'Infections were highly variable by ZIP and differed by race.': [['were', 'VBD', 'O'], ['differed', 'VBN', 'O'], ['race', 'NN', 'B-NP']], 'Overall census-weighted prevalence was 7.8% and the calculated infection fatality rate was 1.63%.': [['Overall', 'JJ', 'B-NP'], ['census-weighted', 'JJ', 'I-NP'], ['prevalence', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['calculated', 'JJ', 'I-NP'], ['infection', 'NN', 'I-NP'], ['fatality', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['%', 'NN', 'B-NP']]}","{'Using a novel recruitment method to reduce selection bias with paired molecular and antibody testing for SARS-CoV-2 infection, we determined point prevalence in a racially diverse municipality.': [{'noun_phrase': '', 'noun_connectors': ['Using']}, {'noun_phrase': ' recruitment method', 'noun_connectors': ['reduce']}, {'noun_phrase': ' selection bias', 'noun_connectors': ['paired', 'and']}, {'noun_phrase': ' antibody testing SARS CoV-2 infection', 'noun_connectors': ['determined']}, {'noun_phrase': ' point prevalence', 'noun_connectors': ['racially']}], 'Infections were highly variable by ZIP and differed by race.': [{'noun_phrase': ' Infections', 'noun_connectors': ['highly']}, {'noun_phrase': ' ZIP', 'noun_connectors': ['and', 'differed']}], 'Overall census-weighted prevalence was 7.8% and the calculated infection fatality rate was 1.63%.': [{'noun_phrase': ' Overall census', 'noun_connectors': ['weighted']}, {'noun_phrase': ' prevalence %', 'noun_connectors': ['and']}]}"
"[{'author_name': 'Haoxuan Chen', 'author_inst': 'Peking University'}, {'author_name': 'Xiao Qi', 'author_inst': 'Center for Disease Control and Prevention of Chaoyang District of Beijing, Beijing, China.'}, {'author_name': 'Jianxin Ma', 'author_inst': 'Center for Disease Control and Prevention of Chaoyang District of Beijing, Beijing, China'}, {'author_name': 'Chunyang Zhang', 'author_inst': 'Respiratory Department of the Sixth Medical Center of PLA General Hospital'}, {'author_name': 'Huasong Feng', 'author_inst': 'Respiratory Department of the Sixth Medical Center of PLA General Hospital'}, {'author_name': 'Maosheng Yao', 'author_inst': 'Peking University'}]",http://medrxiv.org/cgi/content/short/2020.06.21.20136523,Breath-borne VOC Biomarkers for COVID-19,"Rapid diagnosis of COVID-19 is key to controlling the pandemic. Here we report the potential breath-borne volatile organic compound (VOC) biomarkers for COVID-19. Higher levels of ethyl butanoate were detected in exhaled breath of COVID-19 patients (N=10) than healthy controls/health care workers (N=21), lung cancer (LC) patients (N=7) and backgrounds. In contrast, breath-borne butyraldehyde and isopropanol (an efficient SARS-CoV-2 inactivation agent) were significantly higher for non-COVID-19 respiratory infections (URTI) (N=22) than COVID-19, HC, LC patients and backgrounds. Breath-borne isopropanol emission from COVID-19 patients varied greatly up to ~100-fold difference. COVID-19 patients had lower acetone levels than other subjects, except LC patients. The monitoring of ethyl butanoate, butyraldehyde and isopropanol could lend considerable support in rapidly screening COVID-19; and alerting the presence of COVID-19 patient in particular environments.",2020-06-24,medrxiv,6,"[{'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'CANCER': [{'label': 'lung cancer', 'alias': ['Carcinoma of lung', 'of lung carcinoma', 'CARCINOMA OF LUNG', 'CARCINOMA OF LUNG', 'CARCINOMA OF LUNG', 'Carcinoma of Lung', 'carcinoma of lung', 'LUNG CARCINOMA', 'LUNG CARCINOMA', 'CARCINOMA LUNG', 'carcinoma lungs', 'carcinoma lung', 'carcinomas lung', 'Lung Carcinoma', 'Carcinoma of the Lung', 'lung carcinoma', 'PULMONARY CARCINOMA', 'PULMONARY CARCINOMA', 'pulmonary carcinoma', 'LUNG CANCER', 'LUNG CANCER', 'Lung Cancer', 'lung cancer', 'lung cancer', 'lung cancer', 'lung cancer', 'lung cancer', 'lung cancer', 'lung cancer', 'Lung cancer', '-- Lung Cancer', 'Lung cancer, NOS', 'Cancer of Lung', 'Cancer of the Lung'], 'meaning': ['A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.', 'C0684249', 1]}]}, {'CANCER': [{'label': 'lung cancer', 'alias': ['Primary malignant neoplasm of lung', 'Lung cancer', 'Primary malignant neoplasm of lung (disorder)'], 'meaning': [None, 'C1306460', 1]}]}, {'CANCER': [{'label': 'LC', 'alias': ['Liquid Chromatography', 'Liquid Chromatography', 'Liquid Chromatography', 'chromatography liquid', 'liquid chromatography', 'liquid chromatography', 'liquid chromatography', 'Liquid chromatography', 'Chromatography, Liquid', 'Liquid chromatography measurement', 'Liquid chromatography measurement', 'Liquid chromatography measurement, NOS', 'Liquid chromatography measurement (procedure)', 'LC'], 'meaning': ['Chromatographic techniques in which the mobile phase is a liquid.', 'C0008565', 1]}]}, {'CANCER': [{'label': 'LC', 'alias': ['Saint Lucia', 'Saint Lucia', 'Saint Lucia', 'Saint Lucia', 'saint lucia', 'SAINT LUCIA', 'SAINT LUCIA', 'St. Lucia', 'St. Lucia', 'St. Lucia', 'st lucia', 'LCA', 'LCA', 'LCA', 'ST', 'St. Lucia (geographic location)', 'LC', 'LC'], 'meaning': [""An independent state in the West Indies. Its capital is Castries. It was probably discovered by Columbus in 1502 and first settled by the English in 1605. Contended for by the French and English in the 17th century, it was regarded as neutral in 1748 but changed hands many times in the wars of the 19th century. It became a self-governing state in association with Great Britain in 1967 and achieved independence in 1979. Columbus named it for the day on which he discovered it, the feast of St. Lucy, a Sicilian virgin martyr. (From Webster's New Geographical Dictionary, 1988, p1051 & Room, Brewer's Dictionary of Names, 1992, p477)"", 'C0036056', 1]}]}, {'SIMPLE_CHEMICAL': [{'label': 'isopropanol', 'alias': ['Isopropyl Alcohol', 'Isopropyl Alcohol', 'Isopropyl Alcohol', 'Isopropyl Alcohol', 'Isopropyl Alcohol', 'Isopropyl Alcohol', 'Isopropyl Alcohol', 'Isopropyl Alcohol', 'ALCOHOL,ISOPROPYL', 'ALCOHOL,ISOPROPYL', 'ALCOHOL,ISOPROPYL', 'Isopropyl alcohol', 'Isopropyl alcohol', 'Isopropyl alcohol', 'Isopropyl alcohol', 'Isopropyl alcohol', 'Isopropyl alcohol', 'isopropyl alcohol', 'isopropyl alcohol', 'isopropyl alcohol', 'isopropyl alcohol', 'ISOPROPYL ALCOHOL', 'ISOPROPYL ALCOHOL', 'ISOPROPYL ALCOHOL', 'ISOPROPYL ALCOHOL', 'ISOPROPYL ALCOHOL', 'Alcohol, Isopropyl', '2-Propanol', '2-Propanol', '2-Propanol', '2-Propanol', '2 Propanol', 'Isopropanol', 'Isopropanol', 'Isopropanol', 'Isopropanol', 'Isopropanol', 'Isopropanol', 'Isopropanol', 'isopropanol', 'isopropanol', 'isopropanol', 'Rubbing Alcohol', 'Rubbing Alcohol', 'alcohol rubbing', 'Rubbing alcohol', 'Rubbing alcohol', 'rubbing alcohol', 'rubbing alcohol', 'alcohol rub', 'Alcohol, Rubbing', 'Propan-2-ol', 'Propan-2-ol', 'Propan-2-ol (substance)', 'Isopropyl alcohol (product)', 'Isopropanolol', '2-Propanol [Chemical/Ingredient]', 'Dimethylcarbinol'], 'meaning': ['An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.', 'C0022237', 0.9999999403953552]}]}, {'CELL': [{'label': 'LC patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.7322871088981628]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 1]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Veterinary Patient', 'Patient'], 'meaning': ['A non-human animal that is a subject in a study.', 'C1705908', 1]}]}]","{'Rapid diagnosis of COVID-19 is key to controlling the pandemic.': [['Rapid', 'JJ', 'B-NP'], ['diagnosis', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['controlling', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['pandemic', 'NN', 'I-NP']], 'Here we report the potential breath-borne volatile organic compound (VOC) biomarkers for COVID-19.': [['report', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['potential', 'JJ', 'I-NP'], ['breath-borne', 'JJ', 'I-NP'], ['volatile', 'JJ', 'I-NP'], ['organic', 'JJ', 'I-NP'], ['compound', 'NN', 'I-NP']], 'Higher levels of ethyl butanoate were detected in exhaled breath of COVID-19 patients (N=10) than healthy controls/health care workers (N=21), lung cancer (LC) patients (N=7) and backgrounds.': [['ethyl', 'NN', 'B-NP'], ['butanoate', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['detected', 'VBN', 'O'], ['exhaled', 'JJ', 'B-NP'], ['breath', 'NN', 'I-NP'], ['healthy', 'JJ', 'B-NP'], ['controls/health', 'NN', 'I-NP'], ['care', 'NN', 'B-NP'], ['lung', 'JJ', 'B-NP'], ['cancer', 'NN', 'I-NP'], ['backgrounds', 'VBZ', 'O']], 'In contrast, breath-borne butyraldehyde and isopropanol (an efficient SARS-CoV-2 inactivation agent) were significantly higher for non-COVID-19 respiratory infections (URTI) (N=22) than COVID-19, HC, LC patients and backgrounds.': [['contrast', 'NN', 'B-NP'], ['breath-borne', 'JJ', 'B-NP'], ['butyraldehyde', 'NN', 'I-NP'], ['isopropanol', 'NN', 'B-NP'], ['an', 'DT', 'B-NP'], ['efficient', 'JJ', 'I-NP'], ['SARS-CoV-2', 'JJ', 'I-NP'], ['inactivation', 'NN', 'I-NP'], ['agent', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['non-COVID-19', 'JJ', 'B-NP'], ['respiratory', 'NN', 'I-NP']], 'Breath-borne isopropanol emission from COVID-19 patients varied greatly up to ~100-fold difference.': [['Breath-borne', 'JJ', 'B-NP'], ['isopropanol', 'JJ', 'I-NP'], ['emission', 'NN', 'I-NP'], ['varied', 'VBD', 'O'], ['~100-fold', 'JJ', 'B-NP'], ['difference', 'NN', 'I-NP']], 'COVID-19 patients had lower acetone levels than other subjects, except LC patients.': [['had', 'VBD', 'O'], ['acetone', 'NN', 'B-NP']], 'The monitoring of ethyl butanoate, butyraldehyde and isopropanol could lend considerable support in rapidly screening COVID-19; and alerting the presence of COVID-19 patient in particular environments.': [['The', 'DT', 'B-NP'], ['monitoring', 'NN', 'I-NP'], ['ethyl', 'JJ', 'B-NP'], ['butanoate', 'NN', 'I-NP'], ['butyraldehyde', 'NN', 'B-NP'], ['isopropanol', 'NN', 'B-NP'], ['lend', 'VB', 'O'], ['considerable', 'JJ', 'B-NP'], ['support', 'NN', 'I-NP'], ['screening', 'VBG', 'O'], ['alerting', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['presence', 'NN', 'I-NP'], ['patient', 'NN', 'B-NP']]}","{'Rapid diagnosis of COVID-19 is key to controlling the pandemic.': [{'noun_phrase': ' Rapid diagnosis COVID-19 key', 'noun_connectors': ['controlling']}], 'Here we report the potential breath-borne volatile organic compound (VOC) biomarkers for COVID-19.': [{'noun_phrase': '', 'noun_connectors': ['Here', 'report']}, {'noun_phrase': ' breath', 'noun_connectors': ['borne']}], 'Higher levels of ethyl butanoate were detected in exhaled breath of COVID-19 patients (N=10) than healthy controls/health care workers (N=21), lung cancer (LC) patients (N=7) and backgrounds.': [{'noun_phrase': ' Higher levels ethyl butanoate', 'noun_connectors': ['detected', 'exhaled']}, {'noun_phrase': ' breath COVID-19 patients N=10 healthy controls health care workers N=21 lung cancer LC patients N=7', 'noun_connectors': ['and']}], 'In contrast, breath-borne butyraldehyde and isopropanol (an efficient SARS-CoV-2 inactivation agent) were significantly higher for non-COVID-19 respiratory infections (URTI) (N=22) than COVID-19, HC, LC patients and backgrounds.': [{'noun_phrase': ' contrast breath borne butyraldehyde', 'noun_connectors': ['and']}, {'noun_phrase': ' CoV-2 inactivation agent', 'noun_connectors': ['significantly']}, {'noun_phrase': ' infections URTI N=22 COVID-19 HC LC patients', 'noun_connectors': ['and']}], 'Breath-borne isopropanol emission from COVID-19 patients varied greatly up to ~100-fold difference.': [{'noun_phrase': ' Breath borne isopropanol emission COVID-19 patients', 'noun_connectors': ['varied', 'greatly']}], 'COVID-19 patients had lower acetone levels than other subjects, except LC patients.': [], 'The monitoring of ethyl butanoate, butyraldehyde and isopropanol could lend considerable support in rapidly screening COVID-19; and alerting the presence of COVID-19 patient in particular environments.': [{'noun_phrase': ' monitoring ethyl butanoate butyraldehyde', 'noun_connectors': ['and', 'could', 'lend']}, {'noun_phrase': ' support', 'noun_connectors': ['rapidly', 'screening', 'COVID-19', 'and', 'alerting']}]}"
"[{'author_name': 'David J Baker', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Gemma L Kay', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Alp Aydin', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Thanh Le-Viet', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Steven Rudder', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Ana P Tedim', 'author_inst': 'Quadram Institute Bioscience, Grupo de Investigacion Biomedica en Sepsis - BioSepsis. Hospital Universitario Rio Hortega/Instituto de Investigacion Biomedica de'}, {'author_name': 'Anastasia Kolyva', 'author_inst': 'Quadram Institute Bioscience, Norfolk and Norwich University Hospital'}, {'author_name': 'Maria Diaz', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Leonardo de Oliveira Martins', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Nabil-Fareed Alikhan', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Lizzie Meadows', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Andrew Bell', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Ana Victoria Gutierrez', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Alexander J Trotter', 'author_inst': 'Quadram Institute Bioscience, University of East Anglia'}, {'author_name': 'Nicholas M Thomson', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Rachel Gilroy', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Luke Griffith', 'author_inst': 'University of East Anglia'}, {'author_name': 'Evelien M Adriaenssens', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Rachael Stanley', 'author_inst': 'Norfolk and Norwich University Hospital'}, {'author_name': 'Ian G Charles', 'author_inst': 'Quadram Institute Bioscience, University of East Anglia'}, {'author_name': 'Ngozi Elumogo', 'author_inst': 'Quadram Institute Bioscience, Norfolk and Norwich University Hospital'}, {'author_name': 'John Wain', 'author_inst': 'Quadram Institute Bioscience, University of East Anglia'}, {'author_name': 'Reenesh Prakash', 'author_inst': 'Norfolk and Norwich University Hospital'}, {'author_name': 'Emma Meader', 'author_inst': 'Norfolk and Norwich University Hospital'}, {'author_name': 'Alison E Mather', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Mark A Webber', 'author_inst': 'Quadram Institute Bioscience'}, {'author_name': 'Samir Dervisevic', 'author_inst': 'Norfolk and Norwich University Hospital'}, {'author_name': 'Andrew J Page', 'author_inst': 'Quadram Institute Bioscience'}]",http://biorxiv.org/cgi/content/short/2020.06.24.162156,CoronaHiT: large scale multiplexing of SARS-CoV-2 genomes using Nanopore sequencing,"The COVID-19 pandemic has spread to almost every country in the world since it started in China in late 2019. Controlling the pandemic requires a multifaceted approach including whole genome sequencing to support public health interventions at local and national levels. One of the most widely used methods for sequencing is the ARTIC protocol, a tiling PCR approach followed by Oxford Nanopore sequencing (ONT) of up to 24 samples at a time. There is a need for a higher throughput method to reduce cost per genome. Here we present CoronaHiT, a method capable of multiplexing up to 95 small genomes on a single Nanopore flowcell, which uses transposase mediated addition of adapters and PCR based addition of symmetric barcodes. We demonstrate the method using 48 and 94 SARS-CoV-2 genomes per flowcell, amplified using the ARTIC protocol, and compare performance with Illumina and ARTIC ONT sequencing. Results demonstrate that all sequencing methods produce inaccurate genomes when the RNA extract from SARS-CoV-2 positive clinical sample has a cycle threshold (Ct) >= 32. Results from set same set of 23 samples with a broad range of Cts show that the consensus genomes have >90% coverage (GISAID criteria) for 78.2% of samples for CoronaHiT-48, 73.9% for CoronaHiT-94, 78.2% for Illumina and 73.9% for ARTIC ONT, and all have the same clustering on a maximum likelihood tree. In conclusion, we demonstrate that CoronaHiT can multiplex up to 94 SARS-CoV-2 genomes per nanopore flowcell without compromising the quality of the resulting genomes while reducing library preparation complexity and significantly reducing cost. This protocol will aid the rapid expansion of SARS-CoV-2 genome sequencing globally, to help control the pandemic.",2020-06-24,biorxiv,28,"[{'ORGANISM': [{'label': 'extract', 'alias': ['Extract Dosage Form', 'Extract', 'Extract', 'Extract', 'extract', 'EXTRACT', 'EXTRACT', 'EXTRACT', 'EXTRACT', 'Extract Dose Form'], 'meaning': ['A distillate composed of active and/or inert ingredient(s) extracted from plant or animal matter, and represented in concentrated form.', 'C1705851', 0.9999998807907104]}]}, {'ORGANISM': [{'label': 'extract', 'alias': ['Extract', 'Extract (qualifier value)'], 'meaning': [None, 'C2752151', 0.9999998807907104]}]}]","{'The COVID-19 pandemic has spread to almost every country in the world since it started in China in late 2019.': [['pandemic', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['spread', 'VBN', 'O'], ['every', 'DT', 'B-NP'], ['country', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['world', 'NN', 'I-NP'], ['started', 'VBD', 'O']], 'Controlling the pandemic requires a multifaceted approach including whole genome sequencing to support public health interventions at local and national levels.': [['Controlling', 'VBG', 'O'], ['requires', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['multifaceted', 'JJ', 'I-NP'], ['approach', 'NN', 'I-NP'], ['including', 'VBG', 'O'], ['whole', 'JJ', 'B-NP'], ['genome', 'NN', 'I-NP'], ['sequencing', 'VBG', 'O'], ['support', 'VB', 'O'], ['public', 'JJ', 'B-NP'], ['health', 'NN', 'I-NP']], 'One of the most widely used methods for sequencing is the ARTIC protocol, a tiling PCR approach followed by Oxford Nanopore sequencing (ONT) of up to 24 samples at a time.': [['used', 'VBN', 'O'], ['sequencing', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['protocol', 'NN', 'B-NP'], ['a', 'DT', 'B-NP'], ['tiling', 'NN', 'I-NP'], ['approach', 'NN', 'B-NP'], ['followed', 'VBN', 'O'], ['sequencing', 'NN', 'B-NP'], ['a', 'DT', 'B-NP'], ['time', 'NN', 'I-NP']], 'There is a need for a higher throughput method to reduce cost per genome.': [['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['need', 'NN', 'I-NP'], ['throughput', 'NN', 'B-NP'], ['method', 'NN', 'B-NP'], ['reduce', 'VB', 'O'], ['cost', 'NN', 'B-NP'], ['genome', 'NN', 'B-NP']], 'Here we present CoronaHiT, a method capable of multiplexing up to 95 small genomes on a single Nanopore flowcell, which uses transposase mediated addition of adapters and PCR based addition of symmetric barcodes.': [['present', 'VBP', 'O'], ['a', 'DT', 'B-NP'], ['method', 'NN', 'I-NP'], ['multiplexing', 'VBG', 'O'], ['flowcell', 'NN', 'B-NP'], ['uses', 'VBZ', 'O'], ['transposase', 'NN', 'B-NP'], ['mediated', 'VBD', 'O'], ['addition', 'NN', 'B-NP'], ['based', 'VBN', 'O'], ['addition', 'NN', 'B-NP']], 'We demonstrate the method using 48 and 94 SARS-CoV-2 genomes per flowcell, amplified using the ARTIC protocol, and compare performance with Illumina and ARTIC ONT sequencing.': [['demonstrate', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['method', 'NN', 'I-NP'], ['using', 'VBG', 'O'], ['flowcell', 'NN', 'B-NP'], ['amplified', 'VBD', 'O'], ['using', 'VBG', 'O'], ['protocol', 'NN', 'B-NP'], ['compare', 'JJ', 'B-NP'], ['performance', 'NN', 'I-NP'], ['sequencing', 'NN', 'B-NP']], 'Results demonstrate that all sequencing methods produce inaccurate genomes when the RNA extract from SARS-CoV-2 positive clinical sample has a cycle threshold (Ct) >= 32.': [['demonstrate', 'VBP', 'O'], ['sequencing', 'VBG', 'O'], ['produce', 'VBP', 'O'], ['extract', 'NN', 'B-NP'], ['positive', 'JJ', 'B-NP'], ['clinical', 'JJ', 'I-NP'], ['sample', 'NN', 'I-NP'], ['has', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['cycle', 'NN', 'I-NP'], ['threshold', 'NN', 'B-NP'], ['>', 'VBD', 'O']], 'Results from set same set of 23 samples with a broad range of Cts show that the consensus genomes have >90% coverage (GISAID criteria) for 78.2% of samples for CoronaHiT-48, 73.9% for CoronaHiT-94, 78.2% for Illumina and 73.9% for ARTIC ONT, and all have the same clustering on a maximum likelihood tree.': [['set', 'JJ', 'B-NP'], ['same', 'JJ', 'I-NP'], ['set', 'NN', 'I-NP'], ['a', 'DT', 'B-NP'], ['broad', 'JJ', 'I-NP'], ['range', 'NN', 'I-NP'], ['show', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['consensus', 'NN', 'I-NP'], ['have', 'VBP', 'O'], ['>', 'VBN', 'O'], ['%', 'NN', 'B-NP'], ['coverage', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['have', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['same', 'JJ', 'I-NP'], ['clustering', 'NN', 'I-NP'], ['a', 'DT', 'B-NP'], ['maximum', 'JJ', 'I-NP'], ['likelihood', 'NN', 'I-NP'], ['tree', 'NN', 'B-NP']], 'In conclusion, we demonstrate that CoronaHiT can multiplex up to 94 SARS-CoV-2 genomes per nanopore flowcell without compromising the quality of the resulting genomes while reducing library preparation complexity and significantly reducing cost.': [['conclusion', 'NN', 'B-NP'], ['demonstrate', 'VBP', 'O'], ['multiplex', 'VB', 'O'], ['flowcell', 'NN', 'B-NP'], ['compromising', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['quality', 'NN', 'I-NP'], ['resulting', 'VBG', 'O'], ['reducing', 'VBG', 'O'], ['library', 'JJ', 'B-NP'], ['preparation', 'NN', 'I-NP'], ['complexity', 'NN', 'B-NP'], ['reducing', 'VBG', 'O'], ['cost', 'NN', 'B-NP']], 'This protocol will aid the rapid expansion of SARS-CoV-2 genome sequencing globally, to help control the pandemic.': [['This', 'DT', 'B-NP'], ['protocol', 'NN', 'I-NP'], ['aid', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['rapid', 'JJ', 'I-NP'], ['expansion', 'NN', 'I-NP'], ['genome', 'NN', 'B-NP'], ['sequencing', 'VBG', 'O'], ['help', 'VB', 'O'], ['control', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['pandemic', 'NN', 'I-NP']]}","{'The COVID-19 pandemic has spread to almost every country in the world since it started in China in late 2019.': [{'noun_phrase': ' COVID-19 pandemic', 'noun_connectors': ['spread', 'almost']}], 'Controlling the pandemic requires a multifaceted approach including whole genome sequencing to support public health interventions at local and national levels.': [{'noun_phrase': '', 'noun_connectors': ['Controlling']}, {'noun_phrase': ' pandemic', 'noun_connectors': ['requires', 'multifaceted']}, {'noun_phrase': ' approach', 'noun_connectors': ['including']}, {'noun_phrase': ' genome sequencing', 'noun_connectors': ['support']}, {'noun_phrase': ' health interventions local', 'noun_connectors': ['and']}], 'One of the most widely used methods for sequencing is the ARTIC protocol, a tiling PCR approach followed by Oxford Nanopore sequencing (ONT) of up to 24 samples at a time.': [{'noun_phrase': '', 'noun_connectors': ['most', 'widely', 'used']}, {'noun_phrase': ' methods sequencing ARTIC protocol', 'noun_connectors': ['tiling']}, {'noun_phrase': ' approach', 'noun_connectors': ['followed']}], 'There is a need for a higher throughput method to reduce cost per genome.': [{'noun_phrase': ' need higher throughput method', 'noun_connectors': ['reduce']}], 'Here we present CoronaHiT, a method capable of multiplexing up to 95 small genomes on a single Nanopore flowcell, which uses transposase mediated addition of adapters and PCR based addition of symmetric barcodes.': [{'noun_phrase': '', 'noun_connectors': ['Here', 'present']}, {'noun_phrase': ' method capable', 'noun_connectors': ['multiplexing']}, {'noun_phrase': ' genomes single Nanopore flowcell', 'noun_connectors': ['uses']}, {'noun_phrase': ' transposase', 'noun_connectors': ['mediated']}, {'noun_phrase': ' addition adapters', 'noun_connectors': ['and', 'based']}], 'We demonstrate the method using 48 and 94 SARS-CoV-2 genomes per flowcell, amplified using the ARTIC protocol, and compare performance with Illumina and ARTIC ONT sequencing.': [{'noun_phrase': '', 'noun_connectors': ['demonstrate']}, {'noun_phrase': ' method', 'noun_connectors': ['using', 'and']}, {'noun_phrase': ' CoV-2 genomes flowcell', 'noun_connectors': ['amplified', 'using']}, {'noun_phrase': ' protocol', 'noun_connectors': ['and', 'compare']}, {'noun_phrase': ' performance Illumina', 'noun_connectors': ['and']}], 'Results demonstrate that all sequencing methods produce inaccurate genomes when the RNA extract from SARS-CoV-2 positive clinical sample has a cycle threshold (Ct) >= 32.': [{'noun_phrase': ' Results', 'noun_connectors': ['demonstrate']}, {'noun_phrase': ' sequencing methods', 'noun_connectors': ['produce']}, {'noun_phrase': ' genomes', 'noun_connectors': ['when']}, {'noun_phrase': ' extract SARS', 'noun_connectors': ['CoV-2']}], 'Results from set same set of 23 samples with a broad range of Cts show that the consensus genomes have >90% coverage (GISAID criteria) for 78.2% of samples for CoronaHiT-48, 73.9% for CoronaHiT-94, 78.2% for Illumina and 73.9% for ARTIC ONT, and all have the same clustering on a maximum likelihood tree.': [{'noun_phrase': ' Results', 'noun_connectors': ['set']}, {'noun_phrase': ' set samples broad range Cts', 'noun_connectors': ['show']}, {'noun_phrase': ' consensus genomes % coverage GISAID criteria % samples CoronaHiT-48 % CoronaHiT-94 % Illumina', 'noun_connectors': ['and']}, {'noun_phrase': ' % ARTIC ONT', 'noun_connectors': ['and']}], 'In conclusion, we demonstrate that CoronaHiT can multiplex up to 94 SARS-CoV-2 genomes per nanopore flowcell without compromising the quality of the resulting genomes while reducing library preparation complexity and significantly reducing cost.': [{'noun_phrase': ' conclusion', 'noun_connectors': ['demonstrate', 'can', 'multiplex']}, {'noun_phrase': ' SARS CoV-2 genomes nanopore flowcell', 'noun_connectors': ['compromising']}, {'noun_phrase': ' quality', 'noun_connectors': ['resulting']}, {'noun_phrase': ' genomes', 'noun_connectors': ['reducing']}, {'noun_phrase': ' library preparation complexity', 'noun_connectors': ['and', 'significantly', 'reducing']}], 'This protocol will aid the rapid expansion of SARS-CoV-2 genome sequencing globally, to help control the pandemic.': [{'noun_phrase': ' protocol', 'noun_connectors': ['will', 'aid']}, {'noun_phrase': ' expansion SARS CoV-2 genome sequencing', 'noun_connectors': ['globally', 'help', 'control']}]}"
"[{'author_name': 'Carolina Lucas', 'author_inst': 'Yale University'}, {'author_name': 'Patrick Wong', 'author_inst': 'Yale University'}, {'author_name': 'Jon Klein', 'author_inst': 'Yale University'}, {'author_name': 'Tiago Castro', 'author_inst': 'Rockefeller University'}, {'author_name': 'Julio Silva', 'author_inst': 'Yale University'}, {'author_name': 'Maria Sundaram', 'author_inst': 'Emory University'}, {'author_name': 'Mallory Ellingson', 'author_inst': 'Yale University'}, {'author_name': 'Tianyang Mao', 'author_inst': 'Yale University'}, {'author_name': 'Jieun Oh', 'author_inst': 'Yale University'}, {'author_name': 'Benjamin Israelow', 'author_inst': 'Yale University'}, {'author_name': 'Maria Tokuyama', 'author_inst': 'Yale University'}, {'author_name': 'Peiwen Lu', 'author_inst': 'Yale University'}, {'author_name': 'Arvind Venkataraman', 'author_inst': 'Yale University'}, {'author_name': 'Annsea Park', 'author_inst': 'Yale University'}, {'author_name': 'Subhasis Mohanty', 'author_inst': 'Yale University'}, {'author_name': 'Haowei Wang', 'author_inst': 'Yale University'}, {'author_name': 'Anne Louise Wyllie', 'author_inst': 'Yale School of Public Health'}, {'author_name': 'Chantal B.F. Vogels', 'author_inst': 'Yale School of Public Health'}, {'author_name': 'Rebecca Earnest', 'author_inst': 'Yale University'}, {'author_name': 'Sarah Lapidus', 'author_inst': 'Yale University'}, {'author_name': 'Isabel Ott', 'author_inst': 'Yale University'}, {'author_name': 'Adam Moore', 'author_inst': 'Yale University'}, {'author_name': 'Catherine Muenker', 'author_inst': 'Yale University'}, {'author_name': 'John Fournier', 'author_inst': 'Yale University'}, {'author_name': 'Melissa Campbell', 'author_inst': 'Yale University'}, {'author_name': 'Camila Odio', 'author_inst': 'Yale University'}, {'author_name': 'Arnau Casanovas-Massana', 'author_inst': 'Yale University'}, {'author_name': '- Yale IMPACT Team', 'author_inst': ''}, {'author_name': 'Roy Herbst', 'author_inst': 'Yale University'}, {'author_name': 'Albert Shaw', 'author_inst': 'Yale University'}, {'author_name': 'Ruslan Medzhitov', 'author_inst': 'Yale University'}, {'author_name': 'Wade L Schulz', 'author_inst': 'Yale School of Medicine'}, {'author_name': 'Nathan Grubaugh', 'author_inst': 'Yale University'}, {'author_name': 'Charles Dela Cruz', 'author_inst': 'Yale University'}, {'author_name': 'Shelli Farhadian', 'author_inst': 'Yale School of Medicine'}, {'author_name': 'Albert Ko', 'author_inst': 'Yale University School of Public Health'}, {'author_name': 'Saad Omer', 'author_inst': 'Yale University'}, {'author_name': 'Akiko Iwasaki', 'author_inst': 'Yale University School of Medicine'}]",http://medrxiv.org/cgi/content/short/2020.06.23.20138289,Longitudinal immunological analyses reveal inflammatory misfiring in severe COVID-19 patients,"Recent studies have provided insights into the pathogenesis of coronavirus disease 2019 (COVID-19)1-4. Yet, longitudinal immunological correlates of disease outcome remain unclear. Here, we serially analysed immune responses in 113 COVID-19 patients with moderate (non-ICU) and severe (ICU) disease. Immune profiling revealed an overall increase in innate cell lineages with a concomitant reduction in T cell number. We identify an association between early, elevated cytokines and worse disease outcomes. Following an early increase in cytokines, COVID-19 patients with moderate disease displayed a progressive reduction in type-1 (antiviral) and type-3 (antifungal) responses. In contrast, patients with severe disease maintained these elevated responses throughout the course of disease. Moreover, severe disease was accompanied by an increase in multiple type 2 (anti-helminths) effectors including, IL-5, IL-13, IgE and eosinophils. Unsupervised clustering analysis of plasma and peripheral blood leukocyte data identified 4 immune signatures, representing (A) growth factors, (B) type-2/3 cytokines, (C) mixed type-1/2/3 cytokines, and (D) chemokines that correlated with three distinct disease trajectories of patients. The immune profile of patients who recovered with moderate disease was enriched in tissue reparative growth factor signature (A), while the profile for those with worsened disease trajectory had elevated levels of all four signatures. Thus, we identified development of a maladapted immune response profile associated with severe COVID-19 outcome and early immune signatures that correlate with divergent disease trajectories.",2020-06-24,medrxiv,38,"[{'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'CELL': [{'label': 'cell', 'alias': ['Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'cells', 'cells', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'The Cell', 'Cell, NOS', 'cell', 'cell', 'cell', 'cell', 'THE CELL', 'the cell', '{Cells}', 'Cellular', 'Cell structure', 'Cellular structures', 'Cellular structure', 'Cell Type', 'Cell Types', 'Cellula', 'Cellula', 'Set of cells', 'Set of cells', 'Cells set', 'Cell structure (cell structure)', 'Normal cell', 'Normal Cell'], 'meaning': ['The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.', 'C0007634', 1]}]}, {'CELL': [{'label': 'cell', 'alias': ['Cell'], 'meaning': ['Any small compartment.', 'C1948049', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'IL-5', 'alias': ['Recombinant Interleukin-5', 'B-Cell Growth Factor-II', 'BCGF-II', 'Eosinophil Differentiation Factor', 'IL-5', 'Interleukin 5', 'T-Cell Replacing Factor', 'Eo-CSF'], 'meaning': ['A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-5 (IL-5). Produced by T cells, IL-5 stimulates the growth, differentiation, and activation of eosinophils, and promotes the conversion of B-cells into antibody- producing cells. (NCI04)', 'C1527131', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'IL-5', 'alias': ['IL5 protein, human', 'B-Cell Growth Factor-II', 'BCGF-II', 'Eosinophil Differentiation Factor', 'IL-5', 'Interleukin-5', 'Interleukin 5', 'T-Cell Replacing Factor', 'IL5', 'Eo-CSF', 'EDF', 'TRF', 'Interleukin 5 Precursor', 'B Cell Differentiation Factor I', 'B-Cell Differentiation Factor I', 'interleukin 5 (colony-stimulating factor, eosinophil) protein, human', 'IL-5 protein, human'], 'meaning': ['One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. IL-5 is made mainly by some T lymphocytes. It causes B lymphocytes to make more antibodies and increases the number of eosinophils. IL-5 made in the laboratory is used as a biological response modifier to boost the immune system in cancer therapy. It is a type of cytokine.', 'C1702088', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'IL-13', 'alias': ['Interleukin-13', 'Interleukin-13', 'Interleukin-13', 'Interleukin-13', 'Interleukin-13', 'interleukin-13', 'interleukin-13', 'interleukin 13', 'Interleukin 13', 'Interleukin 13', 'Interleukin 13', 'Interleukin 13', 'Interleukin 13', 'Interleukin 13', 'IL-13', 'IL-13', 'IL-13', 'IL-13', 'il-13', 'IL 13', 'IL 13', 'IL13', 'IL13', 'IL13', 'IL13', 'il13', 'Interleukin 13 (substance)', 'Interleukin-13 [Chemical/Ingredient]'], 'meaning': ['A cytokine synthesized by T-LYMPHOCYTES that produces proliferation, immunoglobulin isotype switching, and immunoglobulin production by immature B-LYMPHOCYTES. It appears to play a role in regulating inflammatory and immune responses.', 'C0214743', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'IL-13', 'alias': ['IL-13', 'IL-13 binding', 'interleukin-13 binding'], 'meaning': ['Interacting selectively and non-covalently with interleukin-13. [GOC:jl]', 'C1149220', 1]}]}, {'CELL': [{'label': 'eosinophils', 'alias': ['eosinophil', 'eosinophil', 'eosinophil', 'eosinophil', 'Eosinophil', 'Eosinophil', 'Eosinophil', 'Eosinophil', 'Eosinophil', 'Eosinophil', 'Eosinophil', 'Eosinophils', 'Eosinophils', 'Eosinophils', 'Eosinophils', 'Eosinophils', 'Eosinophils', 'Eosinophils', 'Eosinophils', 'Eosinophils', 'eosinophils', 'Blood Eosinophil', 'Blood eosinophil', 'blood eosinophils', 'Marrow eosinophil', 'Eosinocyte', 'eosinocyte', 'Acidophilic Leukocyte', 'acidophilic leukocyte', 'Eosinophilic Granulocyte', 'eosinophilic granulocyte', 'Eosinophilic Leukocyte', 'eosinophilic leukocyte', 'Eosinophil, segmented (cell)', 'Eosinophil leucocyte', 'Eosinophil leukocyte', 'Eosinophil, segmented'], 'meaning': ['Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin.', 'C0014467', 1]}]}, {'CELL': [{'label': 'eosinophils', 'alias': ['Eosinophils'], 'meaning': [None, 'C1546620', 1]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'plasma', 'alias': ['Plasma', 'Plasma', 'Plasma', 'Plasma', 'Plasma', 'Plasma', 'Plasma', 'Plasma', 'Plasma', 'plasma', 'plasma', 'plasma', 'plasma', 'PLASMA', 'Plasmas', 'Blood Plasma', 'Blood Plasma', 'Blood plasma', 'Blood plasma', 'Blood plasma', 'Blood plasma', 'Blood plasma', 'blood plasma', 'blood plasma', 'blood plasma', 'Blood Plasmas', 'Plasmas, Blood', 'Plasma, Blood', 'Plasma (substance)', 'Blood plasma (product)', 'Portion of plasma'], 'meaning': ['The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.', 'C0032105', 1]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'plasma', 'alias': ['Plasma', 'Plasma'], 'meaning': [None, 'C1609077', 1]}]}, {'CELL': [{'label': 'peripheral blood leukocyte', 'alias': ['Leukocytes', 'Leukocytes', 'Leukocytes', 'Leukocytes', 'Leukocytes', 'Leukocytes', 'Leukocytes', 'Leukocytes', 'Leukocytes', 'leukocytes', 'leukocytes', 'leukocytes', 'Leukocyte', 'Leukocyte', 'Leukocyte', 'Leukocyte', 'Leukocyte', 'Leukocyte', 'Leukocyte', 'Leukocyte, NOS', 'leukocyte', 'leukocyte', 'leukocyte', 'Leucocyte', 'Leucocyte', 'leucocytes', 'leucocyte', 'Leucocytes', 'WBC', 'WBC', 'WBC', 'WBC', 'White Blood Cells', 'White Blood Cells', 'blood white cells', 'White blood cells', 'white blood cells', 'Blood Cell, White', 'White Blood Cell', 'White Blood Cell', 'White blood cell, NOS', 'White blood cell', 'White blood cell', 'blood white cell', 'bloods cells white', 'white blood cell', 'white blood cell', 'white blood cell', 'Blood Cells, White', 'WBC - White blood cell', 'white blood cell (WBC)', 'WBC (white blood cell)', 'Leukocytic', 'leukocytic', 'Blood leukocyte', 'blood leukocytes', 'Marrow leukocyte', 'Blood Corpuscles, White', 'blood corpuscles white', 'white blood corpuscle', 'Blood Corpuscle, White', 'Corpuscle, White Blood', 'White Blood Corpuscle', 'Corpuscles, White Blood', 'White Blood Corpuscles', 'White Cell', 'Leukocyte (cell)', 'cell leukocyte', 'Reticuloendothelial System, Leukocytes'], 'meaning': ['White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES).', 'C0023516', 0.8431175351142883]}]}, {'CELL': [{'label': 'peripheral blood leukocyte', 'alias': ['Peripheral blood mononuclear cell (cell)', 'Peripheral Blood Mononuclear Cells [Chemical/Ingredient]', 'Peripheral blood mononuclear cell', 'Peripheral blood mononuclear cell', 'PERIPHERAL BLOOD MONONUCLEAR CELL', 'Peripheral Blood Mononuclear Cell', 'Peripheral Blood Mononuclear Cells', 'PBMC', 'PBMC', 'Peripheral blood monocyte'], 'meaning': ['A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.', 'C1321301', 0.755481481552124]}]}, {'TISSUE': [{'label': 'tissue', 'alias': ['Body tissue', 'Body tissue', 'body tissue', 'Body Tissues', 'Body tissue, NOS', 'body tissues', 'Tissues', 'Tissues', 'Tissues', 'Tissues', 'tissues', 'tissue', 'tissue', 'tissue', 'tissue', 'Tissue, NOS', 'TISSUE', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Normal Tissue', 'Textus', 'Textus', 'Tiss', 'Body tissue structure (body structure)', 'Body tissue structure', 'Portion of tissue'], 'meaning': ['Collections of differentiated CELLS, such as EPITHELIUM; CONNECTIVE TISSUE; MUSCLES; and NERVE TISSUE. Tissues are cooperatively arranged to form organs with specialized functions such as RESPIRATION; DIGESTION; REPRODUCTION; MOVEMENT; and others.', 'C0040300', 1]}]}, {'TISSUE': [{'label': 'tissue', 'alias': ['Tissue'], 'meaning': [None, 'C1547928', 1]}]}]","{'Recent studies have provided insights into the pathogenesis of coronavirus disease 2019 (COVID-19)1-4.': [['have', 'VBP', 'O'], ['provided', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['pathogenesis', 'NN', 'I-NP'], ['coronavirus', 'NN', 'B-NP'], ['disease', 'NN', 'B-NP']], 'Yet, longitudinal immunological correlates of disease outcome remain unclear.': [['disease', 'NN', 'B-NP'], ['outcome', 'NN', 'B-NP'], ['remain', 'VBP', 'O']], 'Here, we serially analysed immune responses in 113 COVID-19 patients with moderate (non-ICU) and severe (ICU) disease.': [['analysed', 'VBD', 'O'], ['disease', 'NN', 'B-NP']], 'Immune profiling revealed an overall increase in innate cell lineages with a concomitant reduction in T cell number.': [['profiling', 'VBG', 'O'], ['revealed', 'VBD', 'O'], ['an', 'DT', 'B-NP'], ['overall', 'JJ', 'I-NP'], ['increase', 'NN', 'I-NP'], ['innate', 'JJ', 'B-NP'], ['cell', 'NN', 'I-NP'], ['lineages', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['concomitant', 'JJ', 'I-NP'], ['reduction', 'NN', 'I-NP'], ['cell', 'NN', 'B-NP'], ['number', 'NN', 'B-NP']], 'We identify an association between early, elevated cytokines and worse disease outcomes.': [['identify', 'VBP', 'O'], ['an', 'DT', 'B-NP'], ['association', 'NN', 'I-NP'], ['elevated', 'VBN', 'O'], ['disease', 'NN', 'B-NP']], 'Following an early increase in cytokines, COVID-19 patients with moderate disease displayed a progressive reduction in type-1 (antiviral) and type-3 (antifungal) responses.': [['Following', 'VBG', 'O'], ['an', 'DT', 'B-NP'], ['early', 'JJ', 'I-NP'], ['increase', 'NN', 'I-NP'], ['moderate', 'JJ', 'B-NP'], ['disease', 'NN', 'I-NP'], ['displayed', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['progressive', 'JJ', 'I-NP'], ['reduction', 'NN', 'I-NP'], ['type-1', 'NN', 'B-NP']], 'In contrast, patients with severe disease maintained these elevated responses throughout the course of disease.': [['contrast', 'NN', 'B-NP'], ['severe', 'JJ', 'B-NP'], ['disease', 'NN', 'I-NP'], ['maintained', 'VBD', 'O'], ['elevated', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['course', 'NN', 'I-NP'], ['disease', 'NN', 'B-NP']], 'Moreover, severe disease was accompanied by an increase in multiple type 2 (anti-helminths) effectors including, IL-5, IL-13, IgE and eosinophils.': [['severe', 'JJ', 'B-NP'], ['disease', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['accompanied', 'VBN', 'O'], ['an', 'DT', 'B-NP'], ['increase', 'NN', 'I-NP'], ['multiple', 'JJ', 'B-NP'], ['type', 'NN', 'I-NP'], ['including', 'VBG', 'O']], 'Unsupervised clustering analysis of plasma and peripheral blood leukocyte data identified 4 immune signatures, representing (A) growth factors, (B) type-2/3 cytokines, (C) mixed type-1/2/3 cytokines, and (D) chemokines that correlated with three distinct disease trajectories of patients.': [['Unsupervised', 'VBN', 'O'], ['clustering', 'VBG', 'O'], ['analysis', 'NN', 'B-NP'], ['plasma', 'NN', 'B-NP'], ['peripheral', 'JJ', 'B-NP'], ['blood', 'NN', 'I-NP'], ['leukocyte', 'NN', 'B-NP'], ['identified', 'VBD', 'O'], ['representing', 'VBG', 'O'], ['growth', 'NN', 'B-NP'], ['type-2/3', 'NN', 'B-NP'], ['mixed', 'VBD', 'O'], ['chemokines', 'VBZ', 'O'], ['correlated', 'VBD', 'O'], ['distinct', 'JJ', 'B-NP'], ['disease', 'NN', 'I-NP']], 'The immune profile of patients who recovered with moderate disease was enriched in tissue reparative growth factor signature (A), while the profile for those with worsened disease trajectory had elevated levels of all four signatures.': [['The', 'DT', 'B-NP'], ['immune', 'JJ', 'I-NP'], ['profile', 'NN', 'I-NP'], ['recovered', 'VBD', 'O'], ['moderate', 'JJ', 'B-NP'], ['disease', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['enriched', 'VBN', 'O'], ['tissue', 'NN', 'B-NP'], ['reparative', 'JJ', 'B-NP'], ['growth', 'NN', 'I-NP'], ['factor', 'NN', 'B-NP'], ['signature', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['profile', 'NN', 'I-NP'], ['worsened', 'JJ', 'B-NP'], ['disease', 'NN', 'I-NP'], ['trajectory', 'NN', 'B-NP'], ['had', 'VBD', 'O'], ['elevated', 'VBN', 'O']], 'Thus, we identified development of a maladapted immune response profile associated with severe COVID-19 outcome and early immune signatures that correlate with divergent disease trajectories.': [['identified', 'VBD', 'O'], ['development', 'NN', 'B-NP'], ['maladapted', 'VBN', 'O'], ['immune', 'JJ', 'B-NP'], ['response', 'NN', 'I-NP'], ['profile', 'NN', 'B-NP'], ['associated', 'VBN', 'O'], ['outcome', 'NN', 'B-NP'], ['early', 'JJ', 'B-NP'], ['immune', 'NN', 'I-NP'], ['correlate', 'VBP', 'O'], ['divergent', 'JJ', 'B-NP'], ['disease', 'NN', 'I-NP']]}","{'Recent studies have provided insights into the pathogenesis of coronavirus disease 2019 (COVID-19)1-4.': [{'noun_phrase': ' Recent studies', 'noun_connectors': ['provided']}], 'Yet, longitudinal immunological correlates of disease outcome remain unclear.': [{'noun_phrase': '', 'noun_connectors': ['Yet']}], 'Here, we serially analysed immune responses in 113 COVID-19 patients with moderate (non-ICU) and severe (ICU) disease.': [{'noun_phrase': '', 'noun_connectors': ['Here', 'serially', 'analysed']}, {'noun_phrase': ' responses COVID-19 patients moderate non - ICU', 'noun_connectors': ['and']}], 'Immune profiling revealed an overall increase in innate cell lineages with a concomitant reduction in T cell number.': [{'noun_phrase': ' Immune profiling', 'noun_connectors': ['revealed']}], 'We identify an association between early, elevated cytokines and worse disease outcomes.': [{'noun_phrase': '', 'noun_connectors': ['identify']}, {'noun_phrase': ' association early elevated cytokines', 'noun_connectors': ['and']}], 'Following an early increase in cytokines, COVID-19 patients with moderate disease displayed a progressive reduction in type-1 (antiviral) and type-3 (antifungal) responses.': [{'noun_phrase': '', 'noun_connectors': ['Following']}, {'noun_phrase': ' increase cytokines COVID-19 patients moderate disease', 'noun_connectors': ['displayed']}, {'noun_phrase': ' reduction type-1 antiviral', 'noun_connectors': ['and']}], 'In contrast, patients with severe disease maintained these elevated responses throughout the course of disease.': [{'noun_phrase': ' contrast patients severe disease', 'noun_connectors': ['maintained']}], 'Moreover, severe disease was accompanied by an increase in multiple type 2 (anti-helminths) effectors including, IL-5, IL-13, IgE and eosinophils.': [{'noun_phrase': '', 'noun_connectors': ['Moreover']}, {'noun_phrase': ' disease', 'noun_connectors': ['accompanied']}, {'noun_phrase': ' increase multiple type anti - helminths effectors', 'noun_connectors': ['including']}, {'noun_phrase': ' IgE', 'noun_connectors': ['and']}], 'Unsupervised clustering analysis of plasma and peripheral blood leukocyte data identified 4 immune signatures, representing (A) growth factors, (B) type-2/3 cytokines, (C) mixed type-1/2/3 cytokines, and (D) chemokines that correlated with three distinct disease trajectories of patients.': [{'noun_phrase': '', 'noun_connectors': ['Unsupervised', 'clustering']}, {'noun_phrase': ' analysis plasma', 'noun_connectors': ['and']}, {'noun_phrase': ' blood leukocyte data', 'noun_connectors': ['identified']}, {'noun_phrase': ' signatures', 'noun_connectors': ['representing']}, {'noun_phrase': ' growth factors B type-2/3 cytokines C mixed type-1/2/3 cytokines', 'noun_connectors': ['and']}, {'noun_phrase': ' chemokines', 'noun_connectors': ['correlated']}], 'The immune profile of patients who recovered with moderate disease was enriched in tissue reparative growth factor signature (A), while the profile for those with worsened disease trajectory had elevated levels of all four signatures.': [{'noun_phrase': ' immune profile patients', 'noun_connectors': ['recovered']}, {'noun_phrase': ' disease', 'noun_connectors': ['enriched']}, {'noun_phrase': ' tissue reparative growth factor signature A profile', 'noun_connectors': ['worsened']}, {'noun_phrase': ' disease trajectory', 'noun_connectors': ['elevated']}], 'Thus, we identified development of a maladapted immune response profile associated with severe COVID-19 outcome and early immune signatures that correlate with divergent disease trajectories.': [{'noun_phrase': '', 'noun_connectors': ['Thus', 'identified']}, {'noun_phrase': ' development maladapted immune response profile', 'noun_connectors': ['associated']}, {'noun_phrase': ' outcome', 'noun_connectors': ['and']}, {'noun_phrase': ' signatures', 'noun_connectors': ['correlate']}]}"
"[{'author_name': 'Scott E Guimond', 'author_inst': 'University of Keele'}, {'author_name': 'Courtney J Mycroft-West', 'author_inst': 'University of Keele'}, {'author_name': 'Neha S Gandhi', 'author_inst': 'University of Queensland'}, {'author_name': 'Julia A Tree', 'author_inst': 'Public Health England'}, {'author_name': 'Karen R Buttigieg', 'author_inst': 'Public Health England'}, {'author_name': 'Naomi Coombes', 'author_inst': 'Public Health England'}, {'author_name': 'Kristina Nystrom', 'author_inst': 'University of Gothenburg'}, {'author_name': 'Joanna Said', 'author_inst': 'University of Gothenburg'}, {'author_name': 'Yin Xiang Setoh', 'author_inst': 'University of Queensland'}, {'author_name': 'Alberto Amarilla', 'author_inst': 'University of Queensland'}, {'author_name': 'Naphak Modhiran', 'author_inst': 'University of Queensland'}, {'author_name': 'Du Jun Julian Sng', 'author_inst': 'University of Queensland'}, {'author_name': 'Mohit Chhabra', 'author_inst': 'University of Queensland'}, {'author_name': 'Daniel Watterson', 'author_inst': 'University of Queensland'}, {'author_name': 'Paul R Young', 'author_inst': 'University of Queensland'}, {'author_name': 'Alexander A Khromykh', 'author_inst': 'University of Queensland'}, {'author_name': 'Marcelo A Lima', 'author_inst': 'University of Keele'}, {'author_name': 'David G Fernig', 'author_inst': 'University of Liverpool'}, {'author_name': 'Dunhao Su', 'author_inst': 'University of Liverpool'}, {'author_name': 'Edwin A Yates', 'author_inst': 'University of Liverpool'}, {'author_name': 'Edward Hammond', 'author_inst': 'Zucero Ltd'}, {'author_name': 'Keith Dredge', 'author_inst': 'Zucero Ltd'}, {'author_name': 'Miles W Carroll', 'author_inst': 'Public Health England'}, {'author_name': 'Edward Trybala', 'author_inst': 'University of Gothenburg'}, {'author_name': 'Tomas Bergstrom', 'author_inst': 'University of Gothenburg'}, {'author_name': 'Vito Ferro', 'author_inst': 'University of Queensland'}, {'author_name': 'Mark A Skidmore', 'author_inst': 'University of Keele'}, {'author_name': 'Jeremy E Turnbull', 'author_inst': 'University of Liverpool'}]",http://biorxiv.org/cgi/content/short/2020.06.24.169334,"Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS-CoV-2 virus","A major global effort is currently ongoing to search for therapeutics and vaccines to treat or prevent infection by the SARS-CoV-2 virus. Repurposing existing entities is one attractive approach. The heparan sulfate mimetic pixatimod is a clinical-stage synthetic sulfated compound that is a potent inhibitor of the glycosidase heparanase, and has known anti-cancer, anti-inflammatory and also antiviral properties. Here we show that pixatimod binds directly to the SARS-CoV-2 spike protein S1 receptor binding domain (RBD) and alters its conformation. Notably, this site overlaps with the known ACE2 binding site in the S1 RBD. We find that pixatimod inhibits binding of recombinant S1 RBD to Vero cells which express the ACE2 receptor. Moreover, in assays with three different isolates of live SARS-CoV-2 virus we show that pixatimod effectively inhibits viral infection of Vero cells. Importantly, its potency is well within its safe therapeutic dose range. These data provide evidence that pixatimod is a potent antiviral agent against SARS-CoV-2. Together with its other known activities this provides a strong rationale for its clinical investigation as a new multimodal therapeutic for the current COVID-19 pandemic.",2020-06-24,biorxiv,28,"[{'CANCER': [{'label': 'anti-cancer', 'alias': ['Antineoplastic Agents', 'agents antineoplastic', 'Antineoplastic agents', 'Antineoplastic agents', 'ANTINEOPLASTIC AGENTS', 'ANTINEOPLASTIC AGENTS', 'antineoplastic agents', 'antineoplastic agents', 'Antineoplastic agent, NOS', 'agents antineoplastics', 'antineoplastic agent', 'Antineoplastic agent', 'Antineoplastic agent', 'Antineoplastic Agent', 'Antineoplastic Agent', 'Agents, Antineoplastic', 'Antineoplastic Drugs', 'Antineoplastic Drugs', 'Antineoplastic Drugs', 'antineoplastic drugs', 'Antineoplastic drug', 'antineoplastic drug', 'Drugs, Antineoplastic', 'Antineoplastics', 'Antineoplastics', 'Antineoplastics', 'antineoplastics', 'ANTINEOPLASTICS', 'ANTINEOPLASTICS', 'antineoplastic', 'antineoplastic', 'antineoplastic', 'antineoplastic', 'Antineoplastic', 'Antineoplastic', 'miscellaneous antineoplastic', 'Cancer Chemotherapy Agents', 'Agents, Cancer Chemotherapy', 'Chemotherapy Agents, Cancer', 'Chemotherapeutic Anticancer Agents', 'Agents, Chemotherapeutic Anticancer', 'Chemotherapeutic Anticancer Drug', 'Drug, Chemotherapeutic Anticancer', 'Cancer Chemotherapy Drugs', 'Chemotherapy Drugs, Cancer', 'Drugs, Cancer Chemotherapy', 'Anticancer Agents', 'Agents, Anticancer', 'anti-neoplastic agents', 'anti-neoplastic agents', 'chemotherapeutic agent', 'Antineoplastic agent (product)', 'Antineoplastic agent (substance)', '[AN000] ANTINEOPLASTICS', 'Anti-Cancer Agents', 'Anti-Tumor Agents', 'Antiproliferative Agents', 'Chemotherapeutic Agents, Neoplastic Disease', 'Tumor-Specific Treatment Agents', 'Anti-Tumor Drugs', 'Antiproliferative Drugs', 'Cancer Drug', 'Antitumor Agents', 'antitumor agent', 'Agents, Antitumor', 'Antitumor Drugs', 'Drugs, Antitumor', 'Antineoplastic Agent [TC]'], 'meaning': ['Substances that inhibit or prevent the proliferation of NEOPLASMS.', 'C0003392', 0.8335165977478027]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['ACE2 gene', 'ACE2 Gene', 'peptidyl-dipeptidase A', 'ACEH', 'Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene', 'ANGIOTENSIN I-CONVERTING ENZYME 2', 'angiotensin I converting enzyme 2', 'ACE2', 'ACE2', 'ACE2'], 'meaning': ['This gene plays a role in both proteolysis and vasodilation.', 'C1422064', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['BACE2 gene', 'BACE2 Gene', 'BETA-SITE APP-CLEAVING ENZYME 2', 'beta-site APP-cleaving enzyme 2', 'Beta-Site APP-Cleaving Enzyme 2 Gene', 'ALP56', 'ALP56', 'CEAP1', 'DRAP', 'DRAP', 'ASPARTIC-LIKE PROTEASE, 56-KD', 'DOWN SYNDROME REGION ASPARTIC PROTEASE', 'BACE2', 'BACE2', 'BACE2', 'BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2'], 'meaning': ['This gene is involved in proteolytic processing.', 'C1412728', 0.8900668025016785]}]}, {'CELL': [{'label': 'Vero cells', 'alias': ['cells vero', 'vero cells', 'Cell, Vero', 'Vero Cell', 'vero cell', 'Vero cell', 'Cells, Vero'], 'meaning': ['A CELL LINE derived from the kidney of the African green (vervet) monkey, (CERCOPITHECUS AETHIOPS) used primarily in virus replication studies and plaque assays.', 'C0042542', 1]}]}, {'CELL': [{'label': 'Vero cells', 'alias': ['Lymphocyte, Pro-B', 'Pro B Lymphocytes', 'Pro-B Lymphocyte', 'Lymphocytes, Pro-B', 'Progenitor B-Cells', 'B-Cell, Progenitor', 'Progenitor B Cells', 'Progenitor B-Cell', 'B-Cells, Progenitor', 'Progenitor B-Lymphocytes', 'B-Lymphocyte, Progenitor', 'Progenitor B Lymphocytes', 'Progenitor B-Lymphocyte', 'B-Lymphocytes, Progenitor', 'Pro-B Cells', 'Cell, Pro-B', 'Pro B Cells', 'Pro-B Cell', 'Pro-B-Cells', 'Pro-B-Cell', 'Cells, Pro-B'], 'meaning': ['Cells from the stage of B LYMPHOCYTE development where B-CELL GENE REARRANGEMENT begins. The pro-B cell stage is followed by the pre-B cell stage.', 'C1955926', 0.7530066967010498]}]}]","{'A major global effort is currently ongoing to search for therapeutics and vaccines to treat or prevent infection by the SARS-CoV-2 virus.': [['A', 'DT', 'B-NP'], ['major', 'JJ', 'I-NP'], ['global', 'JJ', 'I-NP'], ['effort', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['ongoing', 'VBG', 'O'], ['search', 'VB', 'O'], ['treat', 'VB', 'O'], ['prevent', 'VB', 'O'], ['infection', 'NN', 'B-NP'], ['virus', 'NN', 'B-NP']], 'Repurposing existing entities is one attractive approach.': [['Repurposing', 'VBG', 'O'], ['existing', 'VBG', 'O'], ['is', 'VBZ', 'O'], ['attractive', 'JJ', 'B-NP'], ['approach', 'NN', 'I-NP']], 'The heparan sulfate mimetic pixatimod is a clinical-stage synthetic sulfated compound that is a potent inhibitor of the glycosidase heparanase, and has known anti-cancer, anti-inflammatory and also antiviral properties.': [['The', 'DT', 'B-NP'], ['heparan', 'NN', 'I-NP'], ['sulfate', 'NN', 'B-NP'], ['mimetic', 'JJ', 'B-NP'], ['pixatimod', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['sulfated', 'VBN', 'O'], ['compound', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['potent', 'JJ', 'I-NP'], ['inhibitor', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['glycosidase', 'NN', 'I-NP'], ['heparanase', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['known', 'VBN', 'O']], 'Here we show that pixatimod binds directly to the SARS-CoV-2 spike protein S1 receptor binding domain (RBD) and alters its conformation.': [['show', 'VBP', 'O'], ['pixatimod', 'NN', 'B-NP'], ['binds', 'VBZ', 'O'], ['spike', 'NN', 'B-NP'], ['protein', 'NN', 'B-NP'], ['receptor', 'NN', 'B-NP'], ['binding', 'VBG', 'O'], ['domain', 'NN', 'B-NP'], ['alters', 'VBZ', 'O'], ['conformation', 'NN', 'B-NP']], 'Notably, this site overlaps with the known ACE2 binding site in the S1 RBD.': [['this', 'DT', 'B-NP'], ['site', 'NN', 'I-NP'], ['overlaps', 'VBZ', 'O'], ['known', 'VBN', 'O'], ['binding', 'VBG', 'O'], ['site', 'NN', 'B-NP']], 'We find that pixatimod inhibits binding of recombinant S1 RBD to Vero cells which express the ACE2 receptor.': [['find', 'VBP', 'O'], ['pixatimod', 'NN', 'B-NP'], ['binding', 'NN', 'B-NP'], ['express', 'VBP', 'O'], ['receptor', 'NN', 'B-NP']], 'Moreover, in assays with three different isolates of live SARS-CoV-2 virus we show that pixatimod effectively inhibits viral infection of Vero cells.': [['virus', 'NN', 'B-NP'], ['show', 'VBP', 'O'], ['pixatimod', 'NN', 'B-NP'], ['inhibits', 'VBZ', 'O'], ['viral', 'JJ', 'B-NP'], ['infection', 'NN', 'I-NP']], 'Importantly, its potency is well within its safe therapeutic dose range.': [['potency', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['safe', 'JJ', 'B-NP'], ['therapeutic', 'JJ', 'I-NP'], ['dose', 'NN', 'I-NP'], ['range', 'NN', 'B-NP']], 'These data provide evidence that pixatimod is a potent antiviral agent against SARS-CoV-2.': [['provide', 'VBP', 'O'], ['evidence', 'NN', 'B-NP'], ['pixatimod', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['potent', 'JJ', 'I-NP'], ['antiviral', 'JJ', 'I-NP'], ['agent', 'NN', 'I-NP']], 'Together with its other known activities this provides a strong rationale for its clinical investigation as a new multimodal therapeutic for the current COVID-19 pandemic.': [['provides', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['strong', 'JJ', 'I-NP'], ['rationale', 'NN', 'I-NP'], ['clinical', 'JJ', 'B-NP'], ['investigation', 'NN', 'I-NP'], ['a', 'DT', 'B-NP'], ['new', 'JJ', 'I-NP'], ['multimodal', 'NN', 'I-NP'], ['therapeutic', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['current', 'JJ', 'I-NP'], ['COVID-19', 'JJ', 'I-NP'], ['pandemic', 'NN', 'I-NP']]}","{'A major global effort is currently ongoing to search for therapeutics and vaccines to treat or prevent infection by the SARS-CoV-2 virus.': [{'noun_phrase': ' major global effort', 'noun_connectors': ['currently', 'search']}, {'noun_phrase': ' therapeutics', 'noun_connectors': ['and']}, {'noun_phrase': ' vaccines', 'noun_connectors': ['treat', 'or', 'prevent']}], 'Repurposing existing entities is one attractive approach.': [{'noun_phrase': '', 'noun_connectors': ['Repurposing', 'existing']}], 'The heparan sulfate mimetic pixatimod is a clinical-stage synthetic sulfated compound that is a potent inhibitor of the glycosidase heparanase, and has known anti-cancer, anti-inflammatory and also antiviral properties.': [{'noun_phrase': ' heparan sulfate mimetic pixatimod clinical stage synthetic sulfated compound potent inhibitor glycosidase heparanase', 'noun_connectors': ['and', 'known', 'and', 'also']}], 'Here we show that pixatimod binds directly to the SARS-CoV-2 spike protein S1 receptor binding domain (RBD) and alters its conformation.': [{'noun_phrase': '', 'noun_connectors': ['Here', 'show']}, {'noun_phrase': ' pixatimod binds', 'noun_connectors': ['directly']}, {'noun_phrase': ' CoV-2 spike protein S1 receptor', 'noun_connectors': ['binding']}, {'noun_phrase': ' domain RBD', 'noun_connectors': ['and', 'alters']}], 'Notably, this site overlaps with the known ACE2 binding site in the S1 RBD.': [{'noun_phrase': '', 'noun_connectors': ['Notably']}, {'noun_phrase': ' site', 'noun_connectors': ['overlaps', 'known', 'binding']}], 'We find that pixatimod inhibits binding of recombinant S1 RBD to Vero cells which express the ACE2 receptor.': [{'noun_phrase': '', 'noun_connectors': ['find']}, {'noun_phrase': ' pixatimod inhibits', 'noun_connectors': ['binding']}, {'noun_phrase': ' cells', 'noun_connectors': ['express']}], 'Moreover, in assays with three different isolates of live SARS-CoV-2 virus we show that pixatimod effectively inhibits viral infection of Vero cells.': [{'noun_phrase': '', 'noun_connectors': ['Moreover']}, {'noun_phrase': ' assays different isolates live SARS CoV-2 virus', 'noun_connectors': ['show', 'pixatimod', 'effectively', 'inhibits']}], 'Importantly, its potency is well within its safe therapeutic dose range.': [{'noun_phrase': '', 'noun_connectors': ['Importantly']}, {'noun_phrase': ' potency', 'noun_connectors': ['well']}], 'These data provide evidence that pixatimod is a potent antiviral agent against SARS-CoV-2.': [{'noun_phrase': ' data', 'noun_connectors': ['provide']}], 'Together with its other known activities this provides a strong rationale for its clinical investigation as a new multimodal therapeutic for the current COVID-19 pandemic.': [{'noun_phrase': '', 'noun_connectors': ['Together', 'known']}, {'noun_phrase': ' activities', 'noun_connectors': ['provides']}]}"
"[{'author_name': 'Benjamin Lopman', 'author_inst': 'Rollins School of Public Health, Emory University'}, {'author_name': 'Carol Liu', 'author_inst': 'Emory University Rollins School of Public Health'}, {'author_name': 'Adrien Le Guillou', 'author_inst': 'Emory University Rollins School of Public Health'}, {'author_name': 'Timothy L Lash', 'author_inst': 'Emory University Rollins School of Public Health'}, {'author_name': 'Alexander Isakov', 'author_inst': 'Emory University Rollins School of Public Health'}, {'author_name': 'Samuel Jenness', 'author_inst': 'Emory University Rollins School of Public Health'}]",http://medrxiv.org/cgi/content/short/2020.06.23.20138677,A model of COVID-19 transmission and control on university campuses,"In response to the COVID-19 pandemic, institutions of higher education in almost every nation closed in the first half of 2020. University administrators are now facing decisions about how to safely return students, staff and faculty to campus. To provide a framework to evaluate various strategies, we developed a susceptible-exposed-infectious-recovered (SEIR) type of deterministic compartmental transmission model of SARS-CoV-2 among students, staff and faculty. Our goals were to support the immediate pandemic planning at our own university, and to provide a flexible modeling framework to inform the planning efforts at similar academic institutions. We parameterized the model for our institution, Emory University, a medium-size private university in Atlanta, Georgia. Control strategies of isolation and quarantine are initiated by screening (regardless of symptoms) or testing (of symptomatic individuals). We explore a range of screening and testing frequencies and perform a probabilistic sensitivity analysis of input parameters. We find that monthly and weekly screening can reduce cumulative incidence by 42% and 80% in students, respectively, while testing with a 2-, 4- and 7-day delay results in an 88%, 79% and 67% reduction in cumulative incidence in students over the semester, respectively. Similar reductions are observed among staff and faculty. A testing strategy requires far fewer diagnostic assays to be implemented than a screening assay. Our intervention model is conservative in that we assume a fairly high reproductive number that is not reduced through social distancing measures. We find that community-introduction of SARS-CoV-2 infection onto campus can be controlled with effective testing, isolation, contract tracing and quarantine, but that cases, hospitalization, and (in some scenarios) deaths may still occur. In addition to estimating health impacts, this model can help to predict the resource requirements in terms of diagnostic capacity and isolation/quarantine facilities associated with different strategies.",2020-06-24,medrxiv,6,"[{'ORGANISM': [{'label': 'isolation/quarantine', 'alias': ['Quarantine', 'Quarantine', 'Quarantine', 'Quarantine', 'Quarantine', 'quarantine', 'quarantine', 'quarantine', 'Quarantines', 'isolation/quarantine', 'isolation quarantine', 'Isolation after contact with infectious disease', 'Isolation after contact with infectious disease', 'Isolation after contact with infectious disease', 'Isolation after contact with infectious disease', 'Isolation because of infection', 'Isolation of infection contact', 'Contact isolation', 'contact isolation', 'Isolation because of infection (procedure)', 'Isolation of infection contact (procedure)'], 'meaning': [""Restriction of freedom of movement of individuals who have been exposed to infectious or communicable disease in order to prevent its spread; a period of detention of vessels, vehicles, or travelers coming from infected or suspected places; and detention or isolation on account of suspected contagion. It includes government regulations on the detention of animals at frontiers or ports of entrance for the prevention of infectious disease, through a period of isolation before being allowed to enter a country. (From Dorland, 28th ed & Black's Veterinary Dictionary, 17th ed)"", 'C0034386', 1]}]}]","{'In response to the COVID-19 pandemic, institutions of higher education in almost every nation closed in the first half of 2020.': [['response', 'NN', 'B-NP'], ['pandemic', 'NN', 'B-NP'], ['education', 'NN', 'B-NP'], ['every', 'DT', 'B-NP'], ['nation', 'NN', 'I-NP'], ['closed', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['first', 'JJ', 'I-NP'], ['half', 'NN', 'I-NP']], 'University administrators are now facing decisions about how to safely return students, staff and faculty to campus.': [['are', 'VBP', 'O'], ['facing', 'VBG', 'O'], ['return', 'VB', 'O'], ['staff', 'NN', 'B-NP'], ['faculty', 'NN', 'B-NP'], ['campus', 'VB', 'O']], 'To provide a framework to evaluate various strategies, we developed a susceptible-exposed-infectious-recovered (SEIR) type of deterministic compartmental transmission model of SARS-CoV-2 among students, staff and faculty.': [['provide', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['framework', 'NN', 'I-NP'], ['evaluate', 'VB', 'O'], ['developed', 'VBD', 'O'], ['type', 'NN', 'B-NP'], ['deterministic', 'JJ', 'B-NP'], ['compartmental', 'JJ', 'I-NP'], ['transmission', 'NN', 'I-NP'], ['model', 'NN', 'B-NP'], ['staff', 'NN', 'B-NP'], ['faculty', 'NN', 'B-NP']], 'Our goals were to support the immediate pandemic planning at our own university, and to provide a flexible modeling framework to inform the planning efforts at similar academic institutions.': [['were', 'VBD', 'O'], ['support', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['immediate', 'JJ', 'I-NP'], ['pandemic', 'JJ', 'I-NP'], ['planning', 'NN', 'I-NP'], ['own', 'JJ', 'B-NP'], ['university', 'NN', 'I-NP'], ['provide', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['flexible', 'JJ', 'I-NP'], ['modeling', 'NN', 'I-NP'], ['framework', 'NN', 'B-NP'], ['inform', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['planning', 'NN', 'I-NP']], 'We parameterized the model for our institution, Emory University, a medium-size private university in Atlanta, Georgia.': [['parameterized', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['model', 'NN', 'I-NP'], ['institution', 'NN', 'B-NP'], ['a', 'DT', 'B-NP'], ['medium-size', 'JJ', 'I-NP'], ['private', 'JJ', 'I-NP'], ['university', 'NN', 'I-NP']], 'Control strategies of isolation and quarantine are initiated by screening (regardless of symptoms) or testing (of symptomatic individuals).': [['isolation', 'NN', 'B-NP'], ['quarantine', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['initiated', 'VBN', 'O'], ['screening', 'VBG', 'O'], ['regardless', 'NN', 'B-NP'], ['testing', 'VBG', 'O']], 'We explore a range of screening and testing frequencies and perform a probabilistic sensitivity analysis of input parameters.': [['explore', 'VBP', 'O'], ['a', 'DT', 'B-NP'], ['range', 'NN', 'I-NP'], ['screening', 'NN', 'B-NP'], ['testing', 'VBG', 'O'], ['perform', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['probabilistic', 'JJ', 'I-NP'], ['sensitivity', 'NN', 'I-NP'], ['analysis', 'NN', 'B-NP'], ['input', 'NN', 'B-NP']], 'We find that monthly and weekly screening can reduce cumulative incidence by 42% and 80% in students, respectively, while testing with a 2-, 4- and 7-day delay results in an 88%, 79% and 67% reduction in cumulative incidence in students over the semester, respectively.': [['find', 'VBP', 'O'], ['weekly', 'JJ', 'B-NP'], ['screening', 'NN', 'I-NP'], ['reduce', 'VB', 'O'], ['cumulative', 'JJ', 'B-NP'], ['incidence', 'NN', 'I-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['testing', 'VBG', 'O'], ['7-day', 'JJ', 'B-NP'], ['delay', 'NN', 'I-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['reduction', 'NN', 'B-NP'], ['cumulative', 'JJ', 'B-NP'], ['incidence', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['semester', 'NN', 'I-NP']], 'Similar reductions are observed among staff and faculty.': [['are', 'VBP', 'O'], ['observed', 'VBN', 'O'], ['staff', 'NN', 'B-NP'], ['faculty', 'NN', 'B-NP']], 'A testing strategy requires far fewer diagnostic assays to be implemented than a screening assay.': [['testing', 'VBG', 'O'], ['strategy', 'NN', 'B-NP'], ['requires', 'VBZ', 'O'], ['be', 'VB', 'O'], ['implemented', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['screening', 'JJ', 'I-NP'], ['assay', 'NN', 'I-NP']], 'Our intervention model is conservative in that we assume a fairly high reproductive number that is not reduced through social distancing measures.': [['intervention', 'NN', 'B-NP'], ['model', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['assume', 'VBP', 'O'], ['high', 'JJ', 'B-NP'], ['reproductive', 'JJ', 'I-NP'], ['number', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['reduced', 'VBN', 'O'], ['social', 'JJ', 'B-NP'], ['distancing', 'NN', 'I-NP']], 'We find that community-introduction of SARS-CoV-2 infection onto campus can be controlled with effective testing, isolation, contract tracing and quarantine, but that cases, hospitalization, and (in some scenarios) deaths may still occur.': [['find', 'VBP', 'O'], ['community-introduction', 'NN', 'B-NP'], ['infection', 'NN', 'B-NP'], ['campus', 'NN', 'B-NP'], ['be', 'VB', 'O'], ['controlled', 'VBN', 'O'], ['effective', 'JJ', 'B-NP'], ['testing', 'NN', 'I-NP'], ['isolation', 'NN', 'B-NP'], ['contract', 'NN', 'B-NP'], ['tracing', 'NN', 'B-NP'], ['quarantine', 'NN', 'B-NP'], ['hospitalization', 'NN', 'B-NP'], ['occur', 'VB', 'O']], 'In addition to estimating health impacts, this model can help to predict the resource requirements in terms of diagnostic capacity and isolation/quarantine facilities associated with different strategies.': [['addition', 'NN', 'B-NP'], ['estimating', 'VBG', 'O'], ['health', 'NN', 'B-NP'], ['this', 'DT', 'B-NP'], ['model', 'NN', 'I-NP'], ['help', 'VB', 'O'], ['predict', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['resource', 'NN', 'I-NP'], ['diagnostic', 'JJ', 'B-NP'], ['capacity', 'NN', 'I-NP'], ['isolation/quarantine', 'NN', 'B-NP'], ['associated', 'VBN', 'O']]}","{'In response to the COVID-19 pandemic, institutions of higher education in almost every nation closed in the first half of 2020.': [{'noun_phrase': ' response COVID-19 pandemic institutions higher education', 'noun_connectors': ['almost']}, {'noun_phrase': ' nation', 'noun_connectors': ['closed']}], 'University administrators are now facing decisions about how to safely return students, staff and faculty to campus.': [{'noun_phrase': ' University administrators', 'noun_connectors': ['now', 'facing']}, {'noun_phrase': ' decisions', 'noun_connectors': ['how', 'safely', 'return']}, {'noun_phrase': ' students staff', 'noun_connectors': ['and']}], 'To provide a framework to evaluate various strategies, we developed a susceptible-exposed-infectious-recovered (SEIR) type of deterministic compartmental transmission model of SARS-CoV-2 among students, staff and faculty.': [{'noun_phrase': '', 'noun_connectors': ['provide']}, {'noun_phrase': ' framework', 'noun_connectors': ['evaluate']}, {'noun_phrase': ' strategies', 'noun_connectors': ['developed', 'exposed']}, {'noun_phrase': ' type deterministic compartmental transmission model SARS CoV-2 students staff', 'noun_connectors': ['and']}], 'Our goals were to support the immediate pandemic planning at our own university, and to provide a flexible modeling framework to inform the planning efforts at similar academic institutions.': [{'noun_phrase': ' goals', 'noun_connectors': ['support']}, {'noun_phrase': ' planning own university', 'noun_connectors': ['and', 'provide']}, {'noun_phrase': ' modeling framework', 'noun_connectors': ['inform']}], 'We parameterized the model for our institution, Emory University, a medium-size private university in Atlanta, Georgia.': [{'noun_phrase': '', 'noun_connectors': ['parameterized']}], 'Control strategies of isolation and quarantine are initiated by screening (regardless of symptoms) or testing (of symptomatic individuals).': [{'noun_phrase': ' Control strategies isolation', 'noun_connectors': ['and']}, {'noun_phrase': ' quarantine', 'noun_connectors': ['initiated', 'screening', 'regardless']}, {'noun_phrase': ' symptoms', 'noun_connectors': ['or']}], 'We explore a range of screening and testing frequencies and perform a probabilistic sensitivity analysis of input parameters.': [{'noun_phrase': '', 'noun_connectors': ['explore']}, {'noun_phrase': ' range screening', 'noun_connectors': ['and']}, {'noun_phrase': ' testing frequencies', 'noun_connectors': ['and', 'perform']}], 'We find that monthly and weekly screening can reduce cumulative incidence by 42% and 80% in students, respectively, while testing with a 2-, 4- and 7-day delay results in an 88%, 79% and 67% reduction in cumulative incidence in students over the semester, respectively.': [{'noun_phrase': '', 'noun_connectors': ['find', 'and']}, {'noun_phrase': ' screening', 'noun_connectors': ['can', 'reduce']}, {'noun_phrase': ' incidence %', 'noun_connectors': ['and']}, {'noun_phrase': ' % students', 'noun_connectors': ['respectively', 'testing']}, {'noun_phrase': ' 2- 4-', 'noun_connectors': ['and']}, {'noun_phrase': ' delay results % %', 'noun_connectors': ['and']}], 'Similar reductions are observed among staff and faculty.': [{'noun_phrase': ' Similar reductions', 'noun_connectors': ['observed']}, {'noun_phrase': ' staff', 'noun_connectors': ['and']}], 'A testing strategy requires far fewer diagnostic assays to be implemented than a screening assay.': [{'noun_phrase': ' testing strategy', 'noun_connectors': ['requires', 'far']}, {'noun_phrase': ' assays', 'noun_connectors': ['implemented']}], 'Our intervention model is conservative in that we assume a fairly high reproductive number that is not reduced through social distancing measures.': [{'noun_phrase': ' intervention model conservative', 'noun_connectors': ['assume', 'fairly']}, {'noun_phrase': ' number', 'noun_connectors': ['reduced']}], 'We find that community-introduction of SARS-CoV-2 infection onto campus can be controlled with effective testing, isolation, contract tracing and quarantine, but that cases, hospitalization, and (in some scenarios) deaths may still occur.': [{'noun_phrase': '', 'noun_connectors': ['find']}, {'noun_phrase': ' community introduction SARS CoV-2 infection campus', 'noun_connectors': ['can', 'controlled']}, {'noun_phrase': ' testing isolation contract tracing', 'noun_connectors': ['and']}, {'noun_phrase': ' quarantine', 'noun_connectors': ['but']}, {'noun_phrase': ' cases hospitalization', 'noun_connectors': ['and']}], 'In addition to estimating health impacts, this model can help to predict the resource requirements in terms of diagnostic capacity and isolation/quarantine facilities associated with different strategies.': [{'noun_phrase': ' addition', 'noun_connectors': ['estimating']}, {'noun_phrase': ' health impacts model', 'noun_connectors': ['can', 'help', 'predict']}, {'noun_phrase': ' resource requirements terms diagnostic capacity', 'noun_connectors': ['and']}, {'noun_phrase': ' isolation quarantine facilities', 'noun_connectors': ['associated']}]}"
"[{'author_name': 'Jeremy Ratcliff', 'author_inst': 'University of Oxford'}, {'author_name': 'Dung Nguyen', 'author_inst': 'University of Oxford'}, {'author_name': 'Monique Andersson', 'author_inst': 'Oxford University Hospitals NHS Foundation Trust'}, {'author_name': 'Peter Simmonds', 'author_inst': 'Uinversity of Oxford'}]",http://biorxiv.org/cgi/content/short/2020.06.24.168013,Evaluation of Different PCR Assay Formats for Sensitive and Specific Detection of SARS-CoV-2 RNA,"Accurate identification of individuals infected with SARS-CoV-2 is crucial for efforts to control the ongoing COVID-19 pandemic. Polymerase chain reaction (PCR)-based assays are the gold standard for detecting viral RNA in patient samples and are used extensively in clinical settings. Most currently used quantitative PCR (RT-qPCRs) rely upon real-time detection of PCR product using specialized laboratory equipment. To enable the application of PCR in resource-poor or non-specialist laboratories, we have developed and evaluated a nested PCR method for SARS-CoV-2 RNA using simple agarose gel electrophoresis for product detection. Using clinical samples tested by conventional qPCR methods and RNA transcripts of defined RNA copy number, the nested PCR based on the RdRP gene demonstrated high sensitivity and specificity for SARS-CoV-2 RNA detection in clinical samples, but showed variable and transcript length-dependent sensitivity for RNA transcripts. Samples and transcripts were further evaluated in an additional N protein real-time quantitative PCR assay. As determined by 50% endpoint detection, the sensitivities of three RT-qPCRs and nested PCR methods varied substantially depending on the transcript target with no method approaching single copy detection. Overall, these findings highlight the need for assay validation and optimization and demonstrate the inability to precisely compare viral quantification from different PCR methodologies without calibration.",2020-06-24,biorxiv,4,"[{'GENE_OR_GENE_PRODUCT': [{'label': 'RdRP', 'alias': ['RNA-directed RNA polymerase activity', 'nucleoside-triphosphate:RNA nucleotidyltransferase (RNA-directed)', 'RNA nucleotidyltransferase (RNA-directed) activity', '3D polymerase activity', 'ribonucleic acid replicase activity', 'RNA-dependent RNA polymerase activity', 'RDRP', 'RNA-dependent ribonucleate nucleotidyltransferase activity', 'RNA replicase activity', 'RNA-dependent RNA replicase activity', 'ribonucleic replicase activity', 'ribonucleic acid-dependent ribonucleate nucleotidyltransferase activity', 'ribonucleic acid-dependent ribonucleic acid polymerase activity', 'Q-beta replicase activity'], 'meaning': ['Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); uses an RNA template. [EC:2.7.7.48, GOC:mah]', 'C1152412', 1]}]}]","{'Accurate identification of individuals infected with SARS-CoV-2 is crucial for efforts to control the ongoing COVID-19 pandemic.': [['identification', 'NN', 'B-NP'], ['infected', 'VBN', 'O'], ['is', 'VBZ', 'O'], ['control', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['ongoing', 'JJ', 'I-NP'], ['COVID-19', 'JJ', 'I-NP'], ['pandemic', 'NN', 'I-NP']], 'Polymerase chain reaction (PCR)-based assays are the gold standard for detecting viral RNA in patient samples and are used extensively in clinical settings.': [['chain', 'NN', 'B-NP'], ['reaction', 'NN', 'B-NP'], ['-based', 'VBD', 'O'], ['are', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['gold', 'JJ', 'I-NP'], ['standard', 'NN', 'I-NP'], ['detecting', 'VBG', 'O'], ['patient', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['used', 'VBN', 'O']], 'Most currently used quantitative PCR (RT-qPCRs) rely upon real-time detection of PCR product using specialized laboratory equipment.': [['used', 'VBN', 'O'], ['real-time', 'JJ', 'B-NP'], ['detection', 'NN', 'I-NP'], ['product', 'NN', 'B-NP'], ['using', 'VBG', 'O'], ['specialized', 'JJ', 'B-NP'], ['laboratory', 'NN', 'I-NP'], ['equipment', 'NN', 'B-NP']], 'To enable the application of PCR in resource-poor or non-specialist laboratories, we have developed and evaluated a nested PCR method for SARS-CoV-2 RNA using simple agarose gel electrophoresis for product detection.': [['enable', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['application', 'NN', 'I-NP'], ['have', 'VBP', 'O'], ['developed', 'VBN', 'O'], ['evaluated', 'VBN', 'O'], ['method', 'NN', 'B-NP'], ['using', 'VBG', 'O'], ['electrophoresis', 'NN', 'B-NP'], ['product', 'NN', 'B-NP'], ['detection', 'NN', 'B-NP']], 'Using clinical samples tested by conventional qPCR methods and RNA transcripts of defined RNA copy number, the nested PCR based on the RdRP gene demonstrated high sensitivity and specificity for SARS-CoV-2 RNA detection in clinical samples, but showed variable and transcript length-dependent sensitivity for RNA transcripts.': [['Using', 'VBG', 'O'], ['tested', 'VBN', 'O'], ['copy', 'NN', 'B-NP'], ['number', 'NN', 'B-NP'], ['nested', 'VBN', 'O'], ['based', 'VBN', 'O'], ['gene', 'NN', 'B-NP'], ['demonstrated', 'VBD', 'O'], ['high', 'JJ', 'B-NP'], ['sensitivity', 'NN', 'I-NP'], ['specificity', 'NN', 'B-NP'], ['detection', 'NN', 'B-NP'], ['showed', 'VBD', 'O'], ['transcript', 'JJ', 'B-NP'], ['length-dependent', 'JJ', 'I-NP'], ['sensitivity', 'NN', 'I-NP']], 'Samples and transcripts were further evaluated in an additional N protein real-time quantitative PCR assay.': [['were', 'VBD', 'O'], ['evaluated', 'VBN', 'O'], ['protein', 'NN', 'B-NP'], ['assay', 'NN', 'B-NP']], 'As determined by 50% endpoint detection, the sensitivities of three RT-qPCRs and nested PCR methods varied substantially depending on the transcript target with no method approaching single copy detection.': [['determined', 'VBN', 'O'], ['%', 'NN', 'B-NP'], ['endpoint', 'NN', 'B-NP'], ['detection', 'NN', 'B-NP'], ['varied', 'VBD', 'O'], ['depending', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['transcript', 'NN', 'I-NP'], ['target', 'NN', 'B-NP'], ['no', 'DT', 'B-NP'], ['method', 'NN', 'I-NP'], ['approaching', 'VBG', 'O'], ['single', 'JJ', 'B-NP'], ['copy', 'NN', 'I-NP'], ['detection', 'NN', 'B-NP']], 'Overall, these findings highlight the need for assay validation and optimization and demonstrate the inability to precisely compare viral quantification from different PCR methodologies without calibration.': [['highlight', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['need', 'NN', 'I-NP'], ['assay', 'JJ', 'B-NP'], ['validation', 'NN', 'I-NP'], ['optimization', 'NN', 'B-NP'], ['demonstrate', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['inability', 'NN', 'I-NP'], ['compare', 'VB', 'O'], ['viral', 'JJ', 'B-NP'], ['quantification', 'NN', 'I-NP'], ['calibration', 'NN', 'B-NP']]}","{'Accurate identification of individuals infected with SARS-CoV-2 is crucial for efforts to control the ongoing COVID-19 pandemic.': [{'noun_phrase': ' Accurate identification individuals', 'noun_connectors': ['infected']}], 'Polymerase chain reaction (PCR)-based assays are the gold standard for detecting viral RNA in patient samples and are used extensively in clinical settings.': [{'noun_phrase': ' Polymerase chain reaction', 'noun_connectors': ['PCR)-based']}, {'noun_phrase': ' assays gold standard', 'noun_connectors': ['detecting']}, {'noun_phrase': ' samples', 'noun_connectors': ['and', 'used', 'extensively']}], 'Most currently used quantitative PCR (RT-qPCRs) rely upon real-time detection of PCR product using specialized laboratory equipment.': [{'noun_phrase': '', 'noun_connectors': ['Most', 'currently', 'used', 'rely']}, {'noun_phrase': ' time detection PCR product', 'noun_connectors': ['using']}], 'To enable the application of PCR in resource-poor or non-specialist laboratories, we have developed and evaluated a nested PCR method for SARS-CoV-2 RNA using simple agarose gel electrophoresis for product detection.': [{'noun_phrase': '', 'noun_connectors': ['enable']}, {'noun_phrase': ' application PCR resource poor', 'noun_connectors': ['or']}, {'noun_phrase': ' laboratories', 'noun_connectors': ['developed', 'and', 'evaluated']}, {'noun_phrase': ' method SARS CoV-2 RNA', 'noun_connectors': ['using']}], 'Using clinical samples tested by conventional qPCR methods and RNA transcripts of defined RNA copy number, the nested PCR based on the RdRP gene demonstrated high sensitivity and specificity for SARS-CoV-2 RNA detection in clinical samples, but showed variable and transcript length-dependent sensitivity for RNA transcripts.': [{'noun_phrase': '', 'noun_connectors': ['Using']}, {'noun_phrase': ' samples', 'noun_connectors': ['tested']}, {'noun_phrase': ' qPCR methods', 'noun_connectors': ['and']}, {'noun_phrase': ' transcripts', 'noun_connectors': ['defined']}, {'noun_phrase': ' copy number nested PCR', 'noun_connectors': ['based']}, {'noun_phrase': ' gene', 'noun_connectors': ['demonstrated']}, {'noun_phrase': ' sensitivity', 'noun_connectors': ['and']}, {'noun_phrase': ' specificity SARS CoV-2 RNA detection clinical samples', 'noun_connectors': ['but', 'showed', 'and']}], 'Samples and transcripts were further evaluated in an additional N protein real-time quantitative PCR assay.': [{'noun_phrase': ' Samples', 'noun_connectors': ['and']}, {'noun_phrase': ' transcripts', 'noun_connectors': ['further', 'evaluated']}], 'As determined by 50% endpoint detection, the sensitivities of three RT-qPCRs and nested PCR methods varied substantially depending on the transcript target with no method approaching single copy detection.': [{'noun_phrase': '', 'noun_connectors': ['determined']}, {'noun_phrase': ' % endpoint detection sensitivities RT qPCRs', 'noun_connectors': ['and', 'nested']}, {'noun_phrase': ' methods', 'noun_connectors': ['varied', 'substantially', 'depending']}, {'noun_phrase': ' transcript target method', 'noun_connectors': ['approaching']}], 'Overall, these findings highlight the need for assay validation and optimization and demonstrate the inability to precisely compare viral quantification from different PCR methodologies without calibration.': [{'noun_phrase': '', 'noun_connectors': ['Overall']}, {'noun_phrase': ' findings', 'noun_connectors': ['highlight']}, {'noun_phrase': ' need assay validation', 'noun_connectors': ['and']}, {'noun_phrase': ' optimization', 'noun_connectors': ['and', 'demonstrate']}, {'noun_phrase': ' inability', 'noun_connectors': ['precisely', 'compare']}]}"
"[{'author_name': 'Sanjiv Jha', 'author_inst': 'Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute'}, {'author_name': 'Kiran Shetty', 'author_inst': 'Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute'}, {'author_name': 'Sonali Vadi', 'author_inst': 'Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute'}, {'author_name': 'Sourabh Phadtare', 'author_inst': 'Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute'}, {'author_name': 'Vatsal Kothari', 'author_inst': 'Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute'}, {'author_name': 'Abhijit Raut', 'author_inst': 'Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute'}, {'author_name': 'Sweta Shah', 'author_inst': 'Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute'}, {'author_name': 'Pallavi Bhargava', 'author_inst': 'Henry Ford Hospital System'}, {'author_name': 'Tanu Singhal', 'author_inst': 'Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute'}]",http://medrxiv.org/cgi/content/short/2020.06.23.20137471,Initial experience with short-course corticosteroids in a small cohort of adults with severe COVID-19 in a tertiary care hospital in India,"Abstract Severe COVID 19 disease is associated with high morbidity and mortality with limited therapeutic options. The role of glucocorticoids in treatment of COVID 19 has been riddled with controversy. The study site has been using glucocorticoids in patients with severe COVID 19 since the first few patients of COVID 19 that were admitted. In the initial cohort of 7 patients with severe COVID disease, use of methylprednisolone in a dose of 30 mg twice daily was associated with rapid improvement in oxygenation and decline in CRP levels. While six patients made a complete clinical recovery, one patient died. There were no secondary infections.",2020-06-24,medrxiv,9,"[{'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'SIMPLE_CHEMICAL': [{'label': 'methylprednisolone', 'alias': ['Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'Methylprednisolone', 'methylprednisolone', 'methylprednisolone', 'methylprednisolone', 'methylprednisolone', 'methylprednisolone', 'methylprednisolone', 'methylprednisolone', 'methylprednisolone', 'methylprednisolone', 'METHYLPREDNISOLONE', 'METHYLPREDNISOLONE', 'METHYLPREDNISOLONE', 'METHYLPREDNISOLONE', 'METHYLPREDNISOLONE', 'methylPREDNISolone', 'methylPREDNISolone', 'MethylPREDNISolone', '6-Methylprednisolone', '6-Methylprednisolone', '6 Methylprednisolone', 'Metipred', 'Metipred', 'Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-', 'Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-', '6-alpha-Methylprednisolone preparation', '6-alpha-Methylprednisolone preparation', 'Methylprednisolone preparation', 'Methylprednisolone preparation', '1-dehydro-6alpha-Methylhydrocortisone', '1-dehydro-6α-methylhydrocortisone', '6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione', 'Metilprednisolona', 'delta(1)-6alpha-Methylhydrocortisone', 'Methylprednisolon', 'Methylprednisolone preparation (product)', 'Methylprednisolone (substance)', 'MePRDL', '6Alpha-Methylprednisolone', '6Alpha-Methylprednisolone', 'Methylprednisolonum', 'Methylprednisolonum', 'Methylprednisolonum', '(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione', '(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione', '(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione', '(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione', 'Methylprednisolone [Chemical/Ingredient]'], 'meaning': ['A PREDNISOLONE derivative with similar anti-inflammatory action.', 'C0025815', 1]}]}, {'SIMPLE_CHEMICAL': [{'label': 'methylprednisolone', 'alias': ['Oral form methylprednisolone', 'oral methylprednisolone', 'methylprednisolone oral', 'Methylprednisolone Oral Product', 'methylPREDNISolone Oral Product', 'Oral form methylprednisolone (product)'], 'meaning': [None, 'C0360556', 0.9512985348701477]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'CRP', 'alias': ['CRP gene', 'CRP Gene', 'PTX1', 'PTX1', 'C-REACTIVE PROTEIN, PENTRAXIN-RELATED', 'C-reactive protein, pentraxin-related', 'C-Reactive Protein, Pentraxin-Related Gene', 'CRP', 'CRP', 'CRP', 'pentraxin 1', 'PENTRAXIN 1, SHORT'], 'meaning': ['This gene plays a role in immune and inflammatory processes.', 'C1413716', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'CRP', 'alias': ['CSRP1 gene', 'CYSTEINE-RICH PROTEIN', 'CRP1', 'CSRP', 'CSRP', 'CYSTEINE- AND GLYCINE-RICH PROTEIN 1', 'cysteine and glycine rich protein 1', 'CRP', 'D1S181E', 'CYSTEINE-RICH PROTEIN 1', 'CSRP1', 'CSRP1'], 'meaning': [None, 'C1413766', 1]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 1]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Veterinary Patient', 'Patient'], 'meaning': ['A non-human animal that is a subject in a study.', 'C1705908', 1]}]}]","{'Abstract Severe COVID 19 disease is associated with high morbidity and mortality with limited therapeutic options.': [['disease', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['associated', 'VBN', 'O'], ['high', 'JJ', 'B-NP'], ['morbidity', 'NN', 'I-NP'], ['mortality', 'NN', 'B-NP']], 'The role of glucocorticoids in treatment of COVID 19 has been riddled with controversy.': [['The', 'DT', 'B-NP'], ['role', 'NN', 'I-NP'], ['treatment', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['been', 'VBN', 'O'], ['riddled', 'VBN', 'O'], ['controversy', 'NN', 'B-NP']], 'The study site has been using glucocorticoids in patients with severe COVID 19 since the first few patients of COVID 19 that were admitted.': [['The', 'DT', 'B-NP'], ['study', 'NN', 'I-NP'], ['site', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['been', 'VBN', 'O'], ['using', 'VBG', 'O'], ['were', 'VBD', 'O'], ['admitted', 'VBN', 'O']], 'In the initial cohort of 7 patients with severe COVID disease, use of methylprednisolone in a dose of 30 mg twice daily was associated with rapid improvement in oxygenation and decline in CRP levels.': [['the', 'DT', 'B-NP'], ['initial', 'JJ', 'I-NP'], ['cohort', 'NN', 'I-NP'], ['disease', 'NN', 'B-NP'], ['use', 'NN', 'B-NP'], ['methylprednisolone', 'NN', 'B-NP'], ['a', 'DT', 'B-NP'], ['dose', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['associated', 'VBN', 'O'], ['rapid', 'JJ', 'B-NP'], ['improvement', 'NN', 'I-NP'], ['oxygenation', 'NN', 'B-NP'], ['decline', 'NN', 'B-NP']], 'While six patients made a complete clinical recovery, one patient died.': [['made', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['complete', 'JJ', 'I-NP'], ['clinical', 'JJ', 'I-NP'], ['recovery', 'NN', 'I-NP'], ['patient', 'NN', 'B-NP'], ['died', 'VBD', 'O']], 'There were no secondary infections.': [['were', 'VBD', 'O']]}","{'Abstract Severe COVID 19 disease is associated with high morbidity and mortality with limited therapeutic options.': [{'noun_phrase': ' Abstract Severe COVID disease', 'noun_connectors': ['associated']}, {'noun_phrase': ' morbidity', 'noun_connectors': ['and']}], 'The role of glucocorticoids in treatment of COVID 19 has been riddled with controversy.': [{'noun_phrase': ' role glucocorticoids treatment COVID', 'noun_connectors': ['riddled']}], 'The study site has been using glucocorticoids in patients with severe COVID 19 since the first few patients of COVID 19 that were admitted.': [{'noun_phrase': ' study site', 'noun_connectors': ['using']}], 'In the initial cohort of 7 patients with severe COVID disease, use of methylprednisolone in a dose of 30 mg twice daily was associated with rapid improvement in oxygenation and decline in CRP levels.': [{'noun_phrase': ' initial cohort patients severe COVID disease use methylprednisolone dose mg', 'noun_connectors': ['twice', 'associated']}, {'noun_phrase': ' improvement oxygenation', 'noun_connectors': ['and']}], 'While six patients made a complete clinical recovery, one patient died.': [{'noun_phrase': ' patients', 'noun_connectors': ['made']}], 'There were no secondary infections.': []}"
"[{'author_name': 'Sangappa B Chadchan', 'author_inst': 'Washington University School of Medicine'}, {'author_name': 'Vineet K Maurya', 'author_inst': 'Washington University School of Medicine'}, {'author_name': 'Pooja Popli', 'author_inst': 'Washington University School of Medicine'}, {'author_name': 'Ramakrishna Kommagani', 'author_inst': 'Washington University School of Medicine'}]",http://biorxiv.org/cgi/content/short/2020.06.23.168252,"The SARS-CoV-2 receptor, Angiotensin converting enzyme 2 (ACE2) is required for human endometrial stromal cell decidualization","STUDY QUESTION: Is SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE 2) expressed in the human endometrium during the menstrual cycle, and does it participate in endometrial decidualization? SUMMARY ANSWER: ACE2 protein is highly expressed in human endometrial stromal cells during the secretory phase and is essential for human endometrial stromal cell decidualization. WHAT IS KNOWN ALREADY: ACE2 is expressed in numerous human tissues including the lungs, heart, intestine, kidneys and placenta. ACE2 is also the receptor by which SARS-CoV-2 enters human cells. STUDY DESIGN, SIZE, DURATION: Proliferative (n = 9) and secretory (n = 6) phase endometrium biopsies from healthy reproductive-age women and primary human endometrial stromal cells from proliferative phase endometrium were used in the study. PARTICIPANTS/MATERIALS, SETTING, METHODS: ACE2 expression and localization were examined by qRT-PCR, Western blot, and immunofluorescence in both human endometrial samples and mouse uterine tissue. The effect of ACE2 knockdown on morphological and molecular changes of human endometrial stromal cell decidualization were assessed. Ovariectomized mice were treated with estrogen or progesterone to determine the effects of these hormones on ACE2 expression. MAIN RESULTS AND THE ROLE OF CHANCE: In human tissue, ACE2 protein is expressed in both endometrial epithelial and stromal cells in the proliferative phase of the menstrual cycle, and expression increases in stromal cells in the secretory phase. The ACE2 mRNA (P 0.0001) and protein abundance increased during primary human endometrial stromal cell (HESC) decidualization. HESCs transfected with ACE2-targeting siRNA were less able to decidualize than controls, as evidenced by a lack of morphology change and lower expression of the decidualization markers PRL and IGFBP1 (P 0.05). In mice during pregnancy, ACE2 protein was expressed in uterine epithelial and stromal cells increased through day six of pregnancy. Finally, progesterone induced expression of Ace2 mRNA in mouse uteri more than vehicle or estrogen (P 0.05). LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Experiments assessing the function of ACE2 in human endometrial stromal cell decidualization were in vitro. Whether SARS-CoV-2 can enter human endometrial stromal cells and affect decidualization have not been assessed. WIDER IMPLICATIONS OF THE FINDINGS: Expression of ACE2 in the endometrium allow SARS-CoV-2 to enter endometrial epithelial and stromal cells, which could impair in vivo decidualization, embryo implantation, and placentation. If so, women with COVID-19 may be at increased risk of early pregnancy loss. STUDY FUNDINGS/COMPETING INTEREST(S): This study was supported by National Institutes of Health / National Institute of Child Health and Human Development grants R01HD065435 and R00HD080742 to RK and Washington University School of Medicine start-up funds to RK. The authors declare that they have no conflicts of interest.",2020-06-24,biorxiv,4,"[{'TISSUE': [{'label': 'endometrial', 'alias': ['Endometrial', 'Endometrial', 'endometrial', 'endometrial', 'Endometrio-', 'endometrio'], 'meaning': ['Relating to or composed of endometrium.', 'C0227843', 1]}]}, {'TISSUE': [{'label': 'endometrial', 'alias': ['Endometrial Carcinoma', 'Endometrial Carcinoma', 'Endometrial Carcinoma', 'CARCINOMA ENDOMETRIAL', 'ENDOMETRIAL CARCINOMA', 'ENDOMETRIAL CARCINOMA', 'ENDOMETRIAL CARCINOMA', 'endometrial carcinoma', 'endometrial carcinoma', 'Endometrial carcinoma', 'Endometrial carcinoma', 'Endometrial carcinoma', 'ENDOMETRIAL CARCINOMA (NOS)', 'Carcinomas, Endometrial', 'Endometrial Carcinomas', 'Carcinoma, Endometrial', 'Endometrial Cancer', 'endometrial cancer', 'endometrial cancer', 'endometrial cancer', 'endometrial cancer', 'endometrial cancer', 'Endometrial cancer', 'Endometrial cancer', 'ENDOMETRIAL CANCER', 'ENDOMETRIAL CANCER', 'ENDOMETRIAL CANCER', 'ENDOMETRIAL CANCER', 'Cancers, Endometrial', 'Endometrial Cancers', 'endometrial cancers', 'Cancer, Endometrial', 'Cancer of Endometrium', 'cancer of endometrium', 'cancer of the endometrium', 'cancer of the endometrium', 'endometrium cancer', 'Endometrium--Cancer', 'Cancer of the Endometrium', 'Cancers, Endometrium', 'Endometrium Cancer', 'Endometrium Cancers', 'Cancer, Endometrium', 'UTERINE ENDOMETRIAL CANCER, CARCINOMA', 'Carcinoma of Endometrium', 'Carcinoma of Endometrium', 'Carcinoma of Endometrium', 'CARCINOMA OF ENDOMETRIUM', 'CARCINOMA OF ENDOMETRIUM', 'CARCINOMA OF ENDOMETRIUM', 'ENDOMETRIUM, CARCINOMA', 'carcinoma of the endometrium', 'carcinoma of the endometrium', 'endometrium carcinoma', 'Endometrium Carcinoma', 'Endometrium Carcinomas', 'Carcinoma of the Endometrium', 'Carcinoma of the Endometrium', 'CARCINOMA, ENDOMETRIAL, MALIGNANT', 'endometrial ca', 'endometrial ca', 'endometrium ca', 'Endometrial carcinoma (disorder)', 'uterine endometrial cancer'], 'meaning': ['A malignant tumor arising from the epithelium that lines the cavity of the uterine body. The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases. Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma. Uterine bleeding is an initial clinical sign. The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.', 'C0476089', 0.90767502784729]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['ACE2 gene', 'ACE2 Gene', 'peptidyl-dipeptidase A', 'ACEH', 'Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene', 'ANGIOTENSIN I-CONVERTING ENZYME 2', 'angiotensin I converting enzyme 2', 'ACE2', 'ACE2', 'ACE2'], 'meaning': ['This gene plays a role in both proteolysis and vasodilation.', 'C1422064', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['BACE2 gene', 'BACE2 Gene', 'BETA-SITE APP-CLEAVING ENZYME 2', 'beta-site APP-cleaving enzyme 2', 'Beta-Site APP-Cleaving Enzyme 2 Gene', 'ALP56', 'ALP56', 'CEAP1', 'DRAP', 'DRAP', 'ASPARTIC-LIKE PROTEASE, 56-KD', 'DOWN SYNDROME REGION ASPARTIC PROTEASE', 'BACE2', 'BACE2', 'BACE2', 'BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2'], 'meaning': ['This gene is involved in proteolytic processing.', 'C1412728', 0.8900668025016785]}]}, {'ORGANISM': [{'label': 'human endometrial stromal cells', 'alias': ['Endometrial stromal cell', 'Endometrial Stromal Cell'], 'meaning': ['A cell of the uterine wall immediately underling the endometrial epithelium. Endometrial stromal cells proliferate and respond to the cyclic variations of estrogen and progesterone. These cells produce growth factors and hormones that mediate the proliferative response of epithelial cells to the steroid hormones estrogen and progesterone. In response to embryo implantation, endometrial stromal cells accumulate lipid and glycogen.', 'C1516859', 0.8029298186302185]}]}, {'ORGANISM': [{'label': 'human endometrial stromal cells', 'alias': ['Structure of endometrial stroma', 'Endometrial stroma', 'Endometrial stroma', 'Endometrial stroma', 'Endometrial stroma', 'endometrial stroma', 'Endometrial Stroma', 'Structure of endometrial stroma (body structure)', 'Stroma of endometrium'], 'meaning': ['The layer of connective tissue comprised of the endometrial lining of the uterus which fluctuates in thickness throughout the menstrual cycle.', 'C0227849', 0.7085448503494263]}]}, {'ORGANISM': [{'label': 'human endometrial stromal cell', 'alias': ['Endometrial stromal cell', 'Endometrial Stromal Cell'], 'meaning': ['A cell of the uterine wall immediately underling the endometrial epithelium. Endometrial stromal cells proliferate and respond to the cyclic variations of estrogen and progesterone. These cells produce growth factors and hormones that mediate the proliferative response of epithelial cells to the steroid hormones estrogen and progesterone. In response to embryo implantation, endometrial stromal cells accumulate lipid and glycogen.', 'C1516859', 0.8904274702072144]}]}, {'ORGANISM': [{'label': 'human endometrial stromal cell', 'alias': ['Structure of endometrial stroma', 'Endometrial stroma', 'Endometrial stroma', 'Endometrial stroma', 'Endometrial stroma', 'endometrial stroma', 'Endometrial Stroma', 'Structure of endometrial stroma (body structure)', 'Stroma of endometrium'], 'meaning': ['The layer of connective tissue comprised of the endometrial lining of the uterus which fluctuates in thickness throughout the menstrual cycle.', 'C0227849', 0.7408717274665833]}]}, {'ORGANISM': [{'label': 'human tissues', 'alias': ['Human tissue', 'human tissue', 'human tissue', 'human tissues', 'humans tissues', 'Human tissue (substance)'], 'meaning': ['index on projects employing indirectly obtained normal or abnormal tissues, body fluids, excretions, cells, biochemicals, etc; sources can include eye and tissue banks, blood banks, surgically excised tissue, or postmortem tissue.', 'C0440744', 1]}]}, {'ORGANISM': [{'label': 'human tissues', 'alias': ['Body tissue', 'Body tissue', 'body tissue', 'Body Tissues', 'Body tissue, NOS', 'body tissues', 'Tissues', 'Tissues', 'Tissues', 'Tissues', 'tissues', 'tissue', 'tissue', 'tissue', 'tissue', 'Tissue, NOS', 'TISSUE', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Normal Tissue', 'Textus', 'Textus', 'Tiss', 'Body tissue structure (body structure)', 'Body tissue structure', 'Portion of tissue'], 'meaning': ['Collections of differentiated CELLS, such as EPITHELIUM; CONNECTIVE TISSUE; MUSCLES; and NERVE TISSUE. Tissues are cooperatively arranged to form organs with specialized functions such as RESPIRATION; DIGESTION; REPRODUCTION; MOVEMENT; and others.', 'C0040300', 0.7857796549797058]}]}, {'ORGAN': [{'label': 'lungs', 'alias': ['Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'lung', 'lung', 'lung', 'lung', 'LUNG', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lung, NOS', 'LUNGS', 'lungs', 'pulmonary', 'pulmonary', 'Lung structure', 'lung structure', 'lung structures', 'Pulmo', 'Pulmones', 'Set of lungs', 'Set of lungs', 'Lung structure (body structure)', 'Respiratory System, Lung', 'Pair of lungs', 'Lungs pair'], 'meaning': ['Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.', 'C0024109', 1]}]}, {'ORGAN': [{'label': 'lungs', 'alias': ['Left lung', 'Left lung', 'Left lung', 'Left lung', 'Left lung', 'Lung.left', 'LUNG, LEFT', 'Lung, Left', 'left lung', 'Left Lung', 'Left Lung', 'Left Lung', 'Left lung, NOS', 'left lungs', 'Pulmo sinister', 'Left lung structure (body structure)', 'Left lung structure'], 'meaning': ['The 2-lobed lung located on the left side of the body.', 'C0225730', 0.8583177328109741]}]}, {'ORGAN': [{'label': 'heart', 'alias': ['Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'HEART', 'HEART', 'heart', 'heart', 'heart', 'Hearts', 'Heart, NOS', 'Cardiac', 'Cardiac', 'Cardiac', 'Cardiac', 'cardiac', 'cardiac', 'cardiac', 'cardiac', 'Cardio-', 'Cardiac structure', 'cardiac structure', 'Cor', 'Heart structure', 'heart structure', 'coronary', 'cardi(o)-', 'Heart structure (body structure)'], 'meaning': ['The hollow, muscular organ that maintains the circulation of the blood.', 'C0018787', 1]}]}, {'ORGAN': [{'label': 'heart', 'alias': ['heart part', 'Heart Part', 'heart parts', 'heart component', 'Heart part (body structure)'], 'meaning': ['Any component of the organ which receives blood from the veins and ejects it into the arteries.', 'C1268110', 0.8799307346343994]}]}, {'ORGAN': [{'label': 'intestine', 'alias': ['Intestines', 'Intestines', 'Intestines', 'Intestines', 'Intestines', 'intestines', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestines, NOS', 'intestine', 'intestine', 'intestine', 'intestine', 'INTESTINE', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'bowel', 'bowel', 'Bowel, NOS', 'bowels', 'Intestinal tract', 'Intestinal tract', 'Intestinal tract', 'intestinal tract', 'Intestinal tract, NOS', 'Intestinal', 'Intestinal', 'Intestinal', 'Intestinal', 'Intestinal', 'intestinal', 'intestinal', 'Intestino-', 'Intestinal structure', 'intestinal structure', 'Gut', 'Intestinal structure (body structure)', 'Intestinal (qualifier value)'], 'meaning': ['The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE.', 'C0021853', 1]}]}, {'ORGAN': [{'label': 'intestine', 'alias': ['Intestinal Wall Tissue', 'INTESTINE'], 'meaning': ['The tissue that forms the wall of the small and large intestine. It consists of mucosa, submucosa, muscular coat, and serosal surface.', 'C1708548', 1]}]}, {'ORGAN': [{'label': 'kidneys', 'alias': ['Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'kidney', 'kidney', 'kidney', 'kidney', 'KIDNEY', 'Kidneys', 'Kidneys', 'Kidneys', 'Kidneys', 'Kidneys', 'Kidney, NOS', 'KIDNEYS', 'kidneys', 'Renal', 'Renal', 'Renal', 'Renal', 'Renal', 'renal', 'renal', 'renal', 'Reno-', 'Kidney structure', 'kidney structure', 'Ren (Nephros)', 'Renal structure', 'nephr(o)-', 'ren(o)-', 'Kidney structure (body structure)', 'Urinary System, Kidney', 'Ren', 'Nephros'], 'meaning': ['Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.', 'C0022646', 1]}]}, {'ORGAN': [{'label': 'kidneys', 'alias': ['Both kidneys', 'Both kidneys', 'Both kidneys', 'kidney', 'kidneys', 'Bilateral kidneys', 'kidneys bilateral', 'bilateral kidneys', 'bilateral kidney', 'Kidney.bilateral', 'Both kidneys (body structure)'], 'meaning': [None, 'C0227665', 1]}]}, {'TISSUE': [{'label': 'placenta', 'alias': ['Placenta'], 'meaning': [None, 'C1546742', 1]}]}, {'TISSUE': [{'label': 'placenta', 'alias': ['Placenta'], 'meaning': [None, 'C1550656', 1]}]}, {'ORGANISM': [{'label': 'human cells', 'alias': ['cells human', 'human cells', 'cell humans', 'cell human', 'cells humans', 'human cell', 'Human cells (finding)'], 'meaning': [None, 'C0427861', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'human cells', 'alias': ['Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'cells', 'cells', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'The Cell', 'Cell, NOS', 'cell', 'cell', 'cell', 'cell', 'THE CELL', 'the cell', '{Cells}', 'Cellular', 'Cell structure', 'Cellular structures', 'Cellular structure', 'Cell Type', 'Cell Types', 'Cellula', 'Cellula', 'Set of cells', 'Set of cells', 'Cells set', 'Cell structure (cell structure)', 'Normal cell', 'Normal Cell'], 'meaning': ['The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.', 'C0007634', 0.7398422360420227]}]}, {'ORGANISM': [{'label': 'women', 'alias': ['Woman', 'Woman', 'Woman', 'Woman', 'WOMAN', 'woman', 'woman', 'woman', 'Women', 'Women', 'Women', 'Women', 'women', 'women', 'women', 'female', 'Human Females', 'female humans', 'female human', 'human female', 'Girls', 'Girl', 'Woman (person)', 'adult female?'], 'meaning': ['Human females as cultural, psychological, sociological, political, and economic entities.', 'C0043210', 1]}]}, {'ORGANISM': [{'label': 'women', 'alias': ['working women', 'women working', 'Woman, Working', 'Working Woman', 'women work', 'work women', 'Working Women'], 'meaning': ['Women who are engaged in gainful activities usually outside the home.', 'C0043215', 0.7726952433586121]}]}, {'ORGANISM': [{'label': 'human endometrial samples', 'alias': ['Endometrial biopsy', 'Endometrial Biopsy', 'Endometrial Biopsy', 'endometrial biopsy', 'EB - Endometrial biopsy', 'Endometrial sampling', 'Endometrial biopsy (procedure)'], 'meaning': ['Removal of tissue from the endometrial cavity for microscopic examination.', 'C1510477', 0.7304554581642151]}]}, {'ORGANISM': [{'label': 'mice', 'alias': ['MICE gene', 'MICE', 'dJ377H14.7', 'PERB11.5', 'MHC class I polypeptide-related sequence E (pseudogene)'], 'meaning': [None, 'C1417166', 1]}]}, {'ORGANISM': [{'label': 'mice', 'alias': ['CASP14 gene', 'MICE', 'caspase 14', 'CASPASE 14, APOPTOSIS-RELATED CYSTEINE PROTEASE', 'CASP14', 'CASP14', 'MGC119079', 'MGC119078', 'apoptosis-related cysteine protease'], 'meaning': [None, 'C1413131', 1]}]}, {'SIMPLE_CHEMICAL': [{'label': 'estrogen', 'alias': ['Estrogens', 'Estrogens', 'Estrogens', 'Estrogens', 'Estrogens', 'estrogens', 'estrogens', 'ESTROGENS', 'ESTROGENS', 'ESTROGENS', 'Estrogen', 'Estrogen', 'Estrogen', 'Estrogen', 'Estrogen', 'Estrogen', 'Estrogen', 'Estrogen', 'Estrogen', 'Estrogen', 'Estrogen', 'Estrogen', 'estrogen', 'estrogen', 'estrogen', 'estrogen', 'Estrogen, NOS', 'Oestrogens', 'Oestrogen', 'Oestrogen, NOS', 'oestrogens', 'oestrogen', 'Estrogen preparation, NOS', 'Estrogen preparation', 'Oestrogen preparation, NOS', 'Estrogen product', 'Oestrogen product', 'estrogen products', 'oestrogen products', 'Estrogenic preparation', 'estrogenic preparation', 'ESTROGENIC PREPARATIONS', 'Oestrogenic preparation', 'Estrogenic drug', 'Estrogenic drug, NOS', 'Oestrogenic drug, NOS', 'Oestrogenic drug', 'Estrogenic Agents', 'Agents, Estrogenic', 'Estrogenic Compounds', 'Compounds, Estrogenic', 'Estrogen (substance)', 'estrogen substance', 'Estrogenic preparation (product)', 'Estrogen Receptor Agonists', 'Agonists, Estrogen Receptor', 'Receptor Agonists, Estrogen', 'Therapeutic Estrogen'], 'meaning': ['Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.', 'C0014939', 1]}]}, {'SIMPLE_CHEMICAL': [{'label': 'estrogen', 'alias': ['Estrogen [EPC]', 'Estrogen', 'Estrogen-class Agent'], 'meaning': [None, 'C2936882', 1]}]}, {'SIMPLE_CHEMICAL': [{'label': 'progesterone', 'alias': ['Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'Progesterone', 'progesterone', 'progesterone', 'progesterone', 'progesterone', 'progesterone', 'progesterone', 'progesterone', 'progesterone', 'progesterone', 'PROGESTERONE', 'PROGESTERONE', 'PROGESTERONE', 'PROGESTERONE', 'PROGESTERONE', 'progesterones', 'Progestérone', 'Corpus Luteum Hormone', 'Corpus Luteum Hormone', 'Corpus luteum hormone', 'Pregnenedione', 'Pregnenedione', 'Pregn-4-ene-3,20-dione', 'Pregn-4-ene-3,20-dione', 'Pregn-4-ene-3,20-dione', 'Pregn-4-ene-3,20-dione', 'Luteal hormone', 'luteal hormone', 'Luteine', 'Pregnendione preparation', 'Pregnendione preparation', 'Progesterone preparation', 'Progesterone preparation', 'Progesterone product', 'PRG - Progesterone', 'Progesteronum', '(S)-Pregn-4-en-3,20-dione', '17alpha-Progesterone', '17α-progesterone', 'Lutogynon', '(S)-Progesterone', 'Progesterona', 'Gelbkoerperhormon', 'Progesteron', 'delta(4)-Pregnene-3,20-dione', '(S)-4-Pregnene-3,20-dione', 'Progesterone preparation (product)', 'Progesterone (substance)', 'PRG', 'Delta4-pregnene-3,20-dione', 'Delta4-pregnene-3,20-dione', 'Delta4-pregnene-3,20-dione', 'Therapeutic Progesterone', 'Therapeutic Progesterone', '17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione', 'Progesterone [Chemical/Ingredient]'], 'meaning': ['The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.', 'C0033308', 0.9999999403953552]}]}, {'SIMPLE_CHEMICAL': [{'label': 'progesterone', 'alias': ['Progesterone measurement', 'Progesterone measurement', 'Progesterone Measurement', 'Progesterone', 'Progesterone', 'PROGEST', 'Progesterone measurement (procedure)', 'progesterone level test'], 'meaning': ['The determination of the amount of progesterone present in a sample.', 'C0373705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'human tissue', 'alias': ['Human tissue', 'human tissue', 'human tissue', 'human tissues', 'humans tissues', 'Human tissue (substance)'], 'meaning': ['index on projects employing indirectly obtained normal or abnormal tissues, body fluids, excretions, cells, biochemicals, etc; sources can include eye and tissue banks, blood banks, surgically excised tissue, or postmortem tissue.', 'C0440744', 1]}]}, {'ORGANISM': [{'label': 'human tissue', 'alias': ['human fetal tissue', 'human fetus tissue'], 'meaning': ['Any tissue from a human fetus.', 'C0872050', 0.8247498869895935]}]}, {'TISSUE': [{'label': 'endometrial epithelial', 'alias': ['epithelial', 'Epithelial', 'Epithelial', 'Epithelial'], 'meaning': ['A term that refers to the cells that make up the epithelial tissues. They are found in the skin, and in the parenchyma, surface and lumen of internal organs.', 'C0221908', 0.7649301886558533]}]}, {'TISSUE': [{'label': 'endometrial epithelial', 'alias': ['Endometrial', 'Endometrial', 'endometrial', 'endometrial', 'Endometrio-', 'endometrio'], 'meaning': ['Relating to or composed of endometrium.', 'C0227843', 0.7274630665779114]}]}, {'CELL': [{'label': 'stromal cells', 'alias': ['Stromal Cells', 'stromal cells', 'Cell, Stromal', 'Stromal Cell', 'Stromal Cell', 'Stromal Cell', 'stromal cell', 'stromal cell', 'stromal cell', 'Stromal cell', 'Cells, Stromal'], 'meaning': ['Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.', 'C0162597', 1]}]}, {'CELL': [{'label': 'stromal cells', 'alias': ['Stromal Cells/Total Cells', 'Stromal Cells/Total Cells', 'STRMCECE'], 'meaning': ['The determination of the ratio of stromal cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.', 'C4288181', 0.7520079016685486]}]}, {'CELL': [{'label': 'HESC', 'alias': ['HESTRESC', 'SDTM-HESTRESC', 'Holter ECG Results'], 'meaning': ['Terminology associated with the Holter ECG results codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).', 'C4053501', 0.8044604659080505]}]}, {'CELL': [{'label': 'HESCs', 'alias': ['cells embryonic human stem', 'Human Embryonic Stem Cell', 'human embryonic stem cell', 'human embryonic stem cell', 'Cells, Human Embryonic Stem', 'Stem Cells, Human Embryonic', 'hESCs'], 'meaning': ['A type of PLURIPOTENT STEM CELLS derived from early stage human embryos, up to and including the BLASTOCYST stage.', 'C1171346', 1]}]}, {'CELL': [{'label': 'HESCs', 'alias': ['Mouse Embryonic Stem Cell', 'Cells, Mouse Embryonic Stem', 'Stem Cells, Mouse Embryonic', 'mESCs'], 'meaning': ['PLURIPOTENT STEM CELLS derived from the BLASTOCYST INNER CELL MASS of day 3.5 mouse embryos.', 'C4042879', 0.78135085105896]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'PRL', 'alias': ['PBX1 wt Allele', 'PRL', 'MGC126627', 'Pre-B-Cell Leukemia Homeobox 1 wt Allele', 'DKFZp686B09108'], 'meaning': ['Human PBX1 wild-type allele is located in the vicinity of 1q23 and is approximately 296 kb in length. This allele, which encodes pre-B-cell leukemia transcription factor 1 protein, is involved in transcriptional regulation. A chromosomal translocation t(1;19)(q23;p13.3) of this gene and the TCF3 gene is associated with pre-B-cell acute lymphoblastic leukemia. A second translocation of this gene and the EWSR1 gene may be associated with myoepithelioma.', 'C3273356', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'PRL', 'alias': ['Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'Prolactin', 'prolactin', 'prolactin', 'prolactin', 'prolactin', 'PROLACTIN', 'prolactins', 'Lactogenic Hormone, Pituitary', 'Lactogenic Hormone, Pituitary', 'Hormone, Pituitary Lactogenic', 'Pituitary Lactogenic Hormone', 'Luteotropin', 'Luteotropin', 'luteotropin', 'Mammotropic Hormone, Pituitary', 'Mammotropic Hormone, Pituitary', 'Hormone, Pituitary Mammotropic', 'Pituitary Mammotropic Hormone', 'Mammotropin', 'Mammotropin', 'Mammotropin', 'Mammotropin', 'PRL', 'Prolactin preparation', 'Prolactin preparation', 'PRL (Prolactin)', 'PRL (Prolactin)', 'Prl - Prolactin', 'LTH (luteotropic hormone)', 'Lactogenic hormone', 'Lactogenic hormone', 'lactogenic hormone', 'lactogenic hormone', 'luteotropic hormone', 'luteotropic hormone', 'mammary stimulating hormone', 'LTH', 'lth', 'Prolactin preparation (product)', 'Prolactin (substance)', 'Prolactin [Chemical/Ingredient]'], 'meaning': ['A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate.', 'C0033371', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'IGFBP1', 'alias': ['IGFBP1 protein, human', 'Placental Protein 12', 'IGFBP-1', 'PP12', 'Insulin-Like Growth Factor-Binding Protein 1', 'Insulin-Like Growth Factor Binding Protein 1', 'IGF Binding Protein 1', 'IGF-Binding Protein 1', 'insulin-like growth factor binding protein 1, human', 'IGF-binding protein 1, human', 'IBP-1 protein, human', 'IGFBP-1 protein, human', 'IBP-1', 'Binding Protein-25', 'Binding Protein-26', 'Binding Protein-28', 'AFBP', 'Alpha-Pregnancy-Associated Endometrial Globulin', 'Amniotic Fluid Binding Protein', 'Growth Hormone Independent-Binding Protein', 'IGFBP1', 'PAMG-1 protein, human', 'placenta-specific protein 12, human', 'placental protein 12, human'], 'meaning': ['Insulin-like growth factor-binding protein 1 (259 aa, ~28 kDa) is encoded by the human IGFBP1 gene. This protein is involved in cell migration and both insulin-like growth factor binding and signaling.', 'C0071189', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'IGFBP1', 'alias': ['Insulin-like growth factor binding protein 1 measurement', 'Insulin-Like Growth Factor Binding Protein 1 Measurement', 'Insulin-Like Growth Factor Binding Protein 1', 'Insulin-Like Growth Factor Binding Prot1', 'Insulin-Like Growth Factor Binding Prot1', 'IGFBP1 Measurement', 'Insulin-like growth factor binding protein 1 measurement (procedure)', 'IGFBP1'], 'meaning': ['The determination of the amount of insulin-like growth factor binding protein 1 present in a sample.', 'C1295164', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'Ace2', 'alias': ['ACE2 gene', 'ACE2 Gene', 'peptidyl-dipeptidase A', 'ACEH', 'Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene', 'ANGIOTENSIN I-CONVERTING ENZYME 2', 'angiotensin I converting enzyme 2', 'ACE2', 'ACE2', 'ACE2'], 'meaning': ['This gene plays a role in both proteolysis and vasodilation.', 'C1422064', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'Ace2', 'alias': ['BACE2 gene', 'BACE2 Gene', 'BETA-SITE APP-CLEAVING ENZYME 2', 'beta-site APP-cleaving enzyme 2', 'Beta-Site APP-Cleaving Enzyme 2 Gene', 'ALP56', 'ALP56', 'CEAP1', 'DRAP', 'DRAP', 'ASPARTIC-LIKE PROTEASE, 56-KD', 'DOWN SYNDROME REGION ASPARTIC PROTEASE', 'BACE2', 'BACE2', 'BACE2', 'BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2'], 'meaning': ['This gene is involved in proteolytic processing.', 'C1412728', 0.8900668025016785]}]}, {'ORGANISM': [{'label': 'mouse uteri', 'alias': ['Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'Uterus', 'UTERUS', 'UTERUS', 'uterus', 'uterus', 'uterus', 'uterus', 'Uterus, NOS', 'Uteri', 'Uterine', 'Uterine', 'Uterine', 'uterine', 'Utero', 'Utero-', 'Uterine structure', 'Womb structure', 'Womb', 'Womb', 'womb', 'womb', 'womb', 'womb', 'wombs', 'Uterine structure (body structure)', 'Genital System, Female, Uterus'], 'meaning': ['The hollow thick-walled muscular organ in the female PELVIS. It consists of the fundus (the body) which is the site of EMBRYO IMPLANTATION and FETAL DEVELOPMENT. Beyond the isthmus at the perineal end of fundus, is CERVIX UTERI (the neck) opening into VAGINA. Beyond the isthmi at the upper abdominal end of fundus, are the FALLOPIAN TUBES.', 'C0042149', 0.7522316575050354]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'LIMITATIONS', 'alias': ['Limitation', 'Limitation', 'limitation', 'limitations', 'Limitation (attribute)'], 'meaning': [None, 'C0449295', 0.9999999403953552]}]}, {'CANCER': [{'label': 'REASONS', 'alias': ['Indication of (contextual qualifier)', 'Indication of', 'Indication of', 'indication of', 'Indications', 'Indication for', 'Indication for', 'With indication', 'With indication', 'indication for', 'indications', 'indications', 'indication', 'indication', 'Reason for', 'Reason for', 'Reason for', 'reason for', 'reasons', 'reason', 'Reason', 'Reason', 'Justification', 'justification', 'Indication of (contextual qualifier) (qualifier value)', 'Indication for (attribute)', 'Reason for (attribute)', 'Rationale'], 'meaning': ['An explanation of the cause of some phenomenon or action.', 'C0392360', 1]}]}, {'CANCER': [{'label': 'REASONS', 'alias': ['Seasons', 'Seasons', 'seasons', 'seasons', 'Season', 'Season', 'season', 'season', 'seasoned', 'seasonings', 'seasonal time of year'], 'meaning': ['Divisions of the year according to some regularly recurrent phenomena usually astronomical or climatic. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)', 'C0036497', 0.7715360522270203]}]}, {'ORGANISM': [{'label': 'Human', 'alias': ['Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'homo sapiens', 'Humans', 'humans', 'humans', 'Human', 'Human', 'Human', 'Human', 'Human', 'Human', 'Human', 'human', 'human', 'human', 'Man', 'Man', 'Man', 'Man', 'man', 'man', 'Man and woman', 'FAMILY OF MAN', 'Man (Taxonomy)', 'Homo sapiens (organism)', 'Human - origin', 'Human - origin (qualifier value)', 'Man, Modern', 'Modern Man', 'Human, General'], 'meaning': ['Members of the species Homo sapiens.', 'C0086418', 1]}]}, {'ORGANISM': [{'label': 'Human', 'alias': ['Human Use'], 'meaning': ['A product has been approved for use in humans.', 'C4055445', 0.7751905918121338]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'RK', 'alias': ['GRK1 gene', 'GRK1 Gene', 'RHODOPSIN KINASE', 'GRK1', 'GRK1', 'GRK1', 'RHOK', 'RK', 'RK', 'G PROTEIN-COUPLED RECEPTOR KINASE 1', 'G protein-coupled receptor kinase 1', 'G Protein-Coupled Receptor Kinase 1 Gene', 'GPRK1', 'GPRK1'], 'meaning': ['This gene is involved in sensory transduction necessary for vision.', 'C1335620', 0.9999999403953552]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'RK', 'alias': ['MAPK14 wt Allele', 'SAPK2A', 'p38', 'CSBP1', 'CSBP2', 'CSPB1', 'EXIP', 'p38 MAPK Gene', 'Mxi2', 'p38Alpha', 'PRKM14', 'PRKM15', 'RK', 'Mitogen-Activated Protein Kinase 14 wt Allele'], 'meaning': ['Human MAPK14 wild-type allele is located within 6p21.3-p21.2 and is approximately 83 kb in length. This allele, which encodes mitogen-activated protein kinase 14 protein, plays a role in both the production of certain cytokines and the regulation of cellular signaling in response to environmental stress, lipopolysaccharide and pro-inflammatory cytokines.', 'C1705633', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'funds', 'alias': ['funds', 'Fund', 'funded', 'fund'], 'meaning': [None, 'C0016820', 1]}]}, {'ORGANISM': [{'label': 'funds', 'alias': ['Private Funds', 'Private Funds', 'Private funds'], 'meaning': ['Money available for projects or products in the private sector that does not include government contribution, grants or contracts.', 'C3640786', 0.7067033648490906]}]}]","{'STUDY QUESTION: Is SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE 2) expressed in the human endometrium during the menstrual cycle, and does it participate in endometrial decidualization?': [['Is', 'VBZ', 'O'], ['SARS-CoV-2', 'JJ', 'B-NP'], ['receptor', 'NN', 'I-NP'], ['angiotensin-converting', 'JJ', 'B-NP'], ['enzyme', 'NN', 'I-NP'], ['expressed', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['human', 'JJ', 'I-NP'], ['endometrium', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['menstrual', 'JJ', 'I-NP'], ['cycle', 'NN', 'I-NP'], ['does', 'VBZ', 'O'], ['participate', 'VB', 'O'], ['endometrial', 'JJ', 'B-NP'], ['decidualization', 'NN', 'I-NP']], 'SUMMARY ANSWER: ACE2 protein is highly expressed in human endometrial stromal cells during the secretory phase and is essential for human endometrial stromal cell decidualization.': [['protein', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['expressed', 'VBN', 'O'], ['human', 'JJ', 'B-NP'], ['endometrial', 'JJ', 'I-NP'], ['stromal', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['secretory', 'JJ', 'I-NP'], ['phase', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['human', 'JJ', 'B-NP'], ['endometrial', 'JJ', 'I-NP'], ['stromal', 'NN', 'I-NP'], ['cell', 'NN', 'B-NP'], ['decidualization', 'NN', 'B-NP']], 'WHAT IS KNOWN ALREADY: ACE2 is expressed in numerous human tissues including the lungs, heart, intestine, kidneys and placenta.': [['IS', 'VBZ', 'O'], ['KNOWN', 'VBN', 'O'], ['is', 'VBZ', 'O'], ['expressed', 'VBN', 'O'], ['including', 'VBG', 'O'], ['heart', 'NN', 'B-NP'], ['intestine', 'NN', 'B-NP'], ['placenta', 'NN', 'B-NP']], 'ACE2 is also the receptor by which SARS-CoV-2 enters human cells.': [['is', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['receptor', 'NN', 'I-NP']], 'STUDY DESIGN, SIZE, DURATION: Proliferative (n = 9) and secretory (n = 6) phase endometrium biopsies from healthy reproductive-age women and primary human endometrial stromal cells from proliferative phase endometrium were used in the study.': [['secretory', 'NN', 'B-NP'], ['phase', 'NN', 'B-NP'], ['endometrium', 'NN', 'B-NP'], ['primary', 'JJ', 'B-NP'], ['human', 'JJ', 'I-NP'], ['endometrial', 'JJ', 'I-NP'], ['stromal', 'NN', 'I-NP'], ['proliferative', 'JJ', 'B-NP'], ['phase', 'NN', 'I-NP'], ['endometrium', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['used', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['study', 'NN', 'I-NP']], 'PARTICIPANTS/MATERIALS, SETTING, METHODS: ACE2 expression and localization were examined by qRT-PCR, Western blot, and immunofluorescence in both human endometrial samples and mouse uterine tissue.': [['expression', 'NN', 'B-NP'], ['localization', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['examined', 'VBN', 'O'], ['qRT-PCR', 'NN', 'B-NP'], ['Western', 'JJ', 'B-NP'], ['blot', 'NN', 'I-NP'], ['immunofluorescence', 'NN', 'B-NP'], ['both', 'DT', 'B-NP'], ['human', 'JJ', 'I-NP'], ['endometrial', 'NN', 'I-NP'], ['mouse', 'NN', 'B-NP'], ['uterine', 'JJ', 'B-NP'], ['tissue', 'NN', 'I-NP']], 'The effect of ACE2 knockdown on morphological and molecular changes of human endometrial stromal cell decidualization were assessed.': [['The', 'DT', 'B-NP'], ['effect', 'NN', 'I-NP'], ['knockdown', 'NN', 'B-NP'], ['human', 'JJ', 'B-NP'], ['endometrial', 'JJ', 'I-NP'], ['stromal', 'NN', 'I-NP'], ['cell', 'NN', 'B-NP'], ['decidualization', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['assessed', 'VBN', 'O']], 'Ovariectomized mice were treated with estrogen or progesterone to determine the effects of these hormones on ACE2 expression.': [['Ovariectomized', 'VBN', 'O'], ['were', 'VBD', 'O'], ['treated', 'VBN', 'O'], ['estrogen', 'NN', 'B-NP'], ['progesterone', 'NN', 'B-NP'], ['determine', 'VB', 'O'], ['expression', 'NN', 'B-NP']], 'MAIN RESULTS AND THE ROLE OF CHANCE: In human tissue, ACE2 protein is expressed in both endometrial epithelial and stromal cells in the proliferative phase of the menstrual cycle, and expression increases in stromal cells in the secretory phase.': [['human', 'JJ', 'B-NP'], ['tissue', 'NN', 'I-NP'], ['protein', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['expressed', 'VBN', 'O'], ['both', 'DT', 'B-NP'], ['endometrial', 'JJ', 'I-NP'], ['epithelial', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['proliferative', 'JJ', 'I-NP'], ['phase', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['menstrual', 'JJ', 'I-NP'], ['cycle', 'NN', 'I-NP'], ['expression', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['secretory', 'JJ', 'I-NP'], ['phase', 'NN', 'I-NP']], 'The ACE2 mRNA (P 0.0001) and protein abundance increased during primary human endometrial stromal cell (HESC) decidualization.': [['mRNA', 'NN', 'B-NP'], ['protein', 'JJ', 'B-NP'], ['abundance', 'NN', 'I-NP'], ['increased', 'VBD', 'O'], ['primary', 'JJ', 'B-NP'], ['human', 'JJ', 'I-NP'], ['endometrial', 'JJ', 'I-NP'], ['stromal', 'NN', 'I-NP'], ['cell', 'NN', 'B-NP'], ['decidualization', 'NN', 'B-NP']], 'HESCs transfected with ACE2-targeting siRNA were less able to decidualize than controls, as evidenced by a lack of morphology change and lower expression of the decidualization markers PRL and IGFBP1 (P 0.05).': [['transfected', 'VBD', 'O'], ['siRNA', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['decidualize', 'VB', 'O'], ['evidenced', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['lack', 'NN', 'I-NP'], ['morphology', 'NN', 'B-NP'], ['change', 'NN', 'B-NP'], ['expression', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['decidualization', 'NN', 'I-NP']], 'In mice during pregnancy, ACE2 protein was expressed in uterine epithelial and stromal cells increased through day six of pregnancy.': [['mice', 'NN', 'B-NP'], ['pregnancy', 'NN', 'B-NP'], ['protein', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['expressed', 'VBN', 'O'], ['increased', 'VBD', 'O'], ['day', 'NN', 'B-NP'], ['pregnancy', 'NN', 'B-NP']], 'Finally, progesterone induced expression of Ace2 mRNA in mouse uteri more than vehicle or estrogen (P 0.05).': [['progesterone', 'NN', 'B-NP'], ['induced', 'JJ', 'B-NP'], ['expression', 'NN', 'I-NP'], ['mRNA', 'NN', 'B-NP'], ['mouse', 'NN', 'B-NP'], ['uteri', 'NN', 'B-NP'], ['vehicle', 'NN', 'B-NP'], ['estrogen', 'NN', 'B-NP']], 'LARGE SCALE DATA: N/A.': [['N/A', 'NN', 'B-NP']], 'LIMITATIONS, REASONS FOR CAUTION: Experiments assessing the function of ACE2 in human endometrial stromal cell decidualization were in vitro.': [['assessing', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['function', 'NN', 'I-NP'], ['human', 'JJ', 'B-NP'], ['endometrial', 'JJ', 'I-NP'], ['stromal', 'NN', 'I-NP'], ['cell', 'NN', 'B-NP'], ['decidualization', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['vitro', 'NN', 'B-NP']], 'Whether SARS-CoV-2 can enter human endometrial stromal cells and affect decidualization have not been assessed.': [['enter', 'VB', 'O'], ['human', 'JJ', 'B-NP'], ['endometrial', 'JJ', 'I-NP'], ['stromal', 'NN', 'I-NP'], ['affect', 'JJ', 'B-NP'], ['decidualization', 'NN', 'I-NP'], ['have', 'VBP', 'O'], ['been', 'VBN', 'O'], ['assessed', 'VBN', 'O']], 'WIDER IMPLICATIONS OF THE FINDINGS: Expression of ACE2 in the endometrium allow SARS-CoV-2 to enter endometrial epithelial and stromal cells, which could impair in vivo decidualization, embryo implantation, and placentation.': [['Expression', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['endometrium', 'NN', 'I-NP'], ['allow', 'VB', 'O'], ['enter', 'VB', 'O'], ['endometrial', 'JJ', 'B-NP'], ['epithelial', 'NN', 'I-NP'], ['impair', 'VB', 'O'], ['vivo', 'JJ', 'B-NP'], ['decidualization', 'NN', 'I-NP'], ['embryo', 'JJ', 'B-NP'], ['implantation', 'NN', 'I-NP'], ['placentation', 'NN', 'B-NP']], 'If so, women with COVID-19 may be at increased risk of early pregnancy loss.': [['be', 'VB', 'O'], ['increased', 'JJ', 'B-NP'], ['risk', 'NN', 'I-NP'], ['early', 'JJ', 'B-NP'], ['pregnancy', 'NN', 'I-NP'], ['loss', 'NN', 'B-NP']], 'STUDY FUNDINGS/COMPETING INTEREST(S): This study was supported by National Institutes of Health / National Institute of Child Health and Human Development grants R01HD065435 and R00HD080742 to RK and Washington University School of Medicine start-up funds to RK.': [['This', 'DT', 'B-NP'], ['study', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['supported', 'VBN', 'O']], 'The authors declare that they have no conflicts of interest.': [['declare', 'VBP', 'O'], ['have', 'VBP', 'O'], ['interest', 'NN', 'B-NP']]}","{'STUDY QUESTION: Is SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE 2) expressed in the human endometrium during the menstrual cycle, and does it participate in endometrial decidualization?': [{'noun_phrase': ' STUDY QUESTION SARS CoV-2 receptor angiotensin', 'noun_connectors': ['converting']}, {'noun_phrase': ' enzyme ACE', 'noun_connectors': ['expressed']}, {'noun_phrase': ' endometrium menstrual cycle', 'noun_connectors': ['and', 'participate']}], 'SUMMARY ANSWER: ACE2 protein is highly expressed in human endometrial stromal cells during the secretory phase and is essential for human endometrial stromal cell decidualization.': [{'noun_phrase': ' SUMMARY ANSWER ACE2 protein', 'noun_connectors': ['highly', 'expressed']}, {'noun_phrase': ' cells secretory phase', 'noun_connectors': ['and']}], 'WHAT IS KNOWN ALREADY: ACE2 is expressed in numerous human tissues including the lungs, heart, intestine, kidneys and placenta.': [{'noun_phrase': '', 'noun_connectors': ['IS', 'KNOWN', 'expressed']}, {'noun_phrase': ' tissues', 'noun_connectors': ['including']}], 'ACE2 is also the receptor by which SARS-CoV-2 enters human cells.': [{'noun_phrase': ' ACE2', 'noun_connectors': ['also']}], 'STUDY DESIGN, SIZE, DURATION: Proliferative (n = 9) and secretory (n = 6) phase endometrium biopsies from healthy reproductive-age women and primary human endometrial stromal cells from proliferative phase endometrium were used in the study.': [{'noun_phrase': ' STUDY DESIGN SIZE DURATION Proliferative n', 'noun_connectors': ['and']}, {'noun_phrase': ' secretory n phase endometrium biopsies healthy reproductive age women', 'noun_connectors': ['and']}, {'noun_phrase': ' cells proliferative phase endometrium', 'noun_connectors': ['used']}], 'PARTICIPANTS/MATERIALS, SETTING, METHODS: ACE2 expression and localization were examined by qRT-PCR, Western blot, and immunofluorescence in both human endometrial samples and mouse uterine tissue.': [{'noun_phrase': ' PARTICIPANTS MATERIALS SETTING METHODS ACE2 expression', 'noun_connectors': ['and']}, {'noun_phrase': ' localization', 'noun_connectors': ['examined']}, {'noun_phrase': ' qRT PCR Western blot', 'noun_connectors': ['and']}, {'noun_phrase': ' immunofluorescence', 'noun_connectors': ['both']}, {'noun_phrase': ' samples', 'noun_connectors': ['and']}], 'The effect of ACE2 knockdown on morphological and molecular changes of human endometrial stromal cell decidualization were assessed.': [{'noun_phrase': ' effect ACE2', 'noun_connectors': ['knockdown', 'and']}], 'Ovariectomized mice were treated with estrogen or progesterone to determine the effects of these hormones on ACE2 expression.': [{'noun_phrase': '', 'noun_connectors': ['Ovariectomized']}, {'noun_phrase': ' mice', 'noun_connectors': ['treated']}, {'noun_phrase': ' estrogen', 'noun_connectors': ['or']}, {'noun_phrase': ' progesterone', 'noun_connectors': ['determine']}], 'MAIN RESULTS AND THE ROLE OF CHANCE: In human tissue, ACE2 protein is expressed in both endometrial epithelial and stromal cells in the proliferative phase of the menstrual cycle, and expression increases in stromal cells in the secretory phase.': [{'noun_phrase': ' MAIN RESULTS', 'noun_connectors': ['AND']}, {'noun_phrase': ' ROLE CHANCE human tissue ACE2 protein', 'noun_connectors': ['expressed', 'and']}, {'noun_phrase': ' cells proliferative phase menstrual cycle', 'noun_connectors': ['and']}], 'The ACE2 mRNA (P 0.0001) and protein abundance increased during primary human endometrial stromal cell (HESC) decidualization.': [{'noun_phrase': ' ACE2 mRNA P', 'noun_connectors': ['and']}, {'noun_phrase': ' protein abundance', 'noun_connectors': ['increased']}], 'HESCs transfected with ACE2-targeting siRNA were less able to decidualize than controls, as evidenced by a lack of morphology change and lower expression of the decidualization markers PRL and IGFBP1 (P 0.05).': [{'noun_phrase': ' HESCs', 'noun_connectors': ['transfected', 'less', 'decidualize']}, {'noun_phrase': ' controls', 'noun_connectors': ['evidenced']}, {'noun_phrase': ' lack morphology change', 'noun_connectors': ['and']}, {'noun_phrase': ' expression decidualization markers PRL', 'noun_connectors': ['and', 'IGFBP1']}], 'In mice during pregnancy, ACE2 protein was expressed in uterine epithelial and stromal cells increased through day six of pregnancy.': [{'noun_phrase': ' mice pregnancy ACE2 protein', 'noun_connectors': ['expressed', 'and']}, {'noun_phrase': ' cells', 'noun_connectors': ['increased']}], 'Finally, progesterone induced expression of Ace2 mRNA in mouse uteri more than vehicle or estrogen (P 0.05).': [{'noun_phrase': '', 'noun_connectors': ['Finally']}, {'noun_phrase': ' progesterone induced expression Ace2 mRNA mouse uteri', 'noun_connectors': ['more']}, {'noun_phrase': ' vehicle', 'noun_connectors': ['or']}], 'LARGE SCALE DATA: N/A.': [{'noun_phrase': ' LARGE SCALE DATA N A.', 'noun_connectors': []}], 'LIMITATIONS, REASONS FOR CAUTION: Experiments assessing the function of ACE2 in human endometrial stromal cell decidualization were in vitro.': [{'noun_phrase': ' LIMITATIONS REASONS CAUTION Experiments', 'noun_connectors': ['assessing']}], 'Whether SARS-CoV-2 can enter human endometrial stromal cells and affect decidualization have not been assessed.': [{'noun_phrase': ' SARS CoV-2', 'noun_connectors': ['can', 'enter']}, {'noun_phrase': ' cells', 'noun_connectors': ['and', 'affect']}], 'WIDER IMPLICATIONS OF THE FINDINGS: Expression of ACE2 in the endometrium allow SARS-CoV-2 to enter endometrial epithelial and stromal cells, which could impair in vivo decidualization, embryo implantation, and placentation.': [{'noun_phrase': ' WIDER IMPLICATIONS FINDINGS Expression ACE2 endometrium', 'noun_connectors': ['allow']}, {'noun_phrase': ' CoV-2', 'noun_connectors': ['enter', 'and']}, {'noun_phrase': ' cells', 'noun_connectors': ['could', 'impair']}, {'noun_phrase': ' decidualization embryo implantation', 'noun_connectors': ['and']}], 'If so, women with COVID-19 may be at increased risk of early pregnancy loss.': [{'noun_phrase': '', 'noun_connectors': ['so']}, {'noun_phrase': ' women COVID-19', 'noun_connectors': ['may', 'increased']}], 'STUDY FUNDINGS/COMPETING INTEREST(S): This study was supported by National Institutes of Health / National Institute of Child Health and Human Development grants R01HD065435 and R00HD080742 to RK and Washington University School of Medicine start-up funds to RK.': [{'noun_phrase': ' STUDY FUNDINGS COMPETING', 'noun_connectors': ['INTEREST(S']}, {'noun_phrase': ' study', 'noun_connectors': ['supported', 'and']}, {'noun_phrase': ' grants R01HD065435', 'noun_connectors': ['and', 'and', 'start']}], 'The authors declare that they have no conflicts of interest.': [{'noun_phrase': ' authors', 'noun_connectors': ['declare']}]}"
"[{'author_name': 'Heather M Froggatt', 'author_inst': 'Duke University'}, {'author_name': 'Brook E Heaton', 'author_inst': 'Duke University'}, {'author_name': 'Nicholas S Heaton', 'author_inst': 'Duke University'}]",http://biorxiv.org/cgi/content/short/2020.06.24.169565,"Development of a fluorescence based, high-throughput SARS-CoV-2 3CLpro reporter assay","In late 2019 a human coronavirus, now known as SARS-CoV-2, emerged, likely from a zoonotic reservoir. This virus causes COVID-19 disease, has infected millions of people, and has led to hundreds of thousands of deaths across the globe. While the best interventions to control and ultimately stop the pandemic are prophylactic vaccines, antiviral therapeutics are important to limit morbidity and mortality in those already infected. At this time, only one FDA approved anti-SARS-CoV-2 antiviral drug, remdesivir, is available and unfortunately, its efficacy appears to be limited. Thus, the identification of new and efficacious antivirals is of highest importance. In order to facilitate rapid drug discovery, flexible, sensitive, and high-throughput screening methods are required. With respect to drug targets, most attention is focused on either the viral RNA-dependent RNA polymerase or the main viral protease, 3CLpro. 3CLpro is an attractive target for antiviral therapeutics as it is essential for processing newly translated viral proteins, and the viral lifecycle cannot be completed without protease activity. In this work, we present a new assay to identify inhibitors of the SARS-CoV-2 main protease, 3CLpro. Our reporter is based on a GFP-derived protein that only fluoresces after cleavage by 3CLpro. This experimentally optimized reporter assay allows for antiviral drug screening in human cell culture at biosafety level-2 (BSL2) with high-throughput compatible protocols. Using this screening approach in combination with existing drug libraries may lead to the rapid identification of novel antivirals to suppress SARS-CoV-2 replication and spread.",2020-06-24,biorxiv,3,"[{'ORGANISM': [{'label': 'people', 'alias': ['Persons', 'Persons', 'persons', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'person', 'person', 'Individual', 'people', 'People', 'peoples', 'Person (person)'], 'meaning': ['Persons as individuals (e.g., ABORTION APPLICANTS) or as members of a group (e.g., HISPANIC AMERICANS). It is not used for members of the various professions (e.g., PHYSICIANS) or occupations (e.g., LIBRARIANS) for which OCCUPATIONAL GROUPS is available.', 'C0027361', 1]}]}, {'ORGANISM': [{'label': 'people', 'alias': ['chinese people', 'Chinese', 'Chinese', 'Chinese', 'Chinese', 'Chinese', 'Chinese', 'Chinese', 'Chinese', 'CHINESE', 'CHINESE', 'chinese', '-- Chinese', 'Chinese (ethnic group)'], 'meaning': ['A person having origins in any of the original peoples of China.', 'C0152035', 0.7433323264122009]}]}, {'TISSUE': [{'label': 'globe', 'alias': ['Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'Eye', 'eye', 'eye', 'eye', 'EYE', 'EYE', 'EYE', 'EYE', 'Eyes', 'Eyes', 'Eyes', 'Eyes', 'Eye, NOS', 'eyes', '?Eye', 'Eyeball', 'Eyeball', 'Eyeball', 'Eyeball', 'Eyeball', 'Eyeball', 'Eyeball', 'Eyeball', 'eyeball', 'eyeball', 'eyeballs', 'Optic', 'Eye structure', 'Eyeball structure', 'globe', 'Ocular', 'ocular', 'Oculus', 'ophthalmic', 'Ophthalmic', 'Bulbus oculi', 'Structure of eye proper (body structure)', 'Ocular structure', 'Structure of eye proper'], 'meaning': ['The organ of sight constituting a pair of globular organs made up of a three-layered roughly spherical structure specialized for receiving and responding to light.', 'C0015392', 1]}]}, {'TISSUE': [{'label': 'globe', 'alias': ['lobe', 'lobe', 'Lobe', 'Lobe', 'Lobe', 'Lobe', 'Lobe', 'lobes', 'Anatomical lobe', 'Anatomical lobe', 'Lobus'], 'meaning': ['A portion of an organ, such as the liver, lung, breast, thyroid, or brain.', 'C0796494', 0.7343197464942932]}]}, {'SIMPLE_CHEMICAL': [{'label': 'FDA', 'alias': ['United States Food, Drug Administration', 'Food and Drug Administration', 'Food and Drug Administration', 'Food and Drug Administration', 'Food and Drug Administration', 'administration drug food', 'administration drugs food', 'drug administration food', 'food drug administration', 'Food and Drug Administration (U.S.)', 'u.s. food drug administration', 'USFDA', 'usfda', 'FDA', 'FDA'], 'meaning': ['An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.', 'C0041714', 0.9999998807907104]}]}, {'SIMPLE_CHEMICAL': [{'label': 'FDA', 'alias': [], 'meaning': ['A written regulatory communication from FDA to an applicant, who submitted request to the agency to approve marketing or to license medical product, stating that the agency can approve the application or abbreviated application if specific additional information or material is submitted or specific conditions are met. An approvable letter does not constitute approval of any part of an application or abbreviated application and does not permit marketing of the drug that is the subject of the application or abbreviated application. The letter often lists minor deficiencies in the product documentation that have to be corrected, often involves labeling changes, and possibly requests sponsor commitment to do post-approval studies.', 'C2700205', 0.7150661945343018]}]}, {'ORGANISM': [{'label': 'human cell', 'alias': ['cells human', 'human cells', 'cell humans', 'cell human', 'cells humans', 'human cell', 'Human cells (finding)'], 'meaning': [None, 'C0427861', 1]}]}, {'ORGANISM': [{'label': 'human cell', 'alias': ['Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'homo sapiens', 'Humans', 'humans', 'humans', 'Human', 'Human', 'Human', 'Human', 'Human', 'Human', 'Human', 'human', 'human', 'human', 'Man', 'Man', 'Man', 'Man', 'man', 'man', 'Man and woman', 'FAMILY OF MAN', 'Man (Taxonomy)', 'Homo sapiens (organism)', 'Human - origin', 'Human - origin (qualifier value)', 'Man, Modern', 'Modern Man', 'Human, General'], 'meaning': ['Members of the species Homo sapiens.', 'C0086418', 0.7540513873100281]}]}]","{'In late 2019 a human coronavirus, now known as SARS-CoV-2, emerged, likely from a zoonotic reservoir.': [['a', 'DT', 'B-NP'], ['human', 'JJ', 'I-NP'], ['coronavirus', 'NN', 'I-NP'], ['known', 'VBN', 'O'], ['emerged', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['zoonotic', 'JJ', 'I-NP'], ['reservoir', 'NN', 'I-NP']], 'This virus causes COVID-19 disease, has infected millions of people, and has led to hundreds of thousands of deaths across the globe.': [['This', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['causes', 'VBZ', 'O'], ['disease', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['infected', 'VBN', 'O'], ['has', 'VBZ', 'O'], ['led', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['globe', 'NN', 'I-NP']], 'While the best interventions to control and ultimately stop the pandemic are prophylactic vaccines, antiviral therapeutics are important to limit morbidity and mortality in those already infected.': [['control', 'VB', 'O'], ['stop', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['pandemic', 'NN', 'I-NP'], ['are', 'VBP', 'O'], ['are', 'VBP', 'O'], ['limit', 'VB', 'O'], ['morbidity', 'NN', 'B-NP'], ['mortality', 'NN', 'B-NP'], ['infected', 'VBN', 'O']], 'At this time, only one FDA approved anti-SARS-CoV-2 antiviral drug, remdesivir, is available and unfortunately, its efficacy appears to be limited.': [['this', 'DT', 'B-NP'], ['time', 'NN', 'I-NP'], ['approved', 'VBD', 'O'], ['anti-SARS-CoV-2', 'JJ', 'B-NP'], ['antiviral', 'JJ', 'I-NP'], ['drug', 'NN', 'I-NP'], ['remdesivir', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['efficacy', 'NN', 'B-NP'], ['appears', 'VBZ', 'O'], ['be', 'VB', 'O'], ['limited', 'VBN', 'O']], 'Thus, the identification of new and efficacious antivirals is of highest importance.': [['the', 'DT', 'B-NP'], ['identification', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['importance', 'NN', 'B-NP']], 'In order to facilitate rapid drug discovery, flexible, sensitive, and high-throughput screening methods are required.': [['order', 'NN', 'B-NP'], ['facilitate', 'VB', 'O'], ['rapid', 'JJ', 'B-NP'], ['drug', 'NN', 'I-NP'], ['discovery', 'NN', 'B-NP'], ['high-throughput', 'JJ', 'B-NP'], ['screening', 'NN', 'I-NP'], ['are', 'VBP', 'O'], ['required', 'VBN', 'O']], 'With respect to drug targets, most attention is focused on either the viral RNA-dependent RNA polymerase or the main viral protease, 3CLpro.': [['respect', 'NN', 'B-NP'], ['drug', 'NN', 'B-NP'], ['attention', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['focused', 'VBN', 'O'], ['polymerase', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['main', 'JJ', 'I-NP'], ['viral', 'JJ', 'I-NP'], ['protease', 'NN', 'I-NP']], '3CLpro is an attractive target for antiviral therapeutics as it is essential for processing newly translated viral proteins, and the viral lifecycle cannot be completed without protease activity.': [['is', 'VBZ', 'O'], ['an', 'DT', 'B-NP'], ['attractive', 'JJ', 'I-NP'], ['target', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['processing', 'VBG', 'O'], ['translated', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['viral', 'JJ', 'I-NP'], ['lifecycle', 'NN', 'I-NP'], ['be', 'VB', 'O'], ['completed', 'VBN', 'O'], ['protease', 'NN', 'B-NP'], ['activity', 'NN', 'B-NP']], 'In this work, we present a new assay to identify inhibitors of the SARS-CoV-2 main protease, 3CLpro.': [['this', 'DT', 'B-NP'], ['work', 'NN', 'I-NP'], ['present', 'VBP', 'O'], ['a', 'DT', 'B-NP'], ['new', 'JJ', 'I-NP'], ['assay', 'NN', 'I-NP'], ['identify', 'VB', 'O'], ['main', 'JJ', 'B-NP'], ['protease', 'NN', 'I-NP']], 'Our reporter is based on a GFP-derived protein that only fluoresces after cleavage by 3CLpro.': [['reporter', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['based', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['GFP-derived', 'JJ', 'I-NP'], ['protein', 'NN', 'I-NP'], ['cleavage', 'NN', 'B-NP']], 'This experimentally optimized reporter assay allows for antiviral drug screening in human cell culture at biosafety level-2 (BSL2) with high-throughput compatible protocols.': [['optimized', 'JJ', 'B-NP'], ['reporter', 'NN', 'I-NP'], ['assay', 'VBP', 'O'], ['antiviral', 'JJ', 'B-NP'], ['drug', 'NN', 'I-NP'], ['screening', 'NN', 'B-NP'], ['human', 'JJ', 'B-NP'], ['cell', 'NN', 'I-NP'], ['culture', 'NN', 'B-NP'], ['biosafety', 'NN', 'B-NP'], ['level-2', 'NN', 'B-NP'], ['high-throughput', 'NN', 'B-NP']], 'Using this screening approach in combination with existing drug libraries may lead to the rapid identification of novel antivirals to suppress SARS-CoV-2 replication and spread.': [['Using', 'VBG', 'O'], ['screening', 'VBG', 'O'], ['approach', 'NN', 'B-NP'], ['combination', 'NN', 'B-NP'], ['existing', 'VBG', 'O'], ['drug', 'NN', 'B-NP'], ['lead', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['rapid', 'JJ', 'I-NP'], ['identification', 'NN', 'I-NP'], ['suppress', 'VB', 'O'], ['replication', 'NN', 'B-NP'], ['spread', 'NN', 'B-NP']]}","{'In late 2019 a human coronavirus, now known as SARS-CoV-2, emerged, likely from a zoonotic reservoir.': [{'noun_phrase': ' late human coronavirus', 'noun_connectors': ['now', 'known', 'emerged', 'likely']}], 'This virus causes COVID-19 disease, has infected millions of people, and has led to hundreds of thousands of deaths across the globe.': [{'noun_phrase': ' virus', 'noun_connectors': ['causes']}, {'noun_phrase': ' disease', 'noun_connectors': ['infected']}, {'noun_phrase': ' millions people', 'noun_connectors': ['and', 'led']}], 'While the best interventions to control and ultimately stop the pandemic are prophylactic vaccines, antiviral therapeutics are important to limit morbidity and mortality in those already infected.': [{'noun_phrase': ' best interventions', 'noun_connectors': ['control', 'and', 'ultimately', 'stop']}, {'noun_phrase': ' pandemic prophylactic vaccines antiviral therapeutics important', 'noun_connectors': ['limit']}, {'noun_phrase': ' morbidity', 'noun_connectors': ['and']}], 'At this time, only one FDA approved anti-SARS-CoV-2 antiviral drug, remdesivir, is available and unfortunately, its efficacy appears to be limited.': [{'noun_phrase': ' time', 'noun_connectors': ['only', 'approved']}, {'noun_phrase': ' CoV-2 antiviral drug remdesivir available', 'noun_connectors': ['and', 'unfortunately']}], 'Thus, the identification of new and efficacious antivirals is of highest importance.': [{'noun_phrase': '', 'noun_connectors': ['Thus']}, {'noun_phrase': ' identification new', 'noun_connectors': ['and']}], 'In order to facilitate rapid drug discovery, flexible, sensitive, and high-throughput screening methods are required.': [{'noun_phrase': ' order', 'noun_connectors': ['facilitate']}, {'noun_phrase': ' drug discovery flexible sensitive', 'noun_connectors': ['and']}], 'With respect to drug targets, most attention is focused on either the viral RNA-dependent RNA polymerase or the main viral protease, 3CLpro.': [{'noun_phrase': ' respect drug targets most attention', 'noun_connectors': ['focused', 'either']}, {'noun_phrase': ' polymerase', 'noun_connectors': ['or']}], '3CLpro is an attractive target for antiviral therapeutics as it is essential for processing newly translated viral proteins, and the viral lifecycle cannot be completed without protease activity.': [{'noun_phrase': ' attractive target antiviral therapeutics essential', 'noun_connectors': ['processing', 'newly', 'translated']}, {'noun_phrase': ' proteins', 'noun_connectors': ['and']}, {'noun_phrase': ' lifecycle', 'noun_connectors': ['can', 'completed']}], 'In this work, we present a new assay to identify inhibitors of the SARS-CoV-2 main protease, 3CLpro.': [{'noun_phrase': ' work', 'noun_connectors': ['present']}, {'noun_phrase': ' assay', 'noun_connectors': ['identify']}], 'Our reporter is based on a GFP-derived protein that only fluoresces after cleavage by 3CLpro.': [{'noun_phrase': ' reporter', 'noun_connectors': ['based']}, {'noun_phrase': ' GFP', 'noun_connectors': ['derived']}, {'noun_phrase': ' protein', 'noun_connectors': ['only']}], 'This experimentally optimized reporter assay allows for antiviral drug screening in human cell culture at biosafety level-2 (BSL2) with high-throughput compatible protocols.': [{'noun_phrase': '', 'noun_connectors': ['experimentally']}, {'noun_phrase': ' reporter assay', 'noun_connectors': ['allows']}], 'Using this screening approach in combination with existing drug libraries may lead to the rapid identification of novel antivirals to suppress SARS-CoV-2 replication and spread.': [{'noun_phrase': '', 'noun_connectors': ['Using']}, {'noun_phrase': ' screening approach combination', 'noun_connectors': ['existing']}, {'noun_phrase': ' drug libraries', 'noun_connectors': ['may', 'lead']}, {'noun_phrase': ' identification novel antivirals', 'noun_connectors': ['suppress']}, {'noun_phrase': ' CoV-2 replication', 'noun_connectors': ['and']}]}"
"[{'author_name': 'Brian J. Cox', 'author_inst': 'University of Toronto'}]",http://biorxiv.org/cgi/content/short/2020.06.24.169144,Integration of viral transcriptome sequencing with structure and sequence motifs predicts novel regulatory elements in SARS-CoV-2,"In the last twenty years, three separate coronaviruses have left their typical animal hosts and became human pathogens. An area of research interest is coronavirus transcription regulation that uses an RNA-RNA mediated template-switching mechanism. It is not known how different transcriptional stoichiometries of each viral gene are generated. Analysis of SARS-CoV-2 RNA sequencing data from whole RNA transcriptomes identified TRS dependent and independent transcripts. Integration of transcripts and 5prime-UTR sequence motifs identified that the pentaloop and the stem-loop 3 were also located upstream of spliced genes. TRS independent transcripts were detected as likely non-polyadenylated. Additionally, a novel conserved sequence motif was discovered at either end of the TRS independent splice junctions. While similar both SARS viruses generated similar TRS independent transcripts they were more abundant in SARS-CoV-2. TRS independent gene regulation requires investigation to determine its relationship to viral pathogenicity.",2020-06-24,biorxiv,1,"[{'ORGANISM': [{'label': 'human pathogens', 'alias': ['Pathogenic organism', 'pathogenic organism', 'organisms pathogenic', 'Pathogen', 'Pathogen', 'Pathogen', 'Pathogenic', 'Pathogenic organism (navigational concept)'], 'meaning': ['An agent of disease; a disease producer.', 'C0450254', 0.7005693912506104]}]}, {'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'CORONAVIRUS', 'coronavirus', 'Coronaviruses', 'Coronaviruses', 'Coronaviruses', 'Coronavirus, NOS', 'coronaviruses'], 'meaning': ['A genus of the family CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.', 'C0206419', 1]}]}, {'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'coronaviridae', 'CORONAVIRUS', 'Family: Coronavirus group', 'Coronavirus group', 'CORONAVIRUS GROUP', 'Coronavirus group, NOS', 'Family Coronaviridae', 'Family Coronaviridae (organism)'], 'meaning': ['Spherical RNA viruses, in the order NIDOVIRALES, infecting a wide range of animals including humans. Transmission is by fecal-oral and respiratory routes. Mechanical transmission is also common. There are two genera: CORONAVIRUS and TOROVIRUS.', 'C0010076', 1]}]}, {'CELLULAR_COMPONENT': [{'label': 'junctions', 'alias': ['Junction Device Component', 'Junction', 'Junction'], 'meaning': ['A device designed to join two or more things.', 'C1706311', 0.8780555129051208]}]}, {'CELLULAR_COMPONENT': [{'label': 'junctions', 'alias': ['intercellular junctions', 'Intercellular Junction', 'Junction, Intercellular', 'intercellular junction', 'intercellular junction', 'Intercellular junction', 'Intercellular junction', 'Junctions, Intercellular', 'Cell Junctions', 'cell junctions', 'Cell junctions', 'Cell Junction', 'Cell Junction', 'Junction, Cell', 'cell junction', 'cell junction', 'Cell junction', 'Cell junction', 'Junctions, Cell', 'cell-cell junction'], 'meaning': ['Direct contact of a cell with a neighboring cell. Most such junctions are too small to be resolved by light microscopy, but they can be visualized by conventional or freeze-fracture electron microscopy, both of which show that the interacting CELL MEMBRANE and often the underlying CYTOPLASM and the intervening EXTRACELLULAR SPACE are highly specialized in these regions. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p792)', 'C0021721', 0.8583899736404419]}]}]","{'In the last twenty years, three separate coronaviruses have left their typical animal hosts and became human pathogens.': [['the', 'DT', 'B-NP'], ['last', 'JJ', 'I-NP'], ['twenty', 'NN', 'I-NP'], ['have', 'VBP', 'O'], ['left', 'VBN', 'O'], ['became', 'VBD', 'O']], 'An area of research interest is coronavirus transcription regulation that uses an RNA-RNA mediated template-switching mechanism.': [['An', 'DT', 'B-NP'], ['area', 'NN', 'I-NP'], ['research', 'NN', 'B-NP'], ['interest', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['coronavirus', 'JJ', 'B-NP'], ['transcription', 'NN', 'I-NP'], ['regulation', 'NN', 'B-NP'], ['uses', 'VBZ', 'O'], ['an', 'DT', 'B-NP'], ['RNA-RNA', 'JJ', 'I-NP'], ['mediated', 'JJ', 'I-NP'], ['template-switching', 'NN', 'I-NP'], ['mechanism', 'NN', 'B-NP']], 'It is not known how different transcriptional stoichiometries of each viral gene are generated.': [['is', 'VBZ', 'O'], ['known', 'VBN', 'O'], ['each', 'DT', 'B-NP'], ['viral', 'JJ', 'I-NP'], ['gene', 'NN', 'I-NP'], ['are', 'VBP', 'O'], ['generated', 'VBN', 'O']], 'Analysis of SARS-CoV-2 RNA sequencing data from whole RNA transcriptomes identified TRS dependent and independent transcripts.': [['Analysis', 'NN', 'B-NP'], ['sequencing', 'VBG', 'O'], ['identified', 'VBD', 'O'], ['dependent', 'NN', 'B-NP']], 'Integration of transcripts and 5prime-UTR sequence motifs identified that the pentaloop and the stem-loop 3 were also located upstream of spliced genes.': [['Integration', 'NN', 'B-NP'], ['5prime-UTR', 'JJ', 'B-NP'], ['sequence', 'NN', 'I-NP'], ['identified', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['pentaloop', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['located', 'VBN', 'O'], ['upstream', 'NN', 'B-NP']], 'TRS independent transcripts were detected as likely non-polyadenylated.': [['were', 'VBD', 'O'], ['detected', 'VBN', 'O']], 'Additionally, a novel conserved sequence motif was discovered at either end of the TRS independent splice junctions.': [['a', 'DT', 'B-NP'], ['novel', 'NN', 'I-NP'], ['conserved', 'VBN', 'O'], ['sequence', 'NN', 'B-NP'], ['motif', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['discovered', 'VBN', 'O'], ['either', 'DT', 'B-NP'], ['end', 'NN', 'I-NP'], ['independent', 'JJ', 'B-NP'], ['splice', 'NN', 'I-NP']], 'While similar both SARS viruses generated similar TRS independent transcripts they were more abundant in SARS-CoV-2.': [['generated', 'VBD', 'O'], ['were', 'VBD', 'O']], 'TRS independent gene regulation requires investigation to determine its relationship to viral pathogenicity.': [['independent', 'JJ', 'B-NP'], ['gene', 'NN', 'I-NP'], ['regulation', 'NN', 'B-NP'], ['requires', 'VBZ', 'O'], ['investigation', 'NN', 'B-NP'], ['determine', 'VB', 'O'], ['relationship', 'NN', 'B-NP'], ['viral', 'JJ', 'B-NP'], ['pathogenicity', 'NN', 'I-NP']]}","{'In the last twenty years, three separate coronaviruses have left their typical animal hosts and became human pathogens.': [{'noun_phrase': ' last years separate coronaviruses', 'noun_connectors': ['left']}, {'noun_phrase': ' animal hosts', 'noun_connectors': ['and', 'became']}], 'An area of research interest is coronavirus transcription regulation that uses an RNA-RNA mediated template-switching mechanism.': [{'noun_phrase': ' area research interest coronavirus transcription regulation', 'noun_connectors': ['uses', 'mediated']}, {'noun_phrase': ' template', 'noun_connectors': ['switching']}], 'It is not known how different transcriptional stoichiometries of each viral gene are generated.': [{'noun_phrase': '', 'noun_connectors': ['known', 'how']}], 'Analysis of SARS-CoV-2 RNA sequencing data from whole RNA transcriptomes identified TRS dependent and independent transcripts.': [{'noun_phrase': ' Analysis SARS CoV-2 RNA', 'noun_connectors': ['sequencing']}, {'noun_phrase': ' data whole RNA transcriptomes', 'noun_connectors': ['identified']}, {'noun_phrase': ' TRS dependent', 'noun_connectors': ['and']}], 'Integration of transcripts and 5prime-UTR sequence motifs identified that the pentaloop and the stem-loop 3 were also located upstream of spliced genes.': [{'noun_phrase': ' Integration transcripts', 'noun_connectors': ['and']}, {'noun_phrase': ' sequence motifs', 'noun_connectors': ['identified']}, {'noun_phrase': ' pentaloop', 'noun_connectors': ['and']}, {'noun_phrase': ' stem loop', 'noun_connectors': ['also', 'located', 'upstream', 'spliced']}], 'TRS independent transcripts were detected as likely non-polyadenylated.': [], 'Additionally, a novel conserved sequence motif was discovered at either end of the TRS independent splice junctions.': [{'noun_phrase': '', 'noun_connectors': ['Additionally']}, {'noun_phrase': ' novel', 'noun_connectors': ['conserved']}, {'noun_phrase': ' sequence motif', 'noun_connectors': ['discovered']}], 'While similar both SARS viruses generated similar TRS independent transcripts they were more abundant in SARS-CoV-2.': [{'noun_phrase': ' similar SARS viruses', 'noun_connectors': ['generated']}, {'noun_phrase': ' transcripts', 'noun_connectors': ['more']}], 'TRS independent gene regulation requires investigation to determine its relationship to viral pathogenicity.': [{'noun_phrase': ' independent gene regulation', 'noun_connectors': ['requires']}, {'noun_phrase': ' investigation', 'noun_connectors': ['determine']}]}"
"[{'author_name': 'Michael L Li', 'author_inst': 'Massachusetts Institute of Technology'}, {'author_name': 'Hamza Tazi Bouardi', 'author_inst': 'Massachusetts Institute of Technology'}, {'author_name': 'Omar Skali Lami', 'author_inst': 'Massachusetts Institute of Technology'}, {'author_name': 'Thomas A Trikalinos', 'author_inst': 'Brown University'}, {'author_name': 'Nikolaos K Trichakis', 'author_inst': 'Massachusetts Institute of Technology'}, {'author_name': 'Dimitris Bertsimas', 'author_inst': 'Massachusetts Institute of Technology'}]",http://medrxiv.org/cgi/content/short/2020.06.23.20138693,Forecasting COVID-19 and Analyzing the Effect of Government Interventions,"One key question in the ongoing COVID-19 pandemic is understanding the impact of government interventions, and when society can return to normal. To this end, we develop DELPHI, a novel epidemiological model that captures the effect of under-detection and government intervention. We applied DELPHI across 167 geographical areas since early April, and recorded 6% and 11% two-week out-of-sample Median Absolute Percentage Error on cases and deaths respectively. Furthermore, DELPHI successfully predicted the large-scale epidemics in many areas months before, including US, UK and Russia. Using the extracted government response, we find mass gathering restrictions and school closings on average reduced infection rates the most, at 29.9 {+/-} 6.9% and 17.3 {+/-} 6.7%, respectively. The most stringent policy, stay-at-home, on average reduced the infection rate by 74.4 {+/-} 3.7% from baseline across countries that implemented it. We also illustrate how DELPHI can be extended to provide insights on reopening societies under different policies.",2020-06-24,medrxiv,6,"[{'GENE_OR_GENE_PRODUCT': [{'label': 'UK', 'alias': ['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'kingdom united', 'united kingdom', 'UNITED KINGDOM', 'UNITED KINGDOM', 'GBR', 'GBR', 'GBR', 'UK', 'UK - United Kingdom of Great Britain and Northern Ireland', 'United Kingdom of Great Britain and Northern Ireland', 'United Kingdom of Great Britain and Northern Ireland', 'GB', 'GB', 'United Kingdom of Great Britain and Northern Ireland (geographic location)'], 'meaning': ['Country in Northeastern Europe including Great Britain and the northern one-sixth of Ireland, located between the North Sea and north Atlantic Ocean. The capital is London.', 'C0041700', 1]}]}]","{'One key question in the ongoing COVID-19 pandemic is understanding the impact of government interventions, and when society can return to normal.': [['key', 'JJ', 'B-NP'], ['question', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['ongoing', 'JJ', 'I-NP'], ['COVID-19', 'JJ', 'I-NP'], ['pandemic', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['understanding', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['impact', 'NN', 'I-NP'], ['government', 'NN', 'B-NP'], ['society', 'NN', 'B-NP'], ['return', 'VB', 'O']], 'To this end, we develop DELPHI, a novel epidemiological model that captures the effect of under-detection and government intervention.': [['this', 'DT', 'B-NP'], ['end', 'NN', 'I-NP'], ['develop', 'VBP', 'O'], ['a', 'DT', 'B-NP'], ['novel', 'JJ', 'I-NP'], ['epidemiological', 'JJ', 'I-NP'], ['model', 'NN', 'I-NP'], ['captures', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['effect', 'NN', 'I-NP'], ['under-detection', 'NN', 'B-NP'], ['government', 'NN', 'B-NP'], ['intervention', 'NN', 'B-NP']], 'We applied DELPHI across 167 geographical areas since early April, and recorded 6% and 11% two-week out-of-sample Median Absolute Percentage Error on cases and deaths respectively.': [['applied', 'VBD', 'O'], ['recorded', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'Furthermore, DELPHI successfully predicted the large-scale epidemics in many areas months before, including US, UK and Russia.': [['predicted', 'VBD', 'O'], ['including', 'VBG', 'O']], 'Using the extracted government response, we find mass gathering restrictions and school closings on average reduced infection rates the most, at 29.9 {+/-} 6.9% and 17.3 {+/-} 6.7%, respectively.': [['Using', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['extracted', 'JJ', 'I-NP'], ['government', 'NN', 'I-NP'], ['response', 'NN', 'B-NP'], ['find', 'VBP', 'O'], ['mass', 'JJ', 'B-NP'], ['gathering', 'NN', 'I-NP'], ['school', 'NN', 'B-NP'], ['average', 'NN', 'B-NP'], ['reduced', 'VBN', 'O'], ['infection', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'The most stringent policy, stay-at-home, on average reduced the infection rate by 74.4 {+/-} 3.7% from baseline across countries that implemented it.': [['stringent', 'JJ', 'B-NP'], ['policy', 'NN', 'I-NP'], ['average', 'NN', 'B-NP'], ['reduced', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['infection', 'NN', 'I-NP'], ['rate', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['baseline', 'NN', 'B-NP'], ['implemented', 'VBD', 'O']], 'We also illustrate how DELPHI can be extended to provide insights on reopening societies under different policies.': [['illustrate', 'VBP', 'O'], ['be', 'VB', 'O'], ['extended', 'VBN', 'O'], ['provide', 'VB', 'O'], ['reopening', 'VBG', 'O']]}","{'One key question in the ongoing COVID-19 pandemic is understanding the impact of government interventions, and when society can return to normal.': [{'noun_phrase': ' key question ongoing COVID-19 pandemic', 'noun_connectors': ['understanding']}, {'noun_phrase': ' impact government interventions', 'noun_connectors': ['and', 'when']}], 'To this end, we develop DELPHI, a novel epidemiological model that captures the effect of under-detection and government intervention.': [{'noun_phrase': ' end', 'noun_connectors': ['develop']}, {'noun_phrase': ' model', 'noun_connectors': ['captures']}, {'noun_phrase': ' effect detection', 'noun_connectors': ['and']}], 'We applied DELPHI across 167 geographical areas since early April, and recorded 6% and 11% two-week out-of-sample Median Absolute Percentage Error on cases and deaths respectively.': [{'noun_phrase': '', 'noun_connectors': ['applied']}, {'noun_phrase': ' areas early April', 'noun_connectors': ['and', 'recorded']}, {'noun_phrase': ' %', 'noun_connectors': ['and']}, {'noun_phrase': ' % week', 'noun_connectors': ['out']}, {'noun_phrase': ' sample Median Absolute Percentage Error cases', 'noun_connectors': ['and']}], 'Furthermore, DELPHI successfully predicted the large-scale epidemics in many areas months before, including US, UK and Russia.': [{'noun_phrase': '', 'noun_connectors': ['Furthermore', 'successfully', 'predicted']}], 'Using the extracted government response, we find mass gathering restrictions and school closings on average reduced infection rates the most, at 29.9 {+/-} 6.9% and 17.3 {+/-} 6.7%, respectively.': [{'noun_phrase': '', 'noun_connectors': ['Using', 'extracted']}, {'noun_phrase': ' government response', 'noun_connectors': ['find']}, {'noun_phrase': ' gathering restrictions', 'noun_connectors': ['and']}, {'noun_phrase': ' school closings average reduced infection rates', 'noun_connectors': ['most']}, {'noun_phrase': ' %', 'noun_connectors': ['and']}], 'The most stringent policy, stay-at-home, on average reduced the infection rate by 74.4 {+/-} 3.7% from baseline across countries that implemented it.': [{'noun_phrase': '', 'noun_connectors': ['most']}, {'noun_phrase': ' policy', 'noun_connectors': ['stay']}, {'noun_phrase': ' home average', 'noun_connectors': ['reduced']}], 'We also illustrate how DELPHI can be extended to provide insights on reopening societies under different policies.': [{'noun_phrase': '', 'noun_connectors': ['also', 'illustrate', 'how', 'can', 'extended', 'provide']}, {'noun_phrase': ' insights', 'noun_connectors': ['reopening']}]}"
"[{'author_name': 'Bram Verstockt', 'author_inst': 'University Hospitals Leuven and KU Leuven, Leuven, Belgium'}, {'author_name': 'Sare Verstockt', 'author_inst': 'KU Leuven, Leuven, Belgium'}, {'author_name': 'Saeed Adbu Rahiman', 'author_inst': 'KU Leuven, Leuven, Belgium'}, {'author_name': 'Bo-Jun Ke', 'author_inst': 'KU Leuven, Leuven, Belgium'}, {'author_name': 'Kaline Arnauts', 'author_inst': 'KU Leuven, Leuven, Belgium'}, {'author_name': 'Isabelle Cleynen', 'author_inst': 'KU Leuven, Leuven, Belgium'}, {'author_name': 'Joao Sabino', 'author_inst': 'University Hospitals, Leuven and KU Leuven, Leuven, Belgium'}, {'author_name': 'Marc Ferrante', 'author_inst': 'University Hospitals, Leuven and KU Leuven, Leuven, Belgium'}, {'author_name': 'Gianluca Matteoli', 'author_inst': 'KU Leuven'}, {'author_name': 'Severine Vermeire', 'author_inst': 'University Hospitals, Leuven and KU Leuven, Leuven, Belgium'}]",http://biorxiv.org/cgi/content/short/2020.06.24.169383,Intestinal receptor of SARS-CoV-2 in inflamed IBD tissue is downregulated by HNF4A in ileum and upregulated by interferon regulating factors in colon,"Patients with IBD are considered immunosuppressed, but do not seem more vulnerable for COVID-19. Nevertheless, intestinal inflammation has shown an important risk factor for SARS-CoV-2 infection and prognosis. Therefore, we investigated the effect of intestinal inflammation on the viral intestinal entry mechanisms, including ACE2, in IBD. We collected (un)inflamed mucosal biopsies from CD (n=193) and UC (n=158) patients, and 51 matched non-IBD controls for RNA sequencing, differential gene expression and co-expression analysis. Organoids from UC patients were subjected to an inflammatory mix and processed for RNA sequencing. Transmural ileal biopsies were processed for single-cell (sc) sequencing. Publicly available colonic sc-RNA sequencing data, and microarrays from tissue pre/post anti-TNF therapy, were analyzed. In inflamed CD ileum, ACE2 was significantly decreased compared to control ileum (p=4.6E-07), whereas colonic ACE2 expression was higher in inflamed colon of CD/UC compared to control (p=8.3E-03; p=1.9E-03). Sc-RNA sequencing confirmed this ACE2 dysregulation, and exclusive epithelial ACE2 expression. Network analyses highlighted HNF4A as key regulator of ileal ACE2, while pro-inflammatory cytokines and interferon regulating factors regulated colonic ACE2. Inflammatory stimuli upregulated ACE2 in UC organoids (p=1.7E-02), not in non-IBD controls (p=9.1E-01). Anti-TNF therapy restored colonic ACE2 dysregulation in responders. Intestinal inflammation alters SARS-CoV-2 coreceptors in the intestine, with opposing effects in ileum and colon. HNF4A, an IBD susceptibility gene, is an important upstream regulator of ACE2 in ileum, whereas interferon signaling dominates in colon. Our data support the importance of adequate control of IBD in order to reduce risk of (complicated) COVID-19.",2020-06-24,biorxiv,10,"[{'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['ACE2 gene', 'ACE2 Gene', 'peptidyl-dipeptidase A', 'ACEH', 'Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene', 'ANGIOTENSIN I-CONVERTING ENZYME 2', 'angiotensin I converting enzyme 2', 'ACE2', 'ACE2', 'ACE2'], 'meaning': ['This gene plays a role in both proteolysis and vasodilation.', 'C1422064', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['BACE2 gene', 'BACE2 Gene', 'BETA-SITE APP-CLEAVING ENZYME 2', 'beta-site APP-cleaving enzyme 2', 'Beta-Site APP-Cleaving Enzyme 2 Gene', 'ALP56', 'ALP56', 'CEAP1', 'DRAP', 'DRAP', 'ASPARTIC-LIKE PROTEASE, 56-KD', 'DOWN SYNDROME REGION ASPARTIC PROTEASE', 'BACE2', 'BACE2', 'BACE2', 'BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2'], 'meaning': ['This gene is involved in proteolytic processing.', 'C1412728', 0.8900668025016785]}]}, {'PATHOLOGICAL_FORMATION': [{'label': 'UC', 'alias': ['Ulcerative Colitis', 'Ulcerative Colitis', 'Ulcerative Colitis', 'Ulcerative Colitis', 'Ulcerative Colitis', 'Ulcerative Colitis', 'COLITIS ULCERATIVE', 'COLITIS ULCERATIVE', 'COLITIS, ULCERATIVE', 'COLITIS, ULCERATIVE', 'colitis ulcerative', 'Ulcerative colitis', 'Ulcerative colitis', 'Ulcerative colitis', 'Ulcerative colitis', 'Ulcerative colitis', 'Ulcerative colitis', 'Ulcerative colitis', 'ULCERATIVE COLITIS', 'ULCERATIVE COLITIS', 'ULCERATIVE COLITIS', 'ULCERATIVE COLITIS', 'ulcerative colitis', 'ulcerative colitis', 'ulcerative colitis', 'ulcerative colitis', 'ulcerative colitis', 'Ulcerative colitis, NOS', 'Colitis, Ulcerative', 'Colitis, Ulcerative', 'Colitis Ulcerative', 'Idiopathic Proctocolitis', 'Idiopathic Proctocolitis', 'Idiopathic proctocolitis', 'Idiopathic proctocolitis', 'Idiopathic proctocolitis', 'INFLAMMATORY BOWEL DISEASE ULCERATIVE COLITIS', 'Colitis Gravis', 'Colitis Gravis', 'Colitis gravis', 'Colitis gravis, NOS', 'UC - Ulcerative colitis', 'Ulcerative colitis, unspecified', 'Inflammatory Bowel Disease, Ulcerative Colitis Type', 'Inflammatory Bowel Disease, Ulcerative Colitis Type', 'Colitis ulcerosa', 'Ulcerative colitis as main diagnosis for the colon', 'Ulcerative colitis as reason for lower g.i. examination', 'Ulcerative colitis (disorder)', 'Colitis, Ulcerative [Disease/Finding]', 'uc'], 'meaning': ['Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.', 'C0009324', 1]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'TISSUE': [{'label': 'Organoids', 'alias': ['organoids', 'Organoid', 'organoid'], 'meaning': ['An organization of cells into an organ-like structure. Organoids can be generated in culture. They are also found in certain neoplasms.', 'C0029250', 1]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'TISSUE': [{'label': 'tissue', 'alias': ['Body tissue', 'Body tissue', 'body tissue', 'Body Tissues', 'Body tissue, NOS', 'body tissues', 'Tissues', 'Tissues', 'Tissues', 'Tissues', 'tissues', 'tissue', 'tissue', 'tissue', 'tissue', 'Tissue, NOS', 'TISSUE', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Normal Tissue', 'Textus', 'Textus', 'Tiss', 'Body tissue structure (body structure)', 'Body tissue structure', 'Portion of tissue'], 'meaning': ['Collections of differentiated CELLS, such as EPITHELIUM; CONNECTIVE TISSUE; MUSCLES; and NERVE TISSUE. Tissues are cooperatively arranged to form organs with specialized functions such as RESPIRATION; DIGESTION; REPRODUCTION; MOVEMENT; and others.', 'C0040300', 1]}]}, {'TISSUE': [{'label': 'tissue', 'alias': ['Tissue'], 'meaning': [None, 'C1547928', 1]}]}, {'MULTI-TISSUE_STRUCTURE': [{'label': 'ileum', 'alias': ['ileum', 'ileum', 'ileum', 'Ileum', 'Ileum', 'Ileum', 'Ileum', 'Ileum', 'Ileum', 'Ileum', 'Ileum', 'Ileum', 'Ileum', 'Ileum', 'Ileum', 'Ileum', 'ILEUM', 'ILEUM', 'Ileum, NOS', 'Ileal', 'ileal', 'Ileo-', 'ileo', 'ileos', 'SMALL INTESTINE, ILEUM', 'Ileal structure', 'Ileal structure (body structure)'], 'meaning': ['The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.', 'C0020885', 1]}]}, {'MULTI-TISSUE_STRUCTURE': [{'label': 'ileum', 'alias': [], 'meaning': [None, 'C0391906', 0.9698081016540527]}]}, {'ORGAN': [{'label': 'colon', 'alias': ['Colon'], 'meaning': [None, 'C3888384', 1]}]}, {'ORGAN': [{'label': 'colon', 'alias': ['Colon structure (body structure)', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'Colon', 'colon', 'colon', 'colon', 'colon', 'COLON', 'COLON', 'Colon, NOS', 'colons', 'Colo-', 'Colonic', 'Colonic', 'colonic', 'Colon structure', 'colon structure', 'LARGE INTESTINE, COLON', 'Colon (Anatomy)', 'Colon (Anatomy)', 'Colonic (qualifier value)'], 'meaning': ['The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON.', 'C0009368', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['ACE2 gene', 'ACE2 Gene', 'peptidyl-dipeptidase A', 'ACEH', 'Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene', 'ANGIOTENSIN I-CONVERTING ENZYME 2', 'angiotensin I converting enzyme 2', 'ACE2', 'ACE2', 'ACE2'], 'meaning': ['This gene plays a role in both proteolysis and vasodilation.', 'C1422064', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['BACE2 gene', 'BACE2 Gene', 'BETA-SITE APP-CLEAVING ENZYME 2', 'beta-site APP-cleaving enzyme 2', 'Beta-Site APP-Cleaving Enzyme 2 Gene', 'ALP56', 'ALP56', 'CEAP1', 'DRAP', 'DRAP', 'ASPARTIC-LIKE PROTEASE, 56-KD', 'DOWN SYNDROME REGION ASPARTIC PROTEASE', 'BACE2', 'BACE2', 'BACE2', 'BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2'], 'meaning': ['This gene is involved in proteolytic processing.', 'C1412728', 0.8900668025016785]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'HNF4A', 'alias': ['HNF4A gene', 'HNF4A gene', 'HEPATOCYTE NUCLEAR FACTOR 4', 'HEPATOCYTE NUCLEAR FACTOR 4-ALPHA', 'hepatocyte nuclear factor 4 alpha', 'HNF4', 'HNF4', 'NR2A1', 'TRANSCRIPTION FACTOR 14, HEPATIC NUCLEAR FACTOR', 'HNF4-ALPHA', 'HNF4A', 'HNF4A', 'TCF14'], 'meaning': [None, 'C1415629', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['ACE2 gene', 'ACE2 Gene', 'peptidyl-dipeptidase A', 'ACEH', 'Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene', 'ANGIOTENSIN I-CONVERTING ENZYME 2', 'angiotensin I converting enzyme 2', 'ACE2', 'ACE2', 'ACE2'], 'meaning': ['This gene plays a role in both proteolysis and vasodilation.', 'C1422064', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['BACE2 gene', 'BACE2 Gene', 'BETA-SITE APP-CLEAVING ENZYME 2', 'beta-site APP-cleaving enzyme 2', 'Beta-Site APP-Cleaving Enzyme 2 Gene', 'ALP56', 'ALP56', 'CEAP1', 'DRAP', 'DRAP', 'ASPARTIC-LIKE PROTEASE, 56-KD', 'DOWN SYNDROME REGION ASPARTIC PROTEASE', 'BACE2', 'BACE2', 'BACE2', 'BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2'], 'meaning': ['This gene is involved in proteolytic processing.', 'C1412728', 0.8900668025016785]}]}, {'ORGANISM_SUBDIVISION': [{'label': 'Intestinal', 'alias': ['Intestines', 'Intestines', 'Intestines', 'Intestines', 'Intestines', 'intestines', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestines, NOS', 'intestine', 'intestine', 'intestine', 'intestine', 'INTESTINE', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'bowel', 'bowel', 'Bowel, NOS', 'bowels', 'Intestinal tract', 'Intestinal tract', 'Intestinal tract', 'intestinal tract', 'Intestinal tract, NOS', 'Intestinal', 'Intestinal', 'Intestinal', 'Intestinal', 'Intestinal', 'intestinal', 'intestinal', 'Intestino-', 'Intestinal structure', 'intestinal structure', 'Gut', 'Intestinal structure (body structure)', 'Intestinal (qualifier value)'], 'meaning': ['The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE.', 'C0021853', 1]}]}, {'ORGANISM_SUBDIVISION': [{'label': 'Intestinal', 'alias': ['Intestinal Well Differentiated Endocrine Tumor', 'Intestinal NET', 'Intestinal Well Differentiated Endocrine Tumor/Carcinoma'], 'meaning': ['A well differentiated, low or intermediate grade tumor with neuroendocrine differentiation that arises from the small or large intestine.', 'C3272529', 0.8185635805130005]}]}, {'ORGANISM_SUBDIVISION': [{'label': 'intestine', 'alias': ['Intestines', 'Intestines', 'Intestines', 'Intestines', 'Intestines', 'intestines', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestines, NOS', 'intestine', 'intestine', 'intestine', 'intestine', 'INTESTINE', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'bowel', 'bowel', 'Bowel, NOS', 'bowels', 'Intestinal tract', 'Intestinal tract', 'Intestinal tract', 'intestinal tract', 'Intestinal tract, NOS', 'Intestinal', 'Intestinal', 'Intestinal', 'Intestinal', 'Intestinal', 'intestinal', 'intestinal', 'Intestino-', 'Intestinal structure', 'intestinal structure', 'Gut', 'Intestinal structure (body structure)', 'Intestinal (qualifier value)'], 'meaning': ['The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE.', 'C0021853', 1]}]}, {'ORGANISM_SUBDIVISION': [{'label': 'intestine', 'alias': ['Intestinal Wall Tissue', 'INTESTINE'], 'meaning': ['The tissue that forms the wall of the small and large intestine. It consists of mucosa, submucosa, muscular coat, and serosal surface.', 'C1708548', 1]}]}]","{'Patients with IBD are considered immunosuppressed, but do not seem more vulnerable for COVID-19.': [['are', 'VBP', 'O'], ['considered', 'VBN', 'O'], ['do', 'VBP', 'O'], ['seem', 'VB', 'O']], 'Nevertheless, intestinal inflammation has shown an important risk factor for SARS-CoV-2 infection and prognosis.': [['intestinal', 'JJ', 'B-NP'], ['inflammation', 'NN', 'I-NP'], ['has', 'VBZ', 'O'], ['shown', 'VBN', 'O'], ['an', 'DT', 'B-NP'], ['important', 'JJ', 'I-NP'], ['risk', 'NN', 'I-NP'], ['factor', 'NN', 'B-NP'], ['infection', 'NN', 'B-NP'], ['prognosis', 'NN', 'B-NP']], 'Therefore, we investigated the effect of intestinal inflammation on the viral intestinal entry mechanisms, including ACE2, in IBD.': [['investigated', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['effect', 'NN', 'I-NP'], ['intestinal', 'JJ', 'B-NP'], ['inflammation', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['viral', 'JJ', 'I-NP'], ['intestinal', 'JJ', 'I-NP'], ['entry', 'NN', 'I-NP'], ['including', 'VBG', 'O']], 'We collected (un)inflamed mucosal biopsies from CD (n=193) and UC (n=158) patients, and 51 matched non-IBD controls for RNA sequencing, differential gene expression and co-expression analysis.': [['collected', 'VBD', 'O'], ['inflamed', 'VBD', 'O'], ['n=193', 'NN', 'B-NP'], ['matched', 'VBD', 'O'], ['non-IBD', 'NN', 'B-NP'], ['sequencing', 'NN', 'B-NP'], ['differential', 'JJ', 'B-NP'], ['gene', 'NN', 'I-NP'], ['expression', 'NN', 'B-NP'], ['co-expression', 'NN', 'B-NP'], ['analysis', 'NN', 'B-NP']], 'Organoids from UC patients were subjected to an inflammatory mix and processed for RNA sequencing.': [['were', 'VBD', 'O'], ['subjected', 'VBN', 'O'], ['an', 'DT', 'B-NP'], ['inflammatory', 'JJ', 'I-NP'], ['mix', 'NN', 'I-NP'], ['processed', 'VBN', 'O'], ['sequencing', 'NN', 'B-NP']], 'Transmural ileal biopsies were processed for single-cell (sc) sequencing.': [['Transmural', 'JJ', 'B-NP'], ['ileal', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['processed', 'VBN', 'O'], ['single-cell', 'NN', 'B-NP'], ['sc', 'NN', 'B-NP'], ['sequencing', 'NN', 'B-NP']], 'Publicly available colonic sc-RNA sequencing data, and microarrays from tissue pre/post anti-TNF therapy, were analyzed.': [['available', 'JJ', 'B-NP'], ['colonic', 'JJ', 'I-NP'], ['sc-RNA', 'JJ', 'I-NP'], ['sequencing', 'NN', 'I-NP'], ['tissue', 'NN', 'B-NP'], ['pre/post', 'VBN', 'O'], ['anti-TNF', 'JJ', 'B-NP'], ['therapy', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['analyzed', 'VBN', 'O']], 'In inflamed CD ileum, ACE2 was significantly decreased compared to control ileum (p=4.6E-07), whereas colonic ACE2 expression was higher in inflamed colon of CD/UC compared to control (p=8.3E-03; p=1.9E-03).': [['ileum', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['decreased', 'VBN', 'O'], ['compared', 'VBN', 'O'], ['control', 'VB', 'O'], ['ileum', 'NN', 'B-NP'], ['expression', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['inflamed', 'JJ', 'B-NP'], ['colon', 'NN', 'I-NP'], ['compared', 'VBN', 'O'], ['control', 'VB', 'O']], 'Sc-RNA sequencing confirmed this ACE2 dysregulation, and exclusive epithelial ACE2 expression.': [['Sc-RNA', 'JJ', 'B-NP'], ['sequencing', 'NN', 'I-NP'], ['confirmed', 'VBD', 'O'], ['dysregulation', 'NN', 'B-NP'], ['expression', 'NN', 'B-NP']], 'Network analyses highlighted HNF4A as key regulator of ileal ACE2, while pro-inflammatory cytokines and interferon regulating factors regulated colonic ACE2.': [['Network', 'NN', 'B-NP'], ['highlighted', 'VBD', 'O'], ['key', 'JJ', 'B-NP'], ['regulator', 'NN', 'I-NP'], ['interferon', 'NN', 'B-NP'], ['regulating', 'NN', 'B-NP'], ['regulated', 'VBD', 'O']], 'Inflammatory stimuli upregulated ACE2 in UC organoids (p=1.7E-02), not in non-IBD controls (p=9.1E-01).': [['upregulated', 'VBD', 'O'], ['p=1.7E-02', 'NN', 'B-NP'], ['p=9.1E-01', 'NN', 'B-NP']], 'Anti-TNF therapy restored colonic ACE2 dysregulation in responders.': [['Anti-TNF', 'JJ', 'B-NP'], ['therapy', 'NN', 'I-NP'], ['restored', 'VBD', 'O'], ['dysregulation', 'NN', 'B-NP']], 'Intestinal inflammation alters SARS-CoV-2 coreceptors in the intestine, with opposing effects in ileum and colon.': [['Intestinal', 'JJ', 'B-NP'], ['inflammation', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['intestine', 'NN', 'I-NP'], ['opposing', 'VBG', 'O'], ['ileum', 'NN', 'B-NP'], ['colon', 'NN', 'B-NP']], 'HNF4A, an IBD susceptibility gene, is an important upstream regulator of ACE2 in ileum, whereas interferon signaling dominates in colon.': [['susceptibility', 'NN', 'B-NP'], ['gene', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['an', 'DT', 'B-NP'], ['important', 'JJ', 'I-NP'], ['upstream', 'JJ', 'I-NP'], ['regulator', 'NN', 'I-NP'], ['ileum', 'NN', 'B-NP'], ['interferon', 'VBP', 'O'], ['signaling', 'VBG', 'O'], ['colon', 'NN', 'B-NP']], 'Our data support the importance of adequate control of IBD in order to reduce risk of (complicated) COVID-19.': [['support', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['importance', 'NN', 'I-NP'], ['adequate', 'JJ', 'B-NP'], ['control', 'NN', 'I-NP'], ['order', 'NN', 'B-NP'], ['reduce', 'VB', 'O'], ['risk', 'NN', 'B-NP'], ['complicated', 'VBN', 'O']]}","{'Patients with IBD are considered immunosuppressed, but do not seem more vulnerable for COVID-19.': [{'noun_phrase': ' Patients IBD', 'noun_connectors': ['considered', 'but', 'seem', 'more']}], 'Nevertheless, intestinal inflammation has shown an important risk factor for SARS-CoV-2 infection and prognosis.': [{'noun_phrase': '', 'noun_connectors': ['Nevertheless']}, {'noun_phrase': ' inflammation', 'noun_connectors': ['shown']}, {'noun_phrase': ' risk factor SARS CoV-2 infection', 'noun_connectors': ['and']}], 'Therefore, we investigated the effect of intestinal inflammation on the viral intestinal entry mechanisms, including ACE2, in IBD.': [{'noun_phrase': '', 'noun_connectors': ['Therefore', 'investigated']}], 'We collected (un)inflamed mucosal biopsies from CD (n=193) and UC (n=158) patients, and 51 matched non-IBD controls for RNA sequencing, differential gene expression and co-expression analysis.': [{'noun_phrase': '', 'noun_connectors': ['collected']}, {'noun_phrase': ' biopsies CD n=193', 'noun_connectors': ['and']}, {'noun_phrase': ' patients', 'noun_connectors': ['and', 'matched']}, {'noun_phrase': ' controls RNA sequencing differential gene expression', 'noun_connectors': ['and']}], 'Organoids from UC patients were subjected to an inflammatory mix and processed for RNA sequencing.': [{'noun_phrase': ' Organoids UC patients', 'noun_connectors': ['subjected']}, {'noun_phrase': ' mix', 'noun_connectors': ['and', 'processed']}], 'Transmural ileal biopsies were processed for single-cell (sc) sequencing.': [{'noun_phrase': ' Transmural ileal biopsies', 'noun_connectors': ['processed']}], 'Publicly available colonic sc-RNA sequencing data, and microarrays from tissue pre/post anti-TNF therapy, were analyzed.': [{'noun_phrase': '', 'noun_connectors': ['Publicly']}, {'noun_phrase': ' RNA sequencing data', 'noun_connectors': ['and']}, {'noun_phrase': ' microarrays tissue', 'noun_connectors': ['pre']}], 'In inflamed CD ileum, ACE2 was significantly decreased compared to control ileum (p=4.6E-07), whereas colonic ACE2 expression was higher in inflamed colon of CD/UC compared to control (p=8.3E-03; p=1.9E-03).': [{'noun_phrase': ' inflamed CD ileum ACE2', 'noun_connectors': ['significantly', 'decreased', 'compared', 'control']}, {'noun_phrase': ' expression higher', 'noun_connectors': ['inflamed']}, {'noun_phrase': ' colon CD UC', 'noun_connectors': ['compared', 'control']}], 'Sc-RNA sequencing confirmed this ACE2 dysregulation, and exclusive epithelial ACE2 expression.': [{'noun_phrase': ' Sc RNA sequencing', 'noun_connectors': ['confirmed']}, {'noun_phrase': ' dysregulation', 'noun_connectors': ['and']}], 'Network analyses highlighted HNF4A as key regulator of ileal ACE2, while pro-inflammatory cytokines and interferon regulating factors regulated colonic ACE2.': [{'noun_phrase': ' Network analyses', 'noun_connectors': ['highlighted']}, {'noun_phrase': ' regulator ileal ACE2 pro - inflammatory cytokines', 'noun_connectors': ['and']}], 'Inflammatory stimuli upregulated ACE2 in UC organoids (p=1.7E-02), not in non-IBD controls (p=9.1E-01).': [{'noun_phrase': ' Inflammatory stimuli', 'noun_connectors': ['upregulated']}], 'Anti-TNF therapy restored colonic ACE2 dysregulation in responders.': [{'noun_phrase': ' Anti - TNF therapy', 'noun_connectors': ['restored']}], 'Intestinal inflammation alters SARS-CoV-2 coreceptors in the intestine, with opposing effects in ileum and colon.': [{'noun_phrase': ' Intestinal inflammation', 'noun_connectors': ['alters']}, {'noun_phrase': ' CoV-2 coreceptors intestine', 'noun_connectors': ['opposing']}, {'noun_phrase': ' effects ileum', 'noun_connectors': ['and']}], 'HNF4A, an IBD susceptibility gene, is an important upstream regulator of ACE2 in ileum, whereas interferon signaling dominates in colon.': [{'noun_phrase': ' HNF4A IBD susceptibility gene important upstream regulator ACE2 ileum interferon', 'noun_connectors': ['signaling']}], 'Our data support the importance of adequate control of IBD in order to reduce risk of (complicated) COVID-19.': [{'noun_phrase': ' data', 'noun_connectors': ['support']}, {'noun_phrase': ' importance adequate control IBD order', 'noun_connectors': ['reduce']}]}"
"[{'author_name': 'Darshan S Chandrashekar', 'author_inst': 'University of Alabama at Birmingham'}, {'author_name': 'Upender Manne', 'author_inst': 'University of Alabama at Birmingham'}, {'author_name': 'Sooryanarayana Varambally', 'author_inst': 'University of Alabama at Birmingham'}]",http://biorxiv.org/cgi/content/short/2020.06.24.169268,Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells,"Understanding the molecular mechanism of SARS-CoV-2 infection (the cause of COVID-19) is a scientific priority for 2020. Various research groups are working toward development of vaccines and drugs, and many have published genomic and transcriptomic data related to this viral infection. The power inherent in publicly available data can be demonstrated via comparative transcriptome analyses. In the current study, we collected high-throughput gene expression data related to human lung epithelial cells infected with SARS-CoV-2 or other respiratory viruses (SARS, H1N1, rhinovirus, avian influenza, and Dhori) and compared the effect of these viruses on the human transcriptome. The analyses identified fifteen genes specifically expressed in cells transfected with SARS-CoV-2; these included CSF2 (colony-stimulating factor 2) and S100A8 and S100A9 (calcium-binding proteins), all of which are involved in lung/respiratory disorders. The analyses showed that genes involved in the Type1 interferon signaling pathway and the apoptosis process are commonly altered by infection of SARS-CoV-2 and influenza viruses. Furthermore, results of protein-protein interaction analyses were consistent with a functional role of CSF2 in COVID-19 disease. In conclusion, our analysis has revealed cellular genes associated with SARS-CoV-2 infection of the human lung epithelium; these are potential therapeutic targets.",2020-06-24,biorxiv,3,"[{'ORGANISM': [{'label': 'human lung epithelial cells', 'alias': ['Epithelial Cells', 'Epithelial Cells', 'Epithelial Cells', 'cells epithelial', 'Epithelial cells', 'Epithelial cells', 'Epithelial cells', 'Epithelial cells', 'Epithelial cells', 'epithelial cells', 'Epithelial cell, NOS', 'Cell, Epithelial', 'Epithelial Cell', 'Epithelial Cell', 'cell epithelial', 'epithelial cell', 'epithelial cell', 'Epithelial cell', 'Epithelial cell', 'Epithelial cell', 'Cells, Epithelial', 'Epitheliocyte', 'Epitheliocyte', 'Epithelial cell (cell)'], 'meaning': ['Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.', 'C0014597', 0.7833053469657898]}]}, {'ORGANISM': [{'label': 'human lung epithelial cells', 'alias': ['Squamous Transitional Epithelial Cell Count', 'Epithelial Cells', 'Squamous Transitional Epithelial Cells', 'Squamous Transitional Epithelial Cells', 'EPISQTCE'], 'meaning': ['The determination of the number of squamous transitional epithelial cells present in a urine sample.', 'C2699513', 0.7833053469657898]}]}, {'ORGANISM': [{'label': 'H1N1', 'alias': ['Serotype H1N1 (qualifier value)', 'Serotype H1N1'], 'meaning': [None, 'C0580264', 1]}]}, {'ORGANISM': [{'label': 'H1N1', 'alias': ['Influenza A virus subtype H1N1', 'INFLUENZA A VIRUS SUBTYPE H1N1', 'Influenza A Virus H1N1 Subtype', 'H1N1 Virus', 'H1N1 Viruses', 'Viruses, H1N1', 'Virus, H1N1', 'Influenza A (H1N1) virus', 'Influenza A (H1N1) Virus', 'Influenza virus A (H1N1)', 'Influenza A virus subtype H1N1 (organism)', 'Swine-origin influenza A (H1N1) virus', 'Swine Influenza A (H1N1) Virus'], 'meaning': ['A strain of swine influenza A virus identified as the causative agent of the swine flu epidemic of Spring 2009. It is highly contagious and susceptible to the antiviral medications.', 'C1615607', 0.8686911463737488]}]}, {'ORGANISM': [{'label': 'human', 'alias': ['Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'homo sapiens', 'Humans', 'humans', 'humans', 'Human', 'Human', 'Human', 'Human', 'Human', 'Human', 'Human', 'human', 'human', 'human', 'Man', 'Man', 'Man', 'Man', 'man', 'man', 'Man and woman', 'FAMILY OF MAN', 'Man (Taxonomy)', 'Homo sapiens (organism)', 'Human - origin', 'Human - origin (qualifier value)', 'Man, Modern', 'Modern Man', 'Human, General'], 'meaning': ['Members of the species Homo sapiens.', 'C0086418', 1]}]}, {'ORGANISM': [{'label': 'human', 'alias': ['Human Use'], 'meaning': ['A product has been approved for use in humans.', 'C4055445', 0.7751905918121338]}]}, {'CELL': [{'label': 'cells', 'alias': ['Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'cells', 'cells', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'The Cell', 'Cell, NOS', 'cell', 'cell', 'cell', 'cell', 'THE CELL', 'the cell', '{Cells}', 'Cellular', 'Cell structure', 'Cellular structures', 'Cellular structure', 'Cell Type', 'Cell Types', 'Cellula', 'Cellula', 'Set of cells', 'Set of cells', 'Cells set', 'Cell structure (cell structure)', 'Normal cell', 'Normal Cell'], 'meaning': ['The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.', 'C0007634', 0.9999999403953552]}]}, {'CELL': [{'label': 'cells', 'alias': ['Cells [Chemical/Ingredient]', 'Cells'], 'meaning': [None, 'C3282337', 0.9999999403953552]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'S100A8', 'alias': ['S100A8 wt Allele', 'CP-10', 'MIF', 'S100 Calcium Binding Protein A8 wt Allele', '60B8AG', 'CAGA', 'CFAG', 'CGLA', 'L1Ag', 'MA387', 'MRP8', 'NIF', 'P8', 'S100A8', 'S100 Calcium Binding Protein A8 (Calgranulin A) Gene'], 'meaning': ['Human S100A8 wild-type allele is located within 1q21 and is approximately 1 kb in length. This allele, which encodes S100-A8 protein, is involved in cell cycle progression and differentiation and may play a role in casein kinase inhibition.', 'C1704875', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'S100A8', 'alias': ['Protein S100-A8', 'Calgranulin A', 'calgranulin A', 'Cystic Fibrosis Antigen', 'CP-10', 'MIF', 'Urinary Stone Protein Band A', 'Migration Inhibitory Factor-Related Protein 8', 'S100 Calcium Binding Protein A8', 'S100 calcium binding protein A8', 'S100 Calcium-Binding Protein A8', 'CAGA', 'Calprotectin L1L Subunit', 'CFAG', 'CGLA', 'Leukocyte L1 Complex Light Chain', 'L1Ag', 'MRP8', 'NIF', 'p8', 'S100A8', 'Myeloid-Related Protein 8'], 'meaning': ['A protein that is made by many different types of cells and is involved in processes that take place both inside and outside of the cell. It is made in larger amounts in inflammatory diseases such as rheumatoid arthritis, and in some types of cancer. It is being studied as a biomarker for breast cancer.', 'C4281719', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'S100A9', 'alias': ['S100A9 gene', 'S100A9 Gene', 'CALGRANULIN B', 'CALPROTECTIN', 'MIF', 'S100 Calcium Binding Protein A9 Gene', '60B8AG', 'S100 CALCIUM-BINDING PROTEIN A9', 'S100 calcium binding protein A9', 'CAGB', 'CGLB', 'CGLB', 'LIAG', 'MAC387', 'MRP14', 'MRP14', 'NIF', 'P14', 'S100A9', 'S100A9', 'S100A9', 'CYSTIC FIBROSIS ANTIGEN B', 'S100A9/S100A8 COMPLEX', 'MYELOID-RELATED PROTEIN 14'], 'meaning': ['This gene plays a regulatory role in calcium-binding interactions and may play a role in intermediate filament regulation.', 'C1335798', 0.9999999403953552]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'S100A9', 'alias': ['Protein S100-A9', 'Calgranulin B', 'calgranulin B', 'Calgranulin-B', 'MIF', 'MRP-14', 'Migration Inhibitory Factor-Related Protein 14', 'S100 Calcium Binding Protein A9', 'S100 calcium binding protein A9', 'S100 Calcium-Binding Protein A9', 'CAGB', 'Calprotectin L1H Subunit', 'CFAG', 'CGLB', 'Leukocyte L1 Complex Heavy Chain', 'L1Ag', 'MRP14', 'NIF', 'p14', 'S100A9', 'Myeloid-Related Protein 14'], 'meaning': ['A protein that is made by many different types of cells and is involved in processes that take place both inside and outside of the cell. It is made in larger amounts in inflammatory diseases such as rheumatoid arthritis, and in some types of cancer. It is being studied as a biomarker for breast cancer.', 'C4281724', 0.9999999403953552]}]}, {'CELL': [{'label': 'cellular', 'alias': ['Cellular', 'cellular', 'CELLULAR', 'Cellularity', 'Cellularity', 'Cellularity', 'Cellularity', 'Cellularity Grade', 'Cellularity Measurement'], 'meaning': ['The determination of the amount of degree, quality or condition of cells present in a sample.', 'C0178539', 0.9999999403953552]}]}, {'CELL': [{'label': 'cellular', 'alias': ['Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'cells', 'cells', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'The Cell', 'Cell, NOS', 'cell', 'cell', 'cell', 'cell', 'THE CELL', 'the cell', '{Cells}', 'Cellular', 'Cell structure', 'Cellular structures', 'Cellular structure', 'Cell Type', 'Cell Types', 'Cellula', 'Cellula', 'Set of cells', 'Set of cells', 'Cells set', 'Cell structure (cell structure)', 'Normal cell', 'Normal Cell'], 'meaning': ['The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.', 'C0007634', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'human lung epithelium', 'alias': ['Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'epithelium', 'epithelium', 'epithelium', 'epithelium', 'Epithelium, NOS', 'Epithelial Tissue', 'Epithelial Tissue', 'Epithelial tissue', 'Epithelial tissue', 'Epithelial tissue', 'Epithelial tissue', 'epithelial tissue', 'epithelial tissue', 'Epithelial tissue, NOS', 'epithelial tissues', 'Epithelial Tissues', 'Tissues, Epithelial', 'Tissue, Epithelial', 'Textus epithelialis', 'Textus epithelialis', 'Epithelium (body structure)', 'Portion of epithelium'], 'meaning': ['The layers of EPITHELIAL CELLS which cover the inner and outer surfaces of the cutaneous, mucus, and serous tissues and glands of the body.', 'C0014609', 0.7193512916564941]}]}]","{'Understanding the molecular mechanism of SARS-CoV-2 infection (the cause of COVID-19) is a scientific priority for 2020.': [['Understanding', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['molecular', 'JJ', 'I-NP'], ['mechanism', 'NN', 'I-NP'], ['infection', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['cause', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['scientific', 'JJ', 'I-NP'], ['priority', 'NN', 'I-NP']], 'Various research groups are working toward development of vaccines and drugs, and many have published genomic and transcriptomic data related to this viral infection.': [['Various', 'JJ', 'B-NP'], ['research', 'NN', 'I-NP'], ['are', 'VBP', 'O'], ['working', 'VBG', 'O'], ['development', 'NN', 'B-NP'], ['have', 'VBP', 'O'], ['published', 'VBN', 'O'], ['related', 'VBN', 'O'], ['this', 'DT', 'B-NP'], ['viral', 'JJ', 'I-NP'], ['infection', 'NN', 'I-NP']], 'The power inherent in publicly available data can be demonstrated via comparative transcriptome analyses.': [['The', 'DT', 'B-NP'], ['power', 'NN', 'I-NP'], ['inherent', 'NN', 'B-NP'], ['be', 'VB', 'O'], ['demonstrated', 'VBN', 'O'], ['comparative', 'JJ', 'B-NP'], ['transcriptome', 'NN', 'I-NP']], 'In the current study, we collected high-throughput gene expression data related to human lung epithelial cells infected with SARS-CoV-2 or other respiratory viruses (SARS, H1N1, rhinovirus, avian influenza, and Dhori) and compared the effect of these viruses on the human transcriptome.': [['the', 'DT', 'B-NP'], ['current', 'JJ', 'I-NP'], ['study', 'NN', 'I-NP'], ['collected', 'VBD', 'O'], ['high-throughput', 'JJ', 'B-NP'], ['gene', 'NN', 'I-NP'], ['expression', 'NN', 'B-NP'], ['related', 'VBN', 'O'], ['human', 'JJ', 'B-NP'], ['lung', 'NN', 'I-NP'], ['infected', 'VBN', 'O'], ['other', 'JJ', 'B-NP'], ['respiratory', 'NN', 'I-NP'], ['rhinovirus', 'NN', 'B-NP'], ['avian', 'JJ', 'B-NP'], ['influenza', 'NN', 'I-NP'], ['compared', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['effect', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['human', 'JJ', 'I-NP'], ['transcriptome', 'NN', 'I-NP']], 'The analyses identified fifteen genes specifically expressed in cells transfected with SARS-CoV-2; these included CSF2 (colony-stimulating factor 2) and S100A8 and S100A9 (calcium-binding proteins), all of which are involved in lung/respiratory disorders.': [['identified', 'VBD', 'O'], ['expressed', 'VBN', 'O'], ['transfected', 'VBN', 'O'], ['included', 'VBD', 'O'], ['colony-stimulating', 'JJ', 'B-NP'], ['factor', 'NN', 'I-NP'], ['are', 'VBP', 'O'], ['involved', 'VBN', 'O'], ['lung/respiratory', 'NN', 'B-NP']], 'The analyses showed that genes involved in the Type1 interferon signaling pathway and the apoptosis process are commonly altered by infection of SARS-CoV-2 and influenza viruses.': [['showed', 'VBD', 'O'], ['involved', 'VBN', 'O'], ['interferon', 'NN', 'B-NP'], ['signaling', 'VBG', 'O'], ['pathway', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['apoptosis', 'NN', 'I-NP'], ['process', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['altered', 'VBN', 'O'], ['infection', 'NN', 'B-NP']], 'Furthermore, results of protein-protein interaction analyses were consistent with a functional role of CSF2 in COVID-19 disease.': [['protein-protein', 'JJ', 'B-NP'], ['interaction', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['functional', 'JJ', 'I-NP'], ['role', 'NN', 'I-NP'], ['disease', 'NN', 'B-NP']], 'In conclusion, our analysis has revealed cellular genes associated with SARS-CoV-2 infection of the human lung epithelium; these are potential therapeutic targets.': [['conclusion', 'NN', 'B-NP'], ['analysis', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['revealed', 'VBN', 'O'], ['associated', 'VBN', 'O'], ['infection', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['human', 'JJ', 'I-NP'], ['lung', 'NN', 'I-NP'], ['epithelium', 'NN', 'B-NP'], ['are', 'VBP', 'O']]}","{'Understanding the molecular mechanism of SARS-CoV-2 infection (the cause of COVID-19) is a scientific priority for 2020.': [{'noun_phrase': '', 'noun_connectors': ['Understanding']}], 'Various research groups are working toward development of vaccines and drugs, and many have published genomic and transcriptomic data related to this viral infection.': [{'noun_phrase': ' Various research groups', 'noun_connectors': ['working']}, {'noun_phrase': ' development vaccines', 'noun_connectors': ['and']}, {'noun_phrase': ' drugs', 'noun_connectors': ['and', 'published', 'and']}, {'noun_phrase': ' data', 'noun_connectors': ['related']}], 'The power inherent in publicly available data can be demonstrated via comparative transcriptome analyses.': [{'noun_phrase': ' power inherent', 'noun_connectors': ['publicly']}, {'noun_phrase': ' data', 'noun_connectors': ['can', 'demonstrated']}], 'In the current study, we collected high-throughput gene expression data related to human lung epithelial cells infected with SARS-CoV-2 or other respiratory viruses (SARS, H1N1, rhinovirus, avian influenza, and Dhori) and compared the effect of these viruses on the human transcriptome.': [{'noun_phrase': ' current study', 'noun_connectors': ['collected']}, {'noun_phrase': ' throughput gene expression data', 'noun_connectors': ['related']}, {'noun_phrase': ' lung epithelial cells', 'noun_connectors': ['infected']}, {'noun_phrase': ' CoV-2', 'noun_connectors': ['or']}, {'noun_phrase': ' viruses SARS H1N1 rhinovirus avian influenza', 'noun_connectors': ['and', 'and', 'compared']}], 'The analyses identified fifteen genes specifically expressed in cells transfected with SARS-CoV-2; these included CSF2 (colony-stimulating factor 2) and S100A8 and S100A9 (calcium-binding proteins), all of which are involved in lung/respiratory disorders.': [{'noun_phrase': ' analyses', 'noun_connectors': ['identified']}, {'noun_phrase': ' genes', 'noun_connectors': ['specifically', 'expressed']}, {'noun_phrase': ' cells', 'noun_connectors': ['transfected']}, {'noun_phrase': ' CoV-2', 'noun_connectors': ['included']}, {'noun_phrase': ' colony', 'noun_connectors': ['stimulating']}, {'noun_phrase': ' factor', 'noun_connectors': ['and']}, {'noun_phrase': ' S100A8', 'noun_connectors': ['and']}, {'noun_phrase': ' calcium', 'noun_connectors': ['binding']}, {'noun_phrase': ' proteins', 'noun_connectors': ['involved']}], 'The analyses showed that genes involved in the Type1 interferon signaling pathway and the apoptosis process are commonly altered by infection of SARS-CoV-2 and influenza viruses.': [{'noun_phrase': ' analyses', 'noun_connectors': ['showed']}, {'noun_phrase': ' genes', 'noun_connectors': ['involved']}, {'noun_phrase': ' interferon', 'noun_connectors': ['signaling']}, {'noun_phrase': ' pathway', 'noun_connectors': ['and']}, {'noun_phrase': ' apoptosis process', 'noun_connectors': ['commonly', 'altered']}, {'noun_phrase': ' infection SARS CoV-2', 'noun_connectors': ['and']}], 'Furthermore, results of protein-protein interaction analyses were consistent with a functional role of CSF2 in COVID-19 disease.': [{'noun_phrase': '', 'noun_connectors': ['Furthermore']}], 'In conclusion, our analysis has revealed cellular genes associated with SARS-CoV-2 infection of the human lung epithelium; these are potential therapeutic targets.': [{'noun_phrase': ' conclusion analysis', 'noun_connectors': ['revealed']}, {'noun_phrase': ' genes', 'noun_connectors': ['associated']}]}"
"[{'author_name': 'Chiara E. Cotroneo', 'author_inst': 'Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy'}, {'author_name': 'Nunzia Mangano', 'author_inst': 'Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy'}, {'author_name': 'Tommaso A. Dragani', 'author_inst': 'Fondazione IRCCS Istituto Nazionale Tumori'}, {'author_name': 'Francesca Colombo', 'author_inst': 'Institute of Biomedical Technologies, National Research Council (ITB-CNR), Segrate (MI), Italy'}]",http://biorxiv.org/cgi/content/short/2020.06.24.168534,Lung expression of genes encoding SARS-CoV-2 cell entry molecules and antiviral restriction factors: interindividual differences are associated with age and germline variants,"Germline variants in genes involved in SARS-CoV-2 cell entry (i.e. ACE2 and TMPRSS2) may influence the susceptibility to infection, as may polymorphisms in genes involved in the innate host response to viruses (e.g. APOBEC3 family). We searched for polymorphisms acting, in lung tissue, as expression quantitative trait loci (eQTLs) for 15 candidate COVID-19 susceptibility genes, selected for their roles in virus cell entry and host antiviral responses. No significant eQTLs were identified for ACE2 and TMPRSS2 genes, whose expression levels did not associate with either sex or age of the 408 patients whose non-diseased lung tissue was analyzed. Instead, we identified seven cis-eQTLs (FDR<0.05) for APOBEC3D and APOBEC3G (rs139296, rs9611092, rs139331, rs8177832, rs17537581, rs61362448, and rs738469). The genetic control of the expression of APOBEC3 genes, which encode enzymes that interfere with virus replication, may explain interindividual differences in risk or severity of viral infections. Future studies should investigate the role of host genetics in COVID-19 patients using a genome-wide approach, to identify other genes whose expression levels are associated with susceptibility to SARS-CoV-2 infection or COVID-19 severity.",2020-06-24,biorxiv,4,"[{'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['ACE2 gene', 'ACE2 Gene', 'peptidyl-dipeptidase A', 'ACEH', 'Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene', 'ANGIOTENSIN I-CONVERTING ENZYME 2', 'angiotensin I converting enzyme 2', 'ACE2', 'ACE2', 'ACE2'], 'meaning': ['This gene plays a role in both proteolysis and vasodilation.', 'C1422064', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['BACE2 gene', 'BACE2 Gene', 'BETA-SITE APP-CLEAVING ENZYME 2', 'beta-site APP-cleaving enzyme 2', 'Beta-Site APP-Cleaving Enzyme 2 Gene', 'ALP56', 'ALP56', 'CEAP1', 'DRAP', 'DRAP', 'ASPARTIC-LIKE PROTEASE, 56-KD', 'DOWN SYNDROME REGION ASPARTIC PROTEASE', 'BACE2', 'BACE2', 'BACE2', 'BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2'], 'meaning': ['This gene is involved in proteolytic processing.', 'C1412728', 0.8900668025016785]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'TMPRSS2', 'alias': ['TMPRSS2 gene', 'TMPRSS2 Gene', 'Transmembrane Protease, Serine 2/V-Ets Erythroblastosis Virus E26 Oncogene Homolog (Avian) Fusion Gene', 'TMPRSS2', 'TMPRSS2', 'TMPRSS2', 'TRANSMEMBRANE PROTEASE, SERINE 2', 'transmembrane protease, serine 2', 'PRSS10', 'Transmembrane Protease, Serine 2 Gene', 'TMPRSS2/ETV1 FUSION GENE', 'ETV1/TMPRSS2 Fusion Gene', 'TMPRSS2/ETV1 Fusion Gene', 'TMPRSS2-ETV1 Fusion Gene', 'TMPRSS2/ERG FUSION GENE', 'ERG/TMPRSS2 Fusion Gene', 'TMPRSS2-ERG Fusion Gene', 'TMPRSS2/ERG Fusion Gene'], 'meaning': [""A fusion gene that results from a genetic translocation event which fuses the 5' end of the androgen-regulated TMPRSS2 gene with the entire coding region of the ERG gene. The androgen-dependent expression of this fusion gene results in overexpression of ERG activity."", 'C1336641', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'TMPRSS2', 'alias': ['TMPRSS2 protein, human', 'Serine Protease 10', 'Epitheliasin', 'TMPRSS2', 'Transmembrane Protease Serine 2', 'EC 3.4.21.-', 'epitheliasin protein, human', 'transmembrane protease, serine 2 protein, human'], 'meaning': ['Transmembrane protease serine 2 (492 aa, ~54 kDa) is encoded by the human TMPRSS2 gene. This protein plays a role in proteolysis.', 'C1742865', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'APOBEC3', 'alias': ['APOBEC3B gene', 'APOBEC3B Gene', 'apolipoprotein B mRNA editing enzyme catalytic subunit 3B', 'APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3B', 'Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B Gene', 'PHRBNL', 'FLJ21201', 'APOBEC3B', 'APOBEC3B', 'APOBEC3B', 'PHORBOLIN 1-RELATED PROTEIN', 'phorbolin 3'], 'meaning': ['This gene plays a role in viral DNA cytosine deamination.', 'C1424925', 0.7436984777450562]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'APOBEC3', 'alias': ['APOBEC3A gene', 'APOBEC3A Gene', 'apolipoprotein B mRNA editing enzyme catalytic subunit 3A', 'PHORBOLIN 1', 'APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3A', 'Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3A Gene', 'PHRBN', 'ARP3', 'APOBEC3A', 'APOBEC3A', 'APOBEC3A', 'phorbolin I'], 'meaning': ['This gene is involved in cytosine deamination of viral DNA.', 'C1424917', 0.7421610951423645]}]}, {'TISSUE': [{'label': 'lung tissue', 'alias': ['Structure of parenchyma of lung', 'LUNG', 'lung tissue', 'Lung Tissue', 'Lung tissue', 'lung tissues', 'lungs tissues', 'lungs tissue', 'tissue lung', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'lung parenchyma', 'Lung Parenchyma', 'lungs parenchyma', 'Parenchyma of lung', 'Respiratory portion of lung', 'Respiratory portion of lung', 'Structure of parenchyma of lung (body structure)', 'Lung tiss'], 'meaning': ['Tissue consisting of an external serous coat, subserous areolar tissue and lung parenchyma. The parenchyma is made up of lobules wound together by connective tissue. A primary lobule consists of a terminal bronchiole, respiratory bronchioles, and alveolar ducts, which communicate with many alveoli, each alveolus being surrounded by a network of capillary blood vessels.', 'C0819757', 1]}]}, {'TISSUE': [{'label': 'lung tissue', 'alias': ['Tissue lung'], 'meaning': [None, 'C1550668', 1]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'APOBEC3G', 'alias': ['APOBEC3G gene', 'APOBEC3G Gene', 'apolipoprotein B mRNA editing enzyme catalytic subunit 3G', 'APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3G', 'Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3G Gene', 'CEM15', 'CEM15', 'MDS019', 'MDS019', 'dJ494G10.1', 'dJ494G10.1', 'FLJ12740', 'FLJ12740', 'bK150C2.7', 'bK150C2.7', 'PHORBOLIN-LIKE PROTEIN MDS019', 'APOBEC3G', 'APOBEC3G', 'APOBEC3G', 'DNA dC->dU-editing enzyme APOBEC-3G'], 'meaning': ['This gene may play a role in cell growth and the cell cycle.', 'C1424930', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'APOBEC3G', 'alias': ['APOBEC-3G Deaminase', 'APOBEC-3G Deaminase', 'APOBEC 3G Deaminase', 'Deaminase, APOBEC-3G', 'APOBEC3G Protein', 'APOBEC3G Protein', 'CEM15 Protein', 'CEM15 Protein', 'APOBEC3G Deaminase', 'APOBEC3G Deaminase', 'Deaminase, APOBEC3G', 'APOBEC-3G dC-dU Editing Enzyme', 'APOBEC-3G dC-dU Editing Enzyme', 'APOBEC 3G dC dU Editing Enzyme', 'APOBEC-3G Deaminase [Chemical/Ingredient]', 'APOBEC-Related Protein', 'APOBEC-Related Protein', 'APOBEC Related Protein', 'APOBEC-Related Cytidine Deaminase', 'APOBEC-Related Cytidine Deaminase', 'APOBEC Related Cytidine Deaminase', 'Cytidine Deaminase, APOBEC-Related', 'APOBEC-3G Protein', 'APOBEC-3G Protein', 'APOBEC 3G Protein'], 'meaning': ['An APOBEC deaminase that functions as an inhibitor of RETROVIRIDAE replication and inhibits the mobility of RETROTRANSPOSONS via deaminase-dependent and independent mechanisms. It is selective for SINGLE-STRANDED DNA and does not deaminate double-stranded DNA or single or DOUBLE-STRANDED RNA. It exhibits potent antiviral activity against VIF PROTEIN deficient HIV-1 through the creation of hypermutations in the VIRAL DNA. It also has anti-viral activity against SIMIAN IMMUNODEFICIENCY VIRUSES and HEPATITIS B VIRUS.', 'C4255227', 0.934700071811676]}]}]","{'Germline variants in genes involved in SARS-CoV-2 cell entry (i.e.': [['involved', 'VBN', 'O'], ['cell', 'NN', 'B-NP'], ['entry', 'NN', 'B-NP'], ['i.e', 'NN', 'B-NP']], 'ACE2 and TMPRSS2) may influence the susceptibility to infection, as may polymorphisms in genes involved in the innate host response to viruses (e.g.': [['influence', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['susceptibility', 'NN', 'I-NP'], ['infection', 'NN', 'B-NP'], ['polymorphisms', 'VB', 'O'], ['involved', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['innate', 'NN', 'I-NP'], ['host', 'NN', 'B-NP'], ['response', 'NN', 'B-NP'], ['e.g', 'NN', 'B-NP']], 'APOBEC3 family).': [['family', 'NN', 'B-NP']], 'We searched for polymorphisms acting, in lung tissue, as expression quantitative trait loci (eQTLs) for 15 candidate COVID-19 susceptibility genes, selected for their roles in virus cell entry and host antiviral responses.': [['searched', 'VBD', 'O'], ['polymorphisms', 'NN', 'B-NP'], ['acting', 'NN', 'B-NP'], ['lung', 'NN', 'B-NP'], ['tissue', 'NN', 'B-NP'], ['expression', 'NN', 'B-NP'], ['quantitative', 'JJ', 'B-NP'], ['trait', 'NN', 'I-NP'], ['loci', 'NN', 'B-NP'], ['eQTLs', 'NN', 'B-NP'], ['susceptibility', 'NN', 'B-NP'], ['selected', 'VBN', 'O'], ['virus', 'NN', 'B-NP'], ['cell', 'NN', 'B-NP'], ['entry', 'NN', 'B-NP'], ['host', 'NN', 'B-NP']], 'No significant eQTLs were identified for ACE2 and TMPRSS2 genes, whose expression levels did not associate with either sex or age of the 408 patients whose non-diseased lung tissue was analyzed.': [['No', 'DT', 'B-NP'], ['significant', 'JJ', 'I-NP'], ['eQTLs', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['identified', 'VBN', 'O'], ['expression', 'NN', 'B-NP'], ['did', 'VBD', 'O'], ['associate', 'VB', 'O'], ['either', 'DT', 'B-NP'], ['sex', 'NN', 'I-NP'], ['age', 'NN', 'B-NP'], ['non-diseased', 'JJ', 'B-NP'], ['lung', 'NN', 'I-NP'], ['tissue', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['analyzed', 'VBN', 'O']], 'Instead, we identified seven cis-eQTLs (FDR<0.05) for APOBEC3D and APOBEC3G (rs139296, rs9611092, rs139331, rs8177832, rs17537581, rs61362448, and rs738469).': [['identified', 'VBD', 'O'], ['cis-eQTLs', 'NN', 'B-NP'], ['rs139296', 'NN', 'B-NP'], ['rs9611092', 'NN', 'B-NP'], ['rs139331', 'NN', 'B-NP'], ['rs8177832', 'NN', 'B-NP'], ['rs17537581', 'NN', 'B-NP'], ['rs61362448', 'NN', 'B-NP'], ['rs738469', 'NN', 'B-NP']], 'The genetic control of the expression of APOBEC3 genes, which encode enzymes that interfere with virus replication, may explain interindividual differences in risk or severity of viral infections.': [['The', 'DT', 'B-NP'], ['genetic', 'JJ', 'I-NP'], ['control', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['expression', 'NN', 'I-NP'], ['encode', 'VBP', 'O'], ['interfere', 'VBP', 'O'], ['virus', 'NN', 'B-NP'], ['replication', 'NN', 'B-NP'], ['explain', 'VB', 'O'], ['risk', 'NN', 'B-NP'], ['severity', 'NN', 'B-NP']], 'Future studies should investigate the role of host genetics in COVID-19 patients using a genome-wide approach, to identify other genes whose expression levels are associated with susceptibility to SARS-CoV-2 infection or COVID-19 severity.': [['investigate', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['role', 'NN', 'I-NP'], ['host', 'NN', 'B-NP'], ['using', 'VBG', 'O'], ['a', 'DT', 'B-NP'], ['genome-wide', 'JJ', 'I-NP'], ['approach', 'NN', 'I-NP'], ['identify', 'VB', 'O'], ['expression', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['associated', 'VBN', 'O'], ['susceptibility', 'NN', 'B-NP'], ['SARS-CoV-2', 'JJ', 'B-NP'], ['infection', 'NN', 'I-NP'], ['COVID-19', 'JJ', 'B-NP'], ['severity', 'NN', 'I-NP']]}","{'Germline variants in genes involved in SARS-CoV-2 cell entry (i.e.': [{'noun_phrase': ' Germline variants genes', 'noun_connectors': ['involved']}, {'noun_phrase': ' CoV-2 cell entry', 'noun_connectors': []}], 'ACE2 and TMPRSS2) may influence the susceptibility to infection, as may polymorphisms in genes involved in the innate host response to viruses (e.g.': [{'noun_phrase': ' ACE2', 'noun_connectors': ['and', 'may', 'influence']}, {'noun_phrase': ' susceptibility infection may polymorphisms genes', 'noun_connectors': ['involved']}, {'noun_phrase': ' host response viruses', 'noun_connectors': ['e.g.']}], 'APOBEC3 family).': [], 'We searched for polymorphisms acting, in lung tissue, as expression quantitative trait loci (eQTLs) for 15 candidate COVID-19 susceptibility genes, selected for their roles in virus cell entry and host antiviral responses.': [{'noun_phrase': '', 'noun_connectors': ['searched']}, {'noun_phrase': ' polymorphisms', 'noun_connectors': ['acting']}, {'noun_phrase': ' lung tissue expression quantitative trait loci eQTLs candidate COVID-19 susceptibility genes', 'noun_connectors': ['selected']}, {'noun_phrase': ' roles virus cell entry', 'noun_connectors': ['and']}], 'No significant eQTLs were identified for ACE2 and TMPRSS2 genes, whose expression levels did not associate with either sex or age of the 408 patients whose non-diseased lung tissue was analyzed.': [{'noun_phrase': ' significant eQTLs', 'noun_connectors': ['identified', 'and']}, {'noun_phrase': ' genes expression levels', 'noun_connectors': ['associate']}, {'noun_phrase': ' sex', 'noun_connectors': ['or']}], 'Instead, we identified seven cis-eQTLs (FDR<0.05) for APOBEC3D and APOBEC3G (rs139296, rs9611092, rs139331, rs8177832, rs17537581, rs61362448, and rs738469).': [{'noun_phrase': '', 'noun_connectors': ['Instead', 'identified']}], 'The genetic control of the expression of APOBEC3 genes, which encode enzymes that interfere with virus replication, may explain interindividual differences in risk or severity of viral infections.': [{'noun_phrase': ' genetic control expression APOBEC3 genes', 'noun_connectors': ['encode']}, {'noun_phrase': ' enzymes', 'noun_connectors': ['interfere']}, {'noun_phrase': ' virus replication', 'noun_connectors': ['may', 'explain']}, {'noun_phrase': ' differences risk', 'noun_connectors': ['or']}], 'Future studies should investigate the role of host genetics in COVID-19 patients using a genome-wide approach, to identify other genes whose expression levels are associated with susceptibility to SARS-CoV-2 infection or COVID-19 severity.': [{'noun_phrase': ' Future studies', 'noun_connectors': ['should', 'investigate']}, {'noun_phrase': ' role host genetics COVID-19 patients', 'noun_connectors': ['using']}, {'noun_phrase': ' approach', 'noun_connectors': ['identify']}, {'noun_phrase': ' genes expression levels', 'noun_connectors': ['associated']}, {'noun_phrase': ' susceptibility SARS CoV-2 infection', 'noun_connectors': ['or']}]}"
"[{'author_name': 'Sridevi Krishnan', 'author_inst': 'University of California Davis'}, {'author_name': 'Giri P Krishnan', 'author_inst': 'University of California San Diego'}]",http://biorxiv.org/cgi/content/short/2020.06.23.167791,N-glycosylation network construction and analysis to modify glycans on the spike S glycoprotein of SARS-CoV-2.,"Background: The spike S-protein of SARS-CoV-2 is N-glycosylated. The N-glycan structure and composition of this glycoprotein influence how the virus interacts with host cells. Objective: To identify a putative N-glycan biosynthesis pathway of SARS-CoV-2 (HEK293 cell recombinant) from previously published mass spectrometric studies, and to identify what effect blocking some enzymes has on the overall glycoprotein profile. Finally, our goal was to provide the biosynthesis network, and glycans in easy-to-use format for further glycoinformatics work. Methods: We reconstructed the glycosylation network based on previously published empirical data using GNAT, a glycosylation network analysis tool. Our compilation of the network tool had 23 glycosyltransferase and glucosidase enzymes, and could infer the pathway of glycosylation machinery based on glycans identified in the virus spike protein. Once the glycan biosynthesis pathway was generated, we simulated the effect of blocking specific enzymes - Mannosidase-II and alpha-1,6-fucosyltransferase to see how they would affect the biosynthesis network. Results: Of the 23 enzymes, a total of 12 were involved in glycosylation of SARS-CoV-2 - Man-Ia, MGAT1, MGAT2, MGAT4, MGAT5, B4GalT, B4GalT, Man II, SiaT, ST3GalI, ST3GalVI and FucT8. Blocking enzymes resulted in a substantially modified glycan profile of the protein. Conclusions: A network analysis of N-glycan biosynthesis of SARS-CoV-2 spike protein shows an elaborate enzymatic pathway with several intermediate glycans, along with the ones identified by mass spectrometric studies. Variations in the final N-glycan profile of the virus, given its site-specific microheterogeneity, could be a factor in the host response to the infection and response to antibodies. Here we provide all the resources generated - the glycans derived from mass spectrometry and intermediate glycans in glycoCT xml format, and the biosynthesis network for future drug and vaccine development work.",2020-06-24,biorxiv,2,"[{'GENE_OR_GENE_PRODUCT': [{'label': 'N-glycan', 'alias': ['Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase', 'Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase', 'Glycopeptidase', 'Glycopeptidase', 'Glycopeptidase', 'Glycopeptidase', 'Glycopeptide N-glycosidase', 'Glycopeptide N-glycosidase', 'Glycopeptide N-glycosidase', 'Glycopeptide N-glycosidase', 'Glycopeptide N glycosidase', 'N-glycosidase, Glycopeptide', 'N-Glycanase', 'N-Glycanase', 'N Glycanase', 'N-Oligosaccharide Glycopeptidase', 'N-Oligosaccharide Glycopeptidase', 'N-Oligosaccharide glycopeptidase', 'N-Oligosaccharide glycopeptidase', 'N Oligosaccharide Glycopeptidase', 'Glycopeptidase, N-Oligosaccharide', 'Peptide N-Glycosidase', 'Peptide N-Glycosidase', 'Peptide N-glycosidase', 'Peptide N-glycosidase', 'Peptide N Glycosidase', 'N-Glycosidase, Peptide', 'Peptide-N-Glycanase', 'Peptide-N-Glycanase', 'Peptide N Glycanase', 'Peptide N-Glycanase', 'Peptide N-Glycanase', 'N-Glycanase, Peptide', 'Peptide-N4-(N-acetyl-b-glucosaminyl) asparagine amidase', 'Peptide-N4-(N-acetyl-b-glucosaminyl) asparagine amidase', 'Peptide-N(4)-(acetyl-beta-glucosaminyl)Asparagine Amidase', 'Peptide-N(4)-(acetyl-beta-glucosaminyl)Asparagine Amidase', 'Peptide-N^4^-(N-acetyl-b-glucosaminyl) asparagine amidase', 'Peptide-N^4^-(N-acetyl-b-glucosaminyl) asparagine amidase (substance)', 'Peptide-N<sup>4</sup>-(N-acetyl-b-glucosaminyl) asparagine amidase (substance)', 'Peptide-N<sup>4</sup>-(N-acetyl-b-glucosaminyl) asparagine amidase', 'Peptide-N4-(N-acetyl-b-glucosaminyl) asparagine amidase (substance)', 'Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase [Chemical/Ingredient]'], 'meaning': ['An amidohydrolase that removes intact asparagine-linked oligosaccharide chains from glycoproteins. It requires the presence of more than two amino-acid residues in the substrate for activity. This enzyme was previously listed as EC 3.2.2.18.', 'C0061642', 0.8656588196754456]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'N-glycan', 'alias': ['N-linked glycoprotein maturation'], 'meaning': ['The conversion of N-linked glycan (N = nitrogen) structures from the initially transferred oligosaccharide to a mature form, by the actions of glycosidases and glycosyltransferases. The early processing steps are conserved and play roles in glycoprotein folding and trafficking. [ISBN:0879695595, PMID:12736198]', 'C1157446', 0.7965070605278015]}]}, {'CELL': [{'label': 'HEK293 cell', 'alias': ['Cell, HEK293', 'HEK293 Cell', 'Cells, HEK293', 'Human Embryonic Kidney Cell Line 293', '293T Cells', '293T Cell', 'Cell, 293T', 'Cells, 293T', 'HEK 293 Cells', 'Cell, HEK 293', 'HEK 293 Cell', '293 Cell, HEK', 'Cells, HEK 293', '293 Cells, HEK', 'Human Kidney Cell Line 293', 'HEK 293 Cell Line'], 'meaning': ['A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5.', 'C2936239', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'MGAT1', 'alias': ['MGAT1 gene', 'N-ACETYLGLUCOSAMINYLTRANSFERASE I', 'UDP-N-ACETYLGLUCOSAMINE:ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE I', 'GLCNAC-TI', 'ALPHA-1,3-MANNOSYL-GLYCOPROTEIN BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE', 'mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase', 'alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase', 'MGAT', 'GnTI', 'GNT-1', 'MGAT1', 'MGAT1', 'GlcNAc-T I', 'GLCT1'], 'meaning': [None, 'C1417133', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'MGAT1', 'alias': ['MOGAT1 gene', 'DIACYLGLYCEROL O-ACYLTRANSFERASE 2 LIKE-1', 'MONOACYLGLYCEROL O-ACYLTRANSFERASE 1', 'monoacylglycerol O-acyltransferase 1', 'DGAT2L', 'MGAT1', 'MGAT1', 'ACYL-CoA:MONOACYLGLYCEROL ACYLTRANSFERASE 1', 'DGAT2L1', 'MOGAT1', 'MOGAT1'], 'meaning': [None, 'C1537930', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'MGAT2', 'alias': ['MGAT2 gene', 'ALPHA-1,6-MANNOSYL-GLYCOPROTEIN BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE', 'mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase', 'GlcNAc-T II', 'MGAT2', 'MGAT2', 'GnT II', 'GNT-II', 'UDP-N-ACETYLGLUCOSAMINE:ALPHA-6-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE II', 'GnT2'], 'meaning': [None, 'C1417134', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'MGAT2', 'alias': ['MOGAT2 gene', 'MONOACYLGLYCEROL O-ACYLTRANSFERASE 2', 'monoacylglycerol O-acyltransferase 2', 'MGAT2', 'MGAT2', 'FLJ22644', 'DGAT2L5', 'MOGAT2', 'MOGAT2', 'ACYL-CoA:MONOACYLGLYCEROL ACYLTRANSFERASE 2'], 'meaning': [None, 'C1537931', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'MGAT5', 'alias': ['MGAT5 gene', 'GNT-V', 'GNT-V', 'N-ACETYLGLUCOSAMINYLTRANSFERASE V', 'mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase', 'MGAT5', 'MGAT5', 'ALPHA-1,6-MANNOSYL-GLYCOPROTEIN BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE', 'GNT-VA'], 'meaning': [None, 'C1417138', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'SiaT', 'alias': ['N-acetyllactosaminide alpha-2,3-sialyltransferase activity', 'cytidine monophosphoacetylneuraminate-beta-galactosyl(1->4)acetylglucosaminide alpha2->3-sialyltransferase activity', 'CMP-N-acetylneuraminate:beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-glycoprotein alpha-2,3-N-acetylneuraminyltransferase activity', 'SiaT', 'alpha2->3 sialyltransferase activity'], 'meaning': ['Catalysis of the reaction: CMP-N-acetylneuraminate + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-glycoprotein = CMP + alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-glycoprotein. [EC:2.4.99.6]', 'C1152176', 1]}]}, {'ORGANISM': [{'label': 'ST3GalVI', 'alias': ['ST3GAL6 gene', 'ST3 BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASE 6', 'ST3 beta-galactoside alpha-2,3-sialyltransferase 6', 'ST3GALVI', 'ST3GALVI', 'ST3GAL6', 'ST3GAL6', 'ALPHA-2,3-SIALYLTRANSFERASE VI'], 'meaning': [None, 'C1539864', 1]}]}]","{'Background: The spike S-protein of SARS-CoV-2 is N-glycosylated.': [['Background', 'NN', 'B-NP'], ['is', 'VBZ', 'O']], 'The N-glycan structure and composition of this glycoprotein influence how the virus interacts with host cells.': [['The', 'DT', 'B-NP'], ['N-glycan', 'JJ', 'I-NP'], ['structure', 'NN', 'I-NP'], ['composition', 'NN', 'B-NP'], ['this', 'DT', 'B-NP'], ['glycoprotein', 'NN', 'I-NP'], ['influence', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['interacts', 'VBZ', 'O'], ['host', 'NN', 'B-NP']], 'Objective: To identify a putative N-glycan biosynthesis pathway of SARS-CoV-2 (HEK293 cell recombinant) from previously published mass spectrometric studies, and to identify what effect blocking some enzymes has on the overall glycoprotein profile.': [['Objective', 'NN', 'B-NP'], ['identify', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['putative', 'JJ', 'I-NP'], ['N-glycan', 'JJ', 'I-NP'], ['biosynthesis', 'NN', 'I-NP'], ['pathway', 'NN', 'B-NP'], ['cell', 'NN', 'B-NP'], ['recombinant', 'NN', 'B-NP'], ['published', 'VBN', 'O'], ['mass', 'NN', 'B-NP'], ['identify', 'VB', 'O'], ['effect', 'NN', 'B-NP'], ['blocking', 'VBG', 'O'], ['has', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['overall', 'JJ', 'I-NP'], ['glycoprotein', 'NN', 'I-NP'], ['profile', 'NN', 'B-NP']], 'Finally, our goal was to provide the biosynthesis network, and glycans in easy-to-use format for further glycoinformatics work.': [['goal', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['provide', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['biosynthesis', 'NN', 'I-NP'], ['network', 'NN', 'B-NP'], ['easy-to-use', 'JJ', 'B-NP'], ['format', 'NN', 'I-NP'], ['work', 'NN', 'B-NP']], 'Methods: We reconstructed the glycosylation network based on previously published empirical data using GNAT, a glycosylation network analysis tool.': [['reconstructed', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['glycosylation', 'NN', 'I-NP'], ['network', 'NN', 'B-NP'], ['based', 'VBN', 'O'], ['published', 'VBN', 'O'], ['using', 'VBG', 'O'], ['a', 'DT', 'B-NP'], ['glycosylation', 'NN', 'I-NP'], ['network', 'NN', 'B-NP'], ['analysis', 'NN', 'B-NP'], ['tool', 'NN', 'B-NP']], 'Our compilation of the network tool had 23 glycosyltransferase and glucosidase enzymes, and could infer the pathway of glycosylation machinery based on glycans identified in the virus spike protein.': [['compilation', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['network', 'NN', 'I-NP'], ['tool', 'NN', 'B-NP'], ['had', 'VBD', 'O'], ['glycosyltransferase', 'NN', 'B-NP'], ['glucosidase', 'NN', 'B-NP'], ['infer', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['pathway', 'NN', 'I-NP'], ['glycosylation', 'NN', 'B-NP'], ['machinery', 'NN', 'B-NP'], ['based', 'VBN', 'O'], ['identified', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['spike', 'NN', 'B-NP'], ['protein', 'NN', 'B-NP']], 'Once the glycan biosynthesis pathway was generated, we simulated the effect of blocking specific enzymes - Mannosidase-II and alpha-1,6-fucosyltransferase to see how they would affect the biosynthesis network.': [['the', 'DT', 'B-NP'], ['glycan', 'JJ', 'I-NP'], ['biosynthesis', 'NN', 'I-NP'], ['pathway', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['generated', 'VBN', 'O'], ['simulated', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['effect', 'NN', 'I-NP'], ['blocking', 'VBG', 'O'], ['see', 'VB', 'O'], ['affect', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['biosynthesis', 'NN', 'I-NP'], ['network', 'NN', 'B-NP']], 'Results: Of the 23 enzymes, a total of 12 were involved in glycosylation of SARS-CoV-2 - Man-Ia, MGAT1, MGAT2, MGAT4, MGAT5, B4GalT, B4GalT, Man II, SiaT, ST3GalI, ST3GalVI and FucT8.': [['a', 'DT', 'B-NP'], ['total', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['involved', 'VBN', 'O'], ['glycosylation', 'NN', 'B-NP'], ['Man-Ia', 'NN', 'B-NP']], 'Blocking enzymes resulted in a substantially modified glycan profile of the protein.': [['Blocking', 'VBG', 'O'], ['resulted', 'VBN', 'O'], ['modified', 'VBN', 'O'], ['glycan', 'JJ', 'B-NP'], ['profile', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['protein', 'NN', 'I-NP']], 'Conclusions: A network analysis of N-glycan biosynthesis of SARS-CoV-2 spike protein shows an elaborate enzymatic pathway with several intermediate glycans, along with the ones identified by mass spectrometric studies.': [['A', 'DT', 'B-NP'], ['network', 'NN', 'I-NP'], ['analysis', 'NN', 'B-NP'], ['N-glycan', 'JJ', 'B-NP'], ['biosynthesis', 'NN', 'I-NP'], ['spike', 'NN', 'B-NP'], ['protein', 'NN', 'B-NP'], ['shows', 'VBZ', 'O'], ['an', 'DT', 'B-NP'], ['elaborate', 'JJ', 'I-NP'], ['enzymatic', 'JJ', 'I-NP'], ['pathway', 'NN', 'I-NP'], ['identified', 'VBN', 'O'], ['mass', 'NN', 'B-NP']], 'Variations in the final N-glycan profile of the virus, given its site-specific microheterogeneity, could be a factor in the host response to the infection and response to antibodies.': [['the', 'DT', 'B-NP'], ['final', 'JJ', 'I-NP'], ['N-glycan', 'JJ', 'I-NP'], ['profile', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['given', 'VBN', 'O'], ['site-specific', 'JJ', 'B-NP'], ['microheterogeneity', 'NN', 'I-NP'], ['be', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['factor', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['host', 'NN', 'I-NP'], ['response', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['infection', 'NN', 'I-NP'], ['response', 'NN', 'B-NP']], 'Here we provide all the resources generated - the glycans derived from mass spectrometry and intermediate glycans in glycoCT xml format, and the biosynthesis network for future drug and vaccine development work.': [['provide', 'VBP', 'O'], ['generated', 'VBD', 'O'], ['derived', 'VBN', 'O'], ['mass', 'NN', 'B-NP'], ['spectrometry', 'NN', 'B-NP'], ['glycoCT', 'NN', 'B-NP'], ['format', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['biosynthesis', 'NN', 'I-NP'], ['network', 'NN', 'B-NP'], ['future', 'JJ', 'B-NP'], ['drug', 'NN', 'I-NP'], ['vaccine', 'NN', 'B-NP'], ['development', 'NN', 'B-NP'], ['work', 'NN', 'B-NP']]}","{'Background: The spike S-protein of SARS-CoV-2 is N-glycosylated.': [], 'The N-glycan structure and composition of this glycoprotein influence how the virus interacts with host cells.': [{'noun_phrase': ' N glycan structure', 'noun_connectors': ['and']}, {'noun_phrase': ' composition glycoprotein influence', 'noun_connectors': ['how']}, {'noun_phrase': ' virus', 'noun_connectors': ['interacts']}], 'Objective: To identify a putative N-glycan biosynthesis pathway of SARS-CoV-2 (HEK293 cell recombinant) from previously published mass spectrometric studies, and to identify what effect blocking some enzymes has on the overall glycoprotein profile.': [{'noun_phrase': ' Objective', 'noun_connectors': ['identify']}, {'noun_phrase': ' biosynthesis pathway SARS CoV-2 HEK293 cell recombinant', 'noun_connectors': ['previously', 'published']}, {'noun_phrase': ' studies', 'noun_connectors': ['and', 'identify']}, {'noun_phrase': ' effect', 'noun_connectors': ['blocking']}], 'Finally, our goal was to provide the biosynthesis network, and glycans in easy-to-use format for further glycoinformatics work.': [{'noun_phrase': '', 'noun_connectors': ['Finally']}, {'noun_phrase': ' goal', 'noun_connectors': ['provide']}, {'noun_phrase': ' biosynthesis network', 'noun_connectors': ['and']}], 'Methods: We reconstructed the glycosylation network based on previously published empirical data using GNAT, a glycosylation network analysis tool.': [{'noun_phrase': ' Methods', 'noun_connectors': ['reconstructed']}, {'noun_phrase': ' glycosylation network', 'noun_connectors': ['based', 'previously', 'published']}, {'noun_phrase': ' data', 'noun_connectors': ['using']}], 'Our compilation of the network tool had 23 glycosyltransferase and glucosidase enzymes, and could infer the pathway of glycosylation machinery based on glycans identified in the virus spike protein.': [{'noun_phrase': ' compilation network tool glycosyltransferase', 'noun_connectors': ['and']}, {'noun_phrase': ' glucosidase enzymes', 'noun_connectors': ['and', 'could', 'infer']}, {'noun_phrase': ' pathway glycosylation machinery', 'noun_connectors': ['based']}, {'noun_phrase': ' glycans', 'noun_connectors': ['identified']}], 'Once the glycan biosynthesis pathway was generated, we simulated the effect of blocking specific enzymes - Mannosidase-II and alpha-1,6-fucosyltransferase to see how they would affect the biosynthesis network.': [{'noun_phrase': ' glycan biosynthesis pathway', 'noun_connectors': ['generated', 'simulated']}, {'noun_phrase': ' effect', 'noun_connectors': ['blocking']}, {'noun_phrase': ' enzymes Mannosidase II', 'noun_connectors': ['and', 'see', 'how', 'would', 'affect']}], 'Results: Of the 23 enzymes, a total of 12 were involved in glycosylation of SARS-CoV-2 - Man-Ia, MGAT1, MGAT2, MGAT4, MGAT5, B4GalT, B4GalT, Man II, SiaT, ST3GalI, ST3GalVI and FucT8.': [{'noun_phrase': ' Results enzymes total', 'noun_connectors': ['involved']}, {'noun_phrase': ' glycosylation SARS CoV-2 Man Ia', 'noun_connectors': ['MGAT1']}], 'Blocking enzymes resulted in a substantially modified glycan profile of the protein.': [{'noun_phrase': '', 'noun_connectors': ['Blocking']}, {'noun_phrase': ' enzymes', 'noun_connectors': ['resulted', 'substantially', 'modified']}], 'Conclusions: A network analysis of N-glycan biosynthesis of SARS-CoV-2 spike protein shows an elaborate enzymatic pathway with several intermediate glycans, along with the ones identified by mass spectrometric studies.': [{'noun_phrase': ' Conclusions network analysis N glycan biosynthesis SARS CoV-2 spike protein', 'noun_connectors': ['shows']}, {'noun_phrase': ' pathway several intermediate glycans ones', 'noun_connectors': ['identified']}], 'Variations in the final N-glycan profile of the virus, given its site-specific microheterogeneity, could be a factor in the host response to the infection and response to antibodies.': [{'noun_phrase': ' Variations final N glycan profile virus', 'noun_connectors': ['given']}, {'noun_phrase': ' site specific microheterogeneity', 'noun_connectors': ['could']}, {'noun_phrase': ' factor host response infection', 'noun_connectors': ['and']}], 'Here we provide all the resources generated - the glycans derived from mass spectrometry and intermediate glycans in glycoCT xml format, and the biosynthesis network for future drug and vaccine development work.': [{'noun_phrase': '', 'noun_connectors': ['Here', 'provide']}, {'noun_phrase': ' resources', 'noun_connectors': ['generated']}, {'noun_phrase': ' glycans', 'noun_connectors': ['derived']}, {'noun_phrase': ' spectrometry', 'noun_connectors': ['and']}, {'noun_phrase': ' glycans glycoCT xml format', 'noun_connectors': ['and']}, {'noun_phrase': ' biosynthesis network future drug', 'noun_connectors': ['and']}]}"
"[{'author_name': 'Vikramjeet Singh', 'author_inst': 'Institute for Experimental Immunology and Imaging, University Hospital Essen, University of Duisburg-Essen, DE-45147 Essen, Germany'}, {'author_name': 'Alexander Beer', 'author_inst': 'Institute for Experimental Immunology and Imaging, University Hospital Essen, University of Duisburg-Essen, DE-45147 Essen, Germany'}, {'author_name': 'Andreas Kraus', 'author_inst': 'Institute for Experimental Immunology and Imaging, University Hospital Essen, University of Duisburg-Essen, DE-45147 Essen, Germany'}, {'author_name': 'Xiaoni Zhang', 'author_inst': 'Department of Neurology, University Hospital Essen, University of Duisburg-Essen, DE-45147 Essen, Germany'}, {'author_name': 'Jinhua Xue', 'author_inst': 'Institute for Experimental Immunology and Imaging, University Hospital Essen, University of Duisburg-Essen, DE-45147 Essen, Germany'}, {'author_name': 'Dirk M Hermann', 'author_inst': 'Department of Neurology, University Hospital Essen, University of Duisburg-Essen, DE-45147 Essen, Germany'}, {'author_name': 'Matthias Gunzer', 'author_inst': 'Institute for Experimental Immunology and Imaging, University Hospital Essen, University of Duisburg-Essen, DE-45147 Essen, Germany'}]",http://biorxiv.org/cgi/content/short/2020.06.24.162941,"Stroke increases the expression of ACE2, the SARS-CoV-2 binding receptor, in murine lungs","Background: The newly emerged severe acute respiratory syndrome coronavirus (SARS-CoV-2) has caused a worldwide pandemic of human respiratory disease. Angiotensin-converting enzyme (ACE) 2 is the key receptor on lung epithelial cells to facilitate initial binding and infection of SARS-CoV-2. The binding to ACE2 is mediated via the spike glycoprotein present on the virus surface. Recent clinical data have demonstrated that patients suffering from stroke are particularly susceptible to severe courses of SARS-CoV-2 infection, thus forming a defined risk group. However, a mechanistic explanation for this finding is lacking. Sterile tissue injuries including stroke induce lymphocytopenia and systemic inflammation that might modulate the expression levels of surface proteins in distant organs. Whether systemic inflammation following stroke can specifically modulate ACE2 expression in the lung has not been investigated. Methods: Mice were subjected to transient middle cerebral artery occlusion (MCAO) for 45 min and sacrificed after 24 h and 72 h for analysis of brain and lung tissues. Gene expression and protein levels of ACE2, ACE, IL-6 and IL1{beta} were measured by quantitative PCR and Western blot, respectively. Immune cell populations in lymphoid organs were analyzed by flow cytometry. Results: Strikingly, 24 h after stroke, we observed a substantial increase in the expression of ACE2 both on the transcriptional and protein levels in the lungs of MCAO mice compared to sham-operated mice. This increased expression persisted until day 3 after stroke. In addition, MCAO increased the expression of inflammatory cytokines IL-6 and IL-1{beta} in the lungs. Higher gene expression of cytokines IL-6 and IL-1{beta} was found in ischemic brain hemispheres and a reduced number of T-lymphocytes were present in the blood and spleen as an indicator of sterile tissue injury-induced immunosuppression. Conclusions: We demonstrate significantly augmented ACE2 levels and inflammation in murine lungs after experimental stroke. These pre-clinical findings might explain the clinical observation that patients with pre-existing stroke represent a high-risk group for the development of severe SARS-CoV-2 infections. Our studies call for further investigations into the underlying signaling mechanisms and possible therapeutic interventions.",2020-06-24,biorxiv,7,"[{'ORGANISM': [{'label': 'human', 'alias': ['Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'homo sapiens', 'Humans', 'humans', 'humans', 'Human', 'Human', 'Human', 'Human', 'Human', 'Human', 'Human', 'human', 'human', 'human', 'Man', 'Man', 'Man', 'Man', 'man', 'man', 'Man and woman', 'FAMILY OF MAN', 'Man (Taxonomy)', 'Homo sapiens (organism)', 'Human - origin', 'Human - origin (qualifier value)', 'Man, Modern', 'Modern Man', 'Human, General'], 'meaning': ['Members of the species Homo sapiens.', 'C0086418', 1]}]}, {'ORGANISM': [{'label': 'human', 'alias': ['Human Use'], 'meaning': ['A product has been approved for use in humans.', 'C4055445', 0.7751905918121338]}]}, {'CELL': [{'label': 'lung epithelial cells', 'alias': ['Epithelial Cells', 'Epithelial Cells', 'Epithelial Cells', 'cells epithelial', 'Epithelial cells', 'Epithelial cells', 'Epithelial cells', 'Epithelial cells', 'Epithelial cells', 'epithelial cells', 'Epithelial cell, NOS', 'Cell, Epithelial', 'Epithelial Cell', 'Epithelial Cell', 'cell epithelial', 'epithelial cell', 'epithelial cell', 'Epithelial cell', 'Epithelial cell', 'Epithelial cell', 'Cells, Epithelial', 'Epitheliocyte', 'Epitheliocyte', 'Epithelial cell (cell)'], 'meaning': ['Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.', 'C0014597', 0.8662098050117493]}]}, {'CELL': [{'label': 'lung epithelial cells', 'alias': ['Squamous Transitional Epithelial Cell Count', 'Epithelial Cells', 'Squamous Transitional Epithelial Cells', 'Squamous Transitional Epithelial Cells', 'EPISQTCE'], 'meaning': ['The determination of the number of squamous transitional epithelial cells present in a urine sample.', 'C2699513', 0.8662098050117493]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['ACE2 gene', 'ACE2 Gene', 'peptidyl-dipeptidase A', 'ACEH', 'Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene', 'ANGIOTENSIN I-CONVERTING ENZYME 2', 'angiotensin I converting enzyme 2', 'ACE2', 'ACE2', 'ACE2'], 'meaning': ['This gene plays a role in both proteolysis and vasodilation.', 'C1422064', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['BACE2 gene', 'BACE2 Gene', 'BETA-SITE APP-CLEAVING ENZYME 2', 'beta-site APP-cleaving enzyme 2', 'Beta-Site APP-Cleaving Enzyme 2 Gene', 'ALP56', 'ALP56', 'CEAP1', 'DRAP', 'DRAP', 'ASPARTIC-LIKE PROTEASE, 56-KD', 'DOWN SYNDROME REGION ASPARTIC PROTEASE', 'BACE2', 'BACE2', 'BACE2', 'BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2'], 'meaning': ['This gene is involved in proteolytic processing.', 'C1412728', 0.8900668025016785]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'ORGAN': [{'label': 'organs', 'alias': ['Organ', 'Organ', 'Organ', 'Organ', 'organ', 'organ', 'organ', 'organs', '{Organ}', '{Organ}', 'Organs (Anatomy)', 'anatomy organs', 'organs anatomy', 'anatomy organ'], 'meaning': ['A unique macroscopic (gross) anatomic structure that performs specific functions. It is composed of various tissues. An organ is part of an anatomic system or a body region. Representative examples include the heart, lung, liver, spleen, and uterus.', 'C0178784', 1]}]}, {'ORGAN': [{'label': 'organs', 'alias': ['Set of organs', 'Organs set'], 'meaning': ['Anatomical set which has as its direct members organs of same type or of different types.', 'C1182742', 0.7942999601364136]}]}, {'ORGAN': [{'label': 'lung', 'alias': ['Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'lung', 'lung', 'lung', 'lung', 'LUNG', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lung, NOS', 'LUNGS', 'lungs', 'pulmonary', 'pulmonary', 'Lung structure', 'lung structure', 'lung structures', 'Pulmo', 'Pulmones', 'Set of lungs', 'Set of lungs', 'Lung structure (body structure)', 'Respiratory System, Lung', 'Pair of lungs', 'Lungs pair'], 'meaning': ['Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.', 'C0024109', 0.9999999403953552]}]}, {'ORGAN': [{'label': 'lung', 'alias': ['Structure of parenchyma of lung', 'LUNG', 'lung tissue', 'Lung Tissue', 'Lung tissue', 'lung tissues', 'lungs tissues', 'lungs tissue', 'tissue lung', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'lung parenchyma', 'Lung Parenchyma', 'lungs parenchyma', 'Parenchyma of lung', 'Respiratory portion of lung', 'Respiratory portion of lung', 'Structure of parenchyma of lung (body structure)', 'Lung tiss'], 'meaning': ['Tissue consisting of an external serous coat, subserous areolar tissue and lung parenchyma. The parenchyma is made up of lobules wound together by connective tissue. A primary lobule consists of a terminal bronchiole, respiratory bronchioles, and alveolar ducts, which communicate with many alveoli, each alveolus being surrounded by a network of capillary blood vessels.', 'C0819757', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'Mice', 'alias': ['Mice, House', 'House Mice', 'house mice', 'House Mouse', 'House Mouse', 'Mouse, House', 'house mouse', 'house mouse', 'House mouse', 'Mouse', 'mouse', 'mouse', 'Mice', 'Mice', 'Mouse, NOS', 'mice', 'Mus musculus', 'Mus musculus', 'Mus musculus', 'Mus musculus', 'Mus musculus', 'Mus musculus', 'mus musculus', 'Common house mouse', 'Common house mouse', 'Old World mouse', 'Old World mouse', 'mouse, mice', 'mouse <Mus musculus>', 'Old World mouse (organism)', 'Mouse (organism)', 'Mus musculus (organism)'], 'meaning': ['The common house mouse, often used as an experimental organism.', 'C0025914', 1]}]}, {'ORGANISM': [{'label': 'Mice', 'alias': ['Mus', 'Mus', 'Mus', 'Mus', 'Mus', 'mus', 'Mice', 'Mice', 'mice', 'mice', 'Mouse', 'Mouse', 'Mouse', 'mouse', 'MOUSE', 'Murine', 'mouse <Mus>', 'Mammals, Mice', 'Genus Mus (organism)', 'Genus Mus'], 'meaning': ['Any of numerous species of small rodents belonging to the genus Mus and various related genera of the family Muridae.', 'C0026809', 1]}]}, {'MULTI-TISSUE_STRUCTURE': [{'label': 'cerebral artery', 'alias': ['Structure of cerebral artery', 'Cerebral Arteries', 'Cerebral Arteries', 'arteries cerebral', 'Cerebral arteries', 'Cerebral arteries', 'Cerebral arteries', 'cerebral arteries', 'Cerebral artery', 'Cerebral artery', 'Cerebral artery', 'Cerebral artery', 'Artery, Cerebral', 'Cerebral Artery', 'Cerebral Artery', 'Cerebral artery, NOS', 'cerebral artery', 'cerebral artery', 'cerebral artery', 'artery cerebral', 'Arteries, Cerebral', 'Structure of cerebral artery (body structure)'], 'meaning': ['The arterial blood vessels supplying the CEREBRUM.', 'C0007770', 1]}]}, {'MULTI-TISSUE_STRUCTURE': [{'label': 'cerebral artery', 'alias': ['Structure of anterior cerebral artery', 'Anterior Cerebral Artery', 'Anterior Cerebral Artery', 'anterior artery cerebral', 'Cerebral artery anterior', 'Cerebral artery anterior', 'Anterior cerebral artery', 'Anterior cerebral artery', 'Anterior cerebral artery', 'Anterior cerebral artery', 'anterior cerebral artery', 'Anterior cerebral artery, NOS', 'Anterior Cerebral Arteries', 'Anterior Cerebral Arteries', 'Arteries, Anterior Cerebral', 'Cerebral Arteries, Anterior', 'Artery, Anterior Cerebral', 'Cerebral Artery, Anterior', 'ACA', 'Arteria cerebri anterior', 'Arteria cerebri anterior', 'Structure of anterior cerebral artery (body structure)'], 'meaning': ['Artery formed by the bifurcation of the internal carotid artery (CAROTID ARTERY, INTERNAL). Branches of the anterior cerebral artery supply the CAUDATE NUCLEUS; INTERNAL CAPSULE; PUTAMEN; SEPTAL NUCLEI; GYRUS CINGULI; and surfaces of the FRONTAL LOBE and PARIETAL LOBE.', 'C0149561', 0.8371303677558899]}]}, {'ORGAN': [{'label': 'brain', 'alias': ['Brain', 'Brain', 'Brain', 'Brain', 'Brain', 'Brain', 'Brain', 'Brain', 'Brain', 'Brain', 'Brain', 'Brain', 'Brain', 'Brain', 'BRAIN', 'brain', 'brain', 'brain', 'Brains', 'Brain, NOS', 'Brain, NOS', 'brains', 'Encephalon', 'Encephalon', 'Encephalon', 'encephalon', 'encephalon', 'Encephalons', 'Brain structure', 'brain structure', 'Cerebral', 'cerebral', 'Brain structure (body structure)', 'Nervous System, Brain', 'Nervous System, Brain'], 'meaning': ['The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.', 'C0006104', 1]}]}, {'ORGAN': [{'label': 'brain', 'alias': ['Brain Stem', 'Brain Stem', 'Brain Stem', 'Brain Stem', 'Brain Stem', 'Brain stem', 'Brain stem', 'Brain stem', 'Brain stem', 'Brain stem', 'Brain stem', 'brain stem', 'brain stem', 'brain stem', 'BRAIN STEM', 'Brain Stems', 'brain stems', 'BRAIN, BRAIN STEM', 'Truncus Cerebri', 'Cerebri, Truncus', 'Cerebrus, Truncus', 'Truncus Cerebrus', 'Brainstem structure', 'Brainstem structure (body structure)', 'Brainstem', 'Brainstem', 'Brainstem', 'brainstem', 'brainstem', 'Brainstems', 'Truncus encephali'], 'meaning': ['The part of the brain that connects the CEREBRAL HEMISPHERES with the SPINAL CORD. It consists of the MESENCEPHALON; PONS; and MEDULLA OBLONGATA.', 'C0006121', 0.8662683367729187]}]}, {'TISSUE': [{'label': 'lung tissues', 'alias': ['Structure of parenchyma of lung', 'LUNG', 'lung tissue', 'Lung Tissue', 'Lung tissue', 'lung tissues', 'lungs tissues', 'lungs tissue', 'tissue lung', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'lung parenchyma', 'Lung Parenchyma', 'lungs parenchyma', 'Parenchyma of lung', 'Respiratory portion of lung', 'Respiratory portion of lung', 'Structure of parenchyma of lung (body structure)', 'Lung tiss'], 'meaning': ['Tissue consisting of an external serous coat, subserous areolar tissue and lung parenchyma. The parenchyma is made up of lobules wound together by connective tissue. A primary lobule consists of a terminal bronchiole, respiratory bronchioles, and alveolar ducts, which communicate with many alveoli, each alveolus being surrounded by a network of capillary blood vessels.', 'C0819757', 1]}]}, {'TISSUE': [{'label': 'lung tissues', 'alias': ['Body tissue', 'Body tissue', 'body tissue', 'Body Tissues', 'Body tissue, NOS', 'body tissues', 'Tissues', 'Tissues', 'Tissues', 'Tissues', 'tissues', 'tissue', 'tissue', 'tissue', 'tissue', 'Tissue, NOS', 'TISSUE', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Normal Tissue', 'Textus', 'Textus', 'Tiss', 'Body tissue structure (body structure)', 'Body tissue structure', 'Portion of tissue'], 'meaning': ['Collections of differentiated CELLS, such as EPITHELIUM; CONNECTIVE TISSUE; MUSCLES; and NERVE TISSUE. Tissues are cooperatively arranged to form organs with specialized functions such as RESPIRATION; DIGESTION; REPRODUCTION; MOVEMENT; and others.', 'C0040300', 0.7683073282241821]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'IL-6', 'alias': ['IL6 protein, human', 'B-Cell Stimulatory Factor-2', 'B-Cell Stimulatory Factor 2', 'B Cell Differentiation Factor 2', 'BSF-2', 'Hybridoma Growth Factor', 'IFN Beta 2', 'IFN-Beta-2', 'Interleukin-6', 'Interleukin 6', 'Plasmacytoma Growth Factor', 'Hepatocyte Stimulating Factor', 'Myeloid Differentiation Inducing Protein', 'B-Cell Differentiation Factor', 'IL-6', 'IL-6', 'IL6', 'CDF', 'HGF', 'HPGF', 'HSF', 'Interferon, Beta-2', 'Interferon Beta-2', 'CTL Differentiation Factor', 'Interleukin BSF-2', 'BSF2', 'IFNB2', 'IL6 Protein', 'interleukin 6 (interferon, beta 2) protein, human', 'IL-6 protein, human', 'Hepatocyte Stimulatory Factor'], 'meaning': ['Interleukin-6 (212 aa, ~24 kDa) is encoded by the human IL6 gene. This protein is involved in signaling affecting a wide variety of cell types including monocytes, lymphocytes, hepatocytes and nerve cells.', 'C1698754', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'IL-6', 'alias': ['Recombinant Interleukin-6', 'recombinant interleukin-6', 'B-Cell Stimulatory Factor-2', 'B Cell Differentiation Factor 2', 'Hybridoma Growth Factor', 'IFN Beta 2', 'interleukin 6', 'Interleukin-6', 'Plasmacytoma Growth Factor', 'Hepatocyte Stimulating Factor', 'Myeloid Differentiation Inducing Protein', 'IL-6', 'IL-6', 'IL-6', 'HPGF', 'HSF'], 'meaning': ['A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-6 (IL-6) with antiapoptotic, proinflammatory, antiinflammatory, proproliferative and proangiogenic activities. IL-6 binds to its receptor (IL-6R), activating a receptor-CD130 receptor complex; the CD130 portion of the complex is a signal transduction protein that activates JAK kinases and Ras-mediated signaling pathways, which in turn activate downstream signaling pathways, resulting in the activation of various transcription factors (STAT, ELK-1, NF-IL-6, etc.) and gene transcription. The physiological effects of IL-6 are complex and varied and include hematopoietic, pyrogenic and thermogenic, proinflammatory, antiinflammatory, proproliferative (anti-apoptotic), and angiogenic effects.', 'C1527132', 1]}]}, {'CELLULAR_COMPONENT': [{'label': 'IL1{beta', 'alias': ['IL1B gene', 'IL1B Gene', 'INTERLEUKIN 1-BETA', 'interleukin 1 beta', 'IL-1B', 'Interleukin 1, Beta Gene', 'IL1B', 'IL1B', 'IL1B', 'IL1F2', 'IL1-BETA', 'IL1-BETA'], 'meaning': ['This gene is involved in the mediation of acute phase inflammatory responses.', 'C1334112', 0.71591717004776]}]}, {'CELLULAR_COMPONENT': [{'label': 'IL1{beta', 'alias': ['Interleukin-1 beta', 'Interleukin-1 beta', 'Interleukin-1 beta', 'beta interleukin-1', 'interleukin-1-beta', 'interleukin-1-beta', 'interleukin 1 beta', 'interleukin-1 beta', 'Interleukin-1 Beta', 'Interleukin 1, Beta', 'Interleukin 1-Beta', 'Interleukin-1-Beta', 'Interleukin 1 beta', 'Interleukin 1 beta', 'Interleukin 1 beta', 'Interleukin-1beta', 'Interleukin-1beta', 'interleukin 1beta', 'interleukin-1beta', 'Interleukin 1beta', 'Catabolin', 'Catabolin', 'Catabolin', 'Catabolin', 'IL-1 beta', 'IL-1 beta', 'il-1 beta', 'IL-1 Beta', 'IL-1-beta', 'IL-1B', 'IL-1B', 'IL-1beta', 'Interleukin-1 beta (substance)', 'IL-1-b', 'IL-1-b', 'Interleukin 1, Beta Proprotein', 'Preinterleukin 1 Beta', 'IL1B', 'IL1B Protein', 'IL1F2', 'IL1-Beta', 'Interleukin-1beta [Chemical/Ingredient]'], 'meaning': ['An interleukin-1 subtype that is synthesized as an inactive membrane-bound pro-protein. Proteolytic processing of the precursor form by CASPASE 1 results in release of the active form of interleukin-1beta from the membrane.', 'C0021753', 0.71591717004776]}]}, {'CELL': [{'label': 'Immune cell', 'alias': ['Immune', 'Immune', 'immune', 'Immune (qualifier value)'], 'meaning': ['Protected against infectious disease by either specific or non-specific mechanisms.(On-line Medical Dictionary)', 'C0439662', 0.816642165184021]}]}, {'CELL': [{'label': 'Immune cell', 'alias': ['leucocyte mediated immunity', 'immune cell mediated immunity', 'leucocyte immune effector process', 'leukocyte immune effector process', 'immune cell effector process'], 'meaning': ['Any process involved in the carrying out of an immune response by a leukocyte. [GO_REF:0000022, GOC:add, GOC:mtg_15nov05, ISBN:0781735149]', 'C1817894', 0.8023785352706909]}]}, {'ORGAN': [{'label': 'lungs', 'alias': ['Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'lung', 'lung', 'lung', 'lung', 'LUNG', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lung, NOS', 'LUNGS', 'lungs', 'pulmonary', 'pulmonary', 'Lung structure', 'lung structure', 'lung structures', 'Pulmo', 'Pulmones', 'Set of lungs', 'Set of lungs', 'Lung structure (body structure)', 'Respiratory System, Lung', 'Pair of lungs', 'Lungs pair'], 'meaning': ['Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.', 'C0024109', 1]}]}, {'ORGAN': [{'label': 'lungs', 'alias': ['Left lung', 'Left lung', 'Left lung', 'Left lung', 'Left lung', 'Lung.left', 'LUNG, LEFT', 'Lung, Left', 'left lung', 'Left Lung', 'Left Lung', 'Left Lung', 'Left lung, NOS', 'left lungs', 'Pulmo sinister', 'Left lung structure (body structure)', 'Left lung structure'], 'meaning': ['The 2-lobed lung located on the left side of the body.', 'C0225730', 0.8583177328109741]}]}, {'ORGANISM': [{'label': 'mice', 'alias': ['Mice, House', 'House Mice', 'house mice', 'House Mouse', 'House Mouse', 'Mouse, House', 'house mouse', 'house mouse', 'House mouse', 'Mouse', 'mouse', 'mouse', 'Mice', 'Mice', 'Mouse, NOS', 'mice', 'Mus musculus', 'Mus musculus', 'Mus musculus', 'Mus musculus', 'Mus musculus', 'Mus musculus', 'mus musculus', 'Common house mouse', 'Common house mouse', 'Old World mouse', 'Old World mouse', 'mouse, mice', 'mouse <Mus musculus>', 'Old World mouse (organism)', 'Mouse (organism)', 'Mus musculus (organism)'], 'meaning': ['The common house mouse, often used as an experimental organism.', 'C0025914', 1]}]}, {'ORGANISM': [{'label': 'mice', 'alias': ['Mus', 'Mus', 'Mus', 'Mus', 'Mus', 'mus', 'Mice', 'Mice', 'mice', 'mice', 'Mouse', 'Mouse', 'Mouse', 'mouse', 'MOUSE', 'Murine', 'mouse <Mus>', 'Mammals, Mice', 'Genus Mus (organism)', 'Genus Mus'], 'meaning': ['Any of numerous species of small rodents belonging to the genus Mus and various related genera of the family Muridae.', 'C0026809', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'IL-1{beta', 'alias': ['Interleukin-1 beta', 'Interleukin-1 beta', 'Interleukin-1 beta', 'beta interleukin-1', 'interleukin-1-beta', 'interleukin-1-beta', 'interleukin 1 beta', 'interleukin-1 beta', 'Interleukin-1 Beta', 'Interleukin 1, Beta', 'Interleukin 1-Beta', 'Interleukin-1-Beta', 'Interleukin 1 beta', 'Interleukin 1 beta', 'Interleukin 1 beta', 'Interleukin-1beta', 'Interleukin-1beta', 'interleukin 1beta', 'interleukin-1beta', 'Interleukin 1beta', 'Catabolin', 'Catabolin', 'Catabolin', 'Catabolin', 'IL-1 beta', 'IL-1 beta', 'il-1 beta', 'IL-1 Beta', 'IL-1-beta', 'IL-1B', 'IL-1B', 'IL-1beta', 'Interleukin-1 beta (substance)', 'IL-1-b', 'IL-1-b', 'Interleukin 1, Beta Proprotein', 'Preinterleukin 1 Beta', 'IL1B', 'IL1B Protein', 'IL1F2', 'IL1-Beta', 'Interleukin-1beta [Chemical/Ingredient]'], 'meaning': ['An interleukin-1 subtype that is synthesized as an inactive membrane-bound pro-protein. Proteolytic processing of the precursor form by CASPASE 1 results in release of the active form of interleukin-1beta from the membrane.', 'C0021753', 0.8865185379981995]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'IL-1{beta', 'alias': ['IL-1', 'IL-1 binding', 'interleukin-1 binding'], 'meaning': ['Interacting selectively and non-covalently with interleukin-1. [GOC:jl, ISBN:0198506732]', 'C1149212', 0.7368263006210327]}]}, {'CELL': [{'label': 'T-lymphocytes', 'alias': ['T-Lymphocyte', 'T-Lymphocyte', 'T lymphocyte', 'T lymphocyte', 'T lymphocyte', 'T lymphocyte', 'T lymphocyte', 'T lymphocyte', 'T lymphocyte', 't lymphocyte', 't-lymphocyte', 'T-lymphocyte', 'T Lymphocytes', 'T-Lymphocytes', 'T-Lymphocytes', 't lymphocytes', 't-lymphocytes', 'T-Cells', 'T-Cells', 't cells', 't-cells', 'T cells', 'T cell', 'T cell', 'T cell', 'T cell', 'T cell', 'T Cells', 'T Cells', 'T-Cell', 'T-Cell', 't cell', 't-cell', 'T-cell', 'T-cell', 'T-cell', 'T Cell', 'Thymus-Dependent Lymphocytes', 'Lymphocyte, Thymus-Dependent', 'Thymus Dependent Lymphocytes', 'Thymus-Dependent Lymphocyte', 'thymus-dependent lymphocyte', 'Lymphocytes, Thymus-Dependent', 'Thymus Derived Lymphocyte', 'thymus derived lymphocyte', 'T lymphocyte (cell)', 'T Cell Lymphocyte'], 'meaning': ['Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.', 'C0039194', 1]}]}, {'CELL': [{'label': 'T-lymphocytes', 'alias': ['T lymphocyte count', 'T-Lymphocyte Count', 'T-Lymphocytes', 'T-Lymphocytes', 'TLYCE', 'T lymphocyte count (procedure)'], 'meaning': ['The determination of the amount of T-lymphocytes in a biological specimen.', 'C1167909', 1]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'blood', 'alias': ['peripheral blood', 'peripheral blood', 'Blood - peripheral', 'Peripheral blood', 'Peripheral blood', 'Peripheral Blood', 'Peripheral Blood', 'Peripheral Blood', 'Peripheral blood, NOS', 'blood peripheral', 'Blood', 'Blood', 'Blood', 'blood', 'BLOOD', 'Whole Blood', 'Peripheral blood (substance)', 'Reticuloendothelial System, Blood'], 'meaning': ['A tissue with red blood cells, white blood cells, platelets, and other substances suspended in fluid called plasma. Blood takes oxygen and nutrients to the tissues, and carries away wastes.', 'C0229664', 1]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'blood', 'alias': ['Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'blood', 'blood', 'blood', 'BLOOD', 'Blood, NOS', 'Blood (substance)', 'Bld', 'Sanguis', 'Portion of blood', 'Haema'], 'meaning': ['The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.', 'C0005767', 1]}]}, {'TISSUE': [{'label': 'spleen', 'alias': ['Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'Spleen', 'SPLEEN', 'SPLEEN', 'spleen', 'spleen', 'spleen', 'spleen', 'Spleen, NOS', 'spleens', 'splenic', 'splenic', 'Splenic', 'Splenic', 'Lienal', 'Spleno-', 'spleno', 'Lieno-', 'Splen', 'Splenic structure', 'Splenic structure (body structure)', 'Reticuloendothelial System, Spleen', 'Lien'], 'meaning': ['An encapsulated lymphatic organ through which venous blood filters.', 'C0037993', 1]}]}, {'TISSUE': [{'label': 'spleen', 'alias': ['SPLEEN', 'Splenic Tissue', 'Splenic Tissue'], 'meaning': ['The largest mass of lymphatic tissue in the body. It consists of cells and vessels contained within a capsule lined by mesothelium, from which trabecula enter the splenic parenchyma. The parenchyma is supported by a framework of reticular fibers. The spleen consists of two types of parenchymal tissue, the white and red pulp. The white pulp is composed of elongated cords of compact lymphatic tissue containing nodules. The red pulp is composed of pulp cords and splenic sinusoids.', 'C0771377', 1]}]}, {'TISSUE': [{'label': 'tissue', 'alias': ['Body tissue', 'Body tissue', 'body tissue', 'Body Tissues', 'Body tissue, NOS', 'body tissues', 'Tissues', 'Tissues', 'Tissues', 'Tissues', 'tissues', 'tissue', 'tissue', 'tissue', 'tissue', 'Tissue, NOS', 'TISSUE', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Tissue', 'Normal Tissue', 'Textus', 'Textus', 'Tiss', 'Body tissue structure (body structure)', 'Body tissue structure', 'Portion of tissue'], 'meaning': ['Collections of differentiated CELLS, such as EPITHELIUM; CONNECTIVE TISSUE; MUSCLES; and NERVE TISSUE. Tissues are cooperatively arranged to form organs with specialized functions such as RESPIRATION; DIGESTION; REPRODUCTION; MOVEMENT; and others.', 'C0040300', 1]}]}, {'TISSUE': [{'label': 'tissue', 'alias': ['Tissue'], 'meaning': [None, 'C1547928', 1]}]}]","{'Background: The newly emerged severe acute respiratory syndrome coronavirus (SARS-CoV-2) has caused a worldwide pandemic of human respiratory disease.': [['Background', 'NN', 'B-NP'], ['emerged', 'VBN', 'O'], ['severe', 'JJ', 'B-NP'], ['acute', 'JJ', 'I-NP'], ['respiratory', 'NN', 'I-NP'], ['syndrome', 'NN', 'B-NP'], ['coronavirus', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['caused', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['worldwide', 'JJ', 'I-NP'], ['pandemic', 'NN', 'I-NP'], ['human', 'JJ', 'B-NP'], ['respiratory', 'NN', 'I-NP'], ['disease', 'NN', 'B-NP']], 'Angiotensin-converting enzyme (ACE) 2 is the key receptor on lung epithelial cells to facilitate initial binding and infection of SARS-CoV-2.': [['Angiotensin-converting', 'JJ', 'B-NP'], ['enzyme', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['key', 'JJ', 'I-NP'], ['receptor', 'NN', 'I-NP'], ['lung', 'NN', 'B-NP'], ['facilitate', 'VB', 'O'], ['initial', 'JJ', 'B-NP'], ['binding', 'NN', 'I-NP'], ['infection', 'NN', 'B-NP']], 'The binding to ACE2 is mediated via the spike glycoprotein present on the virus surface.': [['The', 'DT', 'B-NP'], ['binding', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['mediated', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['spike', 'NN', 'I-NP'], ['glycoprotein', 'NN', 'B-NP'], ['present', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['surface', 'NN', 'B-NP']], 'Recent clinical data have demonstrated that patients suffering from stroke are particularly susceptible to severe courses of SARS-CoV-2 infection, thus forming a defined risk group.': [['have', 'VBP', 'O'], ['demonstrated', 'VBN', 'O'], ['suffering', 'VBG', 'O'], ['stroke', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['infection', 'NN', 'B-NP'], ['forming', 'VBG', 'O'], ['a', 'DT', 'B-NP'], ['defined', 'JJ', 'I-NP'], ['risk', 'NN', 'I-NP'], ['group', 'NN', 'B-NP']], 'However, a mechanistic explanation for this finding is lacking.': [['a', 'DT', 'B-NP'], ['mechanistic', 'JJ', 'I-NP'], ['explanation', 'NN', 'I-NP'], ['this', 'DT', 'B-NP'], ['finding', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['lacking', 'VBG', 'O']], 'Sterile tissue injuries including stroke induce lymphocytopenia and systemic inflammation that might modulate the expression levels of surface proteins in distant organs.': [['Sterile', 'JJ', 'B-NP'], ['tissue', 'NN', 'I-NP'], ['including', 'VBG', 'O'], ['stroke', 'NN', 'B-NP'], ['induce', 'NN', 'B-NP'], ['lymphocytopenia', 'NN', 'B-NP'], ['systemic', 'JJ', 'B-NP'], ['inflammation', 'NN', 'I-NP'], ['modulate', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['expression', 'NN', 'I-NP'], ['surface', 'NN', 'B-NP']], 'Whether systemic inflammation following stroke can specifically modulate ACE2 expression in the lung has not been investigated.': [['systemic', 'JJ', 'B-NP'], ['inflammation', 'NN', 'I-NP'], ['following', 'VBG', 'O'], ['stroke', 'NN', 'B-NP'], ['modulate', 'VB', 'O'], ['expression', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['lung', 'NN', 'I-NP'], ['has', 'VBZ', 'O'], ['been', 'VBN', 'O'], ['investigated', 'VBN', 'O']], 'Methods: Mice were subjected to transient middle cerebral artery occlusion (MCAO) for 45 min and sacrificed after 24 h and 72 h for analysis of brain and lung tissues.': [['were', 'VBD', 'O'], ['subjected', 'VBN', 'O'], ['transient', 'VB', 'O'], ['middle', 'JJ', 'B-NP'], ['cerebral', 'JJ', 'I-NP'], ['artery', 'NN', 'I-NP'], ['occlusion', 'NN', 'B-NP'], ['sacrificed', 'VBD', 'O'], ['h', 'NN', 'B-NP'], ['h', 'NN', 'B-NP'], ['analysis', 'NN', 'B-NP'], ['brain', 'NN', 'B-NP'], ['lung', 'NN', 'B-NP']], 'Gene expression and protein levels of ACE2, ACE, IL-6 and IL1{beta} were measured by quantitative PCR and Western blot, respectively.': [['expression', 'NN', 'B-NP'], ['protein', 'NN', 'B-NP'], ['beta', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['measured', 'VBN', 'O'], ['blot', 'NN', 'B-NP']], 'Immune cell populations in lymphoid organs were analyzed by flow cytometry.': [['cell', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['analyzed', 'VBN', 'O'], ['flow', 'JJ', 'B-NP'], ['cytometry', 'NN', 'I-NP']], 'Results: Strikingly, 24 h after stroke, we observed a substantial increase in the expression of ACE2 both on the transcriptional and protein levels in the lungs of MCAO mice compared to sham-operated mice.': [['h', 'NN', 'B-NP'], ['stroke', 'NN', 'B-NP'], ['observed', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['substantial', 'JJ', 'I-NP'], ['increase', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['expression', 'NN', 'I-NP'], ['mice', 'NN', 'B-NP'], ['compared', 'VBN', 'O'], ['sham-operated', 'JJ', 'B-NP'], ['mice', 'NN', 'I-NP']], 'This increased expression persisted until day 3 after stroke.': [['increased', 'VBN', 'O'], ['expression', 'NN', 'B-NP'], ['persisted', 'VBN', 'O'], ['day', 'NN', 'B-NP'], ['stroke', 'NN', 'B-NP']], 'In addition, MCAO increased the expression of inflammatory cytokines IL-6 and IL-1{beta} in the lungs.': [['addition', 'NN', 'B-NP'], ['increased', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['expression', 'NN', 'I-NP'], ['beta', 'NN', 'B-NP']], 'Higher gene expression of cytokines IL-6 and IL-1{beta} was found in ischemic brain hemispheres and a reduced number of T-lymphocytes were present in the blood and spleen as an indicator of sterile tissue injury-induced immunosuppression.': [['gene', 'NN', 'B-NP'], ['expression', 'NN', 'B-NP'], ['beta', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['found', 'VBN', 'O'], ['ischemic', 'JJ', 'B-NP'], ['brain', 'NN', 'I-NP'], ['a', 'DT', 'B-NP'], ['reduced', 'JJ', 'I-NP'], ['number', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['blood', 'NN', 'I-NP'], ['spleen', 'NN', 'B-NP'], ['an', 'DT', 'B-NP'], ['indicator', 'NN', 'I-NP'], ['sterile', 'JJ', 'B-NP'], ['tissue', 'NN', 'I-NP'], ['injury-induced', 'JJ', 'B-NP'], ['immunosuppression', 'NN', 'I-NP']], 'Conclusions: We demonstrate significantly augmented ACE2 levels and inflammation in murine lungs after experimental stroke.': [['demonstrate', 'VBP', 'O'], ['augmented', 'VBN', 'O'], ['inflammation', 'NN', 'B-NP'], ['murine', 'NN', 'B-NP'], ['experimental', 'JJ', 'B-NP'], ['stroke', 'NN', 'I-NP']], 'These pre-clinical findings might explain the clinical observation that patients with pre-existing stroke represent a high-risk group for the development of severe SARS-CoV-2 infections.': [['explain', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['clinical', 'JJ', 'I-NP'], ['observation', 'NN', 'I-NP'], ['pre-existing', 'JJ', 'B-NP'], ['stroke', 'NN', 'I-NP'], ['represent', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['high-risk', 'JJ', 'I-NP'], ['group', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['development', 'NN', 'I-NP']], 'Our studies call for further investigations into the underlying signaling mechanisms and possible therapeutic interventions.': [['call', 'VBP', 'O'], ['underlying', 'VBG', 'O'], ['signaling', 'VBG', 'O']]}","{'Background: The newly emerged severe acute respiratory syndrome coronavirus (SARS-CoV-2) has caused a worldwide pandemic of human respiratory disease.': [{'noun_phrase': ' Background', 'noun_connectors': ['newly', 'emerged']}, {'noun_phrase': ' syndrome coronavirus SARS CoV-2', 'noun_connectors': ['caused']}], 'Angiotensin-converting enzyme (ACE) 2 is the key receptor on lung epithelial cells to facilitate initial binding and infection of SARS-CoV-2.': [{'noun_phrase': ' Angiotensin', 'noun_connectors': ['converting']}, {'noun_phrase': ' enzyme ACE key receptor lung epithelial cells', 'noun_connectors': ['facilitate']}, {'noun_phrase': ' binding', 'noun_connectors': ['and']}], 'The binding to ACE2 is mediated via the spike glycoprotein present on the virus surface.': [{'noun_phrase': ' binding ACE2', 'noun_connectors': ['mediated']}], 'Recent clinical data have demonstrated that patients suffering from stroke are particularly susceptible to severe courses of SARS-CoV-2 infection, thus forming a defined risk group.': [{'noun_phrase': ' Recent clinical data', 'noun_connectors': ['demonstrated']}, {'noun_phrase': ' patients', 'noun_connectors': ['suffering']}, {'noun_phrase': ' stroke', 'noun_connectors': ['particularly']}, {'noun_phrase': ' courses SARS CoV-2 infection', 'noun_connectors': ['thus', 'forming', 'defined']}], 'However, a mechanistic explanation for this finding is lacking.': [{'noun_phrase': '', 'noun_connectors': ['However']}], 'Sterile tissue injuries including stroke induce lymphocytopenia and systemic inflammation that might modulate the expression levels of surface proteins in distant organs.': [{'noun_phrase': ' Sterile tissue injuries', 'noun_connectors': ['including']}, {'noun_phrase': ' stroke', 'noun_connectors': ['induce', 'and']}, {'noun_phrase': ' inflammation', 'noun_connectors': ['might', 'modulate']}], 'Whether systemic inflammation following stroke can specifically modulate ACE2 expression in the lung has not been investigated.': [{'noun_phrase': ' systemic inflammation', 'noun_connectors': ['following']}, {'noun_phrase': ' stroke', 'noun_connectors': ['can', 'specifically', 'modulate']}], 'Methods: Mice were subjected to transient middle cerebral artery occlusion (MCAO) for 45 min and sacrificed after 24 h and 72 h for analysis of brain and lung tissues.': [{'noun_phrase': ' Methods Mice', 'noun_connectors': ['subjected']}, {'noun_phrase': ' artery occlusion MCAO min', 'noun_connectors': ['and', 'sacrificed']}, {'noun_phrase': ' h', 'noun_connectors': ['and']}, {'noun_phrase': ' h analysis brain', 'noun_connectors': ['and']}], 'Gene expression and protein levels of ACE2, ACE, IL-6 and IL1{beta} were measured by quantitative PCR and Western blot, respectively.': [{'noun_phrase': ' Gene expression', 'noun_connectors': ['and']}, {'noun_phrase': ' protein levels ACE2 ACE IL-6', 'noun_connectors': ['and', 'measured', 'and']}], 'Immune cell populations in lymphoid organs were analyzed by flow cytometry.': [{'noun_phrase': ' Immune cell populations lymphoid organs', 'noun_connectors': ['analyzed']}], 'Results: Strikingly, 24 h after stroke, we observed a substantial increase in the expression of ACE2 both on the transcriptional and protein levels in the lungs of MCAO mice compared to sham-operated mice.': [{'noun_phrase': ' Results', 'noun_connectors': ['Strikingly']}, {'noun_phrase': ' h stroke', 'noun_connectors': ['observed']}, {'noun_phrase': ' increase expression ACE2 transcriptional', 'noun_connectors': ['and']}, {'noun_phrase': ' protein levels lungs MCAO mice', 'noun_connectors': ['compared', 'sham', 'operated']}], 'This increased expression persisted until day 3 after stroke.': [{'noun_phrase': '', 'noun_connectors': ['increased']}, {'noun_phrase': ' expression', 'noun_connectors': ['persisted']}], 'In addition, MCAO increased the expression of inflammatory cytokines IL-6 and IL-1{beta} in the lungs.': [{'noun_phrase': ' addition MCAO', 'noun_connectors': ['increased']}, {'noun_phrase': ' expression inflammatory cytokines', 'noun_connectors': ['IL-6', 'and']}], 'Higher gene expression of cytokines IL-6 and IL-1{beta} was found in ischemic brain hemispheres and a reduced number of T-lymphocytes were present in the blood and spleen as an indicator of sterile tissue injury-induced immunosuppression.': [{'noun_phrase': ' Higher gene expression cytokines IL-6', 'noun_connectors': ['and', 'found']}, {'noun_phrase': ' brain hemispheres', 'noun_connectors': ['and']}, {'noun_phrase': ' number T lymphocytes present blood', 'noun_connectors': ['and', 'spleen']}, {'noun_phrase': ' indicator sterile tissue injury', 'noun_connectors': ['induced']}], 'Conclusions: We demonstrate significantly augmented ACE2 levels and inflammation in murine lungs after experimental stroke.': [{'noun_phrase': ' Conclusions', 'noun_connectors': ['demonstrate', 'significantly', 'augmented']}, {'noun_phrase': ' levels', 'noun_connectors': ['and']}], 'These pre-clinical findings might explain the clinical observation that patients with pre-existing stroke represent a high-risk group for the development of severe SARS-CoV-2 infections.': [{'noun_phrase': ' pre - clinical findings', 'noun_connectors': ['might', 'explain']}, {'noun_phrase': ' observation', 'noun_connectors': ['patients']}, {'noun_phrase': ' stroke', 'noun_connectors': ['represent']}], 'Our studies call for further investigations into the underlying signaling mechanisms and possible therapeutic interventions.': [{'noun_phrase': ' studies', 'noun_connectors': ['call']}, {'noun_phrase': ' investigations underlying signaling mechanisms', 'noun_connectors': ['and']}]}"
"[{'author_name': 'Bader Y. Alhatlani', 'author_inst': 'Qassim University - Unayzah Community College'}]",http://biorxiv.org/cgi/content/short/2020.06.23.167916,In silico identification of conserved cis-acting RNA elements in the SARS-CoV-2 genome,"The aim of this study was to computationally predict conserved RNA sequences and structures known as cis-acting RNA elements (CREs) located within the SARS-CoV-2 genome. Bioinformatics tools were used to analyse and predict cis-acting regulatory elements by obtaining viral sequences from available databases. Computational analysis prediction revealed the presence of RNA stem-loop structures within the 3' end of the ORF1ab region that are analogous to the previously identified SARS-CoV genomic packaging signals. Alignment-based RNA secondary structures prediction of the 5' end of the SARS-CoV-2 genome identified also conserved CREs. These CREs could be used as potential targets for a vaccine and/or antiviral therapeutics developments; however, further studies would be required to confirm their roles in the SARS-CoV-2 life cycle.",2020-06-24,biorxiv,1,"[{'ORGANISM': [{'label': 'SARS-CoV', 'alias': ['SARS coronavirus', 'SARS coronavirus', 'SARS coronavirus', 'SARS coronavirus', 'Coronavirus, SARS', 'SARS Coronavirus', 'SARS Coronavirus', 'SARS CORONAVIRUS', 'coronavirus SARS', 'Severe acute respiratory syndrome-related coronavirus (organism)', 'HCoV-SARS', 'Severe Acute Respiratory Syndrome Virus', 'SARS Virus', 'virus SARS', 'SARS virus', 'SARS virus', 'SARS virus', 'SARS-Associated Coronavirus', 'SARS Associated Coronavirus', 'Coronavirus, SARS-Associated', 'Urbani SARS-Associated Coronavirus', 'Urbani SARS Associated Coronavirus', 'Coronavirus, Urbani SARS-Associated', 'SARS-Associated Coronavirus, Urbani', 'SARS-CoV', 'SARS-CoV', 'SARS-CoV', 'sars-cov', 'SARS-Related Coronavirus', 'SARS Related Coronavirus', 'Coronavirus, SARS-Related', 'SARS', 'SARS', 'Severe acute respiratory syndrome coronavirus', 'Severe Acute Respiratory Syndrome Coronavirus', 'Severe acute respiratory syndrome (SARS) coronavirus', 'Severe acute respiratory syndrome-related coronavirus', 'Severe acute respiratory syndrome-related coronavirus'], 'meaning': ['A species of enveloped, spherical or pleomorphic, kidney-shaped or rod-shaped viruses in the Coronaviridae family and Coronavirus genus. The genome is composed of linear, single-stranded, positive-sense RNA. SARS coronaviruses are found in humans and cause severe acute respiratory syndrome (SARS). SARS coronaviruses are transmitted via direct person-to-person contact with infected secretions or excretions, and aerosols of respiratory droplets.', 'C1175743', 1]}]}, {'ORGANISM': [{'label': 'SARS-CoV', 'alias': ['Severe Acute Respiratory Syndrome', 'Severe Acute Respiratory Syndrome', 'Severe Acute Respiratory Syndrome', 'Severe Acute Respiratory Syndrome', 'Severe Acute Respiratory Syndrome', 'Severe acute respiratory syndrome', 'severe acute respiratory syndrome', 'Respiratory Syndrome, Acute, Severe', 'Respiratory Syndrome, Acute, Severe', 'Respiratory Syndrome, Severe Acute', 'Respiratory Syndrome, Severe Acute', 'Coronavirus Infections', 'SARS-associated coronavirus', 'SARS', 'SARS', 'SARS', 'SARS', 'SARS', 'SARS', 'SARS', 'SARS', 'Severe acute respiratory syndrome (disorder)', 'SARS-CoV infection', 'SARS (Severe Acute Respiratory Syndrome)', 'SARS (Severe Acute Respiratory Syndrome)', 'severe acute respiratory syndrome (SARS)', 'Severe Acute Respiratory Syndrome [Disease/Finding]'], 'meaning': ['A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.', 'C1175175', 0.8561109900474548]}]}]","{'The aim of this study was to computationally predict conserved RNA sequences and structures known as cis-acting RNA elements (CREs) located within the SARS-CoV-2 genome.': [['The', 'DT', 'B-NP'], ['aim', 'NN', 'I-NP'], ['this', 'DT', 'B-NP'], ['study', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['predict', 'VB', 'O'], ['known', 'VBN', 'O'], ['located', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['SARS-CoV-2', 'JJ', 'I-NP'], ['genome', 'NN', 'I-NP']], 'Bioinformatics tools were used to analyse and predict cis-acting regulatory elements by obtaining viral sequences from available databases.': [['were', 'VBD', 'O'], ['used', 'VBN', 'O'], ['analyse', 'VB', 'O'], ['predict', 'VB', 'O'], ['obtaining', 'VBG', 'O']], ""Computational analysis prediction revealed the presence of RNA stem-loop structures within the 3' end of the ORF1ab region that are analogous to the previously identified SARS-CoV genomic packaging signals."": [['Computational', 'JJ', 'B-NP'], ['analysis', 'NN', 'I-NP'], ['prediction', 'NN', 'B-NP'], ['revealed', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['presence', 'NN', 'I-NP'], ['end', 'NN', 'B-NP'], ['region', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['identified', 'VBN', 'O'], ['genomic', 'JJ', 'B-NP'], ['packaging', 'NN', 'I-NP']], ""Alignment-based RNA secondary structures prediction of the 5' end of the SARS-CoV-2 genome identified also conserved CREs."": [['prediction', 'NN', 'B-NP'], ['end', 'NN', 'B-NP'], ['genome', 'NN', 'B-NP'], ['identified', 'VBD', 'O'], ['conserved', 'VBN', 'O']], 'These CREs could be used as potential targets for a vaccine and/or antiviral therapeutics developments; however, further studies would be required to confirm their roles in the SARS-CoV-2 life cycle.': [['be', 'VB', 'O'], ['used', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['vaccine', 'NN', 'I-NP'], ['be', 'VB', 'O'], ['required', 'VBN', 'O'], ['confirm', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['SARS-CoV-2', 'JJ', 'I-NP'], ['life', 'NN', 'I-NP'], ['cycle', 'NN', 'B-NP']]}","{'The aim of this study was to computationally predict conserved RNA sequences and structures known as cis-acting RNA elements (CREs) located within the SARS-CoV-2 genome.': [{'noun_phrase': ' aim study', 'noun_connectors': ['computationally', 'predict', 'conserved']}, {'noun_phrase': ' sequences', 'noun_connectors': ['and']}, {'noun_phrase': ' structures', 'noun_connectors': ['known']}, {'noun_phrase': ' cis', 'noun_connectors': ['acting']}, {'noun_phrase': ' elements CREs', 'noun_connectors': ['located']}], 'Bioinformatics tools were used to analyse and predict cis-acting regulatory elements by obtaining viral sequences from available databases.': [{'noun_phrase': ' Bioinformatics tools', 'noun_connectors': ['used', 'analyse', 'and', 'predict']}, {'noun_phrase': ' cis', 'noun_connectors': ['acting']}, {'noun_phrase': ' elements', 'noun_connectors': ['obtaining']}], ""Computational analysis prediction revealed the presence of RNA stem-loop structures within the 3' end of the ORF1ab region that are analogous to the previously identified SARS-CoV genomic packaging signals."": [{'noun_phrase': ' Computational analysis prediction', 'noun_connectors': ['revealed']}, {'noun_phrase': ' presence RNA stem loop structures end ORF1ab region analogous', 'noun_connectors': ['previously', 'identified']}], ""Alignment-based RNA secondary structures prediction of the 5' end of the SARS-CoV-2 genome identified also conserved CREs."": [{'noun_phrase': ' Alignment', 'noun_connectors': ['based']}, {'noun_phrase': ' structures prediction end SARS CoV-2 genome', 'noun_connectors': ['identified', 'also', 'conserved']}], 'These CREs could be used as potential targets for a vaccine and/or antiviral therapeutics developments; however, further studies would be required to confirm their roles in the SARS-CoV-2 life cycle.': [{'noun_phrase': ' CREs', 'noun_connectors': ['could', 'used']}, {'noun_phrase': ' targets vaccine', 'noun_connectors': ['and/or']}, {'noun_phrase': ' therapeutics developments', 'noun_connectors': ['however']}, {'noun_phrase': ' studies', 'noun_connectors': ['would', 'required', 'confirm']}]}"
"[{'author_name': '- TRAiN study group', 'author_inst': ''}, {'author_name': 'Michael Bretthauer', 'author_inst': 'University of Oslo'}]",http://medrxiv.org/cgi/content/short/2020.06.24.20138768,Randomized Re-Opening of Training Facilities during the COVID-19 pandemic,"Background: Most countries closed training facilities during the COVID-19 pandemic. This may have negative consequences for peoples health and wellbeing. We investigated SARS-CoV-2 virus transmission and COVID-19 disease attributable to training facilities. Methods: we randomized members 18 to 64 years with no COVID-19 relevant comorbidities at five training facilities in Oslo, Norway to access or no access to their facility. Facilities were opened from May 22, 2020 for individuals randomized to training, applying increased social distancing (1 meter for floor exercise, 2 meters for high-intensity classes), enhanced hand and surface hygiene. Locker rooms were open, showers and saunas were closed. We compared SARS-CoV-2 PCR status by self-administered naso-, oropharyngeal and sputum sampling after two weeks and clinical disease by linkage to electronic patient records after three weeks. Results: 3,764 individuals were randomized and included in analyses; 1,896 in the training and 1,868 in no-training arms. In the training arm, 81.8 percent trained at least once at the facilities. Out of 3,016 individuals who returned the SARS-CoV-2 PCR tests, there was one positive test. The positive individual was randomized to training, but had not used the facility before testing day. Contact tracing revealed the workplace as transmission source. A total of 106 individuals had outpatient hospital visits, and six individuals were admitted to hospital during the three weeks after intervention start, with no differences between arms. There were no outpatient visits or hospital admissions due to COVID-19 in either group. Conclusions: Provided good hygiene and social distancing measures, there was no increased COVID-19 spread at training facilities.",2020-06-24,medrxiv,2,"[{'PATHOLOGICAL_FORMATION': [{'label': 'oropharyngeal', 'alias': ['ORO', 'ORO', 'Oropharyngeal', 'Oropharyngeal', 'OROPHARYNGEAL', 'OROPHARYNGEAL', 'OROPHARYNGEAL', 'Oropharyngeal route', 'Oropharyngeal route (qualifier value)', 'OropharyngealRoute', 'OropharyngealRoute', 'Oropharyngeal Route of Administration', 'Oropharyngeal use'], 'meaning': ['Administration of a drug directly to the mouth and pharynx.', 'C1522409', 1]}]}, {'PATHOLOGICAL_FORMATION': [{'label': 'oropharyngeal', 'alias': ['Oropharyngeal', 'oropharyngeal', 'oropharyngeal', 'Oropharynxs', 'oral pharyngeal', 'oral pharyngeal', 'Mesopharynx', 'Mesopharynx, NOS', 'Oropharyngeal structure', 'Oropharynx', 'Oropharynx', 'Oropharynx', 'Oropharynx', 'Oropharynx', 'Oropharynx', 'Oropharynx', 'Oropharynx', 'Oropharynx', 'Oropharynx', 'oropharynx', 'oropharynx', 'oropharynx', 'oropharynx', 'OROPHARYNX', 'Oropharynx, NOS', 'Head+Neck>Oropharynx', 'Head and Neck>Oropharynx', 'Oral part of pharynx', 'Oral part of pharynx', 'Pars oralis pharyngis', 'Pars oralis pharyngis', 'Oropharyngeal structure (body structure)', 'oral pharynx'], 'meaning': ['The middle portion of the pharynx that lies posterior to the mouth, inferior to the SOFT PALATE, and superior to the base of the tongue and EPIGLOTTIS. It has a digestive function as food passes from the mouth into the oropharynx before entering ESOPHAGUS.', 'C0521367', 1]}]}, {'TISSUE': [{'label': 'sputum', 'alias': ['Sputum', 'Sputum', 'Sputum', 'Sputum', 'Sputum', 'Sputum', 'Sputum', 'Sputum', 'Sputum', 'Sputum', 'sputum', 'sputum', 'sputum', 'sputum', 'SPUTUM', 'Sputums', 'Expectoration', 'Expectoration, NOS', 'Portion of sputum', 'Sputum (substance)'], 'meaning': ['Material coughed up from the lungs and expectorated via the mouth. It contains MUCUS, cellular debris, and microorganisms. It may also contain blood or pus.', 'C0038056', 0.9999999403953552]}]}, {'TISSUE': [{'label': 'sputum', 'alias': ['Sputum'], 'meaning': [None, 'C1576419', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 1]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Veterinary Patient', 'Patient'], 'meaning': ['A non-human animal that is a subject in a study.', 'C1705908', 1]}]}]","{'Background: Most countries closed training facilities during the COVID-19 pandemic.': [['Background', 'NN', 'B-NP'], ['closed', 'VBD', 'O'], ['training', 'NN', 'B-NP'], ['pandemic', 'NN', 'B-NP']], 'This may have negative consequences for peoples health and wellbeing.': [['have', 'VB', 'O'], ['health', 'NN', 'B-NP'], ['wellbeing', 'NN', 'B-NP']], 'We investigated SARS-CoV-2 virus transmission and COVID-19 disease attributable to training facilities.': [['investigated', 'VBD', 'O'], ['virus', 'NN', 'B-NP'], ['transmission', 'NN', 'B-NP'], ['disease', 'NN', 'B-NP'], ['training', 'VBG', 'O']], 'Methods: we randomized members 18 to 64 years with no COVID-19 relevant comorbidities at five training facilities in Oslo, Norway to access or no access to their facility.': [['randomized', 'VBD', 'O'], ['training', 'NN', 'B-NP'], ['access', 'NN', 'B-NP'], ['no', 'DT', 'B-NP'], ['access', 'NN', 'I-NP'], ['facility', 'NN', 'B-NP']], 'Facilities were opened from May 22, 2020 for individuals randomized to training, applying increased social distancing (1 meter for floor exercise, 2 meters for high-intensity classes), enhanced hand and surface hygiene.': [['were', 'VBD', 'O'], ['opened', 'VBN', 'O'], ['randomized', 'VBN', 'O'], ['training', 'NN', 'B-NP'], ['applying', 'VBG', 'O'], ['increased', 'VBN', 'O'], ['social', 'JJ', 'B-NP'], ['distancing', 'NN', 'I-NP'], ['meter', 'NN', 'B-NP'], ['floor', 'NN', 'B-NP'], ['exercise', 'NN', 'B-NP'], ['high-intensity', 'NN', 'B-NP'], ['enhanced', 'JJ', 'B-NP'], ['hand', 'NN', 'I-NP'], ['surface', 'NN', 'B-NP'], ['hygiene', 'NN', 'B-NP']], 'Locker rooms were open, showers and saunas were closed.': [['Locker', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['were', 'VBD', 'O'], ['closed', 'VBN', 'O']], 'We compared SARS-CoV-2 PCR status by self-administered naso-, oropharyngeal and sputum sampling after two weeks and clinical disease by linkage to electronic patient records after three weeks.': [['compared', 'VBN', 'O'], ['status', 'NN', 'B-NP'], ['sputum', 'JJ', 'B-NP'], ['sampling', 'NN', 'I-NP'], ['clinical', 'JJ', 'B-NP'], ['disease', 'NN', 'I-NP'], ['linkage', 'NN', 'B-NP'], ['electronic', 'JJ', 'B-NP'], ['patient', 'NN', 'I-NP']], 'Results: 3,764 individuals were randomized and included in analyses; 1,896 in the training and 1,868 in no-training arms.': [['were', 'VBD', 'O'], ['randomized', 'VBN', 'O'], ['included', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['training', 'NN', 'I-NP']], 'In the training arm, 81.8 percent trained at least once at the facilities.': [['the', 'DT', 'B-NP'], ['training', 'NN', 'I-NP'], ['arm', 'NN', 'B-NP'], ['percent', 'NN', 'B-NP'], ['trained', 'VBN', 'O']], 'Out of 3,016 individuals who returned the SARS-CoV-2 PCR tests, there was one positive test.': [['returned', 'VBD', 'O'], ['was', 'VBD', 'O'], ['positive', 'JJ', 'B-NP'], ['test', 'NN', 'I-NP']], 'The positive individual was randomized to training, but had not used the facility before testing day.': [['The', 'DT', 'B-NP'], ['positive', 'JJ', 'I-NP'], ['individual', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['randomized', 'VBN', 'O'], ['training', 'NN', 'B-NP'], ['had', 'VBD', 'O'], ['used', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['facility', 'NN', 'I-NP'], ['testing', 'VBG', 'O'], ['day', 'NN', 'B-NP']], 'Contact tracing revealed the workplace as transmission source.': [['tracing', 'VBG', 'O'], ['revealed', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['workplace', 'NN', 'I-NP'], ['transmission', 'NN', 'B-NP'], ['source', 'NN', 'B-NP']], 'A total of 106 individuals had outpatient hospital visits, and six individuals were admitted to hospital during the three weeks after intervention start, with no differences between arms.': [['A', 'DT', 'B-NP'], ['total', 'NN', 'I-NP'], ['had', 'VBD', 'O'], ['outpatient', 'JJ', 'B-NP'], ['hospital', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['admitted', 'VBN', 'O'], ['hospital', 'VB', 'O'], ['intervention', 'JJ', 'B-NP'], ['start', 'NN', 'I-NP']], 'There were no outpatient visits or hospital admissions due to COVID-19 in either group.': [['were', 'VBD', 'O'], ['either', 'DT', 'B-NP'], ['group', 'NN', 'I-NP']], 'Conclusions: Provided good hygiene and social distancing measures, there was no increased COVID-19 spread at training facilities.': [['Provided', 'VBD', 'O'], ['good', 'JJ', 'B-NP'], ['hygiene', 'NN', 'I-NP'], ['social', 'JJ', 'B-NP'], ['distancing', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['increased', 'VBN', 'O'], ['spread', 'NN', 'B-NP'], ['training', 'NN', 'B-NP']]}","{'Background: Most countries closed training facilities during the COVID-19 pandemic.': [{'noun_phrase': ' Background Most countries', 'noun_connectors': ['closed']}], 'This may have negative consequences for peoples health and wellbeing.': [{'noun_phrase': '', 'noun_connectors': ['may']}, {'noun_phrase': ' consequences peoples health', 'noun_connectors': ['and']}], 'We investigated SARS-CoV-2 virus transmission and COVID-19 disease attributable to training facilities.': [{'noun_phrase': '', 'noun_connectors': ['investigated']}, {'noun_phrase': ' CoV-2 virus transmission', 'noun_connectors': ['and']}], 'Methods: we randomized members 18 to 64 years with no COVID-19 relevant comorbidities at five training facilities in Oslo, Norway to access or no access to their facility.': [{'noun_phrase': ' Methods', 'noun_connectors': ['randomized']}, {'noun_phrase': ' members years', 'noun_connectors': ['COVID-19']}, {'noun_phrase': ' comorbidities training facilities Oslo Norway access', 'noun_connectors': ['or']}], 'Facilities were opened from May 22, 2020 for individuals randomized to training, applying increased social distancing (1 meter for floor exercise, 2 meters for high-intensity classes), enhanced hand and surface hygiene.': [{'noun_phrase': ' Facilities', 'noun_connectors': ['opened']}, {'noun_phrase': ' individuals', 'noun_connectors': ['randomized']}, {'noun_phrase': ' training', 'noun_connectors': ['applying', 'increased']}, {'noun_phrase': ' distancing meter floor exercise meters high intensity classes enhanced hand', 'noun_connectors': ['and']}], 'Locker rooms were open, showers and saunas were closed.': [{'noun_phrase': ' Locker rooms open showers', 'noun_connectors': ['and']}], 'We compared SARS-CoV-2 PCR status by self-administered naso-, oropharyngeal and sputum sampling after two weeks and clinical disease by linkage to electronic patient records after three weeks.': [{'noun_phrase': '', 'noun_connectors': ['compared']}, {'noun_phrase': ' CoV-2 PCR status self', 'noun_connectors': ['administered', 'and']}, {'noun_phrase': ' sputum sampling weeks', 'noun_connectors': ['and']}], 'Results: 3,764 individuals were randomized and included in analyses; 1,896 in the training and 1,868 in no-training arms.': [{'noun_phrase': ' Results individuals', 'noun_connectors': ['randomized', 'and', 'included']}, {'noun_phrase': ' analyses training', 'noun_connectors': ['and', 'training']}], 'In the training arm, 81.8 percent trained at least once at the facilities.': [{'noun_phrase': ' training arm percent', 'noun_connectors': ['trained', 'once']}], 'Out of 3,016 individuals who returned the SARS-CoV-2 PCR tests, there was one positive test.': [{'noun_phrase': ' individuals', 'noun_connectors': ['returned']}], 'The positive individual was randomized to training, but had not used the facility before testing day.': [{'noun_phrase': ' positive individual', 'noun_connectors': ['randomized']}, {'noun_phrase': ' training', 'noun_connectors': ['but', 'used']}], 'Contact tracing revealed the workplace as transmission source.': [{'noun_phrase': ' Contact tracing', 'noun_connectors': ['revealed']}], 'A total of 106 individuals had outpatient hospital visits, and six individuals were admitted to hospital during the three weeks after intervention start, with no differences between arms.': [{'noun_phrase': ' total individuals outpatient hospital visits', 'noun_connectors': ['and']}, {'noun_phrase': ' individuals', 'noun_connectors': ['admitted']}], 'There were no outpatient visits or hospital admissions due to COVID-19 in either group.': [{'noun_phrase': ' outpatient visits', 'noun_connectors': ['or']}], 'Conclusions: Provided good hygiene and social distancing measures, there was no increased COVID-19 spread at training facilities.': [{'noun_phrase': ' Conclusions', 'noun_connectors': ['Provided']}, {'noun_phrase': ' hygiene', 'noun_connectors': ['and']}, {'noun_phrase': ' distancing measures', 'noun_connectors': ['increased']}]}"
"[{'author_name': 'Giovanni Giuseppe Giobbe', 'author_inst': 'University College London - GOS Institute of Child Health'}, {'author_name': 'Francesco Bonfante', 'author_inst': 'izsvenezie'}, {'author_name': 'Elisa Zambaiti', 'author_inst': 'University College London - GOS Institute of Child Health'}, {'author_name': 'Onelia Gagliano', 'author_inst': 'VIMM'}, {'author_name': 'Brendan C. Jones', 'author_inst': 'University College London - GOS Institute of Child Health'}, {'author_name': 'Camilla Luni', 'author_inst': 'ShanghaiTech University'}, {'author_name': 'Cecilia Laterza', 'author_inst': 'VIMM'}, {'author_name': 'Silvia Perin', 'author_inst': 'University College London - GOS Institute of Child Health'}, {'author_name': 'Hannah T. Stuart', 'author_inst': 'VIMM'}, {'author_name': 'Matteo Pagliari', 'author_inst': 'izsvenezie.it'}, {'author_name': 'Alessio Bortolami', 'author_inst': 'izsvenezie'}, {'author_name': 'Eva Mazzetto', 'author_inst': 'izsvenezie'}, {'author_name': 'Anna Manfredi', 'author_inst': 'TIGEM'}, {'author_name': 'Chiara Colantuono', 'author_inst': 'TIGEM'}, {'author_name': 'Lucio Di Filippo', 'author_inst': 'Next Generation Diagnostic srl'}, {'author_name': 'Alessandro Filippo Pellegata', 'author_inst': 'University College London - GOS Institute of Child Health'}, {'author_name': 'Vivian S.W. Li', 'author_inst': 'The Francis Crick Institute'}, {'author_name': 'Simon Eaton', 'author_inst': 'University College London - GOS Institute of Child Health'}, {'author_name': 'Nikhil Thapar', 'author_inst': 'University College London - GOS Institute of Child Health'}, {'author_name': 'Davide Cacchiarelli', 'author_inst': 'TIGEM'}, {'author_name': 'Nicola Elvassore', 'author_inst': 'University College London - GOS Institute of Child Health'}, {'author_name': 'Paolo De Coppi', 'author_inst': 'University College London - GOS Institute of Child Health'}]",http://biorxiv.org/cgi/content/short/2020.06.24.167049,SARS-CoV-2 infection and replication in human fetal and pediatric gastric organoids,"Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global public health emergency. COVID-19 typically manifests as a respiratory illness but an increasing number of clinical reports describe gastrointestinal (GI) symptoms. This is particularly true in children in whom GI symptoms are frequent and viral shedding outlasts viral clearance from the respiratory system. By contrast, fetuses seem to be rarely affected by COVID-19, although the virus has been detected in placentas of affected women. These observations raise the question of whether the virus can infect and replicate within the stomach once ingested. Moreover, it is not yet clear whether active replication of SARS-CoV-2 is possible in the stomach of children or in fetuses at different developmental stages. Here we show the novel derivation of fetal gastric organoids from 8-21 post-conception week (PCW) fetuses, and from pediatric biopsies, to be used as an in vitro model for SARS-CoV-2 gastric infection. Gastric organoids recapitulate human stomach with linear increase of gastric mucin 5AC along developmental stages, and expression of gastric markers pepsinogen, somatostatin, gastrin and chromogranin A. In order to investigate SARS-CoV-2 infection with minimal perturbation and under steady-state conditions, we induced a reversed polarity in the gastric organoids (RP-GOs) in suspension. In this condition of exposed apical polarity, the virus can easily access viral receptor angiotensin-converting enzyme 2 (ACE2). The pediatric RP-GOs are fully susceptible to infection with SARS-CoV-2, where viral nucleoprotein is expressed in cells undergoing programmed cell death, while the efficiency of infection is significantly lower in fetal organoids. The RP-GOs derived from pediatric patients show sustained robust viral replication of SARS-CoV-2, compared with organoids derived from fetal stomachs. Transcriptomic analysis shows a moderate innate antiviral response and the lack of differentially expressed genes belonging to the interferon family. Collectively, we established the first expandable human gastric organoid culture across fetal developmental stages, and we support the hypothesis that fetal tissue seems to be less susceptible to SARS-CoV-2 infection, especially in early stages of development. However, the virus can efficiently infect gastric epithelium in pediatric patients, suggesting that the stomach might have an active role in fecal-oral transmission of SARS-CoV-2.",2020-06-24,biorxiv,22,"[{'ORGAN': [{'label': 'gastrointestinal', 'alias': ['Gastrointestinal:-:Point in time:^Patient:-', 'Gastrointestinal', 'Gastrointestinal:-:Pt:^Patient:-'], 'meaning': [None, 'C2707256', 1]}]}, {'ORGAN': [{'label': 'gastrointestinal', 'alias': ['gastrointestinal', 'gastrointestinal', 'gastrointestinal', 'Gastrointestinal', 'Gastrointestinal', 'Gastrointestinal', 'Gastrointestinal', 'Gastrointestinal', 'Gastrointestinal', 'Gastrointestinal', 'GI', 'GI', 'GI', 'Gastro-intestinal', 'gastro intestinal', 'gastro-intestinal', 'gastrointestinal (GI)'], 'meaning': ['Refers to the stomach and intestines.', 'C0521362', 1]}]}, {'CANCER': [{'label': 'GI', 'alias': ['Gibi', 'gibi', 'gibi', 'Gi'], 'meaning': ['A prefix used in binary numeral system for denoting a quantity of two raised to the power of 30, which is equal to 1 073 741 824.', 'C1553044', 1]}]}, {'CANCER': [{'label': 'GI', 'alias': ['GNAI1 wt Allele', 'Gi', 'Guanine Nucleotide Binding Protein (G Protein), Alpha Inhibiting Activity Polypeptide 1 wt Allele'], 'meaning': ['Human GNAI1 wild-type allele is located in the vicinity of 7p21 and is approximately 85 kb in length. This allele, which encodes guanine nucleotide-binding protein G(i) subunit alpha-1 protein, is involved in the suppression of G-protein coupled receptor signal transduction.', 'C1708130', 1]}]}, {'ORGANISM': [{'label': 'children', 'alias': ['Child', 'Child', 'Child', 'Child', 'Child', 'Child', 'Child', 'Child', 'CHILD', 'CHILD', 'child', 'child', 'child', 'Children', 'Children', 'Children', 'Children', 'Child, NOS', 'children', 'children', 'children', 'Child Youth', '0-11 years old', 'Child (person)', 'Childhood age person', 'Childhood age person (person)', 'Children (0-21)', 'Child [Disease/Finding]'], 'meaning': ['A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.', 'C0008059', 1]}]}, {'ORGANISM': [{'label': 'children', 'alias': ['Offspring', 'Offspring', 'offspring', 'offspring', 'offsprings', 'Child of', 'of child', 'child of', 'Child', 'Children', 'CHILD', 'child', 'RoleClassChild', 'child (family member)', 'kid', 'kid', 'kids', 'Progeny', 'progeny', 'progeny', 'progeny', 'Child of (finding)', 'child find', 'Human, Child'], 'meaning': ['A human descendant (son or daughter) of any age.', 'C0680063', 1]}]}, {'TISSUE': [{'label': 'placentas', 'alias': ['Placenta', 'Placenta', 'Placenta', 'Placenta', 'Placenta', 'Placenta', 'Placenta', 'Placenta', 'Placenta', 'Placenta', 'Placenta', 'Placenta', 'Placenta', 'Placenta', 'placenta', 'placenta', 'placenta', 'placenta', 'PLACENTA', 'Placentas', 'Placenta, NOS', 'placentas', 'Placentoma, Normal', 'Placentome', 'placentome', 'Placentomes', 'Placentomes', 'Placentomes', 'Placental', 'Placental', 'Placental structure (body structure)', 'Placentomes (body structure)', 'Placental structure', 'Placent'], 'meaning': ['A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES).', 'C0032043', 1]}]}, {'TISSUE': [{'label': 'placentas', 'alias': ['Placentation', 'Placentation', 'Placentation', 'Placentation', 'placentation', 'placentation', 'placentation', 'Placental Development', 'placental development', 'placental development', 'Placentation, function (observable entity)', 'Placentation, function', 'placenta development'], 'meaning': ['The development of the PLACENTA, a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products between mother and FETUS. The process begins at FERTILIZATION, through the development of CYTOTROPHOBLASTS and SYNCYTIOTROPHOBLASTS, the formation of CHORIONIC VILLI, to the progressive increase in BLOOD VESSELS to support the growing fetus.', 'C0032058', 0.7289524674415588]}]}, {'ORGANISM': [{'label': 'women', 'alias': ['Woman', 'Woman', 'Woman', 'Woman', 'WOMAN', 'woman', 'woman', 'woman', 'Women', 'Women', 'Women', 'Women', 'women', 'women', 'women', 'female', 'Human Females', 'female humans', 'female human', 'human female', 'Girls', 'Girl', 'Woman (person)', 'adult female?'], 'meaning': ['Human females as cultural, psychological, sociological, political, and economic entities.', 'C0043210', 1]}]}, {'ORGANISM': [{'label': 'women', 'alias': ['working women', 'women working', 'Woman, Working', 'Working Woman', 'women work', 'work women', 'Working Women'], 'meaning': ['Women who are engaged in gainful activities usually outside the home.', 'C0043215', 0.7726952433586121]}]}, {'ORGAN': [{'label': 'stomach', 'alias': ['Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'STOMACH', 'STOMACH', 'stomach', 'stomach', 'stomach', 'stomach', 'Stomachs', 'Stomach, NOS', 'stomachs', 'Ventriculus', 'Gastric', 'gastric', 'Gastro-', 'gastro', 'Gaster', 'Gaster', 'gaster', 'gastr(o)-', 'Gastrointestinal Tract, Stomach'], 'meaning': ['An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the ESOPHAGUS and the beginning of the DUODENUM.', 'C0038351', 1]}]}, {'ORGAN': [{'label': 'stomach', 'alias': ['Stomach structure', 'Stomach', 'Ventriculus', 'Stomach structure (body structure)'], 'meaning': [None, 'C3714551', 1]}]}, {'TISSUE': [{'label': 'biopsies', 'alias': ['Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'Biopsy', 'biopsy', 'biopsy', 'biopsy', 'biopsy', 'BIOPSY', 'Biopsies', 'Biopsy, NOS', 'biopsied', 'biopsies', 'biopsies', 'Biopsy, nos', 'Biopsy - action', 'BX - Biopsy', 'Biopsy - action (qualifier value)', 'Biopsy (procedure)', 'biopsy procedure', 'Bx'], 'meaning': ['Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.', 'C0005558', 1]}]}, {'TISSUE': [{'label': 'biopsies', 'alias': ['Biopsy of bone', 'Biopsy of Bone', 'Bone biopsy', 'Biopsy of bone, NOS', 'biopsies bone', 'bone biopsy', 'Bone Biopsy', 'biopsy bone', 'Biopsy of bone, unspecified site', 'Biopsy of bone (procedure)'], 'meaning': ['Removal of bone tissue for microscopic examination.', 'C0005933', 0.8895615339279175]}]}, {'CANCER': [{'label': 'Gastric organoids', 'alias': ['organoids', 'Organoid', 'organoid'], 'meaning': ['An organization of cells into an organ-like structure. Organoids can be generated in culture. They are also found in certain neoplasms.', 'C0029250', 0.8106654286384583]}]}, {'CANCER': [{'label': 'Gastric organoids', 'alias': ['Gastric Carcinoid Tumor', 'Carcinoid tumor of stomach', 'Carcinoid tumour of stomach', 'carcinoid stomach tumor', 'Gastric NET G1', 'Gastric Enterochromaffin-Like Cell Neuroendocrine Tumor', 'Gastric Neuroendocrine Tumor G1', 'Gastric ECL Cell, Histamine-Producing NET', 'Gastric ECL Cell NET G1', 'Gastric ECL Cell NET', 'gastric carcinoid', 'carcinoids gastric', 'carcinoid gastric', 'Carcinoid tumor of stomach (disorder)', 'Gastric ECL-Cell Carcinoid Tumor', 'Gastric Enterochromaffin-Like Cell Carcinoid Tumor'], 'meaning': ['A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the stomach. The vast majority of cases arise from the corpus-fundus region. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent. It may be associated with autoimmune chronic atrophic gastritis, multiple endocrine neoplasia type 1, or it may be sporadic.', 'C0349529', 0.7046952843666077]}]}, {'ORGANISM': [{'label': 'human stomach', 'alias': ['Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'STOMACH', 'STOMACH', 'stomach', 'stomach', 'stomach', 'stomach', 'Stomachs', 'Stomach, NOS', 'stomachs', 'Ventriculus', 'Gastric', 'gastric', 'Gastro-', 'gastro', 'Gaster', 'Gaster', 'gaster', 'gastr(o)-', 'Gastrointestinal Tract, Stomach'], 'meaning': ['An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the ESOPHAGUS and the beginning of the DUODENUM.', 'C0038351', 0.7660782933235168]}]}, {'ORGANISM': [{'label': 'human stomach', 'alias': ['Gastric Tissue', 'STOMACH'], 'meaning': ['The tissue of the stomach. It is composed of a fibrous outer layer bounded by smooth muscle, the submucosa, and the mucosa. The mucosa of the stomach consists of secretory cells that produce hydrochloric acid and gastric enzymes.', 'C1517454', 0.7660782933235168]}]}, {'CANCER': [{'label': 'gastric', 'alias': ['Gastric (qualifier value)', 'Gastric', 'Gastric', 'Gastric', 'Gastric', 'Gastric', 'gastric', 'gastric'], 'meaning': ['Having to do with the stomach.', 'C1704242', 1]}]}, {'CANCER': [{'label': 'gastric', 'alias': ['Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'Stomach', 'STOMACH', 'STOMACH', 'stomach', 'stomach', 'stomach', 'stomach', 'Stomachs', 'Stomach, NOS', 'stomachs', 'Ventriculus', 'Gastric', 'gastric', 'Gastro-', 'gastro', 'Gaster', 'Gaster', 'gaster', 'gastr(o)-', 'Gastrointestinal Tract, Stomach'], 'meaning': ['An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the ESOPHAGUS and the beginning of the DUODENUM.', 'C0038351', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'pepsinogen', 'alias': ['PEPSINOGEN A', 'PGA', 'PG', 'PEPSINOGEN', 'PEPSINOGEN, GROUP I', 'UROPEPSINOGEN, GROUP A'], 'meaning': [None, 'C1868501', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'pepsinogen', 'alias': ['Pepsinogens', 'Pepsinogens', 'Pepsinogen', 'pepsinogen', 'pepsinogen', 'Pepsinogen, NOS', 'PG - Pepsinogen', 'Pepsinogen (substance)', 'Pepsinogens [Chemical/Ingredient]'], 'meaning': ['Proenzymes secreted by chief cells, mucous neck cells, and pyloric gland cells, which are converted into pepsin in the presence of gastric acid or pepsin itself. (Dorland, 28th ed) In humans there are 2 related pepsinogen systems: PEPSINOGEN A (formerly pepsinogen I or pepsinogen) and PEPSINOGEN C (formerly pepsinogen II or progastricsin). Pepsinogen B is the name of a pepsinogen from pigs.', 'C0030913', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'somatostatin', 'alias': ['Growth Hormone Inhibiting Hormone Measurement', 'Somatostatin', 'Growth Hormone Inhibiting Hormone', 'Growth Hormone Inhibiting Hormone', 'GRWHIH'], 'meaning': ['The determination of the amount of growth hormone inhibiting hormone present in a sample.', 'C2697526', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'somatostatin', 'alias': ['Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'Somatostatin', 'somatostatin', 'somatostatin', 'somatostatin', 'somatostatin', 'SOMATOSTATIN', 'somatostatins', 'Growth hormone inhibiting factor', 'Growth hormone inhibiting factor', 'Growth hormone inhibiting factor', 'Somatotropin release inhibiting factor (SRIF)', 'Somatotropin Release-Inhibiting Hormone', 'Somatotropin Release-Inhibiting Hormone', 'Somatotropin Release Inhibiting Hormone', 'SRIH-14', 'SRIH-14', 'Cyclic Somatostatin', 'Cyclic Somatostatin', 'Somatostatin, Cyclic', 'Somatostatin, Cyclic', 'Somatostatin-14', 'Somatostatin-14', 'Somatostatin-14', 'Somatostatin 14', 'Somatotropin inhibiting factor preparation', 'Somatotropin inhibiting factor preparation', 'Somatotropin Release-Inhibiting Factor', 'Somatotropin Release-Inhibiting Factor', 'Somatotropin release inhibiting factor', 'Somatotropin release inhibiting factor', 'Somatotropin Release Inhibiting Factors', 'Somatotropin Release Inhibiting Factor', 'Somatotropin Release Inhibiting Factor', 'SIF preparation', 'Somatostatin preparation', 'Somatostatin preparation', 'SRIF', 'SRIF', 'SRIF', 'srif', 'Growth hormone release inhibiting hormone', 'SS - Somatostatin', 'GIF (growth hormone release inhibiting factor)', 'Growth Hormone Release Inhibiting Factor', 'growth hormone release inhibiting factor', 'SST', 'Somatostatin preparation (product)', 'Somatostatin (substance)', 'Growth Hormone-Inhibiting Hormone', 'Panhibin', 'Somatostatin [Chemical/Ingredient]'], 'meaning': ['A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.', 'C0037659', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'gastrin', 'alias': ['GAST gene', 'GAST Gene', 'GAS', 'GASTRIN', 'gastrin', 'preprogastrin', 'Gastrin Gene', 'GAST', 'GAST'], 'meaning': ['This gene plays a role in digestion.', 'C1439341', 0.9999999403953552]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'gastrin', 'alias': ['Gastrin', 'Gastrin', 'Gastrin', 'Gastrin', 'Gastrin', 'Gastrin', 'Gastrin', 'Gastrin', 'Gastrin', 'gastrin', 'gastrin', 'gastrin', 'gastrin', 'Gastrin, NOS', 'gastrins', 'Gastrin preparation', 'Gastrin preparation', 'Gastrin preparation (product)', 'Gastrin (substance)'], 'meaning': ['A hormone released from special cells in the lining of the stomach after eating. Gastrin causes the stomach to release an acid that helps digest food.', 'C0376180', 0.9999999403953552]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'chromogranin A.', 'alias': ['Chromogranins', 'Chromogranins', 'Chromogranins', 'chromogranins', 'chromogranin', 'chromogranin', 'Chromogranin, NOS', 'Chromogranin', 'Chromogranin', 'Chromogranin', 'Secretogranins', 'Secretogranins', 'Chromogranin (substance)', 'CHG', 'Granins', 'Granins', 'Chromogranins [Chemical/Ingredient]'], 'meaning': ['A group of acidic proteins that are major components of SECRETORY GRANULES in the endocrine and neuroendocrine cells. They play important roles in the aggregation, packaging, sorting, and processing of secretory protein prior to secretion. They are cleaved to release biologically active peptides. There are various types of granins, usually classified by their sources.', 'C0008586', 0.7792626619338989]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'chromogranin A.', 'alias': ['CHGA gene', 'CHGA Gene', 'CHROMOGRANIN A', 'chromogranin A', 'pancreastatin', 'PARATHYROID SECRETORY PROTEIN', 'CHROMOSTATIN', 'parastatin', 'PSP', 'CATESTATIN', 'CGA', 'vasostatin', 'parathyroid secretory protein 1', 'CHGA', 'CHGA', 'CHGA', 'Chromogranin A (Parathyroid Secretory Protein 1) Gene', 'SECRETORY PROTEIN I'], 'meaning': ['This gene plays a role in the modulation of the neuroendocrine system.', 'C1332754', 0.7347107529640198]}]}, {'CELL': [{'label': 'gastric organoids', 'alias': ['organoids', 'Organoid', 'organoid'], 'meaning': ['An organization of cells into an organ-like structure. Organoids can be generated in culture. They are also found in certain neoplasms.', 'C0029250', 0.8106654286384583]}]}, {'CELL': [{'label': 'gastric organoids', 'alias': ['Gastric Carcinoid Tumor', 'Carcinoid tumor of stomach', 'Carcinoid tumour of stomach', 'carcinoid stomach tumor', 'Gastric NET G1', 'Gastric Enterochromaffin-Like Cell Neuroendocrine Tumor', 'Gastric Neuroendocrine Tumor G1', 'Gastric ECL Cell, Histamine-Producing NET', 'Gastric ECL Cell NET G1', 'Gastric ECL Cell NET', 'gastric carcinoid', 'carcinoids gastric', 'carcinoid gastric', 'Carcinoid tumor of stomach (disorder)', 'Gastric ECL-Cell Carcinoid Tumor', 'Gastric Enterochromaffin-Like Cell Carcinoid Tumor'], 'meaning': ['A well differentiated, low grade neuroendocrine tumor (carcinoid tumor) that arises from the stomach. The vast majority of cases arise from the corpus-fundus region. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent. It may be associated with autoimmune chronic atrophic gastritis, multiple endocrine neoplasia type 1, or it may be sporadic.', 'C0349529', 0.7046952843666077]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['ACE2 gene', 'ACE2 Gene', 'peptidyl-dipeptidase A', 'ACEH', 'Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene', 'ANGIOTENSIN I-CONVERTING ENZYME 2', 'angiotensin I converting enzyme 2', 'ACE2', 'ACE2', 'ACE2'], 'meaning': ['This gene plays a role in both proteolysis and vasodilation.', 'C1422064', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['BACE2 gene', 'BACE2 Gene', 'BETA-SITE APP-CLEAVING ENZYME 2', 'beta-site APP-cleaving enzyme 2', 'Beta-Site APP-Cleaving Enzyme 2 Gene', 'ALP56', 'ALP56', 'CEAP1', 'DRAP', 'DRAP', 'ASPARTIC-LIKE PROTEASE, 56-KD', 'DOWN SYNDROME REGION ASPARTIC PROTEASE', 'BACE2', 'BACE2', 'BACE2', 'BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2'], 'meaning': ['This gene is involved in proteolytic processing.', 'C1412728', 0.8900668025016785]}]}, {'CELL': [{'label': 'cells', 'alias': ['Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'cells', 'cells', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'The Cell', 'Cell, NOS', 'cell', 'cell', 'cell', 'cell', 'THE CELL', 'the cell', '{Cells}', 'Cellular', 'Cell structure', 'Cellular structures', 'Cellular structure', 'Cell Type', 'Cell Types', 'Cellula', 'Cellula', 'Set of cells', 'Set of cells', 'Cells set', 'Cell structure (cell structure)', 'Normal cell', 'Normal Cell'], 'meaning': ['The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.', 'C0007634', 0.9999999403953552]}]}, {'CELL': [{'label': 'cells', 'alias': ['Cells [Chemical/Ingredient]', 'Cells'], 'meaning': [None, 'C3282337', 0.9999999403953552]}]}, {'CELL': [{'label': 'cell', 'alias': ['CEL gene', 'CELL', 'CHOLESTEROL ESTERASE', 'LYSOPHOSPHOLIPASE', 'BILE SALT-STIMULATED LIPASE', 'bile salt-stimulated lipase', 'FETOACINAR PANCREATIC PROTEIN', 'BILE SALT-DEPENDENT LIPASE', 'FAP', 'CARBOXYL-ESTER LIPASE', 'carboxyl ester lipase', 'BSSL', 'BSSL', 'BILE SALT-DEPENDENT LIPASE, ONCOFETAL ISOFORM', 'BSDL', 'CARBOXYL-ESTER HYDROLASE', 'CARBOXYL-ESTER LIPASE-LIKE', 'FAPP', 'MODY8', 'CEL', 'CEL'], 'meaning': [None, 'C1413336', 1]}]}, {'CELL': [{'label': 'cell', 'alias': ['""U"" lymphocyte', '""U"" cell', '""U"" cell'], 'meaning': [None, 'C0301863', 1]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'TISSUE': [{'label': 'organoids', 'alias': ['organoids', 'Organoid', 'organoid'], 'meaning': ['An organization of cells into an organ-like structure. Organoids can be generated in culture. They are also found in certain neoplasms.', 'C0029250', 1]}]}, {'TISSUE': [{'label': 'fetal tissue', 'alias': ['Fetal Tissue', 'Fetal Tissue', 'Fetal tissue', 'fetal tissue', 'fetal tissue', 'Fetal Tissues', 'Tissues, Fetal', 'fetal tissues', 'Tissue, Fetal', 'FETUS', 'fetus tissue', 'fetus tissue'], 'meaning': ['Any tissue from a fetus.', 'C0242291', 1]}]}, {'TISSUE': [{'label': 'fetal tissue', 'alias': ['human fetal tissue', 'human fetus tissue'], 'meaning': ['Any tissue from a human fetus.', 'C0872050', 0.8347292542457581]}]}, {'TISSUE': [{'label': 'gastric epithelium', 'alias': ['Gastric epithelium', 'Gastric epithelium', 'Gastric epithelium', 'Gastric epithelium', 'Epithelium of stomach', 'Epithelium of stomach', 'Gastric epithelium (body structure)'], 'meaning': [None, 'C0227208', 1]}]}, {'TISSUE': [{'label': 'gastric epithelium', 'alias': ['Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'Epithelium', 'epithelium', 'epithelium', 'epithelium', 'epithelium', 'Epithelium, NOS', 'Epithelial Tissue', 'Epithelial Tissue', 'Epithelial tissue', 'Epithelial tissue', 'Epithelial tissue', 'Epithelial tissue', 'epithelial tissue', 'epithelial tissue', 'Epithelial tissue, NOS', 'epithelial tissues', 'Epithelial Tissues', 'Tissues, Epithelial', 'Tissue, Epithelial', 'Textus epithelialis', 'Textus epithelialis', 'Epithelium (body structure)', 'Portion of epithelium'], 'meaning': ['The layers of EPITHELIAL CELLS which cover the inner and outer surfaces of the cutaneous, mucus, and serous tissues and glands of the body.', 'C0014609', 0.8026888966560364]}]}]","{'Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global public health emergency.': [['disease', 'NN', 'B-NP'], ['pandemic', 'NN', 'B-NP'], ['caused', 'VBN', 'O'], ['severe', 'JJ', 'B-NP'], ['acute', 'JJ', 'I-NP'], ['respiratory', 'NN', 'I-NP'], ['syndrome', 'NN', 'B-NP'], ['coronavirus', 'NN', 'B-NP'], ['infection', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['global', 'JJ', 'I-NP'], ['public', 'JJ', 'I-NP'], ['health', 'NN', 'I-NP'], ['emergency', 'NN', 'B-NP']], 'COVID-19 typically manifests as a respiratory illness but an increasing number of clinical reports describe gastrointestinal (GI) symptoms.': [['manifests', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['respiratory', 'NN', 'I-NP'], ['illness', 'NN', 'B-NP'], ['increasing', 'VBG', 'O'], ['number', 'NN', 'B-NP']], 'This is particularly true in children in whom GI symptoms are frequent and viral shedding outlasts viral clearance from the respiratory system.': [['is', 'VBZ', 'O'], ['are', 'VBP', 'O'], ['shedding', 'VBG', 'O'], ['viral', 'JJ', 'B-NP'], ['clearance', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['respiratory', 'NN', 'I-NP'], ['system', 'NN', 'B-NP']], 'By contrast, fetuses seem to be rarely affected by COVID-19, although the virus has been detected in placentas of affected women.': [['contrast', 'NN', 'B-NP'], ['fetuses', 'VBZ', 'O'], ['seem', 'VBP', 'O'], ['be', 'VB', 'O'], ['affected', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['has', 'VBZ', 'O'], ['been', 'VBN', 'O'], ['detected', 'VBN', 'O']], 'These observations raise the question of whether the virus can infect and replicate within the stomach once ingested.': [['raise', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['question', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['infect', 'VB', 'O'], ['replicate', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['stomach', 'NN', 'I-NP'], ['ingested', 'VBN', 'O']], 'Moreover, it is not yet clear whether active replication of SARS-CoV-2 is possible in the stomach of children or in fetuses at different developmental stages.': [['is', 'VBZ', 'O'], ['active', 'JJ', 'B-NP'], ['replication', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['stomach', 'NN', 'I-NP']], 'Here we show the novel derivation of fetal gastric organoids from 8-21 post-conception week (PCW) fetuses, and from pediatric biopsies, to be used as an in vitro model for SARS-CoV-2 gastric infection.': [['show', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['novel', 'JJ', 'I-NP'], ['derivation', 'NN', 'I-NP'], ['8-21', 'JJ', 'B-NP'], ['post-conception', 'NN', 'I-NP'], ['week', 'NN', 'B-NP'], ['fetuses', 'VBZ', 'O'], ['be', 'VB', 'O'], ['used', 'VBN', 'O'], ['vitro', 'NN', 'B-NP'], ['model', 'NN', 'B-NP'], ['gastric', 'JJ', 'B-NP'], ['infection', 'NN', 'I-NP']], 'Gastric organoids recapitulate human stomach with linear increase of gastric mucin 5AC along developmental stages, and expression of gastric markers pepsinogen, somatostatin, gastrin and chromogranin A.': [['recapitulate', 'VBP', 'O'], ['human', 'JJ', 'B-NP'], ['stomach', 'NN', 'I-NP'], ['linear', 'JJ', 'B-NP'], ['increase', 'NN', 'I-NP'], ['gastric', 'JJ', 'B-NP'], ['mucin', 'NN', 'I-NP'], ['expression', 'NN', 'B-NP'], ['pepsinogen', 'VBP', 'O'], ['somatostatin', 'NN', 'B-NP'], ['gastrin', 'NN', 'B-NP'], ['chromogranin', 'VB', 'O']], 'In order to investigate SARS-CoV-2 infection with minimal perturbation and under steady-state conditions, we induced a reversed polarity in the gastric organoids (RP-GOs) in suspension.': [['order', 'NN', 'B-NP'], ['investigate', 'VB', 'O'], ['infection', 'NN', 'B-NP'], ['minimal', 'JJ', 'B-NP'], ['perturbation', 'NN', 'I-NP'], ['induced', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['reversed', 'JJ', 'I-NP'], ['polarity', 'NN', 'I-NP'], ['suspension', 'NN', 'B-NP']], 'In this condition of exposed apical polarity, the virus can easily access viral receptor angiotensin-converting enzyme 2 (ACE2).': [['this', 'DT', 'B-NP'], ['condition', 'NN', 'I-NP'], ['exposed', 'JJ', 'B-NP'], ['apical', 'JJ', 'I-NP'], ['polarity', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['access', 'NN', 'B-NP'], ['viral', 'JJ', 'B-NP'], ['receptor', 'NN', 'I-NP'], ['angiotensin-converting', 'JJ', 'B-NP'], ['enzyme', 'NN', 'I-NP']], 'The pediatric RP-GOs are fully susceptible to infection with SARS-CoV-2, where viral nucleoprotein is expressed in cells undergoing programmed cell death, while the efficiency of infection is significantly lower in fetal organoids.': [['are', 'VBP', 'O'], ['infection', 'NN', 'B-NP'], ['viral', 'JJ', 'B-NP'], ['nucleoprotein', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['expressed', 'VBN', 'O'], ['undergoing', 'VBG', 'O'], ['programmed', 'VBN', 'O'], ['cell', 'NN', 'B-NP'], ['death', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['efficiency', 'NN', 'I-NP'], ['infection', 'NN', 'B-NP'], ['is', 'VBZ', 'O']], 'The RP-GOs derived from pediatric patients show sustained robust viral replication of SARS-CoV-2, compared with organoids derived from fetal stomachs.': [['derived', 'VBD', 'O'], ['show', 'VBP', 'O'], ['sustained', 'VBN', 'O'], ['robust', 'JJ', 'B-NP'], ['viral', 'JJ', 'I-NP'], ['replication', 'NN', 'I-NP'], ['compared', 'VBN', 'O'], ['derived', 'VBN', 'O'], ['fetal', 'JJ', 'B-NP'], ['stomachs', 'NN', 'I-NP']], 'Transcriptomic analysis shows a moderate innate antiviral response and the lack of differentially expressed genes belonging to the interferon family.': [['analysis', 'NN', 'B-NP'], ['shows', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['moderate', 'JJ', 'I-NP'], ['innate', 'NN', 'I-NP'], ['antiviral', 'JJ', 'B-NP'], ['response', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['lack', 'NN', 'I-NP'], ['expressed', 'VBN', 'O'], ['belonging', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['interferon', 'NN', 'I-NP'], ['family', 'NN', 'B-NP']], 'Collectively, we established the first expandable human gastric organoid culture across fetal developmental stages, and we support the hypothesis that fetal tissue seems to be less susceptible to SARS-CoV-2 infection, especially in early stages of development.': [['established', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['first', 'JJ', 'I-NP'], ['expandable', 'JJ', 'I-NP'], ['human', 'JJ', 'I-NP'], ['gastric', 'NN', 'I-NP'], ['organoid', 'JJ', 'B-NP'], ['culture', 'NN', 'I-NP'], ['support', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['hypothesis', 'NN', 'I-NP'], ['fetal', 'JJ', 'B-NP'], ['tissue', 'NN', 'I-NP'], ['seems', 'VBZ', 'O'], ['be', 'VB', 'O'], ['SARS-CoV-2', 'JJ', 'B-NP'], ['infection', 'NN', 'I-NP'], ['development', 'NN', 'B-NP']], 'However, the virus can efficiently infect gastric epithelium in pediatric patients, suggesting that the stomach might have an active role in fecal-oral transmission of SARS-CoV-2.': [['the', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['infect', 'VB', 'O'], ['gastric', 'JJ', 'B-NP'], ['epithelium', 'NN', 'I-NP'], ['suggesting', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['stomach', 'NN', 'I-NP'], ['have', 'VB', 'O'], ['an', 'DT', 'B-NP'], ['active', 'JJ', 'I-NP'], ['role', 'NN', 'I-NP'], ['fecal-oral', 'JJ', 'B-NP'], ['transmission', 'NN', 'I-NP']]}","{'Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global public health emergency.': [{'noun_phrase': ' Coronavirus disease COVID-19 pandemic', 'noun_connectors': ['caused']}], 'COVID-19 typically manifests as a respiratory illness but an increasing number of clinical reports describe gastrointestinal (GI) symptoms.': [{'noun_phrase': ' COVID-19', 'noun_connectors': ['typically', 'manifests']}, {'noun_phrase': ' illness', 'noun_connectors': ['but', 'increasing']}], 'This is particularly true in children in whom GI symptoms are frequent and viral shedding outlasts viral clearance from the respiratory system.': [{'noun_phrase': '', 'noun_connectors': ['particularly']}, {'noun_phrase': ' children GI symptoms frequent', 'noun_connectors': ['and']}, {'noun_phrase': ' shedding', 'noun_connectors': ['outlasts']}], 'By contrast, fetuses seem to be rarely affected by COVID-19, although the virus has been detected in placentas of affected women.': [{'noun_phrase': ' contrast fetuses', 'noun_connectors': ['seem', 'rarely', 'affected']}, {'noun_phrase': ' virus', 'noun_connectors': ['detected']}], 'These observations raise the question of whether the virus can infect and replicate within the stomach once ingested.': [{'noun_phrase': ' observations', 'noun_connectors': ['raise']}, {'noun_phrase': ' question virus', 'noun_connectors': ['can', 'infect', 'and', 'replicate']}], 'Moreover, it is not yet clear whether active replication of SARS-CoV-2 is possible in the stomach of children or in fetuses at different developmental stages.': [{'noun_phrase': '', 'noun_connectors': ['Moreover', 'yet']}, {'noun_phrase': ' replication SARS CoV-2 possible stomach children', 'noun_connectors': ['or']}], 'Here we show the novel derivation of fetal gastric organoids from 8-21 post-conception week (PCW) fetuses, and from pediatric biopsies, to be used as an in vitro model for SARS-CoV-2 gastric infection.': [{'noun_phrase': '', 'noun_connectors': ['Here', 'show']}, {'noun_phrase': ' derivation fetal gastric organoids post - conception week PCW', 'noun_connectors': ['fetuses', 'and']}, {'noun_phrase': ' biopsies', 'noun_connectors': ['used']}], 'Gastric organoids recapitulate human stomach with linear increase of gastric mucin 5AC along developmental stages, and expression of gastric markers pepsinogen, somatostatin, gastrin and chromogranin A.': [{'noun_phrase': ' Gastric organoids', 'noun_connectors': ['recapitulate']}, {'noun_phrase': ' stomach linear increase gastric mucin developmental stages', 'noun_connectors': ['and']}, {'noun_phrase': ' expression gastric markers pepsinogen somatostatin gastrin', 'noun_connectors': ['and']}], 'In order to investigate SARS-CoV-2 infection with minimal perturbation and under steady-state conditions, we induced a reversed polarity in the gastric organoids (RP-GOs) in suspension.': [{'noun_phrase': ' order', 'noun_connectors': ['investigate']}, {'noun_phrase': ' CoV-2 infection minimal perturbation', 'noun_connectors': ['and']}, {'noun_phrase': ' state conditions', 'noun_connectors': ['induced']}], 'In this condition of exposed apical polarity, the virus can easily access viral receptor angiotensin-converting enzyme 2 (ACE2).': [{'noun_phrase': ' condition', 'noun_connectors': ['exposed']}, {'noun_phrase': ' polarity virus', 'noun_connectors': ['can', 'easily', 'access']}, {'noun_phrase': ' receptor angiotensin', 'noun_connectors': ['converting']}], 'The pediatric RP-GOs are fully susceptible to infection with SARS-CoV-2, where viral nucleoprotein is expressed in cells undergoing programmed cell death, while the efficiency of infection is significantly lower in fetal organoids.': [{'noun_phrase': ' pediatric RP GOs', 'noun_connectors': ['fully']}, {'noun_phrase': ' infection SARS CoV-2', 'noun_connectors': ['where', 'expressed']}, {'noun_phrase': ' cells', 'noun_connectors': ['undergoing', 'programmed']}, {'noun_phrase': ' cell death efficiency infection', 'noun_connectors': ['significantly']}], 'The RP-GOs derived from pediatric patients show sustained robust viral replication of SARS-CoV-2, compared with organoids derived from fetal stomachs.': [{'noun_phrase': ' RP GOs', 'noun_connectors': ['derived']}, {'noun_phrase': ' patients', 'noun_connectors': ['show', 'sustained']}, {'noun_phrase': ' replication SARS CoV-2', 'noun_connectors': ['compared']}, {'noun_phrase': ' organoids', 'noun_connectors': ['derived']}], 'Transcriptomic analysis shows a moderate innate antiviral response and the lack of differentially expressed genes belonging to the interferon family.': [{'noun_phrase': ' Transcriptomic analysis', 'noun_connectors': ['shows']}, {'noun_phrase': ' response', 'noun_connectors': ['and']}, {'noun_phrase': ' lack', 'noun_connectors': ['differentially', 'expressed']}, {'noun_phrase': ' genes', 'noun_connectors': ['belonging']}], 'Collectively, we established the first expandable human gastric organoid culture across fetal developmental stages, and we support the hypothesis that fetal tissue seems to be less susceptible to SARS-CoV-2 infection, especially in early stages of development.': [{'noun_phrase': '', 'noun_connectors': ['Collectively', 'established']}, {'noun_phrase': ' organoid culture fetal developmental stages', 'noun_connectors': ['and', 'support']}, {'noun_phrase': ' hypothesis fetal tissue', 'noun_connectors': ['seems', 'less']}, {'noun_phrase': ' CoV-2 infection', 'noun_connectors': ['especially']}], 'However, the virus can efficiently infect gastric epithelium in pediatric patients, suggesting that the stomach might have an active role in fecal-oral transmission of SARS-CoV-2.': [{'noun_phrase': '', 'noun_connectors': ['However']}, {'noun_phrase': ' virus', 'noun_connectors': ['can', 'efficiently', 'infect']}, {'noun_phrase': ' epithelium pediatric patients', 'noun_connectors': ['suggesting']}, {'noun_phrase': ' stomach', 'noun_connectors': ['might']}]}"
"[{'author_name': 'Kate Mc Intyre', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Pauline Lanting', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Patrick Deelen', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Henry Wiersma', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Judith M Vonk', 'author_inst': 'Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands'}, {'author_name': 'Anil PS Ori', 'author_inst': 'University Medical Center Groningen'}, {'author_name': 'Soesma A Jankipersadsing', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Robert Warmerdam', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Irene van Blokland', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Floranne Boulogne', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Marjolein XL Dijkema', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Johanna C Herkert', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Annique Claringbould', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Olivier Bakker', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Esteban A Lopera Maya', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Ute Bultmann', 'author_inst': 'Department of Health Sciences, Community and Occupational Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands'}, {'author_name': 'Alexandra Zhernakova', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Sijmen A Reijneveld', 'author_inst': 'Department of Health Sciences, Community and Occupational Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands'}, {'author_name': 'Elianne Zijlstra', 'author_inst': 'Department of Health Sciences, Community and Occupational Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands'}, {'author_name': 'Morris Swertz', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Sandra Brouwer', 'author_inst': 'Department of Health Sciences, Community and Occupational Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands'}, {'author_name': 'Raun van Ooijen', 'author_inst': 'Department of Health Sciences, Community and Occupational Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands'}, {'author_name': 'Viola Angelini', 'author_inst': 'Faculty of Economics and Business, University of Groningen, Nettelbosje 2, 9747AE Groningen, the Netherlands'}, {'author_name': 'Louise Dekker', 'author_inst': 'Faculty of Economics and Business, University of Groningen, Nettelbosje 2, 9747AE Groningen, the Netherlands'}, {'author_name': 'Anna Sijtsma', 'author_inst': 'Lifelines Cohort Study, Groningen, the Netherlands'}, {'author_name': 'Sicco A Scherjon', 'author_inst': 'Department of Obstetrics and Gynaecology, University of Groningen, University Medical Center Groningen, The Netherlands'}, {'author_name': 'Jackie Dekens', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}, {'author_name': 'Jochen O Mierau', 'author_inst': 'Faculty of Economics and Business, University of Groningen, Nettelbosje 2, 9747AE Groningen, the Netherlands'}, {'author_name': 'H. Marike Boezen', 'author_inst': 'Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands'}, {'author_name': 'Lude Franke', 'author_inst': 'University of Groningen, University Medical Center Groningen, Department of Genetics Groningen, the Netherlands'}]",http://medrxiv.org/cgi/content/short/2020.06.19.20135426,The Lifelines COVID-19 Cohort: a questionnaire-based study to investigate COVID-19 infection and its health and societal impacts in a Dutch population-based cohort,"The COVID-19 pandemic has affected billions of people around the world not only through the infection itself but also through its wider impact on public health and daily life. To assess the effects of the pandemic, a team of researchers across a wide range of disciplines developed and implemented the Lifelines COVID-19 questionnaire, leading to the development of the Lifelines COVID-19 cohort. This cohort is recruited from participants of the Lifelines prospective population cohort and the Lifelines NEXT birth cohort, and participants were asked to fill out detailed questionnaires about their physical and mental health and experiences on a weekly basis starting in late March of 2020 and on a bi-weekly basis staring in June 2020. The Lifelines region covers the three Northern provinces of the Netherlands-Drenthe, Groningen and Friesland-which together account for about 10% of the Dutch population. To date, >70,000 people have responded to the questionnaires at least once, and the questionnaire program is still ongoing. Data collected by the questionnaires will be used to address four aspects of the outbreak: (1) how the COVID-19 pandemic developed in the three northern provinces of the Netherlands, (2) which environmental risk factors predict disease susceptibility and severity, (3) which genetic risk factors predict disease susceptibility and severity and (4) what are the psychological and societal impacts of the crisis.",2020-06-24,medrxiv,30,"[{'ORGANISM': [{'label': 'participants', 'alias': ['Participant', 'participant', 'participant', 'participants'], 'meaning': ['Someone who takes part in an activity.', 'C0679646', 0.9999998807907104]}]}, {'ORGANISM': [{'label': 'participants', 'alias': ['Participant Object', 'Participant', 'Participant Thing'], 'meaning': ['Something that takes part in an activity.', 'C2698741', 0.8850828409194946]}]}]","{'The COVID-19 pandemic has affected billions of people around the world not only through the infection itself but also through its wider impact on public health and daily life.': [['pandemic', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['affected', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['world', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['infection', 'NN', 'I-NP'], ['wider', 'NN', 'B-NP'], ['impact', 'NN', 'B-NP'], ['public', 'JJ', 'B-NP'], ['health', 'NN', 'I-NP'], ['daily', 'JJ', 'B-NP'], ['life', 'NN', 'I-NP']], 'To assess the effects of the pandemic, a team of researchers across a wide range of disciplines developed and implemented the Lifelines COVID-19 questionnaire, leading to the development of the Lifelines COVID-19 cohort.': [['assess', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['pandemic', 'NN', 'I-NP'], ['a', 'DT', 'B-NP'], ['team', 'NN', 'I-NP'], ['a', 'DT', 'B-NP'], ['wide', 'JJ', 'I-NP'], ['range', 'NN', 'I-NP'], ['developed', 'VBN', 'O'], ['implemented', 'VBN', 'O'], ['questionnaire', 'NN', 'B-NP'], ['leading', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['development', 'NN', 'I-NP'], ['cohort', 'NN', 'B-NP']], 'This cohort is recruited from participants of the Lifelines prospective population cohort and the Lifelines NEXT birth cohort, and participants were asked to fill out detailed questionnaires about their physical and mental health and experiences on a weekly basis starting in late March of 2020 and on a bi-weekly basis staring in June 2020.': [['This', 'DT', 'B-NP'], ['cohort', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['recruited', 'VBN', 'O'], ['prospective', 'JJ', 'B-NP'], ['population', 'NN', 'I-NP'], ['cohort', 'NN', 'B-NP'], ['birth', 'NN', 'B-NP'], ['cohort', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['asked', 'VBN', 'O'], ['fill', 'VB', 'O'], ['mental', 'JJ', 'B-NP'], ['health', 'NN', 'I-NP'], ['a', 'DT', 'B-NP'], ['weekly', 'JJ', 'I-NP'], ['basis', 'NN', 'I-NP'], ['starting', 'VBG', 'O'], ['a', 'DT', 'B-NP'], ['bi-weekly', 'JJ', 'I-NP'], ['basis', 'NN', 'I-NP'], ['staring', 'VBG', 'O']], 'The Lifelines region covers the three Northern provinces of the Netherlands-Drenthe, Groningen and Friesland-which together account for about 10% of the Dutch population.': [['region', 'NN', 'B-NP'], ['covers', 'VBZ', 'O'], ['account', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['Dutch', 'JJ', 'I-NP'], ['population', 'NN', 'I-NP']], 'To date, >70,000 people have responded to the questionnaires at least once, and the questionnaire program is still ongoing.': [['date', 'NN', 'B-NP'], ['>', 'VBZ', 'O'], ['have', 'VBP', 'O'], ['responded', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['questionnaire', 'NN', 'I-NP'], ['program', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['ongoing', 'VBG', 'O']], 'Data collected by the questionnaires will be used to address four aspects of the outbreak: (1) how the COVID-19 pandemic developed in the three northern provinces of the Netherlands, (2) which environmental risk factors predict disease susceptibility and severity, (3) which genetic risk factors predict disease susceptibility and severity and (4) what are the psychological and societal impacts of the crisis.': [['collected', 'VBN', 'O'], ['be', 'VB', 'O'], ['used', 'VBN', 'O'], ['address', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['outbreak', 'NN', 'I-NP'], ['pandemic', 'NN', 'B-NP'], ['developed', 'VBD', 'O'], ['environmental', 'JJ', 'B-NP'], ['risk', 'NN', 'I-NP'], ['predict', 'VBP', 'O'], ['disease', 'NN', 'B-NP'], ['susceptibility', 'NN', 'B-NP'], ['severity', 'NN', 'B-NP'], ['genetic', 'JJ', 'B-NP'], ['risk', 'NN', 'I-NP'], ['predict', 'VBP', 'O'], ['disease', 'NN', 'B-NP'], ['susceptibility', 'NN', 'B-NP'], ['severity', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['crisis', 'NN', 'I-NP']]}","{'The COVID-19 pandemic has affected billions of people around the world not only through the infection itself but also through its wider impact on public health and daily life.': [{'noun_phrase': ' COVID-19 pandemic', 'noun_connectors': ['affected']}, {'noun_phrase': ' billions people world', 'noun_connectors': ['only']}, {'noun_phrase': ' infection', 'noun_connectors': ['but', 'also']}, {'noun_phrase': ' impact public health', 'noun_connectors': ['and']}], 'To assess the effects of the pandemic, a team of researchers across a wide range of disciplines developed and implemented the Lifelines COVID-19 questionnaire, leading to the development of the Lifelines COVID-19 cohort.': [{'noun_phrase': '', 'noun_connectors': ['assess']}, {'noun_phrase': ' effects pandemic team researchers wide range disciplines', 'noun_connectors': ['developed', 'and', 'implemented']}, {'noun_phrase': ' questionnaire', 'noun_connectors': ['leading']}], 'This cohort is recruited from participants of the Lifelines prospective population cohort and the Lifelines NEXT birth cohort, and participants were asked to fill out detailed questionnaires about their physical and mental health and experiences on a weekly basis starting in late March of 2020 and on a bi-weekly basis staring in June 2020.': [{'noun_phrase': ' cohort', 'noun_connectors': ['recruited']}, {'noun_phrase': ' participants Lifelines prospective population cohort', 'noun_connectors': ['and']}, {'noun_phrase': ' birth cohort', 'noun_connectors': ['and']}, {'noun_phrase': ' participants', 'noun_connectors': ['asked', 'fill']}, {'noun_phrase': ' questionnaires physical', 'noun_connectors': ['and']}, {'noun_phrase': ' health', 'noun_connectors': ['and']}, {'noun_phrase': ' experiences weekly basis', 'noun_connectors': ['starting', 'and']}], 'The Lifelines region covers the three Northern provinces of the Netherlands-Drenthe, Groningen and Friesland-which together account for about 10% of the Dutch population.': [{'noun_phrase': ' Lifelines region', 'noun_connectors': ['covers']}, {'noun_phrase': ' provinces Netherlands Drenthe Groningen', 'noun_connectors': ['and', 'together', 'account', 'about']}], 'To date, >70,000 people have responded to the questionnaires at least once, and the questionnaire program is still ongoing.': [{'noun_phrase': ' date people', 'noun_connectors': ['responded']}, {'noun_phrase': ' questionnaires least', 'noun_connectors': ['once', 'and']}], 'Data collected by the questionnaires will be used to address four aspects of the outbreak: (1) how the COVID-19 pandemic developed in the three northern provinces of the Netherlands, (2) which environmental risk factors predict disease susceptibility and severity, (3) which genetic risk factors predict disease susceptibility and severity and (4) what are the psychological and societal impacts of the crisis.': [{'noun_phrase': ' Data', 'noun_connectors': ['collected']}, {'noun_phrase': ' questionnaires', 'noun_connectors': ['will', 'used', 'address']}, {'noun_phrase': ' aspects outbreak', 'noun_connectors': ['how']}, {'noun_phrase': ' pandemic', 'noun_connectors': ['developed']}, {'noun_phrase': ' provinces Netherlands environmental risk factors', 'noun_connectors': ['predict']}, {'noun_phrase': ' disease susceptibility', 'noun_connectors': ['and']}, {'noun_phrase': ' severity genetic risk factors', 'noun_connectors': ['predict']}, {'noun_phrase': ' disease susceptibility', 'noun_connectors': ['and']}, {'noun_phrase': ' severity', 'noun_connectors': ['and', 'and']}]}"
"[{'author_name': 'Khondoker Nazmoon Nabi', 'author_inst': 'Bangladesh University of Engineering and Technology'}, {'author_name': 'Islam Md. Robiul', 'author_inst': 'Green University of Bangladesh'}]",http://medrxiv.org/cgi/content/short/2020.06.23.20138685,HAS COUNTRYWIDE LOCKDOWN WORKED AS A FEASIBLE MEASURE IN BENDING THE COVID-19 CURVE IN DEVELOPING COUNTRIES?,"In the absence of any effective vaccine and clinically proven treatment, experts thought that strict lockdown measures could be an effective way to slow down the spread of novel coronavirus. Despite the strict lockdown measures in several developing countries, the number of newly infected cases is getting unbridled as time progresses. This anomaly ignites questions about the effectiveness of the prolonged strict confinement measures. In light of the above view, with an aim to find the answer to this question, trends of four epidemiological parameters: growth factor of daily reported COVID-19 cases, daily incidence proportion, daily cumulative index and effective reproduction number in five developing countries named Bangladesh, Brazil, Chile, Pakistan and South Africa have been analysed meticulously considering the different phases of their national lockdowns. Any compelling evidence has not been found in favor of country-wide lockdown effectiveness in the above-mentioned countries. Numerical results illustrate that stringent nationwide lockdown measures have failed bringing the epidemic threshold (Re) of COVID-19 under unity. In addition, citizens of the aforementioned countries have been struggling with catastrophic socio-economic consequences due to prolonged confinement measures. Our study suggests that a new policy should be proposed for developing countries to battle against future disease outbreaks ensuring a perfect balance between saving lives and confirming livelihoods.",2020-06-24,medrxiv,2,"[{'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'CORONAVIRUS', 'coronavirus', 'Coronaviruses', 'Coronaviruses', 'Coronaviruses', 'Coronavirus, NOS', 'coronaviruses'], 'meaning': ['A genus of the family CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.', 'C0206419', 1]}]}, {'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'coronaviridae', 'CORONAVIRUS', 'Family: Coronavirus group', 'Coronavirus group', 'CORONAVIRUS GROUP', 'Coronavirus group, NOS', 'Family Coronaviridae', 'Family Coronaviridae (organism)'], 'meaning': ['Spherical RNA viruses, in the order NIDOVIRALES, infecting a wide range of animals including humans. Transmission is by fecal-oral and respiratory routes. Mechanical transmission is also common. There are two genera: CORONAVIRUS and TOROVIRUS.', 'C0010076', 1]}]}]","{'In the absence of any effective vaccine and clinically proven treatment, experts thought that strict lockdown measures could be an effective way to slow down the spread of novel coronavirus.': [['the', 'DT', 'B-NP'], ['absence', 'NN', 'I-NP'], ['any', 'DT', 'B-NP'], ['effective', 'JJ', 'I-NP'], ['vaccine', 'NN', 'I-NP'], ['proven', 'JJ', 'B-NP'], ['treatment', 'NN', 'I-NP'], ['thought', 'VBD', 'O'], ['be', 'VB', 'O'], ['an', 'DT', 'B-NP'], ['effective', 'JJ', 'I-NP'], ['way', 'NN', 'I-NP'], ['slow', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['spread', 'NN', 'I-NP'], ['novel', 'JJ', 'B-NP'], ['coronavirus', 'NN', 'I-NP']], 'Despite the strict lockdown measures in several developing countries, the number of newly infected cases is getting unbridled as time progresses.': [['developing', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['number', 'NN', 'I-NP'], ['infected', 'VBN', 'O'], ['is', 'VBZ', 'O'], ['getting', 'VBG', 'O'], ['time', 'NN', 'B-NP'], ['progresses', 'VBZ', 'O']], 'This anomaly ignites questions about the effectiveness of the prolonged strict confinement measures.': [['This', 'DT', 'B-NP'], ['anomaly', 'NN', 'I-NP'], ['ignites', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['effectiveness', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['prolonged', 'JJ', 'I-NP'], ['strict', 'JJ', 'I-NP'], ['confinement', 'NN', 'I-NP']], 'In light of the above view, with an aim to find the answer to this question, trends of four epidemiological parameters: growth factor of daily reported COVID-19 cases, daily incidence proportion, daily cumulative index and effective reproduction number in five developing countries named Bangladesh, Brazil, Chile, Pakistan and South Africa have been analysed meticulously considering the different phases of their national lockdowns.': [['light', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['above', 'JJ', 'I-NP'], ['view', 'NN', 'I-NP'], ['an', 'DT', 'B-NP'], ['aim', 'NN', 'I-NP'], ['find', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['answer', 'NN', 'I-NP'], ['this', 'DT', 'B-NP'], ['question', 'NN', 'I-NP'], ['growth', 'NN', 'B-NP'], ['factor', 'NN', 'B-NP'], ['reported', 'VBD', 'O'], ['daily', 'JJ', 'B-NP'], ['incidence', 'NN', 'I-NP'], ['proportion', 'NN', 'B-NP'], ['cumulative', 'JJ', 'B-NP'], ['index', 'NN', 'I-NP'], ['effective', 'JJ', 'B-NP'], ['reproduction', 'NN', 'I-NP'], ['number', 'NN', 'B-NP'], ['developing', 'VBG', 'O'], ['named', 'VBN', 'O'], ['have', 'VBP', 'O'], ['been', 'VBN', 'O'], ['analysed', 'VBN', 'O'], ['considering', 'VBG', 'O']], 'Any compelling evidence has not been found in favor of country-wide lockdown effectiveness in the above-mentioned countries.': [['Any', 'DT', 'B-NP'], ['compelling', 'JJ', 'I-NP'], ['evidence', 'NN', 'I-NP'], ['has', 'VBZ', 'O'], ['been', 'VBN', 'O'], ['found', 'VBN', 'O'], ['favor', 'NN', 'B-NP'], ['country-wide', 'JJ', 'B-NP'], ['lockdown', 'JJ', 'I-NP'], ['effectiveness', 'NN', 'I-NP']], 'Numerical results illustrate that stringent nationwide lockdown measures have failed bringing the epidemic threshold (Re) of COVID-19 under unity.': [['illustrate', 'VBP', 'O'], ['stringent', 'JJ', 'B-NP'], ['nationwide', 'JJ', 'I-NP'], ['lockdown', 'NN', 'I-NP'], ['have', 'VBP', 'O'], ['failed', 'VBN', 'O'], ['bringing', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['epidemic', 'JJ', 'I-NP'], ['threshold', 'NN', 'I-NP'], ['unity', 'NN', 'B-NP']], 'In addition, citizens of the aforementioned countries have been struggling with catastrophic socio-economic consequences due to prolonged confinement measures.': [['addition', 'NN', 'B-NP'], ['have', 'VBP', 'O'], ['been', 'VBN', 'O'], ['struggling', 'VBG', 'O'], ['prolonged', 'JJ', 'B-NP'], ['confinement', 'NN', 'I-NP']], 'Our study suggests that a new policy should be proposed for developing countries to battle against future disease outbreaks ensuring a perfect balance between saving lives and confirming livelihoods.': [['study', 'NN', 'B-NP'], ['suggests', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['new', 'JJ', 'I-NP'], ['policy', 'NN', 'I-NP'], ['be', 'VB', 'O'], ['proposed', 'VBN', 'O'], ['developing', 'VBG', 'O'], ['battle', 'NN', 'B-NP'], ['future', 'JJ', 'B-NP'], ['disease', 'NN', 'I-NP'], ['ensuring', 'VBG', 'O'], ['a', 'DT', 'B-NP'], ['perfect', 'JJ', 'I-NP'], ['balance', 'NN', 'I-NP'], ['saving', 'VBG', 'O'], ['confirming', 'VBG', 'O']]}","{'In the absence of any effective vaccine and clinically proven treatment, experts thought that strict lockdown measures could be an effective way to slow down the spread of novel coronavirus.': [{'noun_phrase': ' absence effective vaccine', 'noun_connectors': ['and', 'clinically', 'proven']}, {'noun_phrase': ' treatment experts', 'noun_connectors': ['thought']}, {'noun_phrase': ' lockdown measures', 'noun_connectors': ['could']}, {'noun_phrase': ' way', 'noun_connectors': ['slow']}], 'Despite the strict lockdown measures in several developing countries, the number of newly infected cases is getting unbridled as time progresses.': [{'noun_phrase': ' strict lockdown measures several', 'noun_connectors': ['developing']}, {'noun_phrase': ' countries number', 'noun_connectors': ['newly', 'infected']}, {'noun_phrase': ' cases', 'noun_connectors': ['getting']}], 'This anomaly ignites questions about the effectiveness of the prolonged strict confinement measures.': [{'noun_phrase': ' anomaly', 'noun_connectors': ['ignites']}], 'In light of the above view, with an aim to find the answer to this question, trends of four epidemiological parameters: growth factor of daily reported COVID-19 cases, daily incidence proportion, daily cumulative index and effective reproduction number in five developing countries named Bangladesh, Brazil, Chile, Pakistan and South Africa have been analysed meticulously considering the different phases of their national lockdowns.': [{'noun_phrase': ' light above view aim', 'noun_connectors': ['find']}, {'noun_phrase': ' answer question trends epidemiological parameters growth factor daily', 'noun_connectors': ['reported']}, {'noun_phrase': ' cases daily incidence proportion daily cumulative index', 'noun_connectors': ['and']}, {'noun_phrase': ' reproduction number', 'noun_connectors': ['developing']}, {'noun_phrase': ' countries', 'noun_connectors': ['named', 'and', 'analysed', 'meticulously', 'considering']}], 'Any compelling evidence has not been found in favor of country-wide lockdown effectiveness in the above-mentioned countries.': [{'noun_phrase': ' compelling evidence', 'noun_connectors': ['found']}, {'noun_phrase': ' favor country wide lockdown effectiveness', 'noun_connectors': ['above', 'mentioned']}], 'Numerical results illustrate that stringent nationwide lockdown measures have failed bringing the epidemic threshold (Re) of COVID-19 under unity.': [{'noun_phrase': ' Numerical results', 'noun_connectors': ['illustrate']}, {'noun_phrase': ' lockdown measures', 'noun_connectors': ['failed', 'bringing']}], 'In addition, citizens of the aforementioned countries have been struggling with catastrophic socio-economic consequences due to prolonged confinement measures.': [{'noun_phrase': ' addition citizens aforementioned countries', 'noun_connectors': ['struggling']}], 'Our study suggests that a new policy should be proposed for developing countries to battle against future disease outbreaks ensuring a perfect balance between saving lives and confirming livelihoods.': [{'noun_phrase': ' study', 'noun_connectors': ['suggests']}, {'noun_phrase': ' policy', 'noun_connectors': ['should', 'proposed', 'developing']}, {'noun_phrase': ' countries battle future disease outbreaks', 'noun_connectors': ['ensuring']}, {'noun_phrase': ' balance', 'noun_connectors': ['saving']}, {'noun_phrase': ' lives', 'noun_connectors': ['and', 'confirming']}]}"
"[{'author_name': 'Yannick B. Helms', 'author_inst': 'RIVM'}, {'author_name': 'Nora Hamdiui', 'author_inst': 'National Coordination Centre for Communicable Disease Control, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, '}, {'author_name': 'Renske Eilers', 'author_inst': 'National Coordination Centre for Communicable Disease Control, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, '}, {'author_name': 'Christian Hoebe', 'author_inst': 'Department of Sexual Health, Infectious Diseases, and Environmental Health, South Limburg Public Health Service, Heerlen, The Netherlands.'}, {'author_name': 'Nicole Dukers-Muijrers', 'author_inst': 'Department of Sexual Health, Infectious Diseases, and Environmental Health, South Limburg Public Health Service, Heerlen, The Netherlands.'}, {'author_name': 'Hans van den Kerkhof', 'author_inst': 'National Coordination Centre for Communicable Disease Control, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, '}, {'author_name': 'Aura Timen', 'author_inst': 'National Coordination Centre for Communicable Disease Control, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, '}, {'author_name': 'Mart L. Stein', 'author_inst': 'National Coordination Centre for Communicable Disease Control, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, '}]",http://medrxiv.org/cgi/content/short/2020.06.24.20138024,Online respondent-driven detection for enhanced contact tracing of close-contact infectious diseases: benefits and barriers for public health practice,"Background: Online respondent-driven detection (online-RDD) is a novel method of case-finding that can enhance contact tracing. However, the advantages and challenges of online-RDD for contact tracing (CT) have not yet been investigated from the perspective of public health professionals (PHPs). Therefore, it remains unclear if, and under what circumstances, PHPs are willing to apply online-RDD for contact tracing. Methods: First, between March and April 2019, we conducted semi-structured interviews with Dutch PHPs responsible for CT in practice. Questions were derived from the diffusion of innovations theory. Second, between May and June 2019 we distributed an online questionnaire to 260 Dutch PHPs to quantify the main qualitative findings. Using hypothetical scenarios that involved close-contact pathogens (scabies, shigella, and mumps), we assessed anticipated advantages and challenges of online-RDD and PHPs intention to apply online-RDD for contact tracing. Results: Twelve interviews were held and 70 PHPs filled in the online questionnaire. A majority of questionnaire respondents (71%) had a positive intention towards using online-RDD for contact tracing. Anticipated advantages of online-RDD were related to accommodating easy and autonomous participation in contact tracing of patients and contact persons, and reaching contact persons more efficiently. Anticipated challenges with online-RDD were related to limited opportunities for PHPs to support, motivate, and coordinate the execution of contact tracing, adequately conveying measures to patients and contact persons, and anticipated unrest among patients and contact persons. Online-RDD was considered more applicable when patients and their contact persons are reluctant to share sensitive information directly with PHPs, digitally skilled and literate persons are involved, and the scope of contact tracing is large. Online-RDD was considered less applicable when consequences of missing information or individuals are severe for individuals - or public health, when measures that patients and contact persons need to undertake are complex or impactful, and when a disease is perceived as particularly severe or sensitive by patients and their contact persons. Conclusions: PHPs generally perceived online-RDD as beneficial to public health practice. The method can help overcome challenges present in regular CT and could be used during outbreaks of infectious diseases that spread via close-contact, such as the SARS-CoV-2 virus. We propose a staggered implementation study to further investigate the application of online-RDD for enhanced CT during the ongoing COVID-19 pandemic.",2020-06-24,medrxiv,8,"[{'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'ORGANISM': [{'label': 'persons', 'alias': ['Persons', 'Persons', 'persons', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'person', 'person', 'Individual', 'people', 'People', 'peoples', 'Person (person)'], 'meaning': ['Persons as individuals (e.g., ABORTION APPLICANTS) or as members of a group (e.g., HISPANIC AMERICANS). It is not used for members of the various professions (e.g., PHYSICIANS) or occupations (e.g., LIBRARIANS) for which OCCUPATIONAL GROUPS is available.', 'C0027361', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'persons', 'alias': ['Person Observer', 'Person'], 'meaning': ['The name of the individual witnessing an event.', 'C2347489', 0.8327237367630005]}]}]","{'Background: Online respondent-driven detection (online-RDD) is a novel method of case-finding that can enhance contact tracing.': [['Background', 'NN', 'B-NP'], ['Online', 'JJ', 'B-NP'], ['respondent-driven', 'JJ', 'I-NP'], ['detection', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['novel', 'JJ', 'I-NP'], ['method', 'NN', 'I-NP'], ['case-finding', 'NN', 'B-NP'], ['enhance', 'VB', 'O'], ['contact', 'JJ', 'B-NP'], ['tracing', 'NN', 'I-NP']], 'However, the advantages and challenges of online-RDD for contact tracing (CT) have not yet been investigated from the perspective of public health professionals (PHPs).': [['online-RDD', 'NN', 'B-NP'], ['contact', 'NN', 'B-NP'], ['tracing', 'NN', 'B-NP'], ['have', 'VBP', 'O'], ['been', 'VBN', 'O'], ['investigated', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['perspective', 'NN', 'I-NP'], ['public', 'JJ', 'B-NP'], ['health', 'NN', 'I-NP']], 'Therefore, it remains unclear if, and under what circumstances, PHPs are willing to apply online-RDD for contact tracing.': [['remains', 'VBZ', 'O'], ['are', 'VBP', 'O'], ['apply', 'VB', 'O'], ['contact', 'NN', 'B-NP'], ['tracing', 'NN', 'B-NP']], 'Methods: First, between March and April 2019, we conducted semi-structured interviews with Dutch PHPs responsible for CT in practice.': [['conducted', 'VBD', 'O'], ['practice', 'NN', 'B-NP']], 'Questions were derived from the diffusion of innovations theory.': [['were', 'VBD', 'O'], ['derived', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['diffusion', 'NN', 'I-NP'], ['theory', 'NN', 'B-NP']], 'Second, between May and June 2019 we distributed an online questionnaire to 260 Dutch PHPs to quantify the main qualitative findings.': [['distributed', 'VBD', 'O'], ['an', 'DT', 'B-NP'], ['online', 'JJ', 'I-NP'], ['questionnaire', 'NN', 'I-NP'], ['quantify', 'VB', 'O']], 'Using hypothetical scenarios that involved close-contact pathogens (scabies, shigella, and mumps), we assessed anticipated advantages and challenges of online-RDD and PHPs intention to apply online-RDD for contact tracing.': [['Using', 'VBG', 'O'], ['involved', 'VBD', 'O'], ['shigella', 'NN', 'B-NP'], ['assessed', 'VBD', 'O'], ['anticipated', 'VBN', 'O'], ['intention', 'NN', 'B-NP'], ['apply', 'VB', 'O'], ['contact', 'NN', 'B-NP'], ['tracing', 'NN', 'B-NP']], 'Results: Twelve interviews were held and 70 PHPs filled in the online questionnaire.': [['were', 'VBD', 'O'], ['held', 'VBN', 'O'], ['filled', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['online', 'NN', 'I-NP'], ['questionnaire', 'NN', 'B-NP']], 'A majority of questionnaire respondents (71%) had a positive intention towards using online-RDD for contact tracing.': [['A', 'DT', 'B-NP'], ['majority', 'NN', 'I-NP'], ['questionnaire', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['had', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['positive', 'JJ', 'I-NP'], ['intention', 'NN', 'I-NP'], ['using', 'VBG', 'O'], ['online-RDD', 'NN', 'B-NP'], ['contact', 'NN', 'B-NP'], ['tracing', 'NN', 'B-NP']], 'Anticipated advantages of online-RDD were related to accommodating easy and autonomous participation in contact tracing of patients and contact persons, and reaching contact persons more efficiently.': [['were', 'VBD', 'O'], ['related', 'VBN', 'O'], ['accommodating', 'VBG', 'O'], ['autonomous', 'JJ', 'B-NP'], ['participation', 'NN', 'I-NP'], ['contact', 'NN', 'B-NP'], ['tracing', 'NN', 'B-NP'], ['reaching', 'VBG', 'O']], 'Anticipated challenges with online-RDD were related to limited opportunities for PHPs to support, motivate, and coordinate the execution of contact tracing, adequately conveying measures to patients and contact persons, and anticipated unrest among patients and contact persons.': [['Anticipated', 'VBN', 'O'], ['were', 'VBD', 'O'], ['related', 'VBN', 'O'], ['support', 'VB', 'O'], ['motivate', 'NN', 'B-NP'], ['coordinate', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['execution', 'NN', 'I-NP'], ['contact', 'NN', 'B-NP'], ['tracing', 'NN', 'B-NP'], ['conveying', 'VBG', 'O'], ['anticipated', 'JJ', 'B-NP'], ['unrest', 'NN', 'I-NP']], 'Online-RDD was considered more applicable when patients and their contact persons are reluctant to share sensitive information directly with PHPs, digitally skilled and literate persons are involved, and the scope of contact tracing is large.': [['Online-RDD', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['considered', 'VBN', 'O'], ['contact', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['share', 'NN', 'B-NP'], ['sensitive', 'JJ', 'B-NP'], ['information', 'NN', 'I-NP'], ['skilled', 'VBN', 'O'], ['are', 'VBP', 'O'], ['involved', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['scope', 'NN', 'I-NP'], ['contact', 'NN', 'B-NP'], ['tracing', 'NN', 'B-NP'], ['is', 'VBZ', 'O']], 'Online-RDD was considered less applicable when consequences of missing information or individuals are severe for individuals - or public health, when measures that patients and contact persons need to undertake are complex or impactful, and when a disease is perceived as particularly severe or sensitive by patients and their contact persons.': [['Online-RDD', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['considered', 'VBN', 'O'], ['missing', 'VBG', 'O'], ['information', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['public', 'JJ', 'B-NP'], ['health', 'NN', 'I-NP'], ['need', 'VBP', 'O'], ['undertake', 'VB', 'O'], ['are', 'VBP', 'O'], ['a', 'DT', 'B-NP'], ['disease', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['perceived', 'VBN', 'O'], ['contact', 'NN', 'B-NP']], 'Conclusions: PHPs generally perceived online-RDD as beneficial to public health practice.': [['perceived', 'VBD', 'O'], ['public', 'JJ', 'B-NP'], ['health', 'NN', 'I-NP'], ['practice', 'NN', 'B-NP']], 'The method can help overcome challenges present in regular CT and could be used during outbreaks of infectious diseases that spread via close-contact, such as the SARS-CoV-2 virus.': [['The', 'DT', 'B-NP'], ['method', 'NN', 'I-NP'], ['help', 'VB', 'O'], ['overcome', 'VB', 'O'], ['be', 'VB', 'O'], ['used', 'VBN', 'O'], ['spread', 'VBP', 'O'], ['close-contact', 'NN', 'B-NP'], ['virus', 'NN', 'B-NP']], 'We propose a staggered implementation study to further investigate the application of online-RDD for enhanced CT during the ongoing COVID-19 pandemic.': [['propose', 'VBP', 'O'], ['a', 'DT', 'B-NP'], ['staggered', 'JJ', 'I-NP'], ['implementation', 'NN', 'I-NP'], ['study', 'NN', 'B-NP'], ['investigate', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['application', 'NN', 'I-NP'], ['online-RDD', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['ongoing', 'JJ', 'I-NP'], ['COVID-19', 'JJ', 'I-NP'], ['pandemic', 'NN', 'I-NP']]}","{'Background: Online respondent-driven detection (online-RDD) is a novel method of case-finding that can enhance contact tracing.': [{'noun_phrase': ' Background Online respondent', 'noun_connectors': ['driven']}, {'noun_phrase': ' detection online RDD novel method case finding', 'noun_connectors': ['can', 'enhance']}], 'However, the advantages and challenges of online-RDD for contact tracing (CT) have not yet been investigated from the perspective of public health professionals (PHPs).': [{'noun_phrase': '', 'noun_connectors': ['However']}, {'noun_phrase': ' advantages', 'noun_connectors': ['and']}, {'noun_phrase': ' challenges online RDD contact tracing CT', 'noun_connectors': ['yet', 'investigated']}], 'Therefore, it remains unclear if, and under what circumstances, PHPs are willing to apply online-RDD for contact tracing.': [{'noun_phrase': '', 'noun_connectors': ['Therefore', 'remains', 'and']}, {'noun_phrase': ' circumstances PHPs willing', 'noun_connectors': ['apply']}], 'Methods: First, between March and April 2019, we conducted semi-structured interviews with Dutch PHPs responsible for CT in practice.': [{'noun_phrase': ' Methods', 'noun_connectors': ['First', 'and', 'conducted']}], 'Questions were derived from the diffusion of innovations theory.': [{'noun_phrase': ' Questions', 'noun_connectors': ['derived']}], 'Second, between May and June 2019 we distributed an online questionnaire to 260 Dutch PHPs to quantify the main qualitative findings.': [{'noun_phrase': '', 'noun_connectors': ['Second', 'and', 'distributed']}, {'noun_phrase': ' questionnaire Dutch PHPs', 'noun_connectors': ['quantify']}], 'Using hypothetical scenarios that involved close-contact pathogens (scabies, shigella, and mumps), we assessed anticipated advantages and challenges of online-RDD and PHPs intention to apply online-RDD for contact tracing.': [{'noun_phrase': '', 'noun_connectors': ['Using']}, {'noun_phrase': ' scenarios', 'noun_connectors': ['involved']}, {'noun_phrase': ' contact pathogens scabies shigella', 'noun_connectors': ['and', 'assessed']}, {'noun_phrase': ' advantages', 'noun_connectors': ['and']}, {'noun_phrase': ' challenges online RDD', 'noun_connectors': ['and']}, {'noun_phrase': ' intention', 'noun_connectors': ['apply']}], 'Results: Twelve interviews were held and 70 PHPs filled in the online questionnaire.': [{'noun_phrase': ' Results interviews', 'noun_connectors': ['held', 'and']}, {'noun_phrase': ' PHPs', 'noun_connectors': ['filled']}], 'A majority of questionnaire respondents (71%) had a positive intention towards using online-RDD for contact tracing.': [{'noun_phrase': ' majority questionnaire respondents % positive intention', 'noun_connectors': ['using']}], 'Anticipated advantages of online-RDD were related to accommodating easy and autonomous participation in contact tracing of patients and contact persons, and reaching contact persons more efficiently.': [{'noun_phrase': ' Anticipated advantages online RDD', 'noun_connectors': ['related', 'accommodating', 'and']}, {'noun_phrase': ' participation contact tracing patients', 'noun_connectors': ['and']}, {'noun_phrase': ' contact persons', 'noun_connectors': ['and', 'reaching']}], 'Anticipated challenges with online-RDD were related to limited opportunities for PHPs to support, motivate, and coordinate the execution of contact tracing, adequately conveying measures to patients and contact persons, and anticipated unrest among patients and contact persons.': [{'noun_phrase': ' Anticipated challenges online RDD', 'noun_connectors': ['related']}, {'noun_phrase': ' opportunities PHPs', 'noun_connectors': ['support', 'motivate', 'and', 'coordinate']}, {'noun_phrase': ' execution contact tracing', 'noun_connectors': ['adequately', 'conveying']}, {'noun_phrase': ' measures patients', 'noun_connectors': ['and']}, {'noun_phrase': ' contact persons', 'noun_connectors': ['and', 'anticipated']}, {'noun_phrase': ' unrest patients', 'noun_connectors': ['and']}], 'Online-RDD was considered more applicable when patients and their contact persons are reluctant to share sensitive information directly with PHPs, digitally skilled and literate persons are involved, and the scope of contact tracing is large.': [{'noun_phrase': ' Online RDD', 'noun_connectors': ['considered', 'more', 'when']}, {'noun_phrase': ' patients', 'noun_connectors': ['and']}, {'noun_phrase': ' contact persons reluctant', 'noun_connectors': ['share']}, {'noun_phrase': ' information', 'noun_connectors': ['directly']}, {'noun_phrase': ' PHPs', 'noun_connectors': ['digitally', 'and']}, {'noun_phrase': ' persons', 'noun_connectors': ['involved', 'and']}], 'Online-RDD was considered less applicable when consequences of missing information or individuals are severe for individuals - or public health, when measures that patients and contact persons need to undertake are complex or impactful, and when a disease is perceived as particularly severe or sensitive by patients and their contact persons.': [{'noun_phrase': ' Online RDD', 'noun_connectors': ['considered', 'less', 'when']}, {'noun_phrase': ' consequences', 'noun_connectors': ['missing']}, {'noun_phrase': ' information', 'noun_connectors': ['or']}, {'noun_phrase': ' individuals severe individuals', 'noun_connectors': ['or']}, {'noun_phrase': ' health', 'noun_connectors': ['when']}, {'noun_phrase': ' measures patients', 'noun_connectors': ['and']}, {'noun_phrase': ' contact persons', 'noun_connectors': ['need', 'undertake', 'or', 'and', 'when']}, {'noun_phrase': ' disease', 'noun_connectors': ['perceived', 'as', 'particularly', 'or']}, {'noun_phrase': ' patients', 'noun_connectors': ['and']}], 'Conclusions: PHPs generally perceived online-RDD as beneficial to public health practice.': [{'noun_phrase': ' Conclusions PHPs', 'noun_connectors': ['generally', 'perceived']}], 'The method can help overcome challenges present in regular CT and could be used during outbreaks of infectious diseases that spread via close-contact, such as the SARS-CoV-2 virus.': [{'noun_phrase': ' method', 'noun_connectors': ['can', 'help', 'overcome']}, {'noun_phrase': ' challenges present regular CT', 'noun_connectors': ['and', 'could', 'used']}, {'noun_phrase': ' outbreaks infectious diseases', 'noun_connectors': ['spread']}], 'We propose a staggered implementation study to further investigate the application of online-RDD for enhanced CT during the ongoing COVID-19 pandemic.': [{'noun_phrase': '', 'noun_connectors': ['propose']}, {'noun_phrase': ' implementation study', 'noun_connectors': ['further', 'investigate']}]}"
"[{'author_name': 'Ellen Bentlage', 'author_inst': 'University of Muenster, Germany'}, {'author_name': 'Achraf Ammar', 'author_inst': 'Otto-von-Guericke University, Germany'}, {'author_name': 'Hamdi Chtourou', 'author_inst': 'Observatoire National du Sport; Universite de Sfax, Tunisie'}, {'author_name': 'Khaled Trabelsi', 'author_inst': 'Universite de Sfax, ; Sport et Sante, Tunisie'}, {'author_name': 'Daniella How', 'author_inst': 'University of Muenster, Germany'}, {'author_name': 'Mona Ahmed', 'author_inst': 'University of Muenster, Germany'}, {'author_name': 'Michael Brach', 'author_inst': 'University of Muenster, Germany'}]",http://medrxiv.org/cgi/content/short/2020.06.24.20138313,Practical recommendations for staying physically active during the COVID-19 pandemic: A systematic literature review,"Background: Due to home-confinement and social isolation of during the Covid-19 pandemic, reductions in performing physical activities were obsered. A main consequence of inactivity is a poorer general health and a higher mortality rate. Therefore, it is important to inform the public about practical recommendations for staying physically active, especially during the current Covid-19 pandemic. Methods: Through a systematic review of literature in two databases (Pubmed/Medline; Web of Science), studies were analysed which include practical recommendations for staying active during Covid-19 (Q1), or if they did not explicitly deal with Covid-19, research with useful results regarding the adaption to the present situation (Q2). Results: Currently, there are 6 studies published which are related to the first research question. In total, 26 papers, were found to correlate to the second one. Conclusion: Researchers need to be more specific in the exact recommendations for different age-groups and various health statuses. Key sources are the websites of the World Health Organization and the American Heart Association. In addition, exergames need to be adaptable to restrictions by product designers and to integrate social interaction-functions. Furthermore, it is essential that governmental actions need to be taken, with the help of researchers, to inform citizens about possible physical activities, with precise examples, clarification of benefits of the exercises, the exact exercise with duration, intensity and other substitute tasks for different age-groups and for people with diseases.",2020-06-24,medrxiv,7,"[{'CANCER': [{'label': 'Heart', 'alias': ['Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'Heart', 'HEART', 'HEART', 'heart', 'heart', 'heart', 'Hearts', 'Heart, NOS', 'Cardiac', 'Cardiac', 'Cardiac', 'Cardiac', 'cardiac', 'cardiac', 'cardiac', 'cardiac', 'Cardio-', 'Cardiac structure', 'cardiac structure', 'Cor', 'Heart structure', 'heart structure', 'coronary', 'cardi(o)-', 'Heart structure (body structure)'], 'meaning': ['The hollow, muscular organ that maintains the circulation of the blood.', 'C0018787', 1]}]}, {'CANCER': [{'label': 'Heart', 'alias': ['heart part', 'Heart Part', 'heart parts', 'heart component', 'Heart part (body structure)'], 'meaning': ['Any component of the organ which receives blood from the veins and ejects it into the arteries.', 'C1268110', 0.8799307346343994]}]}, {'ORGANISM': [{'label': 'people', 'alias': ['Persons', 'Persons', 'persons', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'Person', 'person', 'person', 'Individual', 'people', 'People', 'peoples', 'Person (person)'], 'meaning': ['Persons as individuals (e.g., ABORTION APPLICANTS) or as members of a group (e.g., HISPANIC AMERICANS). It is not used for members of the various professions (e.g., PHYSICIANS) or occupations (e.g., LIBRARIANS) for which OCCUPATIONAL GROUPS is available.', 'C0027361', 1]}]}, {'ORGANISM': [{'label': 'people', 'alias': ['chinese people', 'Chinese', 'Chinese', 'Chinese', 'Chinese', 'Chinese', 'Chinese', 'Chinese', 'Chinese', 'CHINESE', 'CHINESE', 'chinese', '-- Chinese', 'Chinese (ethnic group)'], 'meaning': ['A person having origins in any of the original peoples of China.', 'C0152035', 0.7433323264122009]}]}]","{'Background: Due to home-confinement and social isolation of during the Covid-19 pandemic, reductions in performing physical activities were obsered.': [['Background', 'NN', 'B-NP'], ['social', 'JJ', 'B-NP'], ['isolation', 'NN', 'I-NP'], ['pandemic', 'NN', 'B-NP'], ['performing', 'VBG', 'O'], ['were', 'VBD', 'O'], ['obsered', 'VBN', 'O']], 'A main consequence of inactivity is a poorer general health and a higher mortality rate.': [['A', 'DT', 'B-NP'], ['main', 'JJ', 'I-NP'], ['consequence', 'NN', 'I-NP'], ['inactivity', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['general', 'JJ', 'B-NP'], ['health', 'NN', 'I-NP'], ['mortality', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP']], 'Therefore, it is important to inform the public about practical recommendations for staying physically active, especially during the current Covid-19 pandemic.': [['is', 'VBZ', 'O'], ['inform', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['public', 'NN', 'I-NP'], ['staying', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['current', 'JJ', 'I-NP'], ['Covid-19', 'JJ', 'I-NP'], ['pandemic', 'NN', 'I-NP']], 'Methods: Through a systematic review of literature in two databases (Pubmed/Medline; Web of Science), studies were analysed which include practical recommendations for staying active during Covid-19 (Q1), or if they did not explicitly deal with Covid-19, research with useful results regarding the adaption to the present situation (Q2).': [['a', 'DT', 'B-NP'], ['systematic', 'JJ', 'I-NP'], ['review', 'NN', 'I-NP'], ['literature', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['analysed', 'VBN', 'O'], ['include', 'VBP', 'O'], ['staying', 'VBG', 'O'], ['did', 'VBD', 'O'], ['deal', 'VB', 'O'], ['research', 'NN', 'B-NP'], ['regarding', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['adaption', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['present', 'JJ', 'I-NP'], ['situation', 'NN', 'I-NP']], 'Results: Currently, there are 6 studies published which are related to the first research question.': [['are', 'VBP', 'O'], ['published', 'VBN', 'O'], ['are', 'VBP', 'O'], ['related', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['first', 'JJ', 'I-NP'], ['research', 'NN', 'I-NP'], ['question', 'NN', 'B-NP']], 'In total, 26 papers, were found to correlate to the second one.': [['were', 'VBD', 'O'], ['found', 'VBN', 'O'], ['correlate', 'VB', 'O']], 'Conclusion: Researchers need to be more specific in the exact recommendations for different age-groups and various health statuses.': [['Conclusion', 'NN', 'B-NP'], ['need', 'VBP', 'O'], ['be', 'VB', 'O'], ['various', 'JJ', 'B-NP'], ['health', 'NN', 'I-NP']], 'Key sources are the websites of the World Health Organization and the American Heart Association.': [['are', 'VBP', 'O']], 'In addition, exergames need to be adaptable to restrictions by product designers and to integrate social interaction-functions.': [['addition', 'NN', 'B-NP'], ['need', 'VB', 'O'], ['be', 'VB', 'O'], ['product', 'NN', 'B-NP'], ['integrate', 'VB', 'O']], 'Furthermore, it is essential that governmental actions need to be taken, with the help of researchers, to inform citizens about possible physical activities, with precise examples, clarification of benefits of the exercises, the exact exercise with duration, intensity and other substitute tasks for different age-groups and for people with diseases.': [['is', 'VBZ', 'O'], ['need', 'VBP', 'O'], ['be', 'VB', 'O'], ['taken', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['help', 'NN', 'I-NP'], ['inform', 'VB', 'O'], ['clarification', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['exact', 'JJ', 'I-NP'], ['exercise', 'NN', 'I-NP'], ['duration', 'NN', 'B-NP'], ['intensity', 'NN', 'B-NP'], ['other', 'JJ', 'B-NP'], ['substitute', 'NN', 'I-NP']]}","{'Background: Due to home-confinement and social isolation of during the Covid-19 pandemic, reductions in performing physical activities were obsered.': [{'noun_phrase': ' Background home confinement', 'noun_connectors': ['and']}, {'noun_phrase': ' isolation Covid-19 pandemic reductions', 'noun_connectors': ['performing']}], 'A main consequence of inactivity is a poorer general health and a higher mortality rate.': [{'noun_phrase': ' main consequence inactivity poorer general health', 'noun_connectors': ['and']}], 'Therefore, it is important to inform the public about practical recommendations for staying physically active, especially during the current Covid-19 pandemic.': [{'noun_phrase': '', 'noun_connectors': ['Therefore', 'inform']}, {'noun_phrase': ' public practical recommendations', 'noun_connectors': ['staying', 'physically', 'especially']}], 'Methods: Through a systematic review of literature in two databases (Pubmed/Medline; Web of Science), studies were analysed which include practical recommendations for staying active during Covid-19 (Q1), or if they did not explicitly deal with Covid-19, research with useful results regarding the adaption to the present situation (Q2).': [{'noun_phrase': ' Methods systematic review literature databases Pubmed Medline Web Science studies', 'noun_connectors': ['analysed', 'include']}, {'noun_phrase': ' recommendations', 'noun_connectors': ['staying', 'or', 'explicitly', 'deal']}, {'noun_phrase': ' research useful results', 'noun_connectors': ['regarding']}], 'Results: Currently, there are 6 studies published which are related to the first research question.': [{'noun_phrase': ' Results', 'noun_connectors': ['Currently']}, {'noun_phrase': ' studies', 'noun_connectors': ['published', 'related']}], 'In total, 26 papers, were found to correlate to the second one.': [{'noun_phrase': ' total papers', 'noun_connectors': ['found', 'correlate']}], 'Conclusion: Researchers need to be more specific in the exact recommendations for different age-groups and various health statuses.': [{'noun_phrase': ' Conclusion Researchers', 'noun_connectors': ['need', 'more']}, {'noun_phrase': ' recommendations different age groups', 'noun_connectors': ['and']}], 'Key sources are the websites of the World Health Organization and the American Heart Association.': [], 'In addition, exergames need to be adaptable to restrictions by product designers and to integrate social interaction-functions.': [{'noun_phrase': ' addition exergames', 'noun_connectors': ['need']}, {'noun_phrase': ' restrictions product designers', 'noun_connectors': ['and', 'integrate']}], 'Furthermore, it is essential that governmental actions need to be taken, with the help of researchers, to inform citizens about possible physical activities, with precise examples, clarification of benefits of the exercises, the exact exercise with duration, intensity and other substitute tasks for different age-groups and for people with diseases.': [{'noun_phrase': '', 'noun_connectors': ['Furthermore']}, {'noun_phrase': ' actions', 'noun_connectors': ['need', 'taken']}, {'noun_phrase': ' help researchers', 'noun_connectors': ['inform']}, {'noun_phrase': ' citizens possible physical activities precise examples clarification benefits exercises exact exercise duration intensity', 'noun_connectors': ['and']}, {'noun_phrase': ' substitute tasks different age groups', 'noun_connectors': ['and']}]}"
"[{'author_name': 'Gaetano Alfano', 'author_inst': 'University of Modena and Reggio Emilia'}, {'author_name': 'Annachiara Ferrari', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Francesco Fontana', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Giacomo Mori', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Riccardo Magistroni', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Meschiari Marianna', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Franceschini Erica', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Marianna Menozzi', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Gianluca Cuomo', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Gabriella Orlando', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Antonella Santoro', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Margherita Di Gaetano', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Cinzia Puzzolante', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Federica Carli', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Andrea Bedini', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Jovana Milic', 'author_inst': 'Policlinico di  Modena'}, {'author_name': 'Paolo Raggi', 'author_inst': 'Division of Cardiology 4A7.050 Mazankowski Alberta Heart Institute'}, {'author_name': 'Massimo Girardis', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Cristina Mussini', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Gianni Cappelli', 'author_inst': 'Policlinico di Modena'}, {'author_name': 'Giovanni Guaraldi', 'author_inst': 'Policlinico di Modena'}]",http://medrxiv.org/cgi/content/short/2020.06.24.20138230,"Incidence, risk factors and mortality outcome in patients with acute kidney injury in COVID-19: a single-center observational study","Background Acute kidney injury (AKI) is a recently recognized complication of coronavirus disease-2019 (COVID-19). This study aims to evaluate the incidence, risk factors and case-fatality rate of AKI in patients with documented COVID-19. Methods We reviewed the health medical records of 307 consecutive patients hospitalized for symptoms of COVID-19 at the University Hospital of Modena, Italy. Results AKI was diagnosed in 69 out of 307 (22.4%) patients. The stages of AKI were stage 1 in 57.9%, stage 2 in 24.6% and stage 3 in 17.3%. Hemodialysis was performed in 7.2% of the subjects. AKI patients had a mean age of 74.7 {+/-} 9.9 years and higher serum levels of the main marker of inflammation and organ involvement (lung, liver, hearth and liver) than non-AKI patients. AKI events were more frequent in subjects with severe lung comprise. Two peaks of AKI events coincided with in-hospital admission and death of the patients. Kidney injury was associate with a higher rate of urinary abnormalities including proteinuria (0.448{+/-} 0.85 vs 0.18 {+/-} 0.29; P=<0.0001) and hematuria (P=0.032) compared to non-AKI patients. At the end of follow-up, 65.2% of the patients did not recover their renal function after AKI. Risk factors for kidney injury were age, male sex, CKD and non-renal SOFA. Adjusted Cox regression analysis revealed that AKI was independently associated with in-hospital death (hazard ratio [HR]=3.74; CI 95%, 1.34-10.46) compared to non-AKI patients. Groups of patients with AKI stage 2-3 and failure to recover kidney function were associated with the highest risk of in-hospital mortality. Lastly, long-hospitalization was positively associated with a decrease of serum creatinine, likely due to muscle depletion occurred with prolonged bed rest. Conclusions AKI was a dire consequence of patients with COVID-19. Identification of patients at high-risk for AKI and prevention of kidney injury by avoiding dehydration and nephrotoxic agents is imperative in this vulnerable cohort of patients.",2020-06-24,medrxiv,21,"[{'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'CORONAVIRUS', 'coronavirus', 'Coronaviruses', 'Coronaviruses', 'Coronaviruses', 'Coronavirus, NOS', 'coronaviruses'], 'meaning': ['A genus of the family CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.', 'C0206419', 1]}]}, {'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'coronaviridae', 'CORONAVIRUS', 'Family: Coronavirus group', 'Coronavirus group', 'CORONAVIRUS GROUP', 'Coronavirus group, NOS', 'Family Coronaviridae', 'Family Coronaviridae (organism)'], 'meaning': ['Spherical RNA viruses, in the order NIDOVIRALES, infecting a wide range of animals including humans. Transmission is by fecal-oral and respiratory routes. Mechanical transmission is also common. There are two genera: CORONAVIRUS and TOROVIRUS.', 'C0010076', 1]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'serum', 'alias': ['Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'SERUM', 'serum', 'serum', 'serum', 'serum', 'serums', 'Serums', 'Sera', 'Sera', 'Blood Serum', 'Blood Serum', 'blood serum', 'blood serum', 'Blood serum', 'Serum, Blood', 'Ser', 'Portion of serum', 'Serum (substance)'], 'meaning': ['The clear portion of BLOOD that is left after BLOOD COAGULATION to remove BLOOD CELLS and clotting proteins.', 'C0229671', 1]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'serum', 'alias': ['Serum'], 'meaning': [None, 'C1546774', 1]}]}, {'ORGAN': [{'label': 'organ', 'alias': ['Organ', 'Organ', 'Organ', 'Organ', 'organ', 'organ', 'organ', 'organs', '{Organ}', '{Organ}', 'Organs (Anatomy)', 'anatomy organs', 'organs anatomy', 'anatomy organ'], 'meaning': ['A unique macroscopic (gross) anatomic structure that performs specific functions. It is composed of various tissues. An organ is part of an anatomic system or a body region. Representative examples include the heart, lung, liver, spleen, and uterus.', 'C0178784', 1]}]}, {'ORGAN': [{'label': 'organ', 'alias': ['Organ with organ cavity'], 'meaning': ['Cavitated organ in which its unshared parts surround one continuous anatomical space. Examples: stomach, urinary bladder, esophagus, uterine tube.', 'C0927230', 0.8018884062767029]}]}, {'ORGAN': [{'label': 'lung', 'alias': ['Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'lung', 'lung', 'lung', 'lung', 'LUNG', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lung, NOS', 'LUNGS', 'lungs', 'pulmonary', 'pulmonary', 'Lung structure', 'lung structure', 'lung structures', 'Pulmo', 'Pulmones', 'Set of lungs', 'Set of lungs', 'Lung structure (body structure)', 'Respiratory System, Lung', 'Pair of lungs', 'Lungs pair'], 'meaning': ['Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.', 'C0024109', 0.9999999403953552]}]}, {'ORGAN': [{'label': 'lung', 'alias': ['Structure of parenchyma of lung', 'LUNG', 'lung tissue', 'Lung Tissue', 'Lung tissue', 'lung tissues', 'lungs tissues', 'lungs tissue', 'tissue lung', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'lung parenchyma', 'Lung Parenchyma', 'lungs parenchyma', 'Parenchyma of lung', 'Respiratory portion of lung', 'Respiratory portion of lung', 'Structure of parenchyma of lung (body structure)', 'Lung tiss'], 'meaning': ['Tissue consisting of an external serous coat, subserous areolar tissue and lung parenchyma. The parenchyma is made up of lobules wound together by connective tissue. A primary lobule consists of a terminal bronchiole, respiratory bronchioles, and alveolar ducts, which communicate with many alveoli, each alveolus being surrounded by a network of capillary blood vessels.', 'C0819757', 0.9999999403953552]}]}, {'ORGAN': [{'label': 'liver', 'alias': ['Liver', 'Liver', 'Liver brand', 'Liver [brand name]'], 'meaning': ['brand name of vitamin B 12', 'C0721399', 1]}]}, {'ORGAN': [{'label': 'liver', 'alias': ['Liver Extract', 'Liver extract', 'Liver extract', 'Liver extract', 'Liver extract', 'liver extract', 'LIVER EXTRACT', 'LIVER EXTRACT', 'LIVER EXTRACT', 'Extracts, Liver', 'Liver Extracts', 'Liver Extracts', 'liver extracts', 'LIVER', 'LIVER', 'LIVER', 'Liver', 'Liver preparation', 'Liver preparation', 'Liver preparation', 'Liver extract preparation', 'Liver extract preparation', 'Liver preparation (product)', 'Liver extract (substance)', 'Liver Extracts [Chemical/Ingredient]'], 'meaning': ['Extracts of liver tissue containing uncharacterized specific factors with specific activities; a soluble thermostable fraction of mammalian liver is used in the treatment of pernicious anemia.', 'C0023899', 1]}]}, {'TISSUE': [{'label': 'Kidney', 'alias': ['Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'kidney', 'kidney', 'kidney', 'kidney', 'KIDNEY', 'Kidneys', 'Kidneys', 'Kidneys', 'Kidneys', 'Kidneys', 'Kidney, NOS', 'KIDNEYS', 'kidneys', 'Renal', 'Renal', 'Renal', 'Renal', 'Renal', 'renal', 'renal', 'renal', 'Reno-', 'Kidney structure', 'kidney structure', 'Ren (Nephros)', 'Renal structure', 'nephr(o)-', 'ren(o)-', 'Kidney structure (body structure)', 'Urinary System, Kidney', 'Ren', 'Nephros'], 'meaning': ['Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.', 'C0022646', 1]}]}, {'TISSUE': [{'label': 'Kidney', 'alias': ['Renal Tissue', 'KIDNEY'], 'meaning': ['Tissue composed of the renal cortex and the renal medulla. The basic functional unit of renal tissue is the nephron.', 'C1514845', 1]}]}, {'ORGAN': [{'label': 'renal', 'alias': ['Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'Kidney', 'kidney', 'kidney', 'kidney', 'kidney', 'KIDNEY', 'Kidneys', 'Kidneys', 'Kidneys', 'Kidneys', 'Kidneys', 'Kidney, NOS', 'KIDNEYS', 'kidneys', 'Renal', 'Renal', 'Renal', 'Renal', 'Renal', 'renal', 'renal', 'renal', 'Reno-', 'Kidney structure', 'kidney structure', 'Ren (Nephros)', 'Renal structure', 'nephr(o)-', 'ren(o)-', 'Kidney structure (body structure)', 'Urinary System, Kidney', 'Ren', 'Nephros'], 'meaning': ['Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.', 'C0022646', 1]}]}, {'ORGAN': [{'label': 'renal', 'alias': ['renal clearance', 'renal clearance', 'Renal clearance', 'Renal Clearance', 'Renal CL', 'Renal CL', 'RENALCL', 'Renal clearance study'], 'meaning': ['The rate at which a substance is removed from the blood via the kidneys.', 'C0699829', 0.7319461703300476]}]}, {'CANCER': [{'label': 'CKD', 'alias': ['Chronic Kidney Diseases', 'Chronic Kidney Disease', 'Chronic Kidney Disease', 'Chronic Kidney Disease', 'Chronic Kidney Disease', 'Disease, Chronic Kidney', 'Kidney Disease, Chronic', 'Chronic kidney disease', 'Chronic kidney disease', 'Chronic kidney disease', 'Chronic kidney disease', 'Chronic kidney disease', 'Diseases, Chronic Kidney', 'Kidney Diseases, Chronic', 'Chronic Renal Failure', 'Chronic Renal Insufficiency', 'CKD', 'CKD', 'Loss of renal function', 'Chronic kidney disease (disorder)', 'Chronic Renal Diseases', 'chronic diseases renal', 'chronic disease renal', 'chronic renal disease', 'renal disease chronic', 'Disease, Chronic Renal', 'Renal Disease, Chronic', 'Chronic Renal Disease', 'Chronic Renal Disease', 'Chronic renal disease', 'Chronic renal disease', 'Diseases, Chronic Renal', 'Renal Diseases, Chronic', 'CKD - chronic kidney disease', 'Chronic kidney disease (CKD)', 'CKD - Chronic Kidney Disease', 'Chronic kidney disease, unspecified'], 'meaning': ['Impairment of the renal function secondary to chronic kidney damage persisting for three or more months.', 'C1561643', 1]}]}, {'CANCER': [{'label': 'CKD', 'alias': ['CKD-516', 'CKD-516', 'Tubulin Polymerization Inhibitor CKD-516', 'CKD516'], 'meaning': ['A benzophenone derivative and water soluble valine prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activity. Upon administration, tubulin polymerization inhibitor CKD-516 is converted into its active metabolite S-516 that binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.', 'C2974542', 0.7592613101005554]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'serum creatinine', 'alias': ['Creatinine measurement, serum (procedure)', 'Serum creatinine', 'creatinine serum', 'Creatinine.serum', 'serum creatinine', 'serum creatinine', 'Serum Creatinine', 'Creatinine measurement, serum', 'Creatinine measurement, serum', 'Serum Creatinine Measurement', 'Serum Creatinine Test', 'creatinine serum test', 'serum creatinine test', 'serum creatinine tests', 'creatinine procedure serum'], 'meaning': ['A quantitative measurement of the amount of creatinine present in a sample of serum.', 'C0201976', 1]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'serum creatinine', 'alias': ['Serum creatinine level', 'serum creatinine level', 'creatinine levels serum', 'serum creatinine', 'creatinine serum', 'Finding of serum creatinine level (finding)', 'Serum creatinine level - finding', 'Finding of serum creatinine level'], 'meaning': [None, 'C0600061', 1]}]}, {'TISSUE': [{'label': 'muscle', 'alias': ['Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'Muscle', 'muscle', 'muscle', 'muscle', 'MUSCLE', 'Muscles', 'Muscles', 'Muscles', 'Muscle, NOS', 'Muscles, NOS', 'muscles', 'Muscle organ', 'muscle (organ)', 'Muscle (organ)', 'muscles organs', 'Muscle Tissue', 'Muscle Tissue', 'Muscle Tissue', 'muscle tissue', 'muscle (tissue)', 'Muscle tissue', 'Muscle tissue', 'Muscle Tissues', 'Tissues, Muscle', 'Tissue, Muscle', 'Muscular', 'Musculus', 'Musculus', 'musculus', 'Skeletal muscle organ', 'Muscle tissue (body structure)'], 'meaning': ['Contractile tissue that produces movement in animals.', 'C0026845', 1]}]}]","{'Background Acute kidney injury (AKI) is a recently recognized complication of coronavirus disease-2019 (COVID-19).': [['injury', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['recognized', 'VBN', 'O'], ['complication', 'NN', 'B-NP'], ['coronavirus', 'NN', 'B-NP'], ['disease-2019', 'NN', 'B-NP']], 'This study aims to evaluate the incidence, risk factors and case-fatality rate of AKI in patients with documented COVID-19.': [['This', 'DT', 'B-NP'], ['study', 'NN', 'I-NP'], ['aims', 'VBZ', 'O'], ['evaluate', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['incidence', 'NN', 'I-NP'], ['risk', 'NN', 'B-NP'], ['case-fatality', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP']], 'Methods We reviewed the health medical records of 307 consecutive patients hospitalized for symptoms of COVID-19 at the University Hospital of Modena, Italy.': [['reviewed', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['health', 'NN', 'I-NP'], ['hospitalized', 'VBN', 'O']], 'Results AKI was diagnosed in 69 out of 307 (22.4%) patients.': [['was', 'VBD', 'O'], ['diagnosed', 'VBN', 'O'], ['%', 'NN', 'B-NP']], 'The stages of AKI were stage 1 in 57.9%, stage 2 in 24.6% and stage 3 in 17.3%.': [['were', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['stage', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['stage', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'Hemodialysis was performed in 7.2% of the subjects.': [['Hemodialysis', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['performed', 'VBN', 'O'], ['%', 'NN', 'B-NP']], 'AKI patients had a mean age of 74.7 {+/-} 9.9 years and higher serum levels of the main marker of inflammation and organ involvement (lung, liver, hearth and liver) than non-AKI patients.': [['had', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['mean', 'JJ', 'I-NP'], ['age', 'NN', 'I-NP'], ['serum', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['main', 'JJ', 'I-NP'], ['marker', 'NN', 'I-NP'], ['inflammation', 'NN', 'B-NP'], ['organ', 'JJ', 'B-NP'], ['involvement', 'NN', 'I-NP'], ['lung', 'NN', 'B-NP'], ['liver', 'NN', 'B-NP'], ['hearth', 'NN', 'B-NP'], ['liver', 'NN', 'B-NP']], 'AKI events were more frequent in subjects with severe lung comprise.': [['were', 'VBD', 'O'], ['severe', 'JJ', 'B-NP'], ['lung', 'NN', 'I-NP'], ['comprise', 'NN', 'B-NP']], 'Two peaks of AKI events coincided with in-hospital admission and death of the patients.': [['coincided', 'VBD', 'O'], ['in-hospital', 'JJ', 'B-NP'], ['admission', 'NN', 'I-NP'], ['death', 'NN', 'B-NP']], 'Kidney injury was associate with a higher rate of urinary abnormalities including proteinuria (0.448{+/-} 0.85 vs 0.18 {+/-} 0.29; P=<0.0001) and hematuria (P=0.032) compared to non-AKI patients.': [['injury', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['rate', 'NN', 'B-NP'], ['including', 'VBG', 'O'], ['proteinuria', 'NN', 'B-NP'], ['hematuria', 'NN', 'B-NP'], ['compared', 'VBN', 'O']], 'At the end of follow-up, 65.2% of the patients did not recover their renal function after AKI.': [['the', 'DT', 'B-NP'], ['end', 'NN', 'I-NP'], ['follow-up', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['did', 'VBD', 'O'], ['recover', 'VB', 'O'], ['renal', 'JJ', 'B-NP'], ['function', 'NN', 'I-NP']], 'Risk factors for kidney injury were age, male sex, CKD and non-renal SOFA.': [['Risk', 'NN', 'B-NP'], ['kidney', 'NN', 'B-NP'], ['injury', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['age', 'NN', 'B-NP'], ['male', 'JJ', 'B-NP'], ['sex', 'NN', 'I-NP']], 'Adjusted Cox regression analysis revealed that AKI was independently associated with in-hospital death (hazard ratio [HR]=3.74; CI 95%, 1.34-10.46) compared to non-AKI patients.': [['Adjusted', 'VBN', 'O'], ['regression', 'NN', 'B-NP'], ['analysis', 'NN', 'B-NP'], ['revealed', 'VBD', 'O'], ['was', 'VBD', 'O'], ['associated', 'VBN', 'O'], ['in-hospital', 'JJ', 'B-NP'], ['death', 'NN', 'I-NP'], ['hazard', 'JJ', 'B-NP'], ['ratio', 'NN', 'I-NP'], ['%', 'NN', 'B-NP'], ['compared', 'VBN', 'O']], 'Groups of patients with AKI stage 2-3 and failure to recover kidney function were associated with the highest risk of in-hospital mortality.': [['stage', 'NN', 'B-NP'], ['failure', 'NN', 'B-NP'], ['recover', 'VB', 'O'], ['kidney', 'NN', 'B-NP'], ['function', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['associated', 'VBN', 'O'], ['risk', 'NN', 'B-NP'], ['in-hospital', 'JJ', 'B-NP'], ['mortality', 'NN', 'I-NP']], 'Lastly, long-hospitalization was positively associated with a decrease of serum creatinine, likely due to muscle depletion occurred with prolonged bed rest.': [['long-hospitalization', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['associated', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['decrease', 'NN', 'I-NP'], ['serum', 'JJ', 'B-NP'], ['creatinine', 'NN', 'I-NP'], ['muscle', 'VB', 'O'], ['depletion', 'NN', 'B-NP'], ['occurred', 'VBD', 'O'], ['prolonged', 'JJ', 'B-NP'], ['bed', 'NN', 'I-NP'], ['rest', 'NN', 'B-NP']], 'Conclusions AKI was a dire consequence of patients with COVID-19.': [['was', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['dire', 'JJ', 'I-NP'], ['consequence', 'NN', 'I-NP']], 'Identification of patients at high-risk for AKI and prevention of kidney injury by avoiding dehydration and nephrotoxic agents is imperative in this vulnerable cohort of patients.': [['Identification', 'NN', 'B-NP'], ['prevention', 'NN', 'B-NP'], ['kidney', 'NN', 'B-NP'], ['injury', 'NN', 'B-NP'], ['avoiding', 'VBG', 'O'], ['dehydration', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['this', 'DT', 'B-NP'], ['vulnerable', 'JJ', 'I-NP'], ['cohort', 'NN', 'I-NP']]}","{'Background Acute kidney injury (AKI) is a recently recognized complication of coronavirus disease-2019 (COVID-19).': [{'noun_phrase': ' Background Acute kidney injury AKI', 'noun_connectors': ['recently', 'recognized']}], 'This study aims to evaluate the incidence, risk factors and case-fatality rate of AKI in patients with documented COVID-19.': [{'noun_phrase': ' study', 'noun_connectors': ['aims', 'evaluate']}, {'noun_phrase': ' incidence risk factors', 'noun_connectors': ['and']}, {'noun_phrase': ' case fatality rate AKI patients', 'noun_connectors': ['documented']}], 'Methods We reviewed the health medical records of 307 consecutive patients hospitalized for symptoms of COVID-19 at the University Hospital of Modena, Italy.': [{'noun_phrase': ' Methods', 'noun_connectors': ['reviewed']}, {'noun_phrase': ' health medical records consecutive patients', 'noun_connectors': ['hospitalized']}], 'Results AKI was diagnosed in 69 out of 307 (22.4%) patients.': [{'noun_phrase': ' Results AKI', 'noun_connectors': ['diagnosed']}], 'The stages of AKI were stage 1 in 57.9%, stage 2 in 24.6% and stage 3 in 17.3%.': [{'noun_phrase': ' stages AKI stage %', 'noun_connectors': ['stage']}, {'noun_phrase': ' %', 'noun_connectors': ['and', 'stage']}], 'Hemodialysis was performed in 7.2% of the subjects.': [{'noun_phrase': ' Hemodialysis', 'noun_connectors': ['performed']}], 'AKI patients had a mean age of 74.7 {+/-} 9.9 years and higher serum levels of the main marker of inflammation and organ involvement (lung, liver, hearth and liver) than non-AKI patients.': [{'noun_phrase': ' AKI patients mean age years', 'noun_connectors': ['and']}, {'noun_phrase': ' serum levels main marker inflammation', 'noun_connectors': ['and']}, {'noun_phrase': ' organ involvement lung liver hearth', 'noun_connectors': ['and']}], 'AKI events were more frequent in subjects with severe lung comprise.': [{'noun_phrase': ' AKI events', 'noun_connectors': ['more']}], 'Two peaks of AKI events coincided with in-hospital admission and death of the patients.': [{'noun_phrase': ' peaks AKI events', 'noun_connectors': ['coincided']}, {'noun_phrase': ' hospital admission', 'noun_connectors': ['and']}], 'Kidney injury was associate with a higher rate of urinary abnormalities including proteinuria (0.448{+/-} 0.85 vs 0.18 {+/-} 0.29; P=<0.0001) and hematuria (P=0.032) compared to non-AKI patients.': [{'noun_phrase': ' Kidney injury associate higher rate urinary abnormalities', 'noun_connectors': ['including', 'and', 'compared']}], 'At the end of follow-up, 65.2% of the patients did not recover their renal function after AKI.': [{'noun_phrase': ' end follow up % patients', 'noun_connectors': ['recover']}], 'Risk factors for kidney injury were age, male sex, CKD and non-renal SOFA.': [{'noun_phrase': ' Risk factors kidney injury age male sex CKD', 'noun_connectors': ['and']}], 'Adjusted Cox regression analysis revealed that AKI was independently associated with in-hospital death (hazard ratio [HR]=3.74; CI 95%, 1.34-10.46) compared to non-AKI patients.': [{'noun_phrase': ' Adjusted Cox regression analysis', 'noun_connectors': ['revealed', 'independently', 'associated']}, {'noun_phrase': ' hospital death hazard ratio HR]=3.74 CI %', 'noun_connectors': ['compared']}], 'Groups of patients with AKI stage 2-3 and failure to recover kidney function were associated with the highest risk of in-hospital mortality.': [{'noun_phrase': ' Groups patients AKI stage', 'noun_connectors': ['and']}, {'noun_phrase': ' failure', 'noun_connectors': ['recover']}, {'noun_phrase': ' kidney function', 'noun_connectors': ['associated']}], 'Lastly, long-hospitalization was positively associated with a decrease of serum creatinine, likely due to muscle depletion occurred with prolonged bed rest.': [{'noun_phrase': '', 'noun_connectors': ['Lastly']}, {'noun_phrase': ' hospitalization', 'noun_connectors': ['positively', 'associated']}, {'noun_phrase': ' decrease serum creatinine', 'noun_connectors': ['likely']}, {'noun_phrase': ' muscle depletion', 'noun_connectors': ['occurred']}], 'Conclusions AKI was a dire consequence of patients with COVID-19.': [], 'Identification of patients at high-risk for AKI and prevention of kidney injury by avoiding dehydration and nephrotoxic agents is imperative in this vulnerable cohort of patients.': [{'noun_phrase': ' Identification patients high risk AKI', 'noun_connectors': ['and']}, {'noun_phrase': ' prevention kidney injury', 'noun_connectors': ['avoiding']}, {'noun_phrase': ' dehydration', 'noun_connectors': ['and']}]}"
"[{'author_name': 'Wei Tse Li', 'author_inst': 'UC San Diego'}, {'author_name': 'Jiayan Ma', 'author_inst': 'UC San Diego'}, {'author_name': 'Neil Shende', 'author_inst': 'UC San Diego'}, {'author_name': 'Grant Castaneda', 'author_inst': 'UC San Diego'}, {'author_name': 'Jaideep Chakladar', 'author_inst': 'UC San Diego'}, {'author_name': 'Joseph C. Tsai', 'author_inst': 'UC San Diego'}, {'author_name': 'Lauren Apostol', 'author_inst': 'UC San Diego'}, {'author_name': 'Christine O. Honda', 'author_inst': 'UC San Diego'}, {'author_name': 'Jingyue Xu', 'author_inst': 'UC San Diego'}, {'author_name': 'Lindsay M. Wong', 'author_inst': 'UC San Diego'}, {'author_name': 'Tianyi Zhang', 'author_inst': 'UC San Diego'}, {'author_name': 'Abby Lee', 'author_inst': 'UC San Diego'}, {'author_name': 'Aditi Gnanasekar', 'author_inst': 'UC San Diego'}, {'author_name': 'Thomas K. Honda', 'author_inst': 'UC San Diego'}, {'author_name': 'Selena Z. Kuo', 'author_inst': 'Columbia University Medical Center'}, {'author_name': 'Michael Andrew Yu', 'author_inst': 'Emory University School of Medicine'}, {'author_name': 'Eric Y. Chang', 'author_inst': 'VA San Diego'}, {'author_name': 'Mahadevan R. Rajasekaran', 'author_inst': 'VA San Diego'}, {'author_name': 'Weg M. Ongkeko', 'author_inst': 'UC San Diego'}]",http://medrxiv.org/cgi/content/short/2020.06.24.20138859,Using Machine Learning of Clinical Data to Diagnose COVID-19,"The recent pandemic of Coronavirus Disease 2019 (COVID-19) has placed severe stress on healthcare systems worldwide, which is amplified by the critical shortage of COVID-19 tests. In this study, we propose to generate a more accurate diagnosis model of COVID-19 based on patient symptoms and routine test results by applying machine learning to reanalyzing COVID-19 data from 151 published studies. We aimed to investigate correlations between clinical variables, cluster COVID-19 patients into subtypes, and generate a computational classification model for discriminating between COVID -19 patients and influenza patients based on clinical variables alone. We discovered several novel associations between clinical variables, including correlations between being male and having higher levels of serum lymphocytes and neutrophils. We found that COVID-19 patients could be clustered into subtypes based on serum levels of immune cells, gender, and reported symptoms. Finally, we trained an XGBoost model to achieve a sensitivity of 92.5% and a specificity of 97.9% in discriminating COVID-19 patients from influenza patients. We demonstrated that computational methods trained on large clinical datasets could yield ever more accurate COVID-19 diagnostic models to mitigate the impact of lack of testing. We also presented previously unknown COVID-19 clinical variable correlations and clinical subgroups.",2020-06-24,medrxiv,19,"[{'ORGANISM': [{'label': 'patient', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 1]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Veterinary Patient', 'Patient'], 'meaning': ['A non-human animal that is a subject in a study.', 'C1705908', 1]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'CELL': [{'label': 'neutrophils', 'alias': ['neutrophil', 'neutrophil', 'neutrophil', 'neutrophil', 'Neutrophil', 'Neutrophil', 'Neutrophil', 'Neutrophil', 'Neutrophil', 'Neutrophils', 'Neutrophils', 'Neutrophils', 'Neutrophils', 'Neutrophils', 'Neutrophils', 'neutrophils', 'neutrophils', 'Neutrophile', 'Polymorphonuclear Leukocytes', 'Polymorphonuclear Leukocytes', 'Polymorphonuclear Leukocytes', 'polymorphonuclear leukocytes', 'Leukocyte, Polymorphonuclear', 'Polymorphonuclear Leukocyte', 'polymorphonuclear leukocyte', 'polymorphonuclear leukocyte', 'polymorphonuclear leukocyte', 'Polymorphonuclear leucocyte', 'Polymorphonuclear leucocyte', 'Polymorphonuclear leukocyte', 'Polymorphonuclear leukocyte', 'Leukocytes, Polymorphonuclear', 'PMN cell', 'PMN cell', 'cells pmn', 'Polymorph', 'polymorph', 'polymorphs', 'Blood neutrophil', 'Blood Segmented Neutrophil', 'Blood segmented neutrophil', 'Blood PMN', 'Marrow neutrophil', 'heterophil granulocyte', 'Neutrophilic Granulocyte', 'neutrophilic granulocyte', 'Neutrophilic Leukocyte', 'neutrophilic leukocyte', 'neutrophilic leukocyte', 'Polymorphonuclear Neutrophils', 'polymorphonuclear neutrophils', 'polymorphonuclear neutrophil', 'polymorphonuclear cells', 'Polymorphonuclear cells', 'Polymorphonuclear cells', 'polymorphonuclear cell', 'Polymorphonuclear Cell', 'Polymorphonuclear leukocyte (cell)', 'Polymorphonuclear cells/leukocytes', 'PMN', 'PMN - polymorphonuclear leukocyte', 'PMN - polymorphonuclear leucocyte', 'Polys', 'Neutrophil leucocyte', 'Neutrophil leukocyte', 'Heterophile leucocyte'], 'meaning': ['Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.', 'C0027950', 0.9999999403953552]}]}, {'CELL': [{'label': 'neutrophils', 'alias': ['Absolute Neutrophil Count', 'absolute neutrophil count', 'absolute count neutrophils', 'Neutrophils', 'Neutrophils', 'NEUT', 'ANC'], 'meaning': ['The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).', 'C0948762', 0.9999999403953552]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'serum', 'alias': ['Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'Serum', 'SERUM', 'serum', 'serum', 'serum', 'serum', 'serums', 'Serums', 'Sera', 'Sera', 'Blood Serum', 'Blood Serum', 'blood serum', 'blood serum', 'Blood serum', 'Serum, Blood', 'Ser', 'Portion of serum', 'Serum (substance)'], 'meaning': ['The clear portion of BLOOD that is left after BLOOD COAGULATION to remove BLOOD CELLS and clotting proteins.', 'C0229671', 1]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'serum', 'alias': ['Serum'], 'meaning': [None, 'C1546774', 1]}]}, {'CELL': [{'label': 'immune cells', 'alias': ['Immune', 'Immune', 'immune', 'Immune (qualifier value)'], 'meaning': ['Protected against infectious disease by either specific or non-specific mechanisms.(On-line Medical Dictionary)', 'C0439662', 0.7461705207824707]}]}]","{'The recent pandemic of Coronavirus Disease 2019 (COVID-19) has placed severe stress on healthcare systems worldwide, which is amplified by the critical shortage of COVID-19 tests.': [['The', 'DT', 'B-NP'], ['recent', 'JJ', 'I-NP'], ['pandemic', 'NN', 'I-NP'], ['has', 'VBZ', 'O'], ['placed', 'VBN', 'O'], ['severe', 'JJ', 'B-NP'], ['stress', 'NN', 'I-NP'], ['healthcare', 'NN', 'B-NP'], ['worldwide', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['amplified', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['critical', 'JJ', 'I-NP'], ['shortage', 'NN', 'I-NP']], 'In this study, we propose to generate a more accurate diagnosis model of COVID-19 based on patient symptoms and routine test results by applying machine learning to reanalyzing COVID-19 data from 151 published studies.': [['this', 'DT', 'B-NP'], ['study', 'NN', 'I-NP'], ['propose', 'VBP', 'O'], ['generate', 'VB', 'O'], ['accurate', 'JJ', 'B-NP'], ['diagnosis', 'NN', 'I-NP'], ['model', 'NN', 'B-NP'], ['based', 'VBN', 'O'], ['patient', 'NN', 'B-NP'], ['routine', 'JJ', 'B-NP'], ['test', 'NN', 'I-NP'], ['applying', 'VBG', 'O'], ['machine', 'NN', 'B-NP'], ['learning', 'NN', 'B-NP'], ['reanalyzing', 'VBG', 'O'], ['published', 'VBN', 'O']], 'We aimed to investigate correlations between clinical variables, cluster COVID-19 patients into subtypes, and generate a computational classification model for discriminating between COVID -19 patients and influenza patients based on clinical variables alone.': [['aimed', 'VBD', 'O'], ['investigate', 'VB', 'O'], ['generate', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['computational', 'JJ', 'I-NP'], ['classification', 'NN', 'I-NP'], ['model', 'NN', 'B-NP'], ['discriminating', 'VBG', 'O'], ['based', 'VBN', 'O']], 'We discovered several novel associations between clinical variables, including correlations between being male and having higher levels of serum lymphocytes and neutrophils.': [['discovered', 'VBD', 'O'], ['including', 'VBG', 'O'], ['being', 'VBG', 'O'], ['male', 'NN', 'B-NP'], ['having', 'VBG', 'O'], ['serum', 'NN', 'B-NP']], 'We found that COVID-19 patients could be clustered into subtypes based on serum levels of immune cells, gender, and reported symptoms.': [['found', 'VBD', 'O'], ['be', 'VB', 'O'], ['clustered', 'VBN', 'O'], ['based', 'VBN', 'O'], ['serum', 'NN', 'B-NP'], ['immune', 'NN', 'B-NP'], ['gender', 'NN', 'B-NP'], ['reported', 'VBD', 'O']], 'Finally, we trained an XGBoost model to achieve a sensitivity of 92.5% and a specificity of 97.9% in discriminating COVID-19 patients from influenza patients.': [['trained', 'VBD', 'O'], ['an', 'DT', 'B-NP'], ['XGBoost', 'NN', 'I-NP'], ['model', 'NN', 'B-NP'], ['achieve', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['sensitivity', 'NN', 'I-NP'], ['%', 'NN', 'B-NP'], ['a', 'DT', 'B-NP'], ['specificity', 'NN', 'I-NP'], ['%', 'NN', 'B-NP'], ['discriminating', 'VBG', 'O']], 'We demonstrated that computational methods trained on large clinical datasets could yield ever more accurate COVID-19 diagnostic models to mitigate the impact of lack of testing.': [['demonstrated', 'VBD', 'O'], ['trained', 'VBN', 'O'], ['yield', 'VB', 'O'], ['mitigate', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['impact', 'NN', 'I-NP'], ['lack', 'NN', 'B-NP'], ['testing', 'VBG', 'O']], 'We also presented previously unknown COVID-19 clinical variable correlations and clinical subgroups.': [['presented', 'VBD', 'O']]}","{'The recent pandemic of Coronavirus Disease 2019 (COVID-19) has placed severe stress on healthcare systems worldwide, which is amplified by the critical shortage of COVID-19 tests.': [{'noun_phrase': ' recent pandemic Coronavirus Disease COVID-19', 'noun_connectors': ['placed']}, {'noun_phrase': ' stress healthcare systems', 'noun_connectors': ['worldwide', 'amplified']}], 'In this study, we propose to generate a more accurate diagnosis model of COVID-19 based on patient symptoms and routine test results by applying machine learning to reanalyzing COVID-19 data from 151 published studies.': [{'noun_phrase': ' study', 'noun_connectors': ['propose', 'generate', 'more']}, {'noun_phrase': ' diagnosis model COVID-19', 'noun_connectors': ['based']}, {'noun_phrase': ' symptoms', 'noun_connectors': ['and']}, {'noun_phrase': ' test results', 'noun_connectors': ['applying']}, {'noun_phrase': ' machine', 'noun_connectors': ['learning', 'reanalyzing']}, {'noun_phrase': ' data', 'noun_connectors': ['published']}], 'We aimed to investigate correlations between clinical variables, cluster COVID-19 patients into subtypes, and generate a computational classification model for discriminating between COVID -19 patients and influenza patients based on clinical variables alone.': [{'noun_phrase': '', 'noun_connectors': ['aimed', 'investigate']}, {'noun_phrase': ' correlations clinical variables', 'noun_connectors': ['cluster']}, {'noun_phrase': ' patients subtypes', 'noun_connectors': ['and', 'generate']}, {'noun_phrase': ' classification model', 'noun_connectors': ['discriminating']}, {'noun_phrase': ' patients', 'noun_connectors': ['and', 'influenza']}, {'noun_phrase': ' patients', 'noun_connectors': ['based']}], 'We discovered several novel associations between clinical variables, including correlations between being male and having higher levels of serum lymphocytes and neutrophils.': [{'noun_phrase': '', 'noun_connectors': ['discovered']}, {'noun_phrase': ' associations clinical variables', 'noun_connectors': ['including']}, {'noun_phrase': ' correlations male', 'noun_connectors': ['and', 'having']}, {'noun_phrase': ' levels serum lymphocytes', 'noun_connectors': ['and']}], 'We found that COVID-19 patients could be clustered into subtypes based on serum levels of immune cells, gender, and reported symptoms.': [{'noun_phrase': '', 'noun_connectors': ['found']}, {'noun_phrase': ' patients', 'noun_connectors': ['could', 'clustered']}, {'noun_phrase': ' subtypes', 'noun_connectors': ['based']}, {'noun_phrase': ' serum levels immune cells gender', 'noun_connectors': ['and', 'reported']}], 'Finally, we trained an XGBoost model to achieve a sensitivity of 92.5% and a specificity of 97.9% in discriminating COVID-19 patients from influenza patients.': [{'noun_phrase': '', 'noun_connectors': ['Finally', 'trained']}, {'noun_phrase': ' model', 'noun_connectors': ['achieve']}, {'noun_phrase': ' sensitivity %', 'noun_connectors': ['and']}, {'noun_phrase': ' specificity %', 'noun_connectors': ['discriminating']}], 'We demonstrated that computational methods trained on large clinical datasets could yield ever more accurate COVID-19 diagnostic models to mitigate the impact of lack of testing.': [{'noun_phrase': '', 'noun_connectors': ['demonstrated']}, {'noun_phrase': ' methods', 'noun_connectors': ['trained']}, {'noun_phrase': ' datasets', 'noun_connectors': ['could', 'yield', 'ever', 'more']}, {'noun_phrase': ' models', 'noun_connectors': ['mitigate']}], 'We also presented previously unknown COVID-19 clinical variable correlations and clinical subgroups.': [{'noun_phrase': '', 'noun_connectors': ['also', 'presented', 'previously']}, {'noun_phrase': ' correlations', 'noun_connectors': ['and']}]}"
"[{'author_name': 'Ramon Mazzucchelli', 'author_inst': 'Rheumatology Unit. Hospital Universitario Fundacion Alcorcon'}, {'author_name': 'Raquel Almodovar-Gonzalez', 'author_inst': 'Rheumatology Unit. Hospital Universitario Fundacion Alcorcon'}, {'author_name': 'Natalia Crespi-Villarias', 'author_inst': 'Health Center La Rivota. Alcorcon'}, {'author_name': 'Elena Garcia-Zamora', 'author_inst': 'Dermatology Unit. Hospital Universitario Fundacion Alcorcon'}, {'author_name': 'Elia Perez-Fernandez', 'author_inst': 'Clinical Research Unit. Hospital Universitario Fundacion Alcorcon'}, {'author_name': 'Javier Quiros-Donate', 'author_inst': 'Rheumatology Unit. Hospital Universitario Fundacion Alcorcon.'}, {'author_name': 'Monserrat Perez-Encinas', 'author_inst': 'Pharmacy Department. Hospital Universitario Fundacion Alcorcon.'}, {'author_name': 'Patricia Sanmartin-Fenollera', 'author_inst': 'Pharmacy Department. Hospital Universitario Fundacion Alcorcon.'}, {'author_name': 'Maria Velasco-Arribas', 'author_inst': 'Infectious Diseases Unit. Hospital universitario Fundacion Alcorcon.'}, {'author_name': 'Pilar Lopez-Serrano', 'author_inst': 'Digestive Unit. Hospital Universitario Fundacion Alcorcon.'}, {'author_name': 'Jose lazaro Perez-Calle', 'author_inst': 'Digestive Unit. Hospital Universitario Fundacion Alcorcon.'}, {'author_name': 'Conrado Fernandez-Rodriguez', 'author_inst': 'Digestive Unit. Hospital Universitario Fundacion Alcorcon.'}, {'author_name': 'Jose Luis Lopez-Estebaranz', 'author_inst': 'Dermatology Unit. Hospital Universitario Fundacion Alcorcon.'}, {'author_name': 'Pedro Zarco-Montejo', 'author_inst': 'Rheumatology Unit. Hospital Universitario Fundacion Alcorcon.'}]",http://medrxiv.org/cgi/content/short/2020.06.21.20136788,Does Biological Therapy Protect against Severe COVID-19?,"Objective. To estimate COVID-19 infection incidence rate with severe affectation (requiring hospitalization) in patients with biological treatment due to rheumatoid arthritis (RA), psoriatic arthritis (PsA), spondyloarthritis (SpA), psoriasis (Ps), and inflammatory bowel disease (IBD) and compare it with incidence rate in the general population. Methods: Retrospective observational study based on information provided by two administrative databases. One of these two databases contains information on all patients seen in our hospital and diagnosed with COVID-19 infection between March 4th 2020 and April 26th 2020. The other database contains data from patients seen at Rheumatology, Dermatology and Digestive Departments in our hospital who are currently receiving biological therapy. We calculated the crude and age and sex adjusted incidence in both groups. To compare both groups we calculated the Incidence Rate Ratio. Results: There was a total of 2,182 patients with COVID-19 requiring hospitalization. Four patients out of a total of 797 patients receiving biological therapy had contracted COVID-19 and required hospital care. Crude incidence rate of COVID-19 requiring hospital care among the general population was 1.41%, and it was 0.50% among the group receiving biological therapy. Rates adjusted by age and sex in the biological group was 0.45% (CI95% 0.11-4.13). The IRR of the group receiving biological therapy compared to the general population was 0.39 (CI95% 0.14-1, p=0.049). Conclusion: Findings suggest that prior use of biological therapy does not associate with severe manifestations of COVID-19, and it is likely to have a protective effect against them when compared to the general population.",2020-06-24,medrxiv,14,"[{'CANCER': [{'label': 'RA', 'alias': ['Axial R', 'AXIAL R', 'DELTA', 'P', 'Ra'], 'meaning': ['Chirality axis based stereochemistry where, using the Cahn-Ingold-Prelog (CIP) priority rules, the priorities (from highest to lowest) of the substituent atoms exist in a clockwise direction.', 'C3538806', 1]}]}, {'CANCER': [{'label': 'RA', 'alias': ['Radium', 'Radium', 'Radium', 'Radium', 'Radium', 'Radium', 'Radium', 'Radium', 'radium', 'radium', 'Radium, NOS', 'Ra', 'Radium (substance)', 'Radium [Chemical/Ingredient]'], 'meaning': ['Radium. A radioactive element of the alkaline earth series of metals. It has the atomic symbol Ra, atomic number 88, and atomic weight 226. Radium is the product of the disintegration of uranium and is present in pitchblende and all ores containing uranium. It is used clinically as a source of beta and gamma-rays in radiotherapy, particularly BRACHYTHERAPY.', 'C0034625', 1]}]}, {'ORGAN': [{'label': 'bowel', 'alias': ['Bowel', 'Bowel Pattern Distress', 'Pattern of Bowel Movements', 'Bowel Pattern'], 'meaning': [""A question about the pattern of an individual's bowel movements."", 'C4083257', 1]}]}, {'ORGAN': [{'label': 'bowel', 'alias': ['Intestines', 'Intestines', 'Intestines', 'Intestines', 'Intestines', 'intestines', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestine', 'Intestines, NOS', 'intestine', 'intestine', 'intestine', 'intestine', 'INTESTINE', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'Bowel', 'bowel', 'bowel', 'Bowel, NOS', 'bowels', 'Intestinal tract', 'Intestinal tract', 'Intestinal tract', 'intestinal tract', 'Intestinal tract, NOS', 'Intestinal', 'Intestinal', 'Intestinal', 'Intestinal', 'Intestinal', 'intestinal', 'intestinal', 'Intestino-', 'Intestinal structure', 'intestinal structure', 'Gut', 'Intestinal structure (body structure)', 'Intestinal (qualifier value)'], 'meaning': ['The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE.', 'C0021853', 1]}]}]","{'Objective.': [[None, None, None]], 'To estimate COVID-19 infection incidence rate with severe affectation (requiring hospitalization) in patients with biological treatment due to rheumatoid arthritis (RA), psoriatic arthritis (PsA), spondyloarthritis (SpA), psoriasis (Ps), and inflammatory bowel disease (IBD) and compare it with incidence rate in the general population.': [['estimate', 'VB', 'O'], ['infection', 'NN', 'B-NP'], ['incidence', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP'], ['severe', 'JJ', 'B-NP'], ['affectation', 'NN', 'I-NP'], ['requiring', 'VBG', 'O'], ['hospitalization', 'NN', 'B-NP'], ['biological', 'JJ', 'B-NP'], ['treatment', 'NN', 'I-NP'], ['rheumatoid', 'VB', 'O'], ['arthritis', 'NN', 'B-NP'], ['psoriatic', 'JJ', 'B-NP'], ['arthritis', 'NN', 'I-NP'], ['spondyloarthritis', 'NN', 'B-NP'], ['psoriasis', 'NN', 'B-NP'], ['inflammatory', 'JJ', 'B-NP'], ['bowel', 'NN', 'I-NP'], ['disease', 'NN', 'B-NP'], ['compare', 'VB', 'O'], ['incidence', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['general', 'JJ', 'I-NP'], ['population', 'NN', 'I-NP']], 'Methods: Retrospective observational study based on information provided by two administrative databases.': [['observational', 'NN', 'B-NP'], ['study', 'NN', 'B-NP'], ['based', 'VBN', 'O'], ['information', 'NN', 'B-NP'], ['provided', 'VBN', 'O']], 'One of these two databases contains information on all patients seen in our hospital and diagnosed with COVID-19 infection between March 4th 2020 and April 26th 2020.': [['contains', 'VBZ', 'O'], ['information', 'NN', 'B-NP'], ['seen', 'VBN', 'O'], ['hospital', 'NN', 'B-NP'], ['diagnosed', 'VBN', 'O'], ['infection', 'NN', 'B-NP']], 'The other database contains data from patients seen at Rheumatology, Dermatology and Digestive Departments in our hospital who are currently receiving biological therapy.': [['The', 'DT', 'B-NP'], ['other', 'JJ', 'I-NP'], ['database', 'NN', 'I-NP'], ['seen', 'VBN', 'O'], ['hospital', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['receiving', 'VBG', 'O'], ['biological', 'JJ', 'B-NP'], ['therapy', 'NN', 'I-NP']], 'We calculated the crude and age and sex adjusted incidence in both groups.': [['calculated', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['crude', 'NN', 'I-NP'], ['age', 'NN', 'B-NP'], ['sex', 'NN', 'B-NP'], ['adjusted', 'VBN', 'O'], ['incidence', 'NN', 'B-NP']], 'To compare both groups we calculated the Incidence Rate Ratio.': [['compare', 'VB', 'O'], ['calculated', 'VBD', 'O']], 'Results: There was a total of 2,182 patients with COVID-19 requiring hospitalization.': [['was', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['total', 'NN', 'I-NP'], ['requiring', 'VBG', 'O'], ['hospitalization', 'NN', 'B-NP']], 'Four patients out of a total of 797 patients receiving biological therapy had contracted COVID-19 and required hospital care.': [['a', 'DT', 'B-NP'], ['total', 'NN', 'I-NP'], ['receiving', 'VBG', 'O'], ['biological', 'JJ', 'B-NP'], ['therapy', 'NN', 'I-NP'], ['had', 'VBD', 'O'], ['contracted', 'VBN', 'O'], ['required', 'VBN', 'O'], ['hospital', 'NN', 'B-NP'], ['care', 'NN', 'B-NP']], 'Crude incidence rate of COVID-19 requiring hospital care among the general population was 1.41%, and it was 0.50% among the group receiving biological therapy.': [['incidence', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP'], ['requiring', 'VBG', 'O'], ['hospital', 'NN', 'B-NP'], ['care', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['general', 'JJ', 'I-NP'], ['population', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['group', 'NN', 'I-NP'], ['receiving', 'VBG', 'O'], ['biological', 'JJ', 'B-NP'], ['therapy', 'NN', 'I-NP']], 'Rates adjusted by age and sex in the biological group was 0.45% (CI95% 0.11-4.13).': [['adjusted', 'VBN', 'O'], ['age', 'NN', 'B-NP'], ['sex', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['biological', 'JJ', 'I-NP'], ['group', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['0.11-4.13', 'NN', 'B-NP']], 'The IRR of the group receiving biological therapy compared to the general population was 0.39 (CI95% 0.14-1, p=0.049).': [['the', 'DT', 'B-NP'], ['group', 'NN', 'I-NP'], ['receiving', 'VBG', 'O'], ['biological', 'JJ', 'B-NP'], ['therapy', 'NN', 'I-NP'], ['compared', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['general', 'JJ', 'I-NP'], ['population', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['0.14-1', 'NN', 'B-NP'], ['p=0.049', 'NN', 'B-NP']], 'Conclusion: Findings suggest that prior use of biological therapy does not associate with severe manifestations of COVID-19, and it is likely to have a protective effect against them when compared to the general population.': [['Conclusion', 'NN', 'B-NP'], ['suggest', 'VBP', 'O'], ['prior', 'JJ', 'B-NP'], ['use', 'NN', 'I-NP'], ['biological', 'JJ', 'B-NP'], ['therapy', 'NN', 'I-NP'], ['does', 'VBZ', 'O'], ['associate', 'VB', 'O'], ['is', 'VBZ', 'O'], ['have', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['protective', 'JJ', 'I-NP'], ['effect', 'NN', 'I-NP'], ['compared', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['general', 'JJ', 'I-NP'], ['population', 'NN', 'I-NP']]}","{'Objective.': [], 'To estimate COVID-19 infection incidence rate with severe affectation (requiring hospitalization) in patients with biological treatment due to rheumatoid arthritis (RA), psoriatic arthritis (PsA), spondyloarthritis (SpA), psoriasis (Ps), and inflammatory bowel disease (IBD) and compare it with incidence rate in the general population.': [{'noun_phrase': '', 'noun_connectors': ['estimate']}, {'noun_phrase': ' infection incidence rate severe affectation', 'noun_connectors': ['requiring']}, {'noun_phrase': ' hospitalization patients biological treatment due', 'noun_connectors': ['rheumatoid']}, {'noun_phrase': ' arthritis RA psoriatic arthritis PsA spondyloarthritis SpA psoriasis Ps', 'noun_connectors': ['and']}, {'noun_phrase': ' bowel disease IBD', 'noun_connectors': ['and', 'compare']}], 'Methods: Retrospective observational study based on information provided by two administrative databases.': [{'noun_phrase': ' Methods Retrospective observational study', 'noun_connectors': ['based']}, {'noun_phrase': ' information', 'noun_connectors': ['provided']}], 'One of these two databases contains information on all patients seen in our hospital and diagnosed with COVID-19 infection between March 4th 2020 and April 26th 2020.': [{'noun_phrase': ' databases', 'noun_connectors': ['contains']}, {'noun_phrase': ' information patients', 'noun_connectors': ['seen']}, {'noun_phrase': ' hospital', 'noun_connectors': ['and', 'diagnosed']}, {'noun_phrase': ' infection March 4th', 'noun_connectors': ['and']}], 'The other database contains data from patients seen at Rheumatology, Dermatology and Digestive Departments in our hospital who are currently receiving biological therapy.': [{'noun_phrase': ' other database', 'noun_connectors': ['contains']}, {'noun_phrase': ' data patients', 'noun_connectors': ['seen', 'and']}, {'noun_phrase': ' hospital', 'noun_connectors': ['currently', 'receiving']}], 'We calculated the crude and age and sex adjusted incidence in both groups.': [{'noun_phrase': '', 'noun_connectors': ['calculated']}, {'noun_phrase': ' crude', 'noun_connectors': ['and']}, {'noun_phrase': ' age', 'noun_connectors': ['and']}, {'noun_phrase': ' sex', 'noun_connectors': ['adjusted']}], 'To compare both groups we calculated the Incidence Rate Ratio.': [{'noun_phrase': '', 'noun_connectors': ['compare']}], 'Results: There was a total of 2,182 patients with COVID-19 requiring hospitalization.': [{'noun_phrase': ' Results total patients COVID-19', 'noun_connectors': ['requiring']}], 'Four patients out of a total of 797 patients receiving biological therapy had contracted COVID-19 and required hospital care.': [{'noun_phrase': ' patients total patients', 'noun_connectors': ['receiving']}, {'noun_phrase': ' therapy', 'noun_connectors': ['contracted', 'and', 'required']}], 'Crude incidence rate of COVID-19 requiring hospital care among the general population was 1.41%, and it was 0.50% among the group receiving biological therapy.': [{'noun_phrase': ' Crude incidence rate COVID-19', 'noun_connectors': ['requiring']}, {'noun_phrase': ' hospital care general population %', 'noun_connectors': ['and']}, {'noun_phrase': ' % group', 'noun_connectors': ['receiving']}], 'Rates adjusted by age and sex in the biological group was 0.45% (CI95% 0.11-4.13).': [{'noun_phrase': ' Rates', 'noun_connectors': ['adjusted']}, {'noun_phrase': ' age', 'noun_connectors': ['and']}], 'The IRR of the group receiving biological therapy compared to the general population was 0.39 (CI95% 0.14-1, p=0.049).': [{'noun_phrase': ' IRR group', 'noun_connectors': ['receiving']}, {'noun_phrase': ' therapy', 'noun_connectors': ['compared']}], 'Conclusion: Findings suggest that prior use of biological therapy does not associate with severe manifestations of COVID-19, and it is likely to have a protective effect against them when compared to the general population.': [{'noun_phrase': ' Conclusion Findings', 'noun_connectors': ['suggest']}, {'noun_phrase': ' use biological therapy', 'noun_connectors': ['associate']}, {'noun_phrase': ' manifestations COVID-19', 'noun_connectors': ['and']}, {'noun_phrase': ' effect', 'noun_connectors': ['when', 'compared']}]}"
"[{'author_name': 'Qiang Su', 'author_inst': 'Department of Oncology,Beijing Friendship Hospital, Capital Medical University'}, {'author_name': 'Jie-xuan Hu', 'author_inst': 'Department of Oncology, Beijing Friendship Hospital, Capital Medical University'}, {'author_name': 'Hai-shan Lin', 'author_inst': 'Department of Oncology, Beijing Friendship Hospital, Capital Medical University'}, {'author_name': 'Zheng Zhang', 'author_inst': 'Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University'}, {'author_name': 'Emily C Zhu', 'author_inst': 'McCoy College of Business, Texas State University, 601 University Dr.'}, {'author_name': 'Chen-guang Zhang', 'author_inst': 'Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University'}, {'author_name': 'Di-ya Wang', 'author_inst': 'Department of Radiation Oncology, University of California'}, {'author_name': 'Zu-hua Gao', 'author_inst': 'Department of Pathology, Research Institute of McGill University Health Center'}, {'author_name': 'Bang-wei Cao', 'author_inst': 'Department of Oncology, Beijing Friendship Hospital, Capital Medical University'}]",http://medrxiv.org/cgi/content/short/2020.06.23.20136200,Prevalence and risks of severe events for cancer patients with COVID-19 infection: a systematic review and meta-analysis,"Background The corona virus disease 2019 (COVID-19) pandemic poses a severe challenge to public health, especially to those patients with underlying diseases. In this meta-analysis, we studied the prevalence of cancer among patients with COVID-19 infection and their risks of severe events. Methods We searched the Pubmed, Embase and MedRxiv databases for studies between December 2019 and May 3, 2020 using the following key words and terms: sars-cov-2, covid-19, 2019-ncov, 2019 novel coronavirus, corona virus disease-2019, clinical, clinical characteristics, clinical course, epidemiologic features, epidemiology, and epidemiological characteristics. We extracted data following PICO (patient, intervention, comparison and outcome) chart. Statistical analyses were performed with R Studio (version 3.5.1) on the group-level data. We assessed the studies risk of bias in accordance to the adjusted Joanna Briggs Institute. We estimated the prevalence or risks for severe events including admission into intensive care unit or death using meta-analysis with random effects. Findings Out of the 2,551 studies identified, 32 studies comprising 21,248 participants have confirmed COVID-19. The total prevalence of cancer in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%), higher than that of the total cancer rate (0.29%) in China. Stratification analysis showed that the overall cancer prevalence of COVID-19 patients in China was 2.59% (95% CI, 1.72% to 3.90%), and the prevalence reached 3.79% in Wuhan (95% CI, 2.51% to 5.70%) and 2.31% (95% CI, 1.16% to 4.57%) in other areas outside Wuhan in China. The incidence of ICU admission in cancer patients with COVID-19 was 26.80% (95% CI, 21.65% to 32.67%) and the mortality was 24.32% (95% CI, 13.95% to 38.91%), much higher than the overall rates of COVID-19 patients in China. The fatality in COVID patients with cancer was lower than those with cardiovascular disease (OR 0.49; 95% CI, 0.34 to 0.71; p=0.39), but comparable with other comorbidities such as diabetes (OR 1.32; 95% CI, 0.42 to 4.11; p=0.19), hypertension (OR 1.27; 95% CI, 0.35 to 4.62; p=0.13), and respiratory diseases (OR 0.79; 95% CI, 0.47 to 1.33; p=0.45). Interpretation This comprehensive meta-analysis on the largest number of patients to date provides solid evidence that COVID-19 infection significantly and negatively affected the disease course and prognosis of cancer patients. Awareness of this could help guide clinicians and health policy makers in combating cancer in the context of COVID-19 pandemic.",2020-06-24,medrxiv,9,"[{'CANCER': [{'label': 'cancer', 'alias': ['malignant neoplasms', 'Neoplasm, malignant', 'Neoplasm, malignant', 'NEOPLASM MALIGNANT', 'NEOPLASM MALIGNANT', 'Malignant neoplasm', 'NEOPLASM, MALIGNANT', 'malignant neoplasm', 'malignant neoplasm', 'Malignant Neoplasm', 'Malignant Neoplasm', 'Malignant Neoplasm', 'Malignant Neoplasm', 'Malignant Neoplasm', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'Cancer', 'CANCER', 'CANCER', 'cancer', 'cancer', 'cancer', 'cancer', 'cancer', 'Cancers', 'Cancers', 'CANCER (NOS)', 'cancers', 'Malignancy', 'Malignancy', 'Malignancy', 'Malignancy', 'Malignancy', 'Malignancy', 'Malignancy', 'Malignancy', 'Malignancy', 'Malignancy', 'Malignancy', 'MALIGNANCY', 'MALIGNANCY', 'malignancy', 'MALIGNANCIES', 'malignancies', 'malignancies', 'Malignant neoplasm without specification of site', 'Malignant neoplasm without specification of site', 'Malignant neoplasm without specification of site', 'Malignant neoplasm without specification of site', 'Malignant neoplasm without specification of site', 'Malignant tumor', 'Tumor, malignant', 'MALIGNANT TUMOR', 'malignant tumor', 'malignant tumor', 'Malignant Tumor', 'Malignant Tumor', 'Malignant tumour', 'Tumor, malignant, NOS', 'Tumour, malignant', 'malignant tumors', 'malignant tumours', 'malignant tumour', 'Unclassified tumor, malignant', 'Unclassified tumor, malignant', 'Unclassified tumour, malignant', 'neoplasm/cancer', 'CA', 'CA', 'Malignant neoplastic disease', 'Malignant neoplastic disease', 'Neoplastic disease, malignant', 'Malignant Neoplastic Disease', 'CA - Cancer', 'Malignant Growth', 'malignant tumoral disease', 'Cancer, unspecified site', 'Malignancy, unspecified site', 'Malignant neoplastic disease (disorder)'], 'meaning': ['A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Malignant cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of malignancy. Carcinoma is a malignancy that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a malignancy that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a malignancy that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and multiple myeloma are malignancies that begin in the cells of the immune system. Central nervous system cancers are malignancies that begin in the tissues of the brain and spinal cord.', 'C0006826', 1]}]}, {'CANCER': [{'label': 'cancer', 'alias': ['Cancer:-:Point in time:^Patient:-', 'Cancer', 'Cancer:-:Pt:^Patient:-'], 'meaning': [None, 'C2707253', 1]}]}, {'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'CORONAVIRUS', 'coronavirus', 'Coronaviruses', 'Coronaviruses', 'Coronaviruses', 'Coronavirus, NOS', 'coronaviruses'], 'meaning': ['A genus of the family CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.', 'C0206419', 1]}]}, {'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'coronaviridae', 'CORONAVIRUS', 'Family: Coronavirus group', 'Coronavirus group', 'CORONAVIRUS GROUP', 'Coronavirus group, NOS', 'Family Coronaviridae', 'Family Coronaviridae (organism)'], 'meaning': ['Spherical RNA viruses, in the order NIDOVIRALES, infecting a wide range of animals including humans. Transmission is by fecal-oral and respiratory routes. Mechanical transmission is also common. There are two genera: CORONAVIRUS and TOROVIRUS.', 'C0010076', 1]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 1]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Veterinary Patient', 'Patient'], 'meaning': ['A non-human animal that is a subject in a study.', 'C1705908', 1]}]}, {'ORGANISM': [{'label': 'participants', 'alias': ['Participant', 'participant', 'participant', 'participants'], 'meaning': ['Someone who takes part in an activity.', 'C0679646', 0.9999998807907104]}]}, {'ORGANISM': [{'label': 'participants', 'alias': ['Participant Object', 'Participant', 'Participant Thing'], 'meaning': ['Something that takes part in an activity.', 'C2698741', 0.8850828409194946]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'CANCER': [{'label': 'cancer patients', 'alias': [], 'meaning': ['A person who receives medical care for the purpose of treating, diagnosing or preventing cancer.', 'C1516213', 0.8665663003921509]}]}, {'CANCER': [{'label': 'cancer patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.7764509320259094]}]}, {'TISSUE': [{'label': 'cardiovascular', 'alias': ['Cardiovascular', 'Cardiovascular', 'Cardiovascular', 'cardiovascular', 'CARDIOVASCULAR'], 'meaning': ['Having to do with the heart and blood vessels.', 'C3887460', 1]}]}, {'TISSUE': [{'label': 'cardiovascular', 'alias': ['Cardiovascular system', 'Cardiovascular system', 'Cardiovascular system', 'Cardiovascular system', 'Cardiovascular system', 'Cardiovascular system', 'Cardiovascular system', 'Cardiovascular system', 'Cardiovascular System', 'Cardiovascular System', 'Cardiovascular System', 'Cardiovascular System', 'CARDIOVASCULAR SYSTEM', 'CARDIOVASCULAR SYSTEM', 'cardiovascular system', 'cardiovascular system', 'cardiovascular system', 'Cardiovascular Systems', 'Cardiovascular system, NOS', 'cardiovascular systems', 'Cardio-pericardial', 'Cardiovascular Body System', 'cardiovascular system body', 'Body System, Cardiovascular', 'Circulatory System', 'Circulatory System', 'circulatory system', 'circulatory system', 'circulatory system', 'circulatory system', 'Circulatory system', 'Circulatory system', 'Circulatory system', 'Circulatory system', '{Circulatory system}', 'Circulatory system, NOS', 'Circulatory Systems', 'Cardiovascular', 'Cardiovascular', 'cardiovascular', 'Organ System, Cardiovascular', 'Cardiovascular Organ System', 'Cardiovascular structure', 'cardiovascular structure', 'Systema cardiovasculare', 'Systema cardiovasculare', 'circulatory', 'CIRCULATORY', 'Circulatory', 'Vascular, Heart', 'Structure of cardiovascular system (body structure)', 'Structure of cardiovascular system', 'CV system'], 'meaning': ['The HEART and the BLOOD VESSELS by which BLOOD is pumped and circulated through the body.', 'C0007226', 1]}]}, {'CANCER': [{'label': 'solid', 'alias': ['Solid Dose Form', 'Solid dose form', 'Solid [Dose Form]', 'Solid', 'Solid', 'Solid', 'Solid Dosage Form', 'Solid dose form (qualifier value)'], 'meaning': ['A substance having definite shape and volume manufactured for the administration of active and/or inert ingredient(s). Solids include tablets, capsules, powders, granules and certain suppositories.', 'C1378566', 1]}]}, {'CANCER': [{'label': 'solid', 'alias': ['solid substance', 'Solid substance', 'Solid substance, NOS', 'Solid', 'Solid, NOS', 'solids', 'Solid substance (substance)'], 'meaning': ['A substance having a definite shape and volume', 'C0302909', 1]}]}]","{'Background The corona virus disease 2019 (COVID-19) pandemic poses a severe challenge to public health, especially to those patients with underlying diseases.': [['The', 'DT', 'B-NP'], ['corona', 'NN', 'I-NP'], ['virus', 'NN', 'B-NP'], ['disease', 'NN', 'B-NP'], ['pandemic', 'VBP', 'O'], ['poses', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['severe', 'JJ', 'I-NP'], ['challenge', 'NN', 'I-NP'], ['public', 'JJ', 'B-NP'], ['health', 'NN', 'I-NP']], 'In this meta-analysis, we studied the prevalence of cancer among patients with COVID-19 infection and their risks of severe events.': [['this', 'DT', 'B-NP'], ['meta-analysis', 'NN', 'I-NP'], ['studied', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['prevalence', 'NN', 'I-NP'], ['cancer', 'NN', 'B-NP'], ['infection', 'NN', 'B-NP']], 'Methods We searched the Pubmed, Embase and MedRxiv databases for studies between December 2019 and May 3, 2020 using the following key words and terms: sars-cov-2, covid-19, 2019-ncov, 2019 novel coronavirus, corona virus disease-2019, clinical, clinical characteristics, clinical course, epidemiologic features, epidemiology, and epidemiological characteristics.': [['searched', 'VBD', 'O'], ['using', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['following', 'JJ', 'I-NP'], ['key', 'NN', 'I-NP'], ['sars-cov-2', 'NN', 'B-NP'], ['novel', 'NN', 'B-NP'], ['coronavirus', 'NN', 'B-NP'], ['corona', 'JJ', 'B-NP'], ['virus', 'NN', 'I-NP'], ['disease-2019', 'NN', 'B-NP'], ['clinical', 'JJ', 'B-NP'], ['course', 'NN', 'I-NP'], ['epidemiology', 'NN', 'B-NP']], 'We extracted data following PICO (patient, intervention, comparison and outcome) chart.': [['extracted', 'VBD', 'O'], ['following', 'VBG', 'O'], ['patient', 'NN', 'B-NP'], ['intervention', 'NN', 'B-NP'], ['comparison', 'NN', 'B-NP'], ['outcome', 'NN', 'B-NP'], ['chart', 'NN', 'B-NP']], 'Statistical analyses were performed with R Studio (version 3.5.1) on the group-level data.': [['were', 'VBD', 'O'], ['performed', 'VBN', 'O'], ['version', 'NN', 'B-NP']], 'We assessed the studies risk of bias in accordance to the adjusted Joanna Briggs Institute.': [['assessed', 'VBD', 'O'], ['risk', 'NN', 'B-NP'], ['bias', 'NN', 'B-NP'], ['accordance', 'NN', 'B-NP'], ['adjusted', 'VBN', 'O']], 'We estimated the prevalence or risks for severe events including admission into intensive care unit or death using meta-analysis with random effects.': [['estimated', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['prevalence', 'NN', 'I-NP'], ['including', 'VBG', 'O'], ['admission', 'NN', 'B-NP'], ['intensive', 'JJ', 'B-NP'], ['care', 'NN', 'I-NP'], ['unit', 'NN', 'B-NP'], ['death', 'NN', 'B-NP'], ['using', 'VBG', 'O'], ['meta-analysis', 'NN', 'B-NP']], 'Findings Out of the 2,551 studies identified, 32 studies comprising 21,248 participants have confirmed COVID-19.': [['identified', 'VBN', 'O'], ['comprising', 'VBG', 'O'], ['have', 'VBP', 'O'], ['confirmed', 'VBN', 'O']], 'The total prevalence of cancer in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%), higher than that of the total cancer rate (0.29%) in China.': [['The', 'DT', 'B-NP'], ['total', 'JJ', 'I-NP'], ['prevalence', 'NN', 'I-NP'], ['cancer', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['total', 'JJ', 'I-NP'], ['cancer', 'NN', 'I-NP'], ['rate', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'Stratification analysis showed that the overall cancer prevalence of COVID-19 patients in China was 2.59% (95% CI, 1.72% to 3.90%), and the prevalence reached 3.79% in Wuhan (95% CI, 2.51% to 5.70%) and 2.31% (95% CI, 1.16% to 4.57%) in other areas outside Wuhan in China.': [['Stratification', 'NN', 'B-NP'], ['analysis', 'NN', 'B-NP'], ['showed', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['overall', 'JJ', 'I-NP'], ['cancer', 'NN', 'I-NP'], ['prevalence', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['prevalence', 'NN', 'I-NP'], ['reached', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'The incidence of ICU admission in cancer patients with COVID-19 was 26.80% (95% CI, 21.65% to 32.67%) and the mortality was 24.32% (95% CI, 13.95% to 38.91%), much higher than the overall rates of COVID-19 patients in China.': [['The', 'DT', 'B-NP'], ['incidence', 'NN', 'I-NP'], ['admission', 'NN', 'B-NP'], ['cancer', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['mortality', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'The fatality in COVID patients with cancer was lower than those with cardiovascular disease (OR 0.49; 95% CI, 0.34 to 0.71; p=0.39), but comparable with other comorbidities such as diabetes (OR 1.32; 95% CI, 0.42 to 4.11; p=0.19), hypertension (OR 1.27; 95% CI, 0.35 to 4.62; p=0.13), and respiratory diseases (OR 0.79; 95% CI, 0.47 to 1.33; p=0.45).': [['The', 'DT', 'B-NP'], ['fatality', 'NN', 'I-NP'], ['cancer', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['cardiovascular', 'JJ', 'B-NP'], ['disease', 'NN', 'I-NP'], ['%', 'NN', 'B-NP'], ['p=0.39', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['p=0.19', 'NN', 'B-NP'], ['hypertension', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['p=0.13', 'NN', 'B-NP'], ['respiratory', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['p=0.45', 'NN', 'B-NP']], 'Interpretation This comprehensive meta-analysis on the largest number of patients to date provides solid evidence that COVID-19 infection significantly and negatively affected the disease course and prognosis of cancer patients.': [['Interpretation', 'NN', 'B-NP'], ['This', 'DT', 'B-NP'], ['comprehensive', 'JJ', 'I-NP'], ['meta-analysis', 'NN', 'I-NP'], ['number', 'NN', 'B-NP'], ['date', 'NN', 'B-NP'], ['provides', 'VBZ', 'O'], ['solid', 'JJ', 'B-NP'], ['evidence', 'NN', 'I-NP'], ['infection', 'NN', 'B-NP'], ['affected', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['disease', 'NN', 'I-NP'], ['course', 'NN', 'B-NP'], ['prognosis', 'NN', 'B-NP'], ['cancer', 'NN', 'B-NP']], 'Awareness of this could help guide clinicians and health policy makers in combating cancer in the context of COVID-19 pandemic.': [['Awareness', 'NN', 'B-NP'], ['help', 'VB', 'O'], ['guide', 'VB', 'O'], ['health', 'NN', 'B-NP'], ['policy', 'NN', 'B-NP'], ['combating', 'VBG', 'O'], ['cancer', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['context', 'NN', 'I-NP'], ['pandemic', 'NN', 'B-NP']]}","{'Background The corona virus disease 2019 (COVID-19) pandemic poses a severe challenge to public health, especially to those patients with underlying diseases.': [{'noun_phrase': '', 'noun_connectors': ['Background']}, {'noun_phrase': ' virus disease COVID-19 pandemic', 'noun_connectors': ['poses']}, {'noun_phrase': ' challenge public health', 'noun_connectors': ['especially']}, {'noun_phrase': ' patients', 'noun_connectors': ['underlying']}], 'In this meta-analysis, we studied the prevalence of cancer among patients with COVID-19 infection and their risks of severe events.': [{'noun_phrase': ' meta analysis', 'noun_connectors': ['studied']}, {'noun_phrase': ' prevalence cancer patients COVID-19 infection', 'noun_connectors': ['and']}], 'Methods We searched the Pubmed, Embase and MedRxiv databases for studies between December 2019 and May 3, 2020 using the following key words and terms: sars-cov-2, covid-19, 2019-ncov, 2019 novel coronavirus, corona virus disease-2019, clinical, clinical characteristics, clinical course, epidemiologic features, epidemiology, and epidemiological characteristics.': [{'noun_phrase': ' Methods', 'noun_connectors': ['searched', 'and']}, {'noun_phrase': ' databases studies December', 'noun_connectors': ['and', 'using', 'following']}, {'noun_phrase': ' words', 'noun_connectors': ['and']}, {'noun_phrase': ' terms sars cov-2 covid-19 novel coronavirus corona virus disease-2019 clinical clinical characteristics clinical course epidemiologic features epidemiology', 'noun_connectors': ['and']}], 'We extracted data following PICO (patient, intervention, comparison and outcome) chart.': [{'noun_phrase': '', 'noun_connectors': ['extracted']}, {'noun_phrase': ' data', 'noun_connectors': ['following']}, {'noun_phrase': ' PICO patient intervention comparison', 'noun_connectors': ['and']}], 'Statistical analyses were performed with R Studio (version 3.5.1) on the group-level data.': [{'noun_phrase': ' Statistical analyses', 'noun_connectors': ['performed']}], 'We assessed the studies risk of bias in accordance to the adjusted Joanna Briggs Institute.': [{'noun_phrase': '', 'noun_connectors': ['assessed']}], 'We estimated the prevalence or risks for severe events including admission into intensive care unit or death using meta-analysis with random effects.': [{'noun_phrase': '', 'noun_connectors': ['estimated']}, {'noun_phrase': ' prevalence', 'noun_connectors': ['or']}, {'noun_phrase': ' risks severe events', 'noun_connectors': ['including']}, {'noun_phrase': ' admission intensive care unit', 'noun_connectors': ['or']}, {'noun_phrase': ' death', 'noun_connectors': ['using']}], 'Findings Out of the 2,551 studies identified, 32 studies comprising 21,248 participants have confirmed COVID-19.': [{'noun_phrase': ' Findings studies', 'noun_connectors': ['identified']}, {'noun_phrase': ' studies', 'noun_connectors': ['comprising']}], 'The total prevalence of cancer in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%), higher than that of the total cancer rate (0.29%) in China.': [], 'Stratification analysis showed that the overall cancer prevalence of COVID-19 patients in China was 2.59% (95% CI, 1.72% to 3.90%), and the prevalence reached 3.79% in Wuhan (95% CI, 2.51% to 5.70%) and 2.31% (95% CI, 1.16% to 4.57%) in other areas outside Wuhan in China.': [{'noun_phrase': ' Stratification analysis', 'noun_connectors': ['showed']}, {'noun_phrase': ' cancer prevalence COVID-19 patients China % % CI % %', 'noun_connectors': ['and']}, {'noun_phrase': ' prevalence', 'noun_connectors': ['reached']}, {'noun_phrase': ' % Wuhan % CI % %', 'noun_connectors': ['and']}], 'The incidence of ICU admission in cancer patients with COVID-19 was 26.80% (95% CI, 21.65% to 32.67%) and the mortality was 24.32% (95% CI, 13.95% to 38.91%), much higher than the overall rates of COVID-19 patients in China.': [{'noun_phrase': ' incidence ICU admission cancer patients COVID-19 % % CI % %', 'noun_connectors': ['and']}, {'noun_phrase': ' mortality % % CI % %', 'noun_connectors': ['much']}], 'The fatality in COVID patients with cancer was lower than those with cardiovascular disease (OR 0.49; 95% CI, 0.34 to 0.71; p=0.39), but comparable with other comorbidities such as diabetes (OR 1.32; 95% CI, 0.42 to 4.11; p=0.19), hypertension (OR 1.27; 95% CI, 0.35 to 4.62; p=0.13), and respiratory diseases (OR 0.79; 95% CI, 0.47 to 1.33; p=0.45).': [{'noun_phrase': ' fatality COVID patients cancer lower cardiovascular disease', 'noun_connectors': ['OR']}, {'noun_phrase': ' % CI p=0.39', 'noun_connectors': ['but']}, {'noun_phrase': ' comorbidities such diabetes', 'noun_connectors': ['OR']}, {'noun_phrase': ' % CI p=0.19 hypertension', 'noun_connectors': ['OR']}, {'noun_phrase': ' % CI p=0.13', 'noun_connectors': ['and']}, {'noun_phrase': ' diseases', 'noun_connectors': ['OR']}], 'Interpretation This comprehensive meta-analysis on the largest number of patients to date provides solid evidence that COVID-19 infection significantly and negatively affected the disease course and prognosis of cancer patients.': [{'noun_phrase': ' Interpretation comprehensive meta analysis largest number patients date', 'noun_connectors': ['provides']}, {'noun_phrase': ' evidence COVID-19 infection', 'noun_connectors': ['significantly', 'and', 'negatively', 'affected']}, {'noun_phrase': ' disease course', 'noun_connectors': ['and']}], 'Awareness of this could help guide clinicians and health policy makers in combating cancer in the context of COVID-19 pandemic.': [{'noun_phrase': ' Awareness', 'noun_connectors': ['could', 'help', 'guide']}, {'noun_phrase': ' clinicians', 'noun_connectors': ['and']}, {'noun_phrase': ' health policy makers', 'noun_connectors': ['combating']}]}"
"[{'author_name': 'Anagh Pathak', 'author_inst': 'National Brain Research Centre'}, {'author_name': 'Varun Madan Mohan', 'author_inst': 'National Brain Research Centre'}, {'author_name': 'Arpan Banerjee', 'author_inst': 'National Brain Research Centre'}]",http://medrxiv.org/cgi/content/short/2020.06.22.20137828,An agent based modelling approach to study lockdown efficacy for infectious disease spreads,"We sought to simulate lockdown scenarios using an Agent Based Modelling (ABM) strategy, which is a new modelling paradigm that seeks to simulate the actions and interactions of autonomous agents within an environment. The spread of infectious viral diseases occur over a connected social network. Specifically, the goal was to understand the effect of network topology and lockdown strategies on disease spreading dynamics. To explore the effect of topology we assumed the social network over which the disease spreads to have small-world or scale-free properties characterized by a rewiring probability and degree distribution respectively. Lockdowns were simulated as intervention strategies that modified the spreading dynamics of infection over a given graph structure through changes in properties of agent interaction. Lockdown efficacy was assessed by the maximum number of infections recorded during a simulation run. Thereafter, lockdown efficacy was evaluated as a function of lockdown start times and duration. Thus, we propose that ABM approach can be used to assess various lockdown strategies that aim to prevent breakdown of medical infrastructure while accounting for realistic social network configurations specific to a local population.",2020-06-24,medrxiv,3,"[{'CANCER': [{'label': 'ABM', 'alias': ['trans-2, cis-3 decenoyl-[acyl-carrier-protein] isomerase activity', 'FabM', 'trans-2,cis-3-decenoyl-ACP isomerase activity', 'trans-2, cis-3 decenoyl-ACP isomerase activity', 'trans-2-cis-3-decenoyl-ACP isomerase activity', 'decenoyl-acyl-carrier-protein delta2-trans-delta3-cis-isomerase activity', 'trans-2-decenoyl-ACP isomerase activity'], 'meaning': ['Catalysis of the reaction: trans-dec-2-enoyl-[acyl-carrier protein] = cis-dec-3-enoyl-[acyl-carrier protein]. [EC:5.3.3.14, IMG:02508]', 'C2248746', 0.8013359904289246]}]}]","{'We sought to simulate lockdown scenarios using an Agent Based Modelling (ABM) strategy, which is a new modelling paradigm that seeks to simulate the actions and interactions of autonomous agents within an environment.': [['sought', 'VBD', 'O'], ['simulate', 'VB', 'O'], ['using', 'VBG', 'O'], ['Based', 'VBD', 'O'], ['strategy', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['new', 'JJ', 'I-NP'], ['modelling', 'NN', 'I-NP'], ['paradigm', 'NN', 'B-NP'], ['seeks', 'VBZ', 'O'], ['simulate', 'VB', 'O'], ['an', 'DT', 'B-NP'], ['environment', 'NN', 'I-NP']], 'The spread of infectious viral diseases occur over a connected social network.': [['The', 'DT', 'B-NP'], ['spread', 'NN', 'I-NP'], ['occur', 'VBP', 'O'], ['connected', 'VBN', 'O'], ['social', 'JJ', 'B-NP'], ['network', 'NN', 'I-NP']], 'Specifically, the goal was to understand the effect of network topology and lockdown strategies on disease spreading dynamics.': [['the', 'DT', 'B-NP'], ['goal', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['understand', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['effect', 'NN', 'I-NP'], ['network', 'NN', 'B-NP'], ['topology', 'NN', 'B-NP'], ['disease', 'NN', 'B-NP'], ['spreading', 'VBG', 'O']], 'To explore the effect of topology we assumed the social network over which the disease spreads to have small-world or scale-free properties characterized by a rewiring probability and degree distribution respectively.': [['explore', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['effect', 'NN', 'I-NP'], ['topology', 'NN', 'B-NP'], ['assumed', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['social', 'JJ', 'I-NP'], ['network', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['disease', 'NN', 'I-NP'], ['spreads', 'VBZ', 'O'], ['have', 'VB', 'O'], ['characterized', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['rewiring', 'NN', 'I-NP'], ['probability', 'NN', 'B-NP'], ['degree', 'JJ', 'B-NP'], ['distribution', 'NN', 'I-NP']], 'Lockdowns were simulated as intervention strategies that modified the spreading dynamics of infection over a given graph structure through changes in properties of agent interaction.': [['were', 'VBD', 'O'], ['simulated', 'VBN', 'O'], ['intervention', 'NN', 'B-NP'], ['modified', 'VBD', 'O'], ['spreading', 'VBG', 'O'], ['infection', 'NN', 'B-NP'], ['given', 'VBN', 'O'], ['graph', 'NN', 'B-NP'], ['structure', 'NN', 'B-NP'], ['agent', 'JJ', 'B-NP'], ['interaction', 'NN', 'I-NP']], 'Lockdown efficacy was assessed by the maximum number of infections recorded during a simulation run.': [['efficacy', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['assessed', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['maximum', 'JJ', 'I-NP'], ['number', 'NN', 'I-NP'], ['recorded', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['simulation', 'NN', 'I-NP'], ['run', 'NN', 'B-NP']], 'Thereafter, lockdown efficacy was evaluated as a function of lockdown start times and duration.': [['lockdown', 'JJ', 'B-NP'], ['efficacy', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['evaluated', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['function', 'NN', 'I-NP'], ['lockdown', 'JJ', 'B-NP'], ['start', 'NN', 'I-NP'], ['duration', 'NN', 'B-NP']], 'Thus, we propose that ABM approach can be used to assess various lockdown strategies that aim to prevent breakdown of medical infrastructure while accounting for realistic social network configurations specific to a local population.': [['propose', 'VBP', 'O'], ['approach', 'NN', 'B-NP'], ['be', 'VB', 'O'], ['used', 'VBN', 'O'], ['assess', 'VB', 'O'], ['aim', 'VBP', 'O'], ['prevent', 'VB', 'O'], ['breakdown', 'NN', 'B-NP'], ['medical', 'JJ', 'B-NP'], ['infrastructure', 'NN', 'I-NP'], ['accounting', 'VBG', 'O'], ['realistic', 'JJ', 'B-NP'], ['social', 'JJ', 'I-NP'], ['network', 'NN', 'I-NP'], ['specific', 'VBP', 'O'], ['a', 'DT', 'B-NP'], ['local', 'JJ', 'I-NP'], ['population', 'NN', 'I-NP']]}","{'We sought to simulate lockdown scenarios using an Agent Based Modelling (ABM) strategy, which is a new modelling paradigm that seeks to simulate the actions and interactions of autonomous agents within an environment.': [{'noun_phrase': '', 'noun_connectors': ['sought', 'simulate']}, {'noun_phrase': ' lockdown scenarios', 'noun_connectors': ['using', 'Based']}, {'noun_phrase': ' strategy new modelling paradigm', 'noun_connectors': ['seeks', 'simulate']}, {'noun_phrase': ' actions', 'noun_connectors': ['and']}], 'The spread of infectious viral diseases occur over a connected social network.': [{'noun_phrase': ' spread infectious viral diseases', 'noun_connectors': ['occur']}], 'Specifically, the goal was to understand the effect of network topology and lockdown strategies on disease spreading dynamics.': [{'noun_phrase': '', 'noun_connectors': ['Specifically']}, {'noun_phrase': ' goal', 'noun_connectors': ['understand']}, {'noun_phrase': ' effect network topology', 'noun_connectors': ['and']}, {'noun_phrase': ' lockdown strategies disease', 'noun_connectors': ['spreading']}], 'To explore the effect of topology we assumed the social network over which the disease spreads to have small-world or scale-free properties characterized by a rewiring probability and degree distribution respectively.': [{'noun_phrase': '', 'noun_connectors': ['explore']}, {'noun_phrase': ' effect topology', 'noun_connectors': ['assumed']}, {'noun_phrase': ' network disease', 'noun_connectors': ['spreads']}, {'noun_phrase': ' world', 'noun_connectors': ['or']}, {'noun_phrase': ' scale free properties', 'noun_connectors': ['characterized', 'rewiring']}, {'noun_phrase': ' probability', 'noun_connectors': ['and']}], 'Lockdowns were simulated as intervention strategies that modified the spreading dynamics of infection over a given graph structure through changes in properties of agent interaction.': [{'noun_phrase': ' Lockdowns', 'noun_connectors': ['simulated']}, {'noun_phrase': ' intervention strategies', 'noun_connectors': ['modified', 'spreading']}, {'noun_phrase': ' dynamics infection', 'noun_connectors': ['given']}], 'Lockdown efficacy was assessed by the maximum number of infections recorded during a simulation run.': [{'noun_phrase': ' Lockdown efficacy', 'noun_connectors': ['assessed']}, {'noun_phrase': ' number infections', 'noun_connectors': ['recorded']}], 'Thereafter, lockdown efficacy was evaluated as a function of lockdown start times and duration.': [{'noun_phrase': '', 'noun_connectors': ['Thereafter']}, {'noun_phrase': ' lockdown efficacy', 'noun_connectors': ['evaluated']}, {'noun_phrase': ' function lockdown start times', 'noun_connectors': ['and']}], 'Thus, we propose that ABM approach can be used to assess various lockdown strategies that aim to prevent breakdown of medical infrastructure while accounting for realistic social network configurations specific to a local population.': [{'noun_phrase': '', 'noun_connectors': ['Thus', 'propose']}, {'noun_phrase': ' approach', 'noun_connectors': ['can', 'used', 'assess']}, {'noun_phrase': ' lockdown strategies', 'noun_connectors': ['aim', 'prevent']}, {'noun_phrase': ' breakdown medical infrastructure', 'noun_connectors': ['accounting']}]}"
"[{'author_name': 'Julia Alcoba-Florez', 'author_inst': 'Servicio de Microbiologia, Hospital Universitario N. S. de Candelaria'}, {'author_name': 'Helena Gil-Campesino', 'author_inst': 'Servicio de Microbiologia, Hospital Universitario N. S. de Candelaria'}, {'author_name': 'Diego Garcia-Martinez de Artola', 'author_inst': 'Servicio de Microbiologia, Hospital Universitario N. S. de Candelaria'}, {'author_name': 'Rafaela Gonzalez-Montelongo', 'author_inst': 'Genomics Division, Instituto Tecnologico y de Energias Renovables'}, {'author_name': 'Agustin Valenzuela-Fernandez', 'author_inst': 'Laboratorio de Inmunologia Celular y Viral, Unidad de Farmacologia, Facultad de Medicina & IUETSPC, Universidad de La Laguna'}, {'author_name': 'Laura Ciuffreda', 'author_inst': 'Research Unit, Hospital Universitario N. S. de Candelaria'}, {'author_name': 'Carlos Flores', 'author_inst': 'Research Unit, Hospital Universitario N.S. de Candelaria'}]",http://medrxiv.org/cgi/content/short/2020.06.23.20137455,Sensitivity of different RT-qPCR solutions for SARS-CoV-2 detection,"Objectives: The ongoing COVID-19 pandemic continues imposing a demand for diagnostic screening. In anticipation that the recurrence of outbreaks and the measures for lifting the lockdown worldwide may cause supply chain issues over the coming months, we assessed the sensitivity of a number of one-step retrotranscription and quantitative PCR (RT-qPCR) solutions to detect SARS-CoV-2. Methods: We evaluated six different RT-qPCR alternatives for SARS-CoV-2/COVID-19 diagnosis based on standard RNA extractions. That of best sensitivity was also assessed with direct nasopharyngeal swab viral transmission medium (VTM) heating, overcoming the RNA extraction step. Results: We found a wide variability in the sensitivity of RT-qPCR solutions that associated with a range of false negatives from as low as 2% (0.3-7.9%) to as much as 39.8% (30.2-50.2). Direct preheating of VTM combined with the best solution provided a sensitivity of 72.5% (62.5-81.0), in the range of some of the solutions based on standard RNA extractions. Conclusions: We evidenced sensitivity limitations of currently used RT-qPCR solutions. Our results will help to calibrate the impact of false negative diagnoses of COVID-19, and to detect and control new SARS-CoV-2 outbreaks and community transmissions.",2020-06-24,medrxiv,7,"[{'CANCER': [{'label': 'nasopharyngeal swab', 'alias': ['Nasopharyngeal swab (specimen)', 'Nasopharyngeal swab'], 'meaning': [None, 'C0444192', 1]}]}, {'CANCER': [{'label': 'nasopharyngeal swab', 'alias': ['Nasopharyngeal swab (physical object)', 'Nasopharyngeal swab'], 'meaning': [None, 'C3854334', 1]}]}]","{'Objectives: The ongoing COVID-19 pandemic continues imposing a demand for diagnostic screening.': [['pandemic', 'NN', 'B-NP'], ['continues', 'VBZ', 'O'], ['imposing', 'VBG', 'O'], ['a', 'DT', 'B-NP'], ['demand', 'NN', 'I-NP'], ['diagnostic', 'JJ', 'B-NP'], ['screening', 'NN', 'I-NP']], 'In anticipation that the recurrence of outbreaks and the measures for lifting the lockdown worldwide may cause supply chain issues over the coming months, we assessed the sensitivity of a number of one-step retrotranscription and quantitative PCR (RT-qPCR) solutions to detect SARS-CoV-2.': [['anticipation', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['recurrence', 'NN', 'I-NP'], ['lifting', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['lockdown', 'JJ', 'I-NP'], ['worldwide', 'NN', 'I-NP'], ['cause', 'VB', 'O'], ['supply', 'NN', 'B-NP'], ['chain', 'NN', 'B-NP'], ['assessed', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['sensitivity', 'NN', 'I-NP'], ['a', 'DT', 'B-NP'], ['number', 'NN', 'I-NP'], ['one-step', 'JJ', 'B-NP'], ['retrotranscription', 'NN', 'I-NP'], ['detect', 'VB', 'O']], 'Methods: We evaluated six different RT-qPCR alternatives for SARS-CoV-2/COVID-19 diagnosis based on standard RNA extractions.': [['evaluated', 'VBD', 'O'], ['diagnosis', 'NN', 'B-NP'], ['based', 'VBN', 'O']], 'That of best sensitivity was also assessed with direct nasopharyngeal swab viral transmission medium (VTM) heating, overcoming the RNA extraction step.': [['sensitivity', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['assessed', 'VBN', 'O'], ['direct', 'JJ', 'B-NP'], ['nasopharyngeal', 'JJ', 'I-NP'], ['swab', 'JJ', 'I-NP'], ['viral', 'JJ', 'I-NP'], ['transmission', 'NN', 'I-NP'], ['medium', 'NN', 'B-NP'], ['heating', 'NN', 'B-NP'], ['overcoming', 'VBG', 'O'], ['extraction', 'NN', 'B-NP'], ['step', 'NN', 'B-NP']], 'Results: We found a wide variability in the sensitivity of RT-qPCR solutions that associated with a range of false negatives from as low as 2% (0.3-7.9%) to as much as 39.8% (30.2-50.2).': [['found', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['wide', 'JJ', 'I-NP'], ['variability', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['sensitivity', 'NN', 'I-NP'], ['associated', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['range', 'NN', 'I-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'Direct preheating of VTM combined with the best solution provided a sensitivity of 72.5% (62.5-81.0), in the range of some of the solutions based on standard RNA extractions.': [['Direct', 'JJ', 'B-NP'], ['preheating', 'NN', 'I-NP'], ['combined', 'VBD', 'O'], ['solution', 'NN', 'B-NP'], ['provided', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['sensitivity', 'NN', 'I-NP'], ['%', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['range', 'NN', 'I-NP'], ['based', 'VBN', 'O']], 'Conclusions: We evidenced sensitivity limitations of currently used RT-qPCR solutions.': [['evidenced', 'VBD', 'O'], ['used', 'VBN', 'O']], 'Our results will help to calibrate the impact of false negative diagnoses of COVID-19, and to detect and control new SARS-CoV-2 outbreaks and community transmissions.': [['help', 'VB', 'O'], ['calibrate', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['impact', 'NN', 'I-NP'], ['detect', 'VB', 'O'], ['control', 'VB', 'O'], ['community', 'NN', 'B-NP']]}","{'Objectives: The ongoing COVID-19 pandemic continues imposing a demand for diagnostic screening.': [{'noun_phrase': ' Objectives ongoing COVID-19 pandemic', 'noun_connectors': ['continues', 'imposing']}], 'In anticipation that the recurrence of outbreaks and the measures for lifting the lockdown worldwide may cause supply chain issues over the coming months, we assessed the sensitivity of a number of one-step retrotranscription and quantitative PCR (RT-qPCR) solutions to detect SARS-CoV-2.': [{'noun_phrase': ' anticipation recurrence outbreaks', 'noun_connectors': ['and']}, {'noun_phrase': ' measures', 'noun_connectors': ['lifting']}, {'noun_phrase': ' lockdown', 'noun_connectors': ['worldwide', 'may', 'cause']}, {'noun_phrase': ' supply chain issues', 'noun_connectors': ['coming']}, {'noun_phrase': ' months', 'noun_connectors': ['assessed']}, {'noun_phrase': ' sensitivity number step retrotranscription', 'noun_connectors': ['and']}, {'noun_phrase': ' solutions', 'noun_connectors': ['detect']}], 'Methods: We evaluated six different RT-qPCR alternatives for SARS-CoV-2/COVID-19 diagnosis based on standard RNA extractions.': [{'noun_phrase': ' Methods', 'noun_connectors': ['evaluated']}, {'noun_phrase': ' alternatives SARS CoV-2 COVID-19 diagnosis', 'noun_connectors': ['based']}], 'That of best sensitivity was also assessed with direct nasopharyngeal swab viral transmission medium (VTM) heating, overcoming the RNA extraction step.': [{'noun_phrase': ' best sensitivity', 'noun_connectors': ['also', 'assessed']}, {'noun_phrase': ' transmission medium VTM heating', 'noun_connectors': ['overcoming']}], 'Results: We found a wide variability in the sensitivity of RT-qPCR solutions that associated with a range of false negatives from as low as 2% (0.3-7.9%) to as much as 39.8% (30.2-50.2).': [{'noun_phrase': ' Results', 'noun_connectors': ['found']}, {'noun_phrase': ' variability sensitivity RT qPCR solutions', 'noun_connectors': ['associated']}, {'noun_phrase': ' range false negatives', 'noun_connectors': ['as']}, {'noun_phrase': ' % %', 'noun_connectors': ['as']}], 'Direct preheating of VTM combined with the best solution provided a sensitivity of 72.5% (62.5-81.0), in the range of some of the solutions based on standard RNA extractions.': [{'noun_phrase': ' Direct preheating VTM', 'noun_connectors': ['combined']}, {'noun_phrase': ' solution', 'noun_connectors': ['provided']}, {'noun_phrase': ' sensitivity % range solutions', 'noun_connectors': ['based']}], 'Conclusions: We evidenced sensitivity limitations of currently used RT-qPCR solutions.': [{'noun_phrase': ' Conclusions', 'noun_connectors': ['evidenced']}, {'noun_phrase': ' sensitivity limitations', 'noun_connectors': ['currently', 'used']}], 'Our results will help to calibrate the impact of false negative diagnoses of COVID-19, and to detect and control new SARS-CoV-2 outbreaks and community transmissions.': [{'noun_phrase': ' results', 'noun_connectors': ['will', 'help', 'calibrate']}, {'noun_phrase': ' impact false negative diagnoses COVID-19', 'noun_connectors': ['and', 'detect', 'and', 'control']}, {'noun_phrase': ' CoV-2 outbreaks', 'noun_connectors': ['and']}]}"
"[{'author_name': 'Aurelio Luis Wanguemert Perez', 'author_inst': 'Pneumology Service, San Juan de Dios Hospital, Santa Cruz de Tenerife, Spain'}, {'author_name': 'Juan Marco Figueira Goncalvez', 'author_inst': 'Pneumology and Thoracic Surgery Service, University Hospital Nuestra Senora de Candelaria, Santa Cruz de Tenerife, Spain'}, {'author_name': 'Jose Maria Hernandez Perez', 'author_inst': 'Pneumology and Thoracic Surgery Service, University Hospital Nuestra Senora de Candelaria, Santa Cruz de Tenerife, Spain'}, {'author_name': 'Yolanda Ramallo Farina', 'author_inst': 'Foundation of the Canary Islands Health Research Institute (FIISC), Santa Cruz de Tenerife, Spain. Health Services Research on Chronic Patients Network (REDISSE'}, {'author_name': 'Jose Carlos Del Castillo Rodriguez', 'author_inst': 'Family and Community Medicine, San Juan de Dios Hospital, Santa Cruz de Tenerife, Spain'}]",http://medrxiv.org/cgi/content/short/2020.06.22.20134270,A link between inflammatory biomarkers and lung ultrasound observations in patients with SARS-CoV-2 infection,"ABSTRACT: Lung ultrasound (LUS) has shown to correlate well with the findings obtained by chest computed tomography (CT) in acute-phase COVID-19. Although there is a significant correlation between blood biomarkers and CT radiological findings, a potential correlation between biochemical parameters and LUS images is still unknown. Our purpose was to evaluate a potential association between lung lesions visualised by LUS and blood biomarkers as well as the ability to predict mortality from two different lung ultrasound scoring systems (LUSS). We performed a retrospective observational study on 45 patients aged >70 years with SARS-CoV-2 infection who required hospitalisation. LUS was carried out at admission and on day 7, when the clinical course was favourable or earlier in case of worsening. Disease severity was scored by means of LUSS in 8 (LUSS8) and in 12 (LUSS12) quadrants. LUS and blood draw for inflammatory marker analysis were performed at the same time. The correlation between biochemical parameters and either LUSS score was significant for ferritin levels. It was 0.486 (p=0.001) for LUSS8 and 0.458 (p=0.002) for LUSS12. Using a threshold score of 15 with LUSS12 predicted mortality in 86.7% of cases (ORcrude 31, CI 95% 4.79-200.51). Applying a threshold of 10 with LUSS8 predicted mortality in 88.9% (ORcrude 69.75, CI 95% 6.90-705.20). There is a correlation between ferritin levels and LUSS. The prognostic capacity of LUSS12 does not surpass that of LUSS8.",2020-06-23,medrxiv,5,"[{'ORGANISM_SUBSTANCE': [{'label': 'blood', 'alias': ['peripheral blood', 'peripheral blood', 'Blood - peripheral', 'Peripheral blood', 'Peripheral blood', 'Peripheral Blood', 'Peripheral Blood', 'Peripheral Blood', 'Peripheral blood, NOS', 'blood peripheral', 'Blood', 'Blood', 'Blood', 'blood', 'BLOOD', 'Whole Blood', 'Peripheral blood (substance)', 'Reticuloendothelial System, Blood'], 'meaning': ['A tissue with red blood cells, white blood cells, platelets, and other substances suspended in fluid called plasma. Blood takes oxygen and nutrients to the tissues, and carries away wastes.', 'C0229664', 1]}]}, {'ORGANISM_SUBSTANCE': [{'label': 'blood', 'alias': ['Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'Blood', 'blood', 'blood', 'blood', 'BLOOD', 'Blood, NOS', 'Blood (substance)', 'Bld', 'Sanguis', 'Portion of blood', 'Haema'], 'meaning': ['The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.', 'C0005767', 1]}]}, {'CANCER': [{'label': 'lung lesions', 'alias': ['lesion of lung', 'lesion lungs', 'lesion lung', 'lesions lungs', 'lesions lung', 'lung lesion', 'Lesion of lung (finding)'], 'meaning': [None, 'C0577916', 0.9999998807907104]}]}, {'CANCER': [{'label': 'lung lesions', 'alias': ['Coin lesion of lung', 'coin lesion of lung', 'coin lung lesion', 'Coin lesion lung', 'Pulmonary Coin Lesion', 'Coin Lesions, Pulmonary', 'Lesions, Pulmonary Coin', 'Pulmonary Coin Lesions', 'pulmonary coin lesions', 'Coin Lesion, Pulmonary', 'Coin Lesion, Pulmonary', 'Lesion, Pulmonary Coin', 'Coin lesion of lung (finding)'], 'meaning': ['A lung lesion that appears as a round coin-shaped shadow in the chest radiographs.', 'C0009250', 0.7468380331993103]}]}, {'ORGAN': [{'label': 'lung', 'alias': ['Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'Lung', 'lung', 'lung', 'lung', 'lung', 'LUNG', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lungs', 'Lung, NOS', 'LUNGS', 'lungs', 'pulmonary', 'pulmonary', 'Lung structure', 'lung structure', 'lung structures', 'Pulmo', 'Pulmones', 'Set of lungs', 'Set of lungs', 'Lung structure (body structure)', 'Respiratory System, Lung', 'Pair of lungs', 'Lungs pair'], 'meaning': ['Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.', 'C0024109', 0.9999999403953552]}]}, {'ORGAN': [{'label': 'lung', 'alias': ['Structure of parenchyma of lung', 'LUNG', 'lung tissue', 'Lung Tissue', 'Lung tissue', 'lung tissues', 'lungs tissues', 'lungs tissue', 'tissue lung', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'Lung parenchyma', 'lung parenchyma', 'Lung Parenchyma', 'lungs parenchyma', 'Parenchyma of lung', 'Respiratory portion of lung', 'Respiratory portion of lung', 'Structure of parenchyma of lung (body structure)', 'Lung tiss'], 'meaning': ['Tissue consisting of an external serous coat, subserous areolar tissue and lung parenchyma. The parenchyma is made up of lobules wound together by connective tissue. A primary lobule consists of a terminal bronchiole, respiratory bronchioles, and alveolar ducts, which communicate with many alveoli, each alveolus being surrounded by a network of capillary blood vessels.', 'C0819757', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ferritin', 'alias': ['Ferritin measurement', 'Ferritin measurement', 'Ferritin Measurement', 'Ferritin', 'Ferritin', 'FERRITIN', 'Ferritin level', 'ferritin test', 'ferritin testing', 'ferritin tests', 'Ferritin measurement (procedure)', 'ferritin level test'], 'meaning': ['The determination of the amount of ferritin present in a sample.', 'C0373607', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ferritin', 'alias': ['Ferritin', 'Ferritin', 'Ferritin', 'Ferritin', 'Ferritin', 'Ferritin', 'Ferritin', 'Ferritin', 'Ferritin', 'Ferritin', 'Ferritin', 'Ferritin', 'ferritin', 'ferritin', 'ferritin', 'Ferritins', 'Ferritins', 'Ferritins', 'ferritins', 'Ferritin (substance)', 'Ferritins [Chemical/Ingredient]'], 'meaning': ['Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types.', 'C0015879', 1]}]}]","{'ABSTRACT: Lung ultrasound (LUS) has shown to correlate well with the findings obtained by chest computed tomography (CT) in acute-phase COVID-19.': [['ABSTRACT', 'NN', 'B-NP'], ['ultrasound', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['shown', 'VBN', 'O'], ['correlate', 'VB', 'O'], ['obtained', 'VBN', 'O'], ['chest', 'NN', 'B-NP'], ['computed', 'VBN', 'O'], ['tomography', 'NN', 'B-NP']], 'Although there is a significant correlation between blood biomarkers and CT radiological findings, a potential correlation between biochemical parameters and LUS images is still unknown.': [['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['significant', 'JJ', 'I-NP'], ['correlation', 'NN', 'I-NP'], ['blood', 'NN', 'B-NP'], ['a', 'DT', 'B-NP'], ['potential', 'JJ', 'I-NP'], ['correlation', 'NN', 'I-NP'], ['is', 'VBZ', 'O']], 'Our purpose was to evaluate a potential association between lung lesions visualised by LUS and blood biomarkers as well as the ability to predict mortality from two different lung ultrasound scoring systems (LUSS).': [['purpose', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['evaluate', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['potential', 'JJ', 'I-NP'], ['association', 'NN', 'I-NP'], ['lung', 'NN', 'B-NP'], ['visualised', 'VBN', 'O'], ['blood', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['ability', 'NN', 'I-NP'], ['predict', 'VB', 'O'], ['mortality', 'NN', 'B-NP'], ['different', 'JJ', 'B-NP'], ['lung', 'NN', 'I-NP'], ['scoring', 'VBG', 'O']], 'We performed a retrospective observational study on 45 patients aged >70 years with SARS-CoV-2 infection who required hospitalisation.': [['performed', 'VBD', 'O'], ['a', 'DT', 'B-NP'], ['retrospective', 'JJ', 'I-NP'], ['observational', 'NN', 'I-NP'], ['study', 'NN', 'B-NP'], ['aged', 'VBN', 'O'], ['infection', 'NN', 'B-NP'], ['required', 'VBD', 'O'], ['hospitalisation', 'NN', 'B-NP']], 'LUS was carried out at admission and on day 7, when the clinical course was favourable or earlier in case of worsening.': [['was', 'VBD', 'O'], ['carried', 'VBN', 'O'], ['admission', 'NN', 'B-NP'], ['day', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['clinical', 'JJ', 'I-NP'], ['course', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['case', 'NN', 'B-NP'], ['worsening', 'NN', 'B-NP']], 'Disease severity was scored by means of LUSS in 8 (LUSS8) and in 12 (LUSS12) quadrants.': [['severity', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['scored', 'VBN', 'O']], 'LUS and blood draw for inflammatory marker analysis were performed at the same time.': [['blood', 'NN', 'B-NP'], ['draw', 'NN', 'B-NP'], ['inflammatory', 'JJ', 'B-NP'], ['marker', 'NN', 'I-NP'], ['analysis', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['performed', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['same', 'JJ', 'I-NP'], ['time', 'NN', 'I-NP']], 'The correlation between biochemical parameters and either LUSS score was significant for ferritin levels.': [['The', 'DT', 'B-NP'], ['correlation', 'NN', 'I-NP'], ['score', 'NN', 'B-NP'], ['was', 'VBD', 'O'], ['ferritin', 'NN', 'B-NP']], 'It was 0.486 (p=0.001) for LUSS8 and 0.458 (p=0.002) for LUSS12.': [['was', 'VBD', 'O'], ['p=0.001', 'NN', 'B-NP'], ['p=0.002', 'NN', 'B-NP']], 'Using a threshold score of 15 with LUSS12 predicted mortality in 86.7% of cases (ORcrude 31, CI 95% 4.79-200.51).': [['Using', 'VBG', 'O'], ['a', 'DT', 'B-NP'], ['threshold', 'JJ', 'I-NP'], ['score', 'NN', 'I-NP'], ['predicted', 'VBD', 'O'], ['mortality', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'Applying a threshold of 10 with LUSS8 predicted mortality in 88.9% (ORcrude 69.75, CI 95% 6.90-705.20).': [['Applying', 'VBG', 'O'], ['a', 'DT', 'B-NP'], ['threshold', 'NN', 'I-NP'], ['predicted', 'VBD', 'O'], ['mortality', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP']], 'There is a correlation between ferritin levels and LUSS.': [['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['correlation', 'NN', 'I-NP'], ['ferritin', 'NN', 'B-NP']], 'The prognostic capacity of LUSS12 does not surpass that of LUSS8.': [['The', 'DT', 'B-NP'], ['prognostic', 'JJ', 'I-NP'], ['capacity', 'NN', 'I-NP'], ['does', 'VBZ', 'O'], ['surpass', 'VB', 'O']]}","{'ABSTRACT: Lung ultrasound (LUS) has shown to correlate well with the findings obtained by chest computed tomography (CT) in acute-phase COVID-19.': [{'noun_phrase': ' ABSTRACT Lung ultrasound LUS', 'noun_connectors': ['shown', 'correlate', 'well']}, {'noun_phrase': ' findings', 'noun_connectors': ['obtained']}, {'noun_phrase': ' chest', 'noun_connectors': ['computed']}], 'Although there is a significant correlation between blood biomarkers and CT radiological findings, a potential correlation between biochemical parameters and LUS images is still unknown.': [{'noun_phrase': ' significant correlation blood biomarkers', 'noun_connectors': ['and']}, {'noun_phrase': ' findings potential correlation biochemical parameters', 'noun_connectors': ['and']}], 'Our purpose was to evaluate a potential association between lung lesions visualised by LUS and blood biomarkers as well as the ability to predict mortality from two different lung ultrasound scoring systems (LUSS).': [{'noun_phrase': ' purpose', 'noun_connectors': ['evaluate']}, {'noun_phrase': ' association lung lesions', 'noun_connectors': ['visualised', 'and']}, {'noun_phrase': ' blood biomarkers', 'noun_connectors': ['as', 'well']}, {'noun_phrase': ' ability', 'noun_connectors': ['predict']}, {'noun_phrase': ' mortality different lung ultrasound', 'noun_connectors': ['scoring']}], 'We performed a retrospective observational study on 45 patients aged >70 years with SARS-CoV-2 infection who required hospitalisation.': [{'noun_phrase': '', 'noun_connectors': ['performed']}, {'noun_phrase': ' study patients aged years SARS CoV-2 infection', 'noun_connectors': ['required']}], 'LUS was carried out at admission and on day 7, when the clinical course was favourable or earlier in case of worsening.': [{'noun_phrase': ' LUS', 'noun_connectors': ['carried']}, {'noun_phrase': ' admission', 'noun_connectors': ['and']}, {'noun_phrase': ' day', 'noun_connectors': ['when']}, {'noun_phrase': ' course favourable', 'noun_connectors': ['or', 'earlier']}], 'Disease severity was scored by means of LUSS in 8 (LUSS8) and in 12 (LUSS12) quadrants.': [{'noun_phrase': ' Disease severity', 'noun_connectors': ['scored']}, {'noun_phrase': ' means LUSS LUSS8', 'noun_connectors': ['and']}], 'LUS and blood draw for inflammatory marker analysis were performed at the same time.': [{'noun_phrase': ' LUS', 'noun_connectors': ['and']}, {'noun_phrase': ' blood draw inflammatory marker analysis', 'noun_connectors': ['performed']}], 'The correlation between biochemical parameters and either LUSS score was significant for ferritin levels.': [{'noun_phrase': ' correlation biochemical parameters', 'noun_connectors': ['and', 'either']}], 'It was 0.486 (p=0.001) for LUSS8 and 0.458 (p=0.002) for LUSS12.': [], 'Using a threshold score of 15 with LUSS12 predicted mortality in 86.7% of cases (ORcrude 31, CI 95% 4.79-200.51).': [{'noun_phrase': '', 'noun_connectors': ['Using']}, {'noun_phrase': ' threshold score LUSS12', 'noun_connectors': ['predicted']}], 'Applying a threshold of 10 with LUSS8 predicted mortality in 88.9% (ORcrude 69.75, CI 95% 6.90-705.20).': [{'noun_phrase': '', 'noun_connectors': ['Applying']}, {'noun_phrase': ' threshold LUSS8', 'noun_connectors': ['predicted']}], 'There is a correlation between ferritin levels and LUSS.': [], 'The prognostic capacity of LUSS12 does not surpass that of LUSS8.': [{'noun_phrase': ' prognostic capacity LUSS12', 'noun_connectors': ['surpass']}]}"
"[{'author_name': 'Priyanka Bajaj', 'author_inst': 'Indian Institute of Science'}, {'author_name': 'Prakash Chandra Arya', 'author_inst': 'Indian Institute of Science'}]",http://biorxiv.org/cgi/content/short/2020.06.18.147074,Climatic-niche evolution of SARS CoV-2,"Adaptation of species to new environments is governed by natural selection that discriminates among genetic variations and favors survival of the fittest. Here, we propose climate plays an important role in the evolution of SARS CoV-2 and the spread of COVID-19 all over the world which was previously not known. To understand the climatic factors responsible for shaping the molecular determinants of the novel coronavirus, genotyping SARS CoV-2 across different latitudes and Koppen climate is imperative. It seems this virus follows inverse latitudinal biodiversity gradient due to its preference towards Koppen temperate (C) and cold climate (D). Our molecular phylogenetic analysis revealed division of 176 SARS CoV-2 strains into two variant groups, G1 and G2, well defined by four mutations. Initially, SARS CoV-2 was restricted to a humid-subtropical (Cfa) climate of south-east China, which soon spread all over the world having C climate. Genomic information superimposed on global Koppen climate map elucidates that the gradation humid-subtropical (Cfa) and marine-temperate (Cfb) to humid-continental (Dfa-Dfb) climate drives the evolution of G1 into G2 variant group. It seems an early infection in Europe and USA is due to the dominance of C climate. Russia and North America were infected through linkage of C to D climate and South America from C to A climate. Our study elucidates viruses are sensitive to climate and combined genomic and climatic studies provide crucial information about the pathogenesis and natural spreading pathways during a pandemic which will enable us to take pre-emptive precautionary measures in such outbreaks.",2020-06-23,biorxiv,2,"[{'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'Coronavirus', 'CORONAVIRUS', 'coronavirus', 'Coronaviruses', 'Coronaviruses', 'Coronaviruses', 'Coronavirus, NOS', 'coronaviruses'], 'meaning': ['A genus of the family CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.', 'C0206419', 1]}]}, {'ORGANISM': [{'label': 'coronavirus', 'alias': ['Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'Coronaviridae', 'coronaviridae', 'CORONAVIRUS', 'Family: Coronavirus group', 'Coronavirus group', 'CORONAVIRUS GROUP', 'Coronavirus group, NOS', 'Family Coronaviridae', 'Family Coronaviridae (organism)'], 'meaning': ['Spherical RNA viruses, in the order NIDOVIRALES, infecting a wide range of animals including humans. Transmission is by fecal-oral and respiratory routes. Mechanical transmission is also common. There are two genera: CORONAVIRUS and TOROVIRUS.', 'C0010076', 1]}]}, {'ORGANISM': [{'label': 'Cfa', 'alias': ['Mosquito cell fusing agent', 'cell fusing agent CFA flavivirus', 'CFA', 'CFA virus', 'cell fusing agent virus (CFAV)'], 'meaning': [None, 'C1003714', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'Cfb', 'alias': ['Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'Clofibrate', 'clofibrate', 'clofibrate', 'clofibrate', 'clofibrate', 'clofibrate', 'clofibrate', 'CLOFIBRATE', 'CLOFIBRATE', 'CLOFIBRATE', 'CLOFIBRATE', 'clofibrates', 'Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, ethyl ester', 'Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, ethyl ester', 'Ethyl Chlorophenoxyisobutyrate', 'Ethyl Chlorophenoxyisobutyrate', 'Ethyl chlorophenoxyisobutyrate', 'Chlorophenoxyisobutyrate, Ethyl', 'Clofibratum', 'Ethyl clofibrate', 'Clofibrato', 'alpha-(p-Chlorophenoxy)isobutyric acid, ethyl ester', 'Ethyl 2-(P-chlorophenoxy)isobutyrate', 'ELPI', 'EPIB', 'alpha-p-Chlorophenoxyisobutyryl ethyl ester', '2-(p-Chlorophenoxy)-2-methylpropionic acid ethyl ester', 'Clofibric Acid, Ethyl Ester', 'Clofibric Acid, Ethyl Ester', 'Clofibrate (product)', 'Clofibrate (substance)', 'CFB', 'CFB', '2-(4-Chlorophenoxy)-2-methylpropanoic acid ethyl ester', '2-(4-Chlorophenoxy)-2-methylpropanoic acid ethyl ester', '2-(4-Chlorophenoxy)-2-methylpropanoic acid ethyl ester', 'Ethyl 2-(4-Chlorophenoxy)-2-methylpropanoate', 'Ethyl 2-(4-Chlorophenoxy)-2-methylpropanoate', 'Ethyl p-Chlorophenoxyisobyturate', 'Ethyl p-Chlorophenoxyisobyturate', 'Clofibrate [Chemical/Ingredient]'], 'meaning': ['A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)', 'C0009002', 0.9999999403953552]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'Cfb', 'alias': ['CFB gene', 'COMPLEMENT FACTOR B', 'complement factor B', 'FACTOR B', 'PROPERDIN FACTOR B', 'FACTOR B, PROPERDIN', 'GLYCINE-RICH BETA-GLYCOPROTEIN', 'C3 PROACTIVATOR', 'GBG', 'FB', 'CFB', 'CFB', 'BF', 'H2-Bf', 'C3 PROACCELERATOR'], 'meaning': [None, 'C1824728', 0.9999999403953552]}]}]","{'Adaptation of species to new environments is governed by natural selection that discriminates among genetic variations and favors survival of the fittest.': [['Adaptation', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['governed', 'VBN', 'O'], ['natural', 'JJ', 'B-NP'], ['selection', 'NN', 'I-NP'], ['discriminates', 'VBZ', 'O'], ['survival', 'NN', 'B-NP']], 'Here, we propose climate plays an important role in the evolution of SARS CoV-2 and the spread of COVID-19 all over the world which was previously not known.': [['propose', 'VBP', 'O'], ['an', 'DT', 'B-NP'], ['important', 'JJ', 'I-NP'], ['role', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['evolution', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['spread', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['world', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['known', 'VBN', 'O']], 'To understand the climatic factors responsible for shaping the molecular determinants of the novel coronavirus, genotyping SARS CoV-2 across different latitudes and Koppen climate is imperative.': [['understand', 'VB', 'O'], ['shaping', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['novel', 'JJ', 'I-NP'], ['coronavirus', 'NN', 'I-NP'], ['genotyping', 'VBG', 'O'], ['climate', 'NN', 'B-NP'], ['is', 'VBZ', 'O']], 'It seems this virus follows inverse latitudinal biodiversity gradient due to its preference towards Koppen temperate (C) and cold climate (D).': [['seems', 'VBZ', 'O'], ['this', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['follows', 'VBZ', 'O'], ['inverse', 'JJ', 'B-NP'], ['latitudinal', 'JJ', 'I-NP'], ['biodiversity', 'NN', 'I-NP'], ['gradient', 'NN', 'B-NP'], ['preference', 'NN', 'B-NP'], ['temperate', 'NN', 'B-NP'], ['cold', 'JJ', 'B-NP'], ['climate', 'NN', 'I-NP']], 'Our molecular phylogenetic analysis revealed division of 176 SARS CoV-2 strains into two variant groups, G1 and G2, well defined by four mutations.': [['molecular', 'JJ', 'B-NP'], ['phylogenetic', 'JJ', 'I-NP'], ['analysis', 'NN', 'I-NP'], ['revealed', 'VBD', 'O'], ['division', 'NN', 'B-NP'], ['defined', 'VBN', 'O']], 'Initially, SARS CoV-2 was restricted to a humid-subtropical (Cfa) climate of south-east China, which soon spread all over the world having C climate.': [['was', 'VBD', 'O'], ['restricted', 'VBN', 'O'], ['climate', 'NN', 'B-NP'], ['spread', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['world', 'NN', 'I-NP'], ['having', 'VBG', 'O'], ['climate', 'NN', 'B-NP']], 'Genomic information superimposed on global Koppen climate map elucidates that the gradation humid-subtropical (Cfa) and marine-temperate (Cfb) to humid-continental (Dfa-Dfb) climate drives the evolution of G1 into G2 variant group.': [['information', 'NN', 'B-NP'], ['superimposed', 'VBD', 'O'], ['climate', 'NN', 'B-NP'], ['map', 'NN', 'B-NP'], ['elucidates', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['gradation', 'NN', 'I-NP'], ['climate', 'NN', 'B-NP'], ['drives', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['evolution', 'NN', 'I-NP'], ['variant', 'JJ', 'B-NP'], ['group', 'NN', 'I-NP']], 'It seems an early infection in Europe and USA is due to the dominance of C climate.': [['seems', 'VBZ', 'O'], ['an', 'DT', 'B-NP'], ['early', 'JJ', 'I-NP'], ['infection', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['dominance', 'NN', 'I-NP'], ['climate', 'NN', 'B-NP']], 'Russia and North America were infected through linkage of C to D climate and South America from C to A climate.': [['were', 'VBD', 'O'], ['infected', 'VBN', 'O'], ['linkage', 'NN', 'B-NP'], ['climate', 'NN', 'B-NP'], ['A', 'DT', 'B-NP'], ['climate', 'NN', 'I-NP']], 'Our study elucidates viruses are sensitive to climate and combined genomic and climatic studies provide crucial information about the pathogenesis and natural spreading pathways during a pandemic which will enable us to take pre-emptive precautionary measures in such outbreaks.': [['study', 'NN', 'B-NP'], ['elucidates', 'VBZ', 'O'], ['are', 'VBP', 'O'], ['climate', 'VB', 'O'], ['combined', 'VBN', 'O'], ['provide', 'VBP', 'O'], ['crucial', 'JJ', 'B-NP'], ['information', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['pathogenesis', 'NN', 'I-NP'], ['natural', 'JJ', 'B-NP'], ['spreading', 'NN', 'I-NP'], ['enable', 'VB', 'O'], ['take', 'VB', 'O']]}","{'Adaptation of species to new environments is governed by natural selection that discriminates among genetic variations and favors survival of the fittest.': [{'noun_phrase': ' Adaptation species new environments', 'noun_connectors': ['governed']}, {'noun_phrase': ' selection discriminates genetic variations', 'noun_connectors': ['and', 'favors']}], 'Here, we propose climate plays an important role in the evolution of SARS CoV-2 and the spread of COVID-19 all over the world which was previously not known.': [{'noun_phrase': '', 'noun_connectors': ['Here', 'propose']}, {'noun_phrase': ' climate', 'noun_connectors': ['plays']}, {'noun_phrase': ' role evolution SARS CoV-2', 'noun_connectors': ['and']}, {'noun_phrase': ' spread COVID-19', 'noun_connectors': ['all']}], 'To understand the climatic factors responsible for shaping the molecular determinants of the novel coronavirus, genotyping SARS CoV-2 across different latitudes and Koppen climate is imperative.': [{'noun_phrase': '', 'noun_connectors': ['understand']}, {'noun_phrase': ' factors responsible', 'noun_connectors': ['shaping']}, {'noun_phrase': ' determinants novel coronavirus', 'noun_connectors': ['genotyping', 'CoV-2']}, {'noun_phrase': ' latitudes', 'noun_connectors': ['and']}], 'It seems this virus follows inverse latitudinal biodiversity gradient due to its preference towards Koppen temperate (C) and cold climate (D).': [{'noun_phrase': '', 'noun_connectors': ['seems']}, {'noun_phrase': ' virus', 'noun_connectors': ['follows']}, {'noun_phrase': ' biodiversity gradient preference Koppen temperate C', 'noun_connectors': ['and']}], 'Our molecular phylogenetic analysis revealed division of 176 SARS CoV-2 strains into two variant groups, G1 and G2, well defined by four mutations.': [{'noun_phrase': ' molecular phylogenetic analysis', 'noun_connectors': ['revealed']}, {'noun_phrase': ' division SARS CoV-2', 'noun_connectors': ['strains']}, {'noun_phrase': ' groups G1', 'noun_connectors': ['and', 'well', 'defined']}], 'Initially, SARS CoV-2 was restricted to a humid-subtropical (Cfa) climate of south-east China, which soon spread all over the world having C climate.': [{'noun_phrase': '', 'noun_connectors': ['Initially']}, {'noun_phrase': ' CoV-2', 'noun_connectors': ['restricted']}, {'noun_phrase': ' climate south east China', 'noun_connectors': ['soon', 'spread', 'all']}, {'noun_phrase': ' world', 'noun_connectors': ['having']}], 'Genomic information superimposed on global Koppen climate map elucidates that the gradation humid-subtropical (Cfa) and marine-temperate (Cfb) to humid-continental (Dfa-Dfb) climate drives the evolution of G1 into G2 variant group.': [{'noun_phrase': ' Genomic information', 'noun_connectors': ['superimposed']}, {'noun_phrase': ' climate map', 'noun_connectors': ['elucidates']}, {'noun_phrase': ' gradation humid subtropical Cfa', 'noun_connectors': ['and']}, {'noun_phrase': ' marine temperate Cfb humid continental Dfa Dfb climate', 'noun_connectors': ['drives']}], 'It seems an early infection in Europe and USA is due to the dominance of C climate.': [{'noun_phrase': '', 'noun_connectors': ['seems']}, {'noun_phrase': ' infection Europe', 'noun_connectors': ['and']}], 'Russia and North America were infected through linkage of C to D climate and South America from C to A climate.': [{'noun_phrase': ' Russia', 'noun_connectors': ['and', 'infected']}, {'noun_phrase': ' linkage C D climate', 'noun_connectors': ['and']}], 'Our study elucidates viruses are sensitive to climate and combined genomic and climatic studies provide crucial information about the pathogenesis and natural spreading pathways during a pandemic which will enable us to take pre-emptive precautionary measures in such outbreaks.': [{'noun_phrase': ' study', 'noun_connectors': ['elucidates']}, {'noun_phrase': ' viruses sensitive climate', 'noun_connectors': ['and', 'combined', 'and']}, {'noun_phrase': ' studies', 'noun_connectors': ['provide']}, {'noun_phrase': ' information pathogenesis', 'noun_connectors': ['and', 'spreading']}, {'noun_phrase': ' pathways pandemic', 'noun_connectors': ['will', 'enable', 'take']}]}"
"[{'author_name': 'Vijairam Selvaraj', 'author_inst': 'The Miriam Hospital'}, {'author_name': 'Kwame Dapaah-Afriyie', 'author_inst': 'The Miriam Hospital'}, {'author_name': 'Arkadiy Finn', 'author_inst': 'The Miriam Hospital'}, {'author_name': 'Timothy Flanigan', 'author_inst': 'Warren Alpert School of Medicine at Brown University'}]",http://medrxiv.org/cgi/content/short/2020.06.19.20109173,Short-Term Corticosteroids in SARS-CoV2 Patients: Hospitalists' Perspective,"Background: Dexamethasone, a synthetic glucocorticoid, has anti-inflammatory and immunosuppressive properties. There is a hyperinflammatory response involved in the clinical course of patients with pneumonia due to SARS-CoV2. To date, there has been no definite therapy for COVID-19. We reviewed the charts of SARS-CoV2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone. Methods: We describe a series of 21 patients who tested positive for SARS-CoV2 and were admitted to The Miriam Hospital in Providence and were treated with a short course of dexamethasone, either alone or in addition to current investigative therapies. Results: CRP levels decreased significantly following the start of dexamethasone from mean initial levels of 129.52 to 40.73 mg/L at time of discharge. 71% percent of the patients were discharged home with a mean length of stay of 7.8 days. None of the patients had escalation of care, leading to mechanical ventilation. Two patients were transferred to inpatient hospice facilities on account of persistent hypoxemia, in line with their documented goals of care. Conclusions: A short course of systemic corticosteroids among inpatients with SARS-CoV2 with hypoxic respiratory failure was well tolerated, and most patients had improved outcomes. This limited case series may not offer concrete evidence towards the benefit of corticosteroids in COVID-19. However, patients positive response to short-term corticosteroids demonstrates that they may help blunt the severity of inflammation and prevent a severe hyperinflammatory phase, in turn reducing the length of stay, ICU admissions, and healthcare costs.",2020-06-23,medrxiv,4,"[{'SIMPLE_CHEMICAL': [{'label': 'glucocorticoid', 'alias': ['Glucocorticoids', 'Glucocorticoids', 'Glucocorticoids', 'Glucocorticoids', 'Glucocorticoids', 'Glucocorticoids', 'Glucocorticoids', 'glucocorticoids', 'glucocorticoids', 'GLUCOCORTICOIDS', 'GLUCOCORTICOIDS', 'glucocorticoid', 'glucocorticoid', 'glucocorticoid', 'glucocorticoid', 'Glucocorticoid', 'Glucocorticoid', 'Glucocorticoid', 'Glucocorticoid', 'Glucocorticoid', 'Glucocorticoid', 'Glucocorticoid hormone', 'Glucocorticoid hormone', 'glucocorticoid hormone', 'glucocorticoid hormones', 'glucocorticoids hormone', 'Glucocorticoid hormone (substance)', 'Glucocorticoid preparation', 'Glucocorticoid preparation (product)', 'Glucocorticoid (substance)', '[HS051] GLUCOCORTICOIDS', 'Therapeutic Glucocorticoid', 'Glucocorticoids [Chemical/Ingredient]'], 'meaning': ['A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.', 'C0017710', 1]}]}, {'SIMPLE_CHEMICAL': [{'label': 'glucocorticoid', 'alias': ['glucocorticoid biosynthesis', 'glucocorticoid anabolism', 'glucocorticoid formation', 'glucocorticoid synthesis'], 'meaning': ['The chemical reactions and pathways resulting in the formation of glucocorticoids, hormonal C21 corticosteroids synthesized from cholesterol. [ISBN:0198506732]', 'C1157311', 0.8501470685005188]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'CRP', 'alias': ['Complete Response with Incomplete Platelet Recovery', 'CRp'], 'meaning': ['The disappearance of all signs of cancer in response to treatment, accompanied by incomplete platelet recovery (platelet count is less than 100,000/uL).', 'C3890735', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'CRP', 'alias': ['CRP gene', 'CRP Gene', 'PTX1', 'PTX1', 'C-REACTIVE PROTEIN, PENTRAXIN-RELATED', 'C-reactive protein, pentraxin-related', 'C-Reactive Protein, Pentraxin-Related Gene', 'CRP', 'CRP', 'CRP', 'pentraxin 1', 'PENTRAXIN 1, SHORT'], 'meaning': ['This gene plays a role in immune and inflammatory processes.', 'C1413716', 1]}]}, {'SIMPLE_CHEMICAL': [{'label': 'dexamethasone', 'alias': ['Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'DEXAMETHASONE', 'DEXAMETHASONE', 'DEXAMETHASONE', 'DEXAMETHASONE', 'DEXAMETHASONE', 'Hexadecadrol', 'Hexadecadrol', 'Hexadecadrol', 'Hexadecadrol', 'Hexadecadrol', 'Methylfluorprednisolone', 'Methylfluorprednisolone', 'Methylfluorprednisolone', 'Methylfluorprednisolone', 'Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-', 'Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-', 'Dexamethasone preparation', 'Dexamethasone preparation', 'DXM', 'DM', 'Dexametasona', '16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol', '16α-Methyl-9α-fluoro-1-dehydrocortisol', 'Dexamethasone preparation (product)', 'Dexamethasone (substance)', '(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione', '(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione', '9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione', '9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione', '16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione', '16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione', '1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone', '1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone', '1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone', '1-Dehydro-16α-methyl-9α-fluorohydrocortisone', '16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone', '16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone', 'Fluoro-9alpha Methyl-16alpha Prednisolone', 'Fluoro-9alpha Methyl-16alpha Prednisolone', '9alpha-Fluoro-16alpha-methylprednisolone', '9Alpha-fluoro-16alpha-methylprednisolone', '9Alpha-fluoro-16alpha-methylprednisolone', '9α-Fluoro-16α-methylprednisolone', '9alpha-Fluoro-16alpha- methylprednisolone', '9alpha-Fluoro-16alpha- methylprednisolone', '16Alpha-methyl-9alpha-fluoroprednisolone', '16Alpha-methyl-9alpha-fluoroprednisolone', 'Desamethasone', 'Desamethasone', 'Desamethasone', 'Dexamethasonum', 'Dexamethasonum', 'Dexamethasonum', 'Dexamethasone [Chemical/Ingredient]', 'dexamethasone (DMX)'], 'meaning': ['An anti-inflammatory 9-fluoro-glucocorticoid.', 'C0011777', 0.9999999403953552]}]}, {'SIMPLE_CHEMICAL': [{'label': 'corticosteroids', 'alias': ['Corticosteroid otologicals', 'Corticosteroids', 'CORTICOSTEROIDS'], 'meaning': [None, 'C3540725', 0.9999999403953552]}]}, {'SIMPLE_CHEMICAL': [{'label': 'corticosteroids', 'alias': ['Corticosteroid ophthalmologic and otologic preparations', 'Corticosteroids', 'CORTICOSTEROIDS'], 'meaning': [None, 'C3540726', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'inpatients', 'alias': ['inpatient', 'inpatient', 'Inpatient', 'Inpatient', 'Inpatient', 'Inpatient', 'Inpatient', 'Inpatients', 'inpatients', 'Hospital patients', 'HOSPITAL PATIENT', 'Inpatient (person)'], 'meaning': ['Persons admitted to health facilities which provide board and room, for the purpose of observation, care, diagnosis or treatment.', 'C0021562', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'inpatients', 'alias': ['Hospitalization', 'Hospitalization', 'Hospitalization', 'Hospitalization', 'Hospitalization', 'hospitalization', 'hospitalization', 'hospitalization', 'HOSPITALIZATION', 'Hospitalizations', 'hospitalisations', 'hospitalisation', 'hospitalizations', 'Inpatient care', 'inpatient care', 'inpatient care', 'inpatient treatment', 'inpatient treatment', 'Inpatient care (regime/therapy)'], 'meaning': ['The confinement of a patient in a hospital.', 'C0019993', 0.7835868000984192]}]}]","{'Background: Dexamethasone, a synthetic glucocorticoid, has anti-inflammatory and immunosuppressive properties.': [['Background', 'NN', 'B-NP'], ['Dexamethasone', 'NN', 'B-NP'], ['a', 'DT', 'B-NP'], ['synthetic', 'JJ', 'I-NP'], ['glucocorticoid', 'NN', 'I-NP'], ['has', 'VBZ', 'O'], ['anti-inflammatory', 'NN', 'B-NP']], 'There is a hyperinflammatory response involved in the clinical course of patients with pneumonia due to SARS-CoV2.': [['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['hyperinflammatory', 'JJ', 'I-NP'], ['response', 'NN', 'I-NP'], ['involved', 'VBN', 'O'], ['the', 'DT', 'B-NP'], ['clinical', 'JJ', 'I-NP'], ['course', 'NN', 'I-NP']], 'To date, there has been no definite therapy for COVID-19.': [['date', 'NN', 'B-NP'], ['has', 'VBZ', 'O'], ['been', 'VBN', 'O'], ['no', 'DT', 'B-NP'], ['definite', 'JJ', 'I-NP'], ['therapy', 'NN', 'I-NP']], 'We reviewed the charts of SARS-CoV2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.': [['reviewed', 'VBD', 'O'], ['pneumonia', 'NN', 'B-NP'], ['moderate', 'VB', 'O'], ['worsening', 'VBG', 'O'], ['hypoxemia', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['treated', 'VBN', 'O'], ['short-term', 'JJ', 'B-NP'], ['dexamethasone', 'NN', 'I-NP']], 'Methods: We describe a series of 21 patients who tested positive for SARS-CoV2 and were admitted to The Miriam Hospital in Providence and were treated with a short course of dexamethasone, either alone or in addition to current investigative therapies.': [['describe', 'VBP', 'O'], ['a', 'DT', 'B-NP'], ['series', 'NN', 'I-NP'], ['tested', 'VBD', 'O'], ['were', 'VBD', 'O'], ['admitted', 'VBN', 'O'], ['were', 'VBD', 'O'], ['treated', 'VBN', 'O'], ['a', 'DT', 'B-NP'], ['short', 'JJ', 'I-NP'], ['course', 'NN', 'I-NP'], ['dexamethasone', 'NN', 'B-NP'], ['addition', 'NN', 'B-NP']], 'Results: CRP levels decreased significantly following the start of dexamethasone from mean initial levels of 129.52 to 40.73 mg/L at time of discharge.': [['decreased', 'VBN', 'O'], ['following', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['start', 'NN', 'I-NP'], ['dexamethasone', 'NN', 'B-NP'], ['time', 'NN', 'B-NP'], ['discharge', 'NN', 'B-NP']], '71% percent of the patients were discharged home with a mean length of stay of 7.8 days.': [['%', 'NN', 'B-NP'], ['percent', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['discharged', 'VBN', 'O'], ['home', 'NN', 'B-NP'], ['a', 'DT', 'B-NP'], ['mean', 'JJ', 'I-NP'], ['length', 'NN', 'I-NP'], ['stay', 'NN', 'B-NP']], 'None of the patients had escalation of care, leading to mechanical ventilation.': [['None', 'NN', 'B-NP'], ['had', 'VBD', 'O'], ['escalation', 'NN', 'B-NP'], ['care', 'NN', 'B-NP'], ['leading', 'VBG', 'O'], ['mechanical', 'JJ', 'B-NP'], ['ventilation', 'NN', 'I-NP']], 'Two patients were transferred to inpatient hospice facilities on account of persistent hypoxemia, in line with their documented goals of care.': [['were', 'VBD', 'O'], ['transferred', 'VBN', 'O'], ['inpatient', 'VB', 'O'], ['hospice', 'NN', 'B-NP'], ['account', 'NN', 'B-NP'], ['persistent', 'JJ', 'B-NP'], ['hypoxemia', 'NN', 'I-NP'], ['line', 'NN', 'B-NP'], ['care', 'NN', 'B-NP']], 'Conclusions: A short course of systemic corticosteroids among inpatients with SARS-CoV2 with hypoxic respiratory failure was well tolerated, and most patients had improved outcomes.': [['A', 'DT', 'B-NP'], ['short', 'JJ', 'I-NP'], ['course', 'NN', 'I-NP'], ['hypoxic', 'JJ', 'B-NP'], ['respiratory', 'JJ', 'I-NP'], ['failure', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['tolerated', 'VBN', 'O'], ['had', 'VBD', 'O'], ['improved', 'VBN', 'O']], 'This limited case series may not offer concrete evidence towards the benefit of corticosteroids in COVID-19.': [['This', 'DT', 'B-NP'], ['limited', 'JJ', 'I-NP'], ['case', 'NN', 'I-NP'], ['series', 'NN', 'B-NP'], ['offer', 'VB', 'O'], ['concrete', 'JJ', 'B-NP'], ['evidence', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['benefit', 'NN', 'I-NP']], 'However, patients positive response to short-term corticosteroids demonstrates that they may help blunt the severity of inflammation and prevent a severe hyperinflammatory phase, in turn reducing the length of stay, ICU admissions, and healthcare costs.': [['positive', 'JJ', 'B-NP'], ['response', 'NN', 'I-NP'], ['demonstrates', 'VBZ', 'O'], ['help', 'VB', 'O'], ['blunt', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['severity', 'NN', 'I-NP'], ['inflammation', 'NN', 'B-NP'], ['prevent', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['severe', 'JJ', 'I-NP'], ['hyperinflammatory', 'NN', 'I-NP'], ['phase', 'NN', 'B-NP'], ['turn', 'NN', 'B-NP'], ['reducing', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['length', 'NN', 'I-NP'], ['stay', 'NN', 'B-NP'], ['healthcare', 'NN', 'B-NP']]}","{'Background: Dexamethasone, a synthetic glucocorticoid, has anti-inflammatory and immunosuppressive properties.': [{'noun_phrase': ' Background Dexamethasone synthetic glucocorticoid anti - inflammatory', 'noun_connectors': ['and']}], 'There is a hyperinflammatory response involved in the clinical course of patients with pneumonia due to SARS-CoV2.': [{'noun_phrase': ' hyperinflammatory response', 'noun_connectors': ['involved']}], 'To date, there has been no definite therapy for COVID-19.': [], 'We reviewed the charts of SARS-CoV2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.': [{'noun_phrase': '', 'noun_connectors': ['reviewed']}, {'noun_phrase': ' charts SARS CoV2 patients pneumonia', 'noun_connectors': ['and', 'severely']}, {'noun_phrase': ' CRP', 'noun_connectors': ['and', 'worsening']}, {'noun_phrase': ' hypoxemia', 'noun_connectors': ['treated']}], 'Methods: We describe a series of 21 patients who tested positive for SARS-CoV2 and were admitted to The Miriam Hospital in Providence and were treated with a short course of dexamethasone, either alone or in addition to current investigative therapies.': [{'noun_phrase': ' Methods', 'noun_connectors': ['describe']}, {'noun_phrase': ' series patients', 'noun_connectors': ['tested', 'and', 'admitted', 'and', 'treated']}, {'noun_phrase': ' course dexamethasone', 'noun_connectors': ['either', 'alone', 'or']}], 'Results: CRP levels decreased significantly following the start of dexamethasone from mean initial levels of 129.52 to 40.73 mg/L at time of discharge.': [{'noun_phrase': ' Results CRP levels', 'noun_connectors': ['decreased', 'significantly', 'following']}], '71% percent of the patients were discharged home with a mean length of stay of 7.8 days.': [{'noun_phrase': ' % percent patients', 'noun_connectors': ['discharged', 'home']}], 'None of the patients had escalation of care, leading to mechanical ventilation.': [{'noun_phrase': ' None patients escalation care', 'noun_connectors': ['leading']}], 'Two patients were transferred to inpatient hospice facilities on account of persistent hypoxemia, in line with their documented goals of care.': [{'noun_phrase': ' patients', 'noun_connectors': ['transferred']}, {'noun_phrase': ' hospice facilities account persistent hypoxemia line', 'noun_connectors': ['documented']}], 'Conclusions: A short course of systemic corticosteroids among inpatients with SARS-CoV2 with hypoxic respiratory failure was well tolerated, and most patients had improved outcomes.': [{'noun_phrase': ' Conclusions short course systemic corticosteroids inpatients SARS CoV2 hypoxic respiratory failure', 'noun_connectors': ['well', 'tolerated', 'and']}, {'noun_phrase': ' patients', 'noun_connectors': ['improved']}], 'This limited case series may not offer concrete evidence towards the benefit of corticosteroids in COVID-19.': [{'noun_phrase': ' limited case series', 'noun_connectors': ['may', 'offer']}], 'However, patients positive response to short-term corticosteroids demonstrates that they may help blunt the severity of inflammation and prevent a severe hyperinflammatory phase, in turn reducing the length of stay, ICU admissions, and healthcare costs.': [{'noun_phrase': '', 'noun_connectors': ['However']}, {'noun_phrase': ' patients positive response short term corticosteroids', 'noun_connectors': ['demonstrates', 'may', 'help', 'blunt']}, {'noun_phrase': ' severity inflammation', 'noun_connectors': ['and', 'prevent']}, {'noun_phrase': ' hyperinflammatory phase turn', 'noun_connectors': ['reducing']}, {'noun_phrase': ' length stay ICU admissions', 'noun_connectors': ['and']}]}"
"[{'author_name': 'Carlos J. Camacho', 'author_inst': 'University of Pittsburgh'}, {'author_name': 'Kristina A. Paris', 'author_inst': 'University ofPittsburgh'}, {'author_name': 'Ulises Santiago', 'author_inst': 'University of Pittsburgh'}]",http://biorxiv.org/cgi/content/short/2020.06.16.155457,Loss of pH switch unique to SARS-CoV2 supports unfamiliar virus pathology,"Cell surface receptor engagement is a critical aspect of viral infection. This paper compares the dynamics of virus-receptor interactions for SARS-CoV (CoV1) and CoV2. At low (endosomal) pH, the binding free energy landscape of CoV1 and CoV2 interactions with the angiotensin-converting enzyme 2 (ACE2) receptor is almost the same. However, at neutral pH the landscape is different due to the loss of a pH-switch (His445Lys) in the receptor binding domain (RBD) of CoV2 relative to CoV1. Namely, CoV1 stabilizes a transition state above the bound state. In situations where small external strains are applied by, say, shear flow in the respiratory system, the off rate of the viral particle is enhanced. As a result, CoV1 virions are expected to detach from cell surfaces in time scales that are much faster than the time needed for other receptors to reach out and stabilize virus attachment. On the other hand, the loss of this pH-switch, which sequence alignments show is unique to CoV2, eliminates the transition state and allows the virus to stay bound to the ACE2 receptor for time scales compatible with the recruitment of additional ACE2 receptors diffusing in the cell membrane. This has important implications for viral infection and its pathology. CoV1 does not trigger high infectivity in the nasal area because it either rapidly drifts down the respiratory tract or is exhaled. By contrast, this novel mutation in CoV2 should not only retain the infection in the nasal cavity until ACE2-rich cells are sufficiently depleted, but also require fewer particles for infection. This mechanism explains observed longer incubation times, extended period of viral shedding, and higher rate of transmission. These considerations governing viral entry suggest that number of ACE2-rich cells in human nasal mucosa, which should be significantly smaller for children (and females relative to males), should also correlate with onset of viral load that could be a determinant of higher virus susceptibility. Critical implications for the development of new vaccines to combat current and future pandemics that, like SARS-CoV2, export evolutionarily successful strains via higher transmission rates by viral retention in nasal epithelium are also discussed.",2020-06-23,biorxiv,3,"[{'ORGANISM': [{'label': 'SARS-CoV', 'alias': ['SARS coronavirus', 'SARS coronavirus', 'SARS coronavirus', 'SARS coronavirus', 'Coronavirus, SARS', 'SARS Coronavirus', 'SARS Coronavirus', 'SARS CORONAVIRUS', 'coronavirus SARS', 'Severe acute respiratory syndrome-related coronavirus (organism)', 'HCoV-SARS', 'Severe Acute Respiratory Syndrome Virus', 'SARS Virus', 'virus SARS', 'SARS virus', 'SARS virus', 'SARS virus', 'SARS-Associated Coronavirus', 'SARS Associated Coronavirus', 'Coronavirus, SARS-Associated', 'Urbani SARS-Associated Coronavirus', 'Urbani SARS Associated Coronavirus', 'Coronavirus, Urbani SARS-Associated', 'SARS-Associated Coronavirus, Urbani', 'SARS-CoV', 'SARS-CoV', 'SARS-CoV', 'sars-cov', 'SARS-Related Coronavirus', 'SARS Related Coronavirus', 'Coronavirus, SARS-Related', 'SARS', 'SARS', 'Severe acute respiratory syndrome coronavirus', 'Severe Acute Respiratory Syndrome Coronavirus', 'Severe acute respiratory syndrome (SARS) coronavirus', 'Severe acute respiratory syndrome-related coronavirus', 'Severe acute respiratory syndrome-related coronavirus'], 'meaning': ['A species of enveloped, spherical or pleomorphic, kidney-shaped or rod-shaped viruses in the Coronaviridae family and Coronavirus genus. The genome is composed of linear, single-stranded, positive-sense RNA. SARS coronaviruses are found in humans and cause severe acute respiratory syndrome (SARS). SARS coronaviruses are transmitted via direct person-to-person contact with infected secretions or excretions, and aerosols of respiratory droplets.', 'C1175743', 1]}]}, {'ORGANISM': [{'label': 'SARS-CoV', 'alias': ['Severe Acute Respiratory Syndrome', 'Severe Acute Respiratory Syndrome', 'Severe Acute Respiratory Syndrome', 'Severe Acute Respiratory Syndrome', 'Severe Acute Respiratory Syndrome', 'Severe acute respiratory syndrome', 'severe acute respiratory syndrome', 'Respiratory Syndrome, Acute, Severe', 'Respiratory Syndrome, Acute, Severe', 'Respiratory Syndrome, Severe Acute', 'Respiratory Syndrome, Severe Acute', 'Coronavirus Infections', 'SARS-associated coronavirus', 'SARS', 'SARS', 'SARS', 'SARS', 'SARS', 'SARS', 'SARS', 'SARS', 'Severe acute respiratory syndrome (disorder)', 'SARS-CoV infection', 'SARS (Severe Acute Respiratory Syndrome)', 'SARS (Severe Acute Respiratory Syndrome)', 'severe acute respiratory syndrome (SARS)', 'Severe Acute Respiratory Syndrome [Disease/Finding]'], 'meaning': ['A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.', 'C1175175', 0.8561109900474548]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'CoV1', 'alias': ['SLC43A1 protein, human', 'Prostate Cancer Overexpressed Gene 1 Protein', 'Large Neutral Amino Acids Transporter Small Subunit 3', 'POV1', 'Solute Carrier Family 43 Member 1', 'Prostate Cancer Overexpressed Protein 1', 'L-Type Amino Acid Transporter 3', 'LAT3', 'SLC43A1', 'solute carrier family 43, member 1 protein, human', 'PB39 protein, human', 'POV1 protein, human', 'L-type amino acid transporter 3, human'], 'meaning': ['Large neutral amino acids transporter small subunit 3 (559 aa, ~61 kDa) is encoded by the human SLC43A1 gene. This protein is involved in the high affinity transport of large neutral amino acids with a preference for those with branched side chains.', 'C0758888', 0.7171934843063354]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'CoV1', 'alias': ['SLC43A1 gene', 'SLC43A1 Gene', 'Solute Carrier Family 43 (Amino Acid System L Transporter), Member 1 Gene', 'POV1', 'solute carrier family 43 member 1', 'L-TYPE AMINO ACID TRANSPORTER 3', 'LAT3', 'PB39', 'R00504', 'SLC43A1', 'SLC43A1', 'SLC43A1', 'PROSTATE CANCER OVEREXPRESSED GENE 1', 'SOLUTE CARRIER FAMILY 43 (L-TYPE AMINO ACID TRANSPORTER), MEMBER 1'], 'meaning': ['This gene plays a role in transport and is frequently overexpressed in prostate cancers.', 'C1418772', 0.7171934843063354]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['ACE2 gene', 'ACE2 Gene', 'peptidyl-dipeptidase A', 'ACEH', 'Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene', 'ANGIOTENSIN I-CONVERTING ENZYME 2', 'angiotensin I converting enzyme 2', 'ACE2', 'ACE2', 'ACE2'], 'meaning': ['This gene plays a role in both proteolysis and vasodilation.', 'C1422064', 1]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'ACE2', 'alias': ['BACE2 gene', 'BACE2 Gene', 'BETA-SITE APP-CLEAVING ENZYME 2', 'beta-site APP-cleaving enzyme 2', 'Beta-Site APP-Cleaving Enzyme 2 Gene', 'ALP56', 'ALP56', 'CEAP1', 'DRAP', 'DRAP', 'ASPARTIC-LIKE PROTEASE, 56-KD', 'DOWN SYNDROME REGION ASPARTIC PROTEASE', 'BACE2', 'BACE2', 'BACE2', 'BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2'], 'meaning': ['This gene is involved in proteolytic processing.', 'C1412728', 0.8900668025016785]}]}, {'CELL': [{'label': 'cell', 'alias': ['""U"" lymphocyte', '""U"" cell', '""U"" cell'], 'meaning': [None, 'C0301863', 1]}]}, {'CELL': [{'label': 'cell', 'alias': ['Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'cells', 'cells', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'The Cell', 'Cell, NOS', 'cell', 'cell', 'cell', 'cell', 'THE CELL', 'the cell', '{Cells}', 'Cellular', 'Cell structure', 'Cellular structures', 'Cellular structure', 'Cell Type', 'Cell Types', 'Cellula', 'Cellula', 'Set of cells', 'Set of cells', 'Cells set', 'Cell structure (cell structure)', 'Normal cell', 'Normal Cell'], 'meaning': ['The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.', 'C0007634', 1]}]}, {'CELLULAR_COMPONENT': [{'label': 'cell membrane', 'alias': ['Plasma membrane', 'Plasma membrane', 'Plasma membrane', 'Plasma membrane', 'Membrane, Plasma', 'membrane plasma', 'Plasma Membrane', 'Plasma Membrane', 'plasma membrane', 'plasma membrane', 'plasma membrane', 'plasma membrane', 'plasma membrane', 'Membranes, Plasma', 'Plasma Membranes', 'membranes plasma', 'plasma membranes', 'Cell Membrane', 'Cell Membrane', 'membrane cell', 'cell membrane', 'cell membrane', 'cell membrane', 'cell membrane', 'Cell membrane', 'Cell membrane', 'Cell membrane', 'Cell membranes', 'Cell membranes', 'Membranes, Cell', 'Cell Membranes', 'Cell membrane, NOS', 'cell membranes', 'cells membrane', 'Membrane, Cell', 'Plasmalemma', 'Plasmalemma', 'Plasmalemma', 'Plasmalemma', 'Plasmalemma', 'plasmalemma', 'plasmalemma', 'plasmalemma', 'Cytoplasmic Membrane', 'cytoplasmic membrane', 'cytoplasmic membrane', 'Cytoplasmic membrane', 'Cytoplasmic Membranes', 'Membranes, Cytoplasmic', 'Membrane, Cytoplasmic', 'plasma membrane lipid bilayer', 'Cell membrane (cell structure)', 'Cellular membrane', 'cellular membrane'], 'meaning': ['The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.', 'C0007603', 0.9999999403953552]}]}, {'CELLULAR_COMPONENT': [{'label': 'cell membrane', 'alias': ['Cellular Membrane', 'Cell Membrane'], 'meaning': ['Any of the lipid bilayer membranes within a cell.', 'C3161472', 0.9999999403953552]}]}, {'TISSUE': [{'label': 'nasal', 'alias': ['Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'Nose', 'NOSE', 'NOSE', 'nose', 'nose', 'nose', 'Noses', 'Nose, NOS', 'noses', 'Nasal', 'Nasal', 'Nasal', 'Nasal', 'Nasal', 'Nasal', 'nasal', 'nasal', 'nasal', 'NASAL', 'nasals', 'Naso-', 'Rhino-', 'Nasal structure', 'nasal structure', 'Nose (Nasal Passage)', 'Nasus', 'Nasal structure (body structure)', 'Nasal (qualifier value)'], 'meaning': ['A part of the upper respiratory tract. It contains the organ of SMELL. The term includes the external nose, the nasal cavity, and the PARANASAL SINUSES.', 'C0028429', 1]}]}, {'TISSUE': [{'label': 'nasal', 'alias': ['Nasal', 'Nasal', 'Nasal', 'Nasal', 'NASAL', 'NASAL', 'NASAL', 'NASAL', 'Nasal route', 'Nasal route', 'Intranasal Route of Administration', 'Nasal route (qualifier value)', 'Nasal use', 'nasal use', 'NasalRoute', 'NasalRoute', 'Nasal Route of Administration', 'Nasal Route of Administration'], 'meaning': ['Administration of a drug by the way of the nose. This often results in systemic action of the agent due to absorption through the nasal mucosa. The richly supplied vascular nature of the nasal mucosa coupled with its high drug permeation makes the nasal route of administration attractive for many drugs, including proteins and peptides.', 'C1522019', 1]}]}, {'IMMATERIAL_ANATOMICAL_ENTITY': [{'label': 'exhaled', 'alias': ['Expiration', 'Expiration', 'Expiration', 'Expiration', 'Expiration', 'Expiration', 'Expiration', 'Expiration', 'Expiration', 'expiration', 'expiration', 'expiration', 'Expiring', 'Expired', 'Breathing out', 'Exhaling', 'Exhaling', 'Exhaling', 'exhaling', 'exhaled', 'Expiratory', 'Expiratory', 'expiration (breathing)', 'Exhalation', 'Exhalation', 'exhalation', 'exhalation', 'exhalation', 'Exhalations', 'Expiration, Respiratory', 'Respiratory Expirations', 'Expirations, Respiratory', 'Respiratory Expiration', 'Exhaling (observable entity)', 'Expiration (observable entity)', 'expiration body function'], 'meaning': ['Expelling modified air from the lungs; breathing out.', 'C0231800', 1]}]}, {'IMMATERIAL_ANATOMICAL_ENTITY': [{'label': 'exhaled', 'alias': ['Exhalation rib dysfunction', 'Exhalation Rib Dysfunction', 'Depressed Rib', 'Exhalation rib dysfunction (finding)', 'Exhaled rib', 'Exhaled Rib', 'Inhalation rib restriction', 'Inhalation Rib Restriction', 'Caught in Exhalation', 'Exhalation Strain'], 'meaning': ['1. Somatic dysfunction usually characterized by a rib being held in a position of exhalation such that motion toward exhalation is more free and motion toward inhalation is restricted. Synonyms: inhalation rib restriction exhalation strain, depressed rib. 2. An anterior rib tender point in counterstrain. . Somatic dysfunction usually characterized by a rib being held in a position of exhalation such that motion toward exhalation is more free and motion toward inhalation is restricted; Synonyms: inhalation rib restriction, exhalation strain, depressed rib. 2. An anterior rib tender point in counterstrain.', 'C1562425', 0.868036150932312]}]}, {'CELL': [{'label': 'cells', 'alias': ['Cells [Chemical/Ingredient]', 'Cells'], 'meaning': [None, 'C3282337', 0.9999999403953552]}]}, {'CELL': [{'label': 'cells', 'alias': ['Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'Cells', 'cells', 'cells', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'Cell', 'The Cell', 'Cell, NOS', 'cell', 'cell', 'cell', 'cell', 'THE CELL', 'the cell', '{Cells}', 'Cellular', 'Cell structure', 'Cellular structures', 'Cellular structure', 'Cell Type', 'Cell Types', 'Cellula', 'Cellula', 'Set of cells', 'Set of cells', 'Cells set', 'Cell structure (cell structure)', 'Normal cell', 'Normal Cell'], 'meaning': ['The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.', 'C0007634', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'human nasal mucosa', 'alias': ['Structure of mucous membrane of nose', 'Nasal Mucosa', 'mucosa nasal', 'Nasal mucosa', 'Nasal mucosa', 'Nasal mucosa', 'Nasal mucosa', 'nasal mucosa', 'Mucosa, Nasal', 'nasal membrane', 'nasal membrane', 'membranes nasal', 'Mucous membrane of nose', 'Mucous membrane of nose', 'Mucous membrane of nose', 'Mucous membrane of nose', 'Mucous membrane of nose', 'Mucosa of nose', 'Mucosa of nose', 'Structure of mucous membrane of nose (body structure)', 'Tunica mucosa nasi', 'Schneiderian Membrane', 'Membranes, Schneiderian', 'Schneiderian Membranes', 'Membrane, Schneiderian'], 'meaning': ['The mucous lining of the NASAL CAVITY, including lining of the nostril (vestibule) and the OLFACTORY MUCOSA. Nasal mucosa consists of ciliated cells, GOBLET CELLS, brush cells, small granule cells, basal cells (STEM CELLS) and glands containing both mucous and serous cells.', 'C0027428', 0.85634446144104]}]}, {'ORGANISM': [{'label': 'children', 'alias': ['Child', 'Child', 'Child', 'Child', 'Child', 'Child', 'Child', 'Child', 'CHILD', 'CHILD', 'child', 'child', 'child', 'Children', 'Children', 'Children', 'Children', 'Child, NOS', 'children', 'children', 'children', 'Child Youth', '0-11 years old', 'Child (person)', 'Childhood age person', 'Childhood age person (person)', 'Children (0-21)', 'Child [Disease/Finding]'], 'meaning': ['A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.', 'C0008059', 1]}]}, {'ORGANISM': [{'label': 'children', 'alias': ['Offspring', 'Offspring', 'offspring', 'offspring', 'offsprings', 'Child of', 'of child', 'child of', 'Child', 'Children', 'CHILD', 'child', 'RoleClassChild', 'child (family member)', 'kid', 'kid', 'kids', 'Progeny', 'progeny', 'progeny', 'progeny', 'Child of (finding)', 'child find', 'Human, Child'], 'meaning': ['A human descendant (son or daughter) of any age.', 'C0680063', 1]}]}]","{'Cell surface receptor engagement is a critical aspect of viral infection.': [['surface', 'NN', 'B-NP'], ['receptor', 'NN', 'B-NP'], ['engagement', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['critical', 'JJ', 'I-NP'], ['aspect', 'NN', 'I-NP'], ['viral', 'JJ', 'B-NP'], ['infection', 'NN', 'I-NP']], 'This paper compares the dynamics of virus-receptor interactions for SARS-CoV (CoV1) and CoV2.': [['This', 'DT', 'B-NP'], ['paper', 'NN', 'I-NP'], ['compares', 'VBZ', 'O'], ['virus-receptor', 'NN', 'B-NP']], 'At low (endosomal) pH, the binding free energy landscape of CoV1 and CoV2 interactions with the angiotensin-converting enzyme 2 (ACE2) receptor is almost the same.': [['pH', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['binding', 'NN', 'I-NP'], ['free', 'JJ', 'B-NP'], ['energy', 'NN', 'I-NP'], ['landscape', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['angiotensin-converting', 'JJ', 'I-NP'], ['enzyme', 'NN', 'I-NP'], ['receptor', 'NN', 'B-NP'], ['is', 'VBZ', 'O']], 'However, at neutral pH the landscape is different due to the loss of a pH-switch (His445Lys) in the receptor binding domain (RBD) of CoV2 relative to CoV1.': [['pH', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['landscape', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['loss', 'NN', 'I-NP'], ['a', 'DT', 'B-NP'], ['pH-switch', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['receptor', 'NN', 'I-NP'], ['binding', 'VBG', 'O'], ['domain', 'NN', 'B-NP'], ['relative', 'VBP', 'O']], 'Namely, CoV1 stabilizes a transition state above the bound state.': [['stabilizes', 'VBZ', 'O'], ['a', 'DT', 'B-NP'], ['transition', 'NN', 'I-NP'], ['state', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['bound', 'NN', 'I-NP'], ['state', 'NN', 'B-NP']], 'In situations where small external strains are applied by, say, shear flow in the respiratory system, the off rate of the viral particle is enhanced.': [['are', 'VBP', 'O'], ['applied', 'VBN', 'O'], ['shear', 'JJ', 'B-NP'], ['flow', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['respiratory', 'NN', 'I-NP'], ['system', 'NN', 'B-NP'], ['rate', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['viral', 'JJ', 'I-NP'], ['particle', 'NN', 'I-NP'], ['is', 'VBZ', 'O'], ['enhanced', 'VBN', 'O']], 'As a result, CoV1 virions are expected to detach from cell surfaces in time scales that are much faster than the time needed for other receptors to reach out and stabilize virus attachment.': [['a', 'DT', 'B-NP'], ['result', 'NN', 'I-NP'], ['are', 'VBP', 'O'], ['expected', 'VBN', 'O'], ['detach', 'VB', 'O'], ['cell', 'NN', 'B-NP'], ['time', 'NN', 'B-NP'], ['are', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['time', 'NN', 'I-NP'], ['needed', 'VBN', 'O'], ['reach', 'VB', 'O'], ['stabilize', 'VB', 'O'], ['virus', 'NN', 'B-NP'], ['attachment', 'NN', 'B-NP']], 'On the other hand, the loss of this pH-switch, which sequence alignments show is unique to CoV2, eliminates the transition state and allows the virus to stay bound to the ACE2 receptor for time scales compatible with the recruitment of additional ACE2 receptors diffusing in the cell membrane.': [['the', 'DT', 'B-NP'], ['other', 'JJ', 'I-NP'], ['hand', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['loss', 'NN', 'I-NP'], ['this', 'DT', 'B-NP'], ['pH-switch', 'NN', 'I-NP'], ['sequence', 'NN', 'B-NP'], ['show', 'VBP', 'O'], ['is', 'VBZ', 'O'], ['eliminates', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['transition', 'NN', 'I-NP'], ['state', 'NN', 'B-NP'], ['allows', 'VBZ', 'O'], ['the', 'DT', 'B-NP'], ['virus', 'NN', 'I-NP'], ['stay', 'VB', 'O'], ['receptor', 'NN', 'B-NP'], ['time', 'NN', 'B-NP'], ['the', 'DT', 'B-NP'], ['recruitment', 'NN', 'I-NP'], ['diffusing', 'VBG', 'O'], ['the', 'DT', 'B-NP'], ['cell', 'NN', 'I-NP'], ['membrane', 'NN', 'B-NP']], 'This has important implications for viral infection and its pathology.': [['has', 'VBZ', 'O'], ['viral', 'JJ', 'B-NP'], ['infection', 'NN', 'I-NP'], ['pathology', 'NN', 'B-NP']], 'CoV1 does not trigger high infectivity in the nasal area because it either rapidly drifts down the respiratory tract or is exhaled.': [['CoV1', 'NN', 'B-NP'], ['does', 'VBZ', 'O'], ['trigger', 'VB', 'O'], ['high', 'JJ', 'B-NP'], ['infectivity', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['nasal', 'JJ', 'I-NP'], ['area', 'NN', 'I-NP'], ['drifts', 'VBP', 'O'], ['the', 'DT', 'B-NP'], ['respiratory', 'NN', 'I-NP'], ['tract', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['exhaled', 'VBN', 'O']], 'By contrast, this novel mutation in CoV2 should not only retain the infection in the nasal cavity until ACE2-rich cells are sufficiently depleted, but also require fewer particles for infection.': [['contrast', 'NN', 'B-NP'], ['this', 'DT', 'B-NP'], ['novel', 'JJ', 'I-NP'], ['mutation', 'NN', 'I-NP'], ['retain', 'VB', 'O'], ['the', 'DT', 'B-NP'], ['infection', 'NN', 'I-NP'], ['the', 'DT', 'B-NP'], ['nasal', 'JJ', 'I-NP'], ['cavity', 'NN', 'I-NP'], ['are', 'VBP', 'O'], ['depleted', 'VBN', 'O'], ['require', 'VBP', 'O'], ['infection', 'NN', 'B-NP']], 'This mechanism explains observed longer incubation times, extended period of viral shedding, and higher rate of transmission.': [['This', 'DT', 'B-NP'], ['mechanism', 'NN', 'I-NP'], ['explains', 'VBZ', 'O'], ['observed', 'VBN', 'O'], ['incubation', 'NN', 'B-NP'], ['extended', 'VBD', 'O'], ['period', 'NN', 'B-NP'], ['viral', 'JJ', 'B-NP'], ['shedding', 'NN', 'I-NP'], ['rate', 'NN', 'B-NP'], ['transmission', 'NN', 'B-NP']], 'These considerations governing viral entry suggest that number of ACE2-rich cells in human nasal mucosa, which should be significantly smaller for children (and females relative to males), should also correlate with onset of viral load that could be a determinant of higher virus susceptibility.': [['governing', 'VBG', 'O'], ['viral', 'JJ', 'B-NP'], ['entry', 'NN', 'I-NP'], ['suggest', 'VBP', 'O'], ['number', 'NN', 'B-NP'], ['human', 'JJ', 'B-NP'], ['nasal', 'NN', 'I-NP'], ['mucosa', 'NN', 'B-NP'], ['be', 'VB', 'O'], ['females', 'VBZ', 'O'], ['correlate', 'VB', 'O'], ['onset', 'NN', 'B-NP'], ['viral', 'JJ', 'B-NP'], ['load', 'NN', 'I-NP'], ['be', 'VB', 'O'], ['a', 'DT', 'B-NP'], ['determinant', 'NN', 'I-NP'], ['virus', 'NN', 'B-NP'], ['susceptibility', 'NN', 'B-NP']], 'Critical implications for the development of new vaccines to combat current and future pandemics that, like SARS-CoV2, export evolutionarily successful strains via higher transmission rates by viral retention in nasal epithelium are also discussed.': [['the', 'DT', 'B-NP'], ['development', 'NN', 'I-NP'], ['combat', 'VB', 'O'], ['export', 'NN', 'B-NP'], ['transmission', 'NN', 'B-NP'], ['viral', 'JJ', 'B-NP'], ['retention', 'NN', 'I-NP'], ['nasal', 'JJ', 'B-NP'], ['epithelium', 'NN', 'I-NP'], ['are', 'VBP', 'O'], ['discussed', 'VBN', 'O']]}","{'Cell surface receptor engagement is a critical aspect of viral infection.': [], 'This paper compares the dynamics of virus-receptor interactions for SARS-CoV (CoV1) and CoV2.': [{'noun_phrase': ' paper', 'noun_connectors': ['compares']}, {'noun_phrase': ' dynamics virus receptor interactions SARS CoV CoV1', 'noun_connectors': ['and']}], 'At low (endosomal) pH, the binding free energy landscape of CoV1 and CoV2 interactions with the angiotensin-converting enzyme 2 (ACE2) receptor is almost the same.': [{'noun_phrase': ' low endosomal pH', 'noun_connectors': ['binding']}, {'noun_phrase': ' energy landscape CoV1', 'noun_connectors': ['and']}, {'noun_phrase': ' CoV2 interactions angiotensin', 'noun_connectors': ['converting']}], 'However, at neutral pH the landscape is different due to the loss of a pH-switch (His445Lys) in the receptor binding domain (RBD) of CoV2 relative to CoV1.': [{'noun_phrase': '', 'noun_connectors': ['However']}, {'noun_phrase': ' landscape different loss pH switch receptor', 'noun_connectors': ['binding']}], 'Namely, CoV1 stabilizes a transition state above the bound state.': [{'noun_phrase': '', 'noun_connectors': ['Namely', 'stabilizes']}, {'noun_phrase': ' transition state', 'noun_connectors': ['bound']}], 'In situations where small external strains are applied by, say, shear flow in the respiratory system, the off rate of the viral particle is enhanced.': [{'noun_phrase': ' situations', 'noun_connectors': ['where']}, {'noun_phrase': ' strains', 'noun_connectors': ['applied', 'shear']}], 'As a result, CoV1 virions are expected to detach from cell surfaces in time scales that are much faster than the time needed for other receptors to reach out and stabilize virus attachment.': [{'noun_phrase': ' result CoV1 virions', 'noun_connectors': ['expected', 'detach']}, {'noun_phrase': ' cell surfaces time scales', 'noun_connectors': ['much']}, {'noun_phrase': ' time', 'noun_connectors': ['needed']}, {'noun_phrase': ' receptors', 'noun_connectors': ['reach', 'and', 'stabilize']}], 'On the other hand, the loss of this pH-switch, which sequence alignments show is unique to CoV2, eliminates the transition state and allows the virus to stay bound to the ACE2 receptor for time scales compatible with the recruitment of additional ACE2 receptors diffusing in the cell membrane.': [{'noun_phrase': ' other hand loss pH', 'noun_connectors': ['switch']}, {'noun_phrase': ' sequence alignments', 'noun_connectors': ['show', 'eliminates']}, {'noun_phrase': ' transition state', 'noun_connectors': ['and', 'allows']}, {'noun_phrase': ' virus', 'noun_connectors': ['stay', 'bound']}, {'noun_phrase': ' receptor time scales compatible recruitment additional ACE2 receptors', 'noun_connectors': ['diffusing']}], 'This has important implications for viral infection and its pathology.': [{'noun_phrase': ' important implications viral infection', 'noun_connectors': ['and']}], 'CoV1 does not trigger high infectivity in the nasal area because it either rapidly drifts down the respiratory tract or is exhaled.': [{'noun_phrase': ' CoV1', 'noun_connectors': ['trigger']}, {'noun_phrase': ' infectivity nasal area', 'noun_connectors': ['either', 'rapidly', 'drifts']}], 'By contrast, this novel mutation in CoV2 should not only retain the infection in the nasal cavity until ACE2-rich cells are sufficiently depleted, but also require fewer particles for infection.': [{'noun_phrase': ' contrast novel mutation CoV2', 'noun_connectors': ['should', 'only', 'retain']}, {'noun_phrase': ' infection nasal cavity ACE2-rich cells', 'noun_connectors': ['sufficiently', 'depleted', 'but', 'also', 'require']}], 'This mechanism explains observed longer incubation times, extended period of viral shedding, and higher rate of transmission.': [{'noun_phrase': ' mechanism', 'noun_connectors': ['explains', 'observed']}, {'noun_phrase': ' incubation times extended period viral shedding', 'noun_connectors': ['and']}], 'These considerations governing viral entry suggest that number of ACE2-rich cells in human nasal mucosa, which should be significantly smaller for children (and females relative to males), should also correlate with onset of viral load that could be a determinant of higher virus susceptibility.': [{'noun_phrase': ' considerations', 'noun_connectors': ['governing']}, {'noun_phrase': ' entry', 'noun_connectors': ['suggest']}, {'noun_phrase': ' number ACE2-rich cells human nasal mucosa', 'noun_connectors': ['should', 'significantly']}, {'noun_phrase': ' children', 'noun_connectors': ['and', 'females']}, {'noun_phrase': ' males', 'noun_connectors': ['should', 'also', 'correlate']}, {'noun_phrase': ' onset viral load', 'noun_connectors': ['could']}], 'Critical implications for the development of new vaccines to combat current and future pandemics that, like SARS-CoV2, export evolutionarily successful strains via higher transmission rates by viral retention in nasal epithelium are also discussed.': [{'noun_phrase': ' Critical implications development new vaccines', 'noun_connectors': ['combat', 'and']}, {'noun_phrase': ' pandemics SARS CoV2 export', 'noun_connectors': ['evolutionarily']}]}"
"[{'author_name': 'Zaneeta Dhesi', 'author_inst': 'University College London'}, {'author_name': 'Virve I Enne', 'author_inst': 'University College London'}, {'author_name': 'David Brealey', 'author_inst': 'University College London Hospitals NHS Foundation Trust'}, {'author_name': 'David M Livermore', 'author_inst': 'Norwich Medical School, University of East Anglia'}, {'author_name': 'Juliet High', 'author_inst': 'Norwich Clinical Trials Unit, University of East Anglia'}, {'author_name': 'Charlotte Russell', 'author_inst': 'Norwich Clinical Trials Unit, University of East Anglia'}, {'author_name': 'Antony Colles', 'author_inst': 'Norwich Clinical Trials Unit, University of East Anglia'}, {'author_name': 'Hala Kandil', 'author_inst': 'Watford General Hospital, West Hertfordshire NHS Trust'}, {'author_name': 'Damien Mack', 'author_inst': 'Royal Free NHS Foundation Trust'}, {'author_name': 'Daniel Martin', 'author_inst': 'Peninsula Medical School, University of Plymouth'}, {'author_name': 'Valerie Page', 'author_inst': 'Watford General Hospital, West Hertfordshire NHS Trust'}, {'author_name': 'Robert Parker', 'author_inst': 'Liverpool University Hospitals NHS Foundation Trust'}, {'author_name': 'Kerry Roulston', 'author_inst': 'Royal Free NHS Foundation Trust'}, {'author_name': 'Suveer Singh', 'author_inst': 'Chelsea and Westminster Hospital NHS Foundation Trust'}, {'author_name': 'Emmanuel Wey', 'author_inst': 'Royal Free NHS Foundation Trust'}, {'author_name': 'Ann Marie Swart', 'author_inst': 'Norwich Clinical Trials Unit, University of East Anglia'}, {'author_name': 'Susan Stirling', 'author_inst': 'University of East Anglia'}, {'author_name': 'Julie A Barber', 'author_inst': 'University College London'}, {'author_name': ""Justin O'Grady"", 'author_inst': 'Quadram Institute Bioscience, Norwich Research Park'}, {'author_name': 'Vanya A Gant', 'author_inst': 'University College London Hospitals NHS Foundation Trust'}]",http://medrxiv.org/cgi/content/short/2020.06.22.20131573,Organisms causing secondary pneumonias in COVID-19 patients at 5 UK ICUs as detected with the FilmArray test,"ABSTRACT Introduction. Several viral respiratory infections - notably influenza - are associated with secondary bacterial infection and additional pathology. The extent to which this applies for COVID-19 is unknown. Accordingly, we aimed to define the bacteria causing secondary pneumonias in COVID-19 ICU patients using the FilmArray Pneumonia Panel, and to determine this tests potential in COVID-19 management. Methods. COVID-19 ICU patients with clinically-suspected secondary infection at 5 UK hospitals were tested with the FilmArray at point of care. We collected patient demographic data and compared FilmArray results with routine culture. Results. We report results of 110 FilmArray tests on 94 patients (16 had 2 tests): 69 patients (73%) were male, the median age was 59 yrs; 92 were ventilated. Median hospital stay before testing was 14 days (range 1-38). Fifty-nine (54%) tests were positive, with 141 bacteria detected. Most were Enterobacterales (n=55, including Klebsiella spp. [n= 35]) or Staphylococcus aureus (n=13), as is typical of hospital and ventilator pneumonia. Community pathogens, including Haemophilus influenzae (n=8) and Streptococcus pneumoniae (n=1), were rarer. FilmArray detected one additional virus (Rhinovirus/Enterovirus) and no atypical bacteria. Fewer samples (28 % vs. 54%) were positive by routine culture, and fewer species were reported per sample; Klebsiella species remained the most prevalent pathogens. Conclusion. FilmArray had a higher diagnostic yield than culture for ICU COVID-19 patients with suspected secondary pneumonias. The bacteria found mostly were Enterobacterales, S. aureus and P. aeruginosa, as in typical HAP/VAP, but with Klebsiella spp. more prominent. We found almost no viral co-infection. Turnaround from sample to results is around 1h 15 min compared with the usual 72h for culture, giving prescribers earlier data to inform antimicrobial decisions.",2020-06-23,medrxiv,20,"[{'ORGANISM': [{'label': 'patients', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 0.9999999403953552]}]}, {'ORGANISM': [{'label': 'patients', 'alias': ['Mentally Ill Person', 'Person, Mentally Ill', 'Persons, Mentally Ill', 'Mental Patients', 'mental patients', 'mental patient', 'Mentally Ill', 'mentally ill', 'mentally ill', 'Mentally ill', 'Ill, Mentally'], 'meaning': ['Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.', 'C0025360', 0.8272134065628052]}]}, {'GENE_OR_GENE_PRODUCT': [{'label': 'UK', 'alias': ['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'kingdom united', 'united kingdom', 'UNITED KINGDOM', 'UNITED KINGDOM', 'GBR', 'GBR', 'GBR', 'UK', 'UK - United Kingdom of Great Britain and Northern Ireland', 'United Kingdom of Great Britain and Northern Ireland', 'United Kingdom of Great Britain and Northern Ireland', 'GB', 'GB', 'United Kingdom of Great Britain and Northern Ireland (geographic location)'], 'meaning': ['Country in Northeastern Europe including Great Britain and the northern one-sixth of Ireland, located between the North Sea and north Atlantic Ocean. The capital is London.', 'C0041700', 1]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Patients', 'Patients', 'Patients', 'Patients', 'patients', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'Patient', 'patient', 'patient', 'patient', 'patient', 'PATIENT', '^Patient', '*^patient', 'PT', 'Patient (person)', 'LAY USER/PATIENT'], 'meaning': ['Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.', 'C0030705', 1]}]}, {'ORGANISM': [{'label': 'patient', 'alias': ['Veterinary Patient', 'Patient'], 'meaning': ['A non-human animal that is a subject in a study.', 'C1705908', 1]}]}, {'ORGANISM': [{'label': 'Haemophilus influenzae', 'alias': ['Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'Haemophilus influenzae', 'haemophilus influenzae', 'HAEMOPHILUS INFLUENZAE', 'HAEMOPHILUS INFLUENZAE', 'Hemophilus influenzae', 'Hemophilus influenzae', 'hemophilus influenzae', ""Pfeiffer's bacillus"", ""Pfeiffer's bacillus"", ""Pfeiffer's bacillus"", 'H-Flu', 'H-flu', 'h influenzae', 'H. influenzae', 'h. influenzae', 'Influenza-bacillus', 'Bacterium influenzae', 'Coccobacillus pfeifferi', 'Haemophilus meningitidis', 'Mycobacterium influenzae', 'Haemophilus influenzae (organism)'], 'meaning': ['A species of HAEMOPHILUS found on the mucous membranes of humans and a variety of animals. The species is further divided into biotypes I through VIII.', 'C0018483', 0.9999998807907104]}]}, {'ORGANISM': [{'label': 'Haemophilus influenzae', 'alias': [], 'meaning': [None, 'C1440658', 0.9751763343811035]}]}, {'ORGANISM': [{'label': 'Streptococcus pneumoniae', 'alias': ['Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'Streptococcus pneumoniae', 'streptococcus pneumoniae', 'STREPTOCOCCUS PNEUMONIAE', 'STREPTOCOCCUS PNEUMONIAE', 'STREPTOCOCCUS PNEUMONIAE', 'Diplococcus pneumoniae', 'Diplococcus pneumoniae', 'Diplococcus pneumoniae', 'Diplococcus pneumoniae', 'Diplococcus pneumoniae', 'Diplococcus pneumoniae', 'Diplococcus pneumoniae', 'Diplococcus pneumoniae', 'diplococcus pneumoniae', 'Pneumococcus', 'Pneumococcus', 'Pneumococcus', 'Pneumococcus', 'Pneumococcus', 'Pneumococcus', 'pneumococcus', 'Pneumococcal', 'pneumococcal', 's. pneumoniae', 'S. pneumoniae', 'Streptococcus (Diplococcus) pneumoniae', 'Micrococcus pneumoniae', 'Streptococcus pneumoniae (organism)', 'streptococcus pneumoniae bacteria'], 'meaning': ['A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals.', 'C0038410', 1]}]}, {'ORGANISM': [{'label': 'Streptococcus pneumoniae', 'alias': [], 'meaning': [None, 'C1441245', 0.9814629554748535]}]}, {'CANCER': [{'label': 'Rhinovirus/Enterovirus', 'alias': ['Rhinovirus', 'Rhinovirus', 'Rhinovirus', 'Rhinovirus', 'rhinovirus', 'rhinovirus', 'rhinovirus', 'RHINOVIRUS', 'Rhinoviruses', 'Rhinoviruses', 'Rhinoviruses', 'Rhinoviruses', 'Rhinovirus, NOS', 'rhinoviruses', 'Common cold virus group, NOS', 'Rhinoviral'], 'meaning': ['A genus of PICORNAVIRIDAE inhabiting primarily the respiratory tract of mammalian hosts. It includes over 100 human serotypes associated with the COMMON COLD.', 'C0035473', 0.7214427590370178]}]}]","{'ABSTRACT Introduction.': [[None, None, None]], 'Several viral respiratory infections - notably influenza - are associated with secondary bacterial infection and additional pathology.': [['Several', 'JJ', 'B-NP'], ['viral', 'JJ', 'I-NP'], ['respiratory', 'NN', 'I-NP'], ['are', 'VBP', 'O'], ['associated', 'VBN', 'O'], ['secondary', 'JJ', 'B-NP'], ['bacterial', 'JJ', 'I-NP'], ['infection', 'NN', 'I-NP'], ['additional', 'JJ', 'B-NP'], ['pathology', 'NN', 'I-NP']], 'The extent to which this applies for COVID-19 is unknown.': [['The', 'DT', 'B-NP'], ['extent', 'NN', 'I-NP'], ['applies', 'VBZ', 'O'], ['is', 'VBZ', 'O']], 'Accordingly, we aimed to define the bacteria causing secondary pneumonias in COVID-19 ICU patients using the FilmArray Pneumonia Panel, and to determine this tests potential in COVID-19 management.': [['aimed', 'VBD', 'O'], ['define', 'VB', 'O'], ['causing', 'VBG', 'O'], ['secondary', 'JJ', 'B-NP'], ['pneumonias', 'NN', 'I-NP'], ['using', 'VBG', 'O'], ['determine', 'VB', 'O'], ['tests', 'VBZ', 'O'], ['management', 'NN', 'B-NP']], 'Methods.': [[None, None, None]], 'COVID-19 ICU patients with clinically-suspected secondary infection at 5 UK hospitals were tested with the FilmArray at point of care.': [['clinically-suspected', 'JJ', 'B-NP'], ['secondary', 'JJ', 'I-NP'], ['infection', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['tested', 'VBN', 'O'], ['point', 'NN', 'B-NP'], ['care', 'NN', 'B-NP']], 'We collected patient demographic data and compared FilmArray results with routine culture.': [['collected', 'VBD', 'O'], ['compared', 'VBN', 'O'], ['routine', 'JJ', 'B-NP'], ['culture', 'NN', 'I-NP']], 'Results.': [[None, None, None]], 'We report results of 110 FilmArray tests on 94 patients (16 had 2 tests): 69 patients (73%) were male, the median age was 59 yrs; 92 were ventilated.': [['report', 'VBP', 'O'], ['had', 'VBD', 'O'], ['%', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['the', 'DT', 'B-NP'], ['median', 'JJ', 'I-NP'], ['age', 'NN', 'I-NP'], ['was', 'VBD', 'O'], ['yrs', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['ventilated', 'VBN', 'O']], 'Median hospital stay before testing was 14 days (range 1-38).': [['Median', 'JJ', 'B-NP'], ['hospital', 'NN', 'I-NP'], ['stay', 'NN', 'B-NP'], ['testing', 'VBG', 'O'], ['was', 'VBD', 'O'], ['range', 'VB', 'O']], 'Fifty-nine (54%) tests were positive, with 141 bacteria detected.': [['%', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['detected', 'VBN', 'O']], 'Most were Enterobacterales (n=55, including Klebsiella spp.': [['were', 'VBD', 'O'], ['including', 'VBG', 'O'], ['spp', 'NN', 'B-NP']], '[n= 35]) or Staphylococcus aureus (n=13), as is typical of hospital and ventilator pneumonia.': [[']', 'NN', 'B-NP'], ['aureus', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['hospital', 'NN', 'B-NP'], ['ventilator', 'NN', 'B-NP'], ['pneumonia', 'NN', 'B-NP']], 'Community pathogens, including Haemophilus influenzae (n=8) and Streptococcus pneumoniae (n=1), were rarer.': [['including', 'VBG', 'O'], ['influenzae', 'NN', 'B-NP'], ['pneumoniae', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['rarer', 'NN', 'B-NP']], 'FilmArray detected one additional virus (Rhinovirus/Enterovirus) and no atypical bacteria.': [['detected', 'VBD', 'O'], ['additional', 'JJ', 'B-NP'], ['virus', 'NN', 'I-NP']], 'Fewer samples (28 % vs. 54%) were positive by routine culture, and fewer species were reported per sample; Klebsiella species remained the most prevalent pathogens.': [['%', 'NN', 'B-NP'], ['%', 'NN', 'B-NP'], ['were', 'VBD', 'O'], ['routine', 'JJ', 'B-NP'], ['culture', 'NN', 'I-NP'], ['were', 'VBD', 'O'], ['reported', 'VBN', 'O'], ['sample', 'NN', 'B-NP'], ['remained', 'VBD', 'O']], 'Conclusion.': [['Conclusion', 'NN', 'B-NP']], 'FilmArray had a higher diagnostic yield than culture for ICU COVID-19 patients with suspected secondary pneumonias.': [['had', 'VBD', 'O'], ['diagnostic', 'JJ', 'B-NP'], ['yield', 'NN', 'I-NP'], ['culture', 'NN', 'B-NP'], ['suspected', 'JJ', 'B-NP'], ['secondary', 'JJ', 'I-NP'], ['pneumonias', 'NN', 'I-NP']], 'The bacteria found mostly were Enterobacterales, S. aureus and P. aeruginosa, as in typical HAP/VAP, but with Klebsiella spp.': [['The', 'DT', 'B-NP'], ['bacteria', 'NN', 'I-NP'], ['found', 'VBD', 'O'], ['were', 'VBD', 'O'], ['aureus', 'NN', 'B-NP'], ['spp', 'NN', 'B-NP']], 'more prominent.': [[None, None, None]], 'We found almost no viral co-infection.': [['found', 'VBD', 'O'], ['no', 'DT', 'B-NP'], ['viral', 'JJ', 'I-NP'], ['co-infection', 'NN', 'I-NP']], 'Turnaround from sample to results is around 1h 15 min compared with the usual 72h for culture, giving prescribers earlier data to inform antimicrobial decisions.': [['Turnaround', 'NN', 'B-NP'], ['sample', 'NN', 'B-NP'], ['is', 'VBZ', 'O'], ['compared', 'VBN', 'O'], ['culture', 'NN', 'B-NP'], ['giving', 'VBG', 'O'], ['inform', 'VB', 'O']]}","{'ABSTRACT Introduction.': [], 'Several viral respiratory infections - notably influenza - are associated with secondary bacterial infection and additional pathology.': [{'noun_phrase': ' Several viral respiratory infections', 'noun_connectors': ['notably']}, {'noun_phrase': ' influenza', 'noun_connectors': ['associated']}, {'noun_phrase': ' infection', 'noun_connectors': ['and']}], 'The extent to which this applies for COVID-19 is unknown.': [{'noun_phrase': ' extent', 'noun_connectors': ['applies']}], 'Accordingly, we aimed to define the bacteria causing secondary pneumonias in COVID-19 ICU patients using the FilmArray Pneumonia Panel, and to determine this tests potential in COVID-19 management.': [{'noun_phrase': '', 'noun_connectors': ['Accordingly', 'aimed', 'define']}, {'noun_phrase': ' bacteria', 'noun_connectors': ['causing']}, {'noun_phrase': ' pneumonias COVID-19 ICU patients', 'noun_connectors': ['using', 'and', 'determine']}], 'Methods.': [], 'COVID-19 ICU patients with clinically-suspected secondary infection at 5 UK hospitals were tested with the FilmArray at point of care.': [{'noun_phrase': ' COVID-19 ICU', 'noun_connectors': ['patients', 'clinically', 'suspected']}, {'noun_phrase': ' infection UK hospitals', 'noun_connectors': ['tested']}], 'We collected patient demographic data and compared FilmArray results with routine culture.': [{'noun_phrase': '', 'noun_connectors': ['collected']}, {'noun_phrase': ' data', 'noun_connectors': ['and', 'compared']}], 'Results.': [], 'We report results of 110 FilmArray tests on 94 patients (16 had 2 tests): 69 patients (73%) were male, the median age was 59 yrs; 92 were ventilated.': [{'noun_phrase': '', 'noun_connectors': ['report']}], 'Median hospital stay before testing was 14 days (range 1-38).': [{'noun_phrase': ' Median hospital', 'noun_connectors': ['stay']}], 'Fifty-nine (54%) tests were positive, with 141 bacteria detected.': [], 'Most were Enterobacterales (n=55, including Klebsiella spp.': [], '[n= 35]) or Staphylococcus aureus (n=13), as is typical of hospital and ventilator pneumonia.': [{'noun_phrase': ' n=', 'noun_connectors': ['or']}], 'Community pathogens, including Haemophilus influenzae (n=8) and Streptococcus pneumoniae (n=1), were rarer.': [{'noun_phrase': ' Community', 'noun_connectors': ['pathogens', 'including']}, {'noun_phrase': ' influenzae n=8', 'noun_connectors': ['and']}], 'FilmArray detected one additional virus (Rhinovirus/Enterovirus) and no atypical bacteria.': [{'noun_phrase': ' FilmArray', 'noun_connectors': ['detected']}, {'noun_phrase': ' virus Rhinovirus Enterovirus', 'noun_connectors': ['and']}], 'Fewer samples (28 % vs. 54%) were positive by routine culture, and fewer species were reported per sample; Klebsiella species remained the most prevalent pathogens.': [{'noun_phrase': ' Fewer samples % % positive routine culture', 'noun_connectors': ['and']}, {'noun_phrase': ' species', 'noun_connectors': ['reported']}, {'noun_phrase': ' sample Klebsiella species', 'noun_connectors': ['remained', 'most']}], 'Conclusion.': [], 'FilmArray had a higher diagnostic yield than culture for ICU COVID-19 patients with suspected secondary pneumonias.': [{'noun_phrase': ' FilmArray higher diagnostic yield culture ICU COVID-19 patients', 'noun_connectors': ['suspected']}], 'The bacteria found mostly were Enterobacterales, S. aureus and P. aeruginosa, as in typical HAP/VAP, but with Klebsiella spp.': [], 'more prominent.': [], 'We found almost no viral co-infection.': [{'noun_phrase': '', 'noun_connectors': ['found', 'almost']}], 'Turnaround from sample to results is around 1h 15 min compared with the usual 72h for culture, giving prescribers earlier data to inform antimicrobial decisions.': [{'noun_phrase': ' Turnaround sample results 1h min', 'noun_connectors': ['compared']}, {'noun_phrase': ' 72h culture', 'noun_connectors': ['giving']}, {'noun_phrase': ' prescribers earlier data', 'noun_connectors': ['inform']}]}"
